US20100022414A1 - Droplet Libraries - Google Patents
Droplet Libraries Download PDFInfo
- Publication number
- US20100022414A1 US20100022414A1 US12/504,764 US50476409A US2010022414A1 US 20100022414 A1 US20100022414 A1 US 20100022414A1 US 50476409 A US50476409 A US 50476409A US 2010022414 A1 US2010022414 A1 US 2010022414A1
- Authority
- US
- United States
- Prior art keywords
- droplets
- droplet
- library
- aqueous
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- QNUDYFAFOCNBFB-UHFFFAOYSA-M C.C.C.C.CC1=CC=C(S(=O)(=O)OCCOCCOS(=O)(=O)C2=CC=C(C)C=C2)C=C1.O=C1C2=C(C=CC=C2)C(=O)N1CCOCCN1C(=O)C2=C(C=CC=C2)C1=O.O=C1C2=C(C=CC=C2)C(=O)[N+]1=[K-] Chemical compound C.C.C.C.CC1=CC=C(S(=O)(=O)OCCOCCOS(=O)(=O)C2=CC=C(C)C=C2)C=C1.O=C1C2=C(C=CC=C2)C(=O)N1CCOCCN1C(=O)C2=C(C=CC=C2)C1=O.O=C1C2=C(C=CC=C2)C(=O)[N+]1=[K-] QNUDYFAFOCNBFB-UHFFFAOYSA-M 0.000 description 1
- YNOZPLDFNXNREJ-UHFFFAOYSA-N C.C.C.C.CC1=CC=C(S(=O)(=O)OCCOCCOS(=O)(=O)C2=CC=C(C)C=C2)C=C1.OCCOCCO Chemical compound C.C.C.C.CC1=CC=C(S(=O)(=O)OCCOCCOS(=O)(=O)C2=CC=C(C)C=C2)C=C1.OCCOCCO YNOZPLDFNXNREJ-UHFFFAOYSA-N 0.000 description 1
- FKRDEBXYQWXCNY-UHFFFAOYSA-N C.C.C.C.NCCOCCN.O=C1C2=C(C=CC=C2)C(=O)N1CCOCCN1C(=O)C2=C(C=CC=C2)C1=O Chemical compound C.C.C.C.NCCOCCN.O=C1C2=C(C=CC=C2)C(=O)N1CCOCCN1C(=O)C2=C(C=CC=C2)C1=O FKRDEBXYQWXCNY-UHFFFAOYSA-N 0.000 description 1
- BJJNKQCANJYAOE-UHFFFAOYSA-N C.C.CCF.CCF.CCF.FCF.FCF.FCF.FCF.FCF.FCF.NCCOCCN.O=C(Cl)C(F)(OC(F)(F)C(F)(F)F)C(F)(F)F.O=C(NCCOCCNC(=O)C(F)(OC(F)(F)C(F)(F)F)C(F)(F)F)C(OC(F)C(F)(F)F)C(F)(F)F Chemical compound C.C.CCF.CCF.CCF.FCF.FCF.FCF.FCF.FCF.FCF.NCCOCCN.O=C(Cl)C(F)(OC(F)(F)C(F)(F)F)C(F)(F)F.O=C(NCCOCCNC(=O)C(F)(OC(F)(F)C(F)(F)F)C(F)(F)F)C(OC(F)C(F)(F)F)C(F)(F)F BJJNKQCANJYAOE-UHFFFAOYSA-N 0.000 description 1
- ZFUDDUZZUIUROR-UHFFFAOYSA-N CCF.CCF.FCF.FCF.FCF.FCF.O=C(Cl)C(F)(OC(F)(F)C(F)(F)F)C(F)(F)F.O=C(O)C(F)(OC(F)(F)C(F)(F)F)C(F)(F)F Chemical compound CCF.CCF.FCF.FCF.FCF.FCF.O=C(Cl)C(F)(OC(F)(F)C(F)(F)F)C(F)(F)F.O=C(O)C(F)(OC(F)(F)C(F)(F)F)C(F)(F)F ZFUDDUZZUIUROR-UHFFFAOYSA-N 0.000 description 1
- SXUVEKQPCANZGU-UHFFFAOYSA-N NCCOCCOCCOCCN.O=C(O)C(F)(OC(F)(F)C(F)(OC(F)(F)C(F)(F)C(F)(F)F)C(F)(F)F)C(F)(F)F.O=C([O-])C(F)(OC(F)(F)C(F)(OC(F)(F)C(F)(F)C(F)(F)F)C(F)(F)F)C(F)(F)F.O=C([O-])C(F)(OC(F)(F)C(F)(OC(F)(F)C(F)(F)C(F)(F)F)C(F)(F)F)C(F)(F)F.[NH3+]CCOCCOCCOCC[NH3+] Chemical compound NCCOCCOCCOCCN.O=C(O)C(F)(OC(F)(F)C(F)(OC(F)(F)C(F)(F)C(F)(F)F)C(F)(F)F)C(F)(F)F.O=C([O-])C(F)(OC(F)(F)C(F)(OC(F)(F)C(F)(F)C(F)(F)F)C(F)(F)F)C(F)(F)F.O=C([O-])C(F)(OC(F)(F)C(F)(OC(F)(F)C(F)(F)C(F)(F)F)C(F)(F)F)C(F)(F)F.[NH3+]CCOCCOCCOCC[NH3+] SXUVEKQPCANZGU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/40—Mixing liquids with liquids; Emulsifying
- B01F23/41—Emulsifying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/40—Static mixers
- B01F25/42—Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
- B01F25/43—Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
- B01F25/433—Mixing tubes wherein the shape of the tube influences the mixing, e.g. mixing tubes with varying cross-section or provided with inwardly extending profiles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/40—Static mixers
- B01F25/42—Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
- B01F25/43—Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
- B01F25/433—Mixing tubes wherein the shape of the tube influences the mixing, e.g. mixing tubes with varying cross-section or provided with inwardly extending profiles
- B01F25/4336—Mixers with a diverging cross-section
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/30—Micromixers
- B01F33/301—Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
- B01F33/3011—Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions using a sheathing stream of a fluid surrounding a central stream of a different fluid, e.g. for reducing the cross-section of the central stream or to produce droplets from the central stream
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
- B01F2101/23—Mixing of laboratory samples e.g. in preparation of analysing or testing properties of materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00279—Features relating to reactor vessels
- B01J2219/00281—Individual reactor vessels
- B01J2219/00286—Reactor vessels with top and bottom openings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00418—Means for dispensing and evacuation of reagents using pressure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00479—Means for mixing reactants or products in the reaction vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/0054—Means for coding or tagging the apparatus or the reagents
- B01J2219/00572—Chemical means
- B01J2219/00576—Chemical means fluorophore
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00585—Parallel processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/0059—Sequential processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00592—Split-and-pool, mix-and-divide processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00599—Solution-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00646—Making arrays on substantially continuous surfaces the compounds being bound to beads immobilised on the solid supports
- B01J2219/0065—Making arrays on substantially continuous surfaces the compounds being bound to beads immobilised on the solid supports by the use of liquid beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00657—One-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00664—Three-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00702—Processes involving means for analysing and characterising the products
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/0074—Biological products
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/0074—Biological products
- B01J2219/00743—Cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
- B01L2200/027—Fluid interfacing between devices or objects, e.g. connectors, inlet details for microfluidic devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0636—Integrated biosensor, microarrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0645—Electrodes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0654—Lenses; Optical fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0415—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2561/00—Nucleic acid detection characterised by assay method
- C12Q2561/119—Fluorescence polarisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Definitions
- the present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets.
- the present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.
- the present invention overcomes the current limitations in the field by providing precise, well-defined, droplet libraries which can be utilized alone, or within microfluidic channels and devices, to perform various biological and chemical assays efficiently and effectively, especially at high speeds.
- the present invention provides for droplet libraries useful to perform large numbers of assays while consuming only limited amounts of reagents.
- the present invention provides an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises the same aqueous fluid and comprises a different library element.
- the present invention also provides a method for forming the emulsion library comprising providing a single aqueous fluid comprising different library elements, encapsulating each library element into an aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises the same aqueous fluid and comprises a different library element and pooling the aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, thereby forming an emulsion library.
- the present invention also provides an emulsion library comprising at least a first aqueous droplet and at least a second aqueous droplet within a fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and comprise a different aqueous fluid and a different library element.
- the present invention also provides a method for forming the emulsion library comprising providing at least a first aqueous fluid comprising at least a first library of elements, providing at least a second aqueous fluid comprising at least a second library of elements, encapsulating each element of said at least first library into at least a first aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, encapsulating each element of said at least second library into at least a second aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and comprise a different aqueous fluid and a different library element and pooling the at least first aqueous droplet and the at least second aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant thereby forming an emulsion library.
- the present invention provides another emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first antibody, and a single element linked to at least a second antibody, wherein said first and second antibodies are different.
- the present invention provides another emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first element linked to at least a first antibody, and at least a second element linked to at least a second antibody, wherein said first and second antibodies are different.
- each droplet within each library comprises no more than one library element. In other embodiments, each droplet within each library comprises a plurality of library elements.
- the fluorosurfactant comprised within immiscible fluorocarbon oil is a block copolymer consisting of one or more perfluorinated polyether (PFPE) blocks and one or more polyethylene glycol (PEG) blocks.
- PFPE perfluorinated polyether
- PEG polyethylene glycol
- the fluorosurfactant is a triblock copolymer consisting of a PEG center block covalently bound to two PFPE blocks by amide linking groups.
- the droplets within each are 10 microns to 100 micros in size.
- the emulsion library is stable for long term storage. Preferably, the emulsion library is stable at least 30 days.
- the droplets within each emulsion library can include any library element.
- the library element is a cell, virus, bacteria, yeast, bead, protein, polypeptide, nucleic acid, polynucleotide or small molecule chemical compound.
- the emulsion library can include any number of library elements.
- the emulsion libraries can be labeled for unique identification of each library element by any means known in the art.
- the label can be an optical label, an enzymatic label or a radioactive label.
- the label can be any detectable label, e.g., a protein, a DNA tag, a dye, a quantum dot or a radio frequency identification tag.
- the label is an optical label.
- the label can be detected by any means known in the art.
- the label is detected by fluorescence polarization, fluorescence intensity, fluorescence lifetime, fluorescence energy transfer, pH, ionic content, temperature or combinations thereof.
- FIG. 1 is an schematic illustrating the interacting modules of a microfluidic device of the present invention.
- FIG. 2 is a schematic illustrating a one emulsion library.
- FIG. 3 is a schematic illustrating an antibody pair library for ELISA Application.
- FIG. 4 Panel A is a schematic illustrating that the cell in the Protein-Fragment Complementation Assay is not secreting any antigen hence the fluorogenic substrate is not converted into a fluorescent product.
- Panel B is a schematic showing the conversion to a fluorescent product.
- FIG. 5 Panel A is a photograph showing droplets containing Ammonium Carboxylate Salt of Krytox 157 FSH 2 Wt % in FC 3283 without PEG amine salt.
- Panel B is a photograph showing droplets containing PEG 600 Diainmonium Carboxylate Salt of Krytox 157 FSH at 4.0% by volume.
- FIG. 6 is a schematic illustrating a primer library generation.
- FIG. 7 is a schematic illustrating enzyme amplified flow cytometry.
- Droplet libraries are useful to perform large numbers of assays while consuming only limited amounts of reagents.
- a “droplet,” as used herein, is an isolated portion of a first fluid that completely surrounded by a second fluid.
- the droplets may be spherical or substantially spherical; however, in other cases, the droplets may be non-spherical, for example, the droplets may have the appearance of “blobs” or other irregular shapes, for instance, depending on the external environment.
- a first entity is “surrounded” by a second entity if a closed loop can be drawn or idealized around the first entity through only the second entity.
- a droplet library is made up of a number of library elements that are pooled together in a single collection. Libraries may vary in complexity from a single library element to 10 15 library elements or more. Each library element is one or more given components at a fixed concentration.
- the element may be, but is not limited to, cells, virus, bacteria, yeast, beads, amino acids, proteins, polypeptides, nucleic acids, polynucleotides or small molecule chemical compounds.
- the element may contain an identifier such as a label.
- the terms “droplet library” or “droplet libraries” are also referred to herein as an “emulsion library” or “emulsion libraries.” These terms are used interchangeably throughout the specification.
- a cell library element can include, but is not limited to, hybridomas, B-cells, primary cells, cultured cell lines, cancer cells, stem cells, or any other cell type.
- Cellular library elements are prepared by encapsulating a number of cells from one to tens of thousands in individual droplets. The number of cells encapsulated is usually given by Poisson statistics from the number density of cells and volume of the droplet. However, in some cases the number deviates from Poisson statistics as described in Edd et al., “Controlled encapsulation of single-cells into monodisperse picolitre drops.” Lab Chip, 8(8): 1262-1264, 2008.
- a bead based library element contains one or more beads, of a given type and may also contain other reagents, such as antibodies, enzymes or other proteins.
- the library elements can all be prepared from a single starting fluid or have a variety of starting fluids.
- the library elements will be prepared from a variety of starting fluids.
- droplet libraries are collections of droplets that have different contents, ranging from beads, cells, small molecules, DNA, primers, antibodies.
- the droplets range in size from roughly 0.5 micron to 500 micron in diameter, which corresponds to about 1 pico liter to 1 nano liter. However, droplets can be as small as 5 microns and as large as 500 microns.
- the droplets are at less than 100 microns, about 1 micron to about 100 microns in diameter. The most preferred size is about 20 to 40 microns in diameter (10 to 100 picoliters).
- the preferred properties examined of droplet libraries include osmotic pressure balance, uniform size, and size ranges.
- the droplets comprised within the droplet library provided by the instant invention are uniform in size. That is, the diameter of any droplet within the library will vary less than 5%, 4%, 3%, 2%, 1% or 0.5% when compared to the diameter of other droplets within the same library.
- the uniform size of the droplets in the library is critical to maintain the stability and integrity of the droplets and is also essential for the subsequent use of the droplets within the library for the various biological and chemical assays described herein.
- the droplets comprised within the emulsion libraries of the present invention are contained within an immiscible fluorocarbon oil comprising at least one fluorosurfactant.
- the fluorosurfactant comprised within immiscible fluorocarbon oil is a block copolymer consisting of one or more perfluorinated polyether (PFPE) blocks and one or more polyethylene glycol (PEG) blocks.
- PFPE perfluorinated polyether
- PEG polyethylene glycol
- the fluorosurfactant is a triblock copolymer consisting of a PEG center block covalently bound to two PFPE blocks by amide linking groups.
- fluorosurfactant similar to uniform size of the droplets in the library
- the presence of the fluorosurfactant is critical to maintain the stability and integrity of the droplets and is also essential for the subsequent use of the droplets within the library for the various biological and chemical assays described herein.
- Fluids e.g., aqueous fluids, immiscible oils, etc.
- surfactants that can be utilized in the droplet libraries of the present invention are described in greater detail herein.
- the droplet libraries of the present invention are very stable and are capable of long-term storage.
- the droplet libraries are determined to be stable if the droplets comprised within the libraries maintain their structural integrity, that is the droplets do not rupture and elements do not diffuse from the droplets.
- the droplets libraries are also determined to be stable if the droplets comprised within the libraries do not coalesce spontaneously (without additional energy input, such as electrical fields described in detail herein). Stability can be measured at any temperature.
- the droplets are very stable and are capable of long-term storage at any temperature; for example, e.g., ⁇ 70° C., 0° C., 4° C., 37° C., room temperature, 75° C. and 95° C.
- the droplet libraries of the present invention are stable for at least 30 days. More preferably, the droplets are stable for at least 60 days. Most preferably, the droplets are stable for at least 90 days.
- the present invention provides an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises the same aqueous fluid and comprises a different library element.
- the present invention also provides a method for forming the emulsion library comprising providing a single aqueous fluid comprising different library elements, encapsulating each library element into an aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises the same aqueous fluid and comprises a different library element, and pooling the aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, thereby forming an emulsion library.
- all different types of elements are pooled in a single source contained in the same medium.
- the cells or beads are then encapsulated in droplets to generate a library of droplets wherein each droplet with a different type of bead or cell is a different library element.
- the dilution of the initial solution enables the encapsulation process.
- the droplets formed will either contain a single cell or bead or will not contain anything, i.e., be empty. In other embodiments, the droplets formed will contain multiple copies of a library element.
- the cells or beads being encapsulated are generally variants on the same type of cell or bead.
- the cells can comprise cancer cells of a tissue biopsy, and each cell type is encapsulated to be screened for genomic data or against different drug therapies.
- each cell type is encapsulated to be screened for genomic data or against different drug therapies.
- One example is a bacterial library where each library element grows into a clonal population that secretes a variant on an enzyme.
- the emulsion library comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil, wherein a single molecule is encapsulated, such that there is a single molecule contained within a droplet for every 20-60 droplets produced (e.g., 20, 25, 30, 35, 40, 45, 50, 55, 60 droplets, or any integer in between).
- Single molecules are encapsulated by diluting the solution containing the molecules to such a low concentration that the encapsulation of single molecules is enabled.
- a LacZ plasmid DNA was encapsulated at a concentration of 20 fM after two hours of incubation such that there was about one gene in 40 droplets, where 10 ⁇ m droplets were made at 10 kHz per second. Formation of these libraries rely on limiting dilutions.
- the present invention also provides an emulsion library comprising at least a first aqueous droplet and at least a second aqueous droplet within a fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and comprise a different aqueous fluid and a different library element.
- the present invention also provides a method for forming the emulsion library comprising providing at least a first aqueous fluid comprising at least a first library of elements, providing at least a second aqueous fluid comprising at least a second library of elements, encapsulating each element of said at least first library into at least a first aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, encapsulating each element of said at least second library into at least a second aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and comprise a different aqueous fluid and a different library element, and pooling the at least first aqueous droplet and the at least second aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant thereby forming an emulsion library.
- emulsion library there are library elements that have different particles, i.e., cells or beads in a different medium and are encapsulated prior to pooling.
- a specified number of library of elements i.e., n number of different cells or beads, are contained within different mediums.
- Each of the library elements are separately emulsified and pooled, at which point each of the n number of pooled different library elements are combined and pooled into a single pool.
- the resultant pool contains a plurality of water-in-oil emulsion droplets each containing a different type of particle.
- the droplets formed will either contain a single library element or will not contain anything, i.e., be empty. In other embodiments, the droplets formed will contain multiple copies of a library element.
- the contents of the beads follow a Poisson distribution, where there is a discrete probability distribution that expresses the probability of a number of events occurring in a fixed period of time if these events occur with a known average rate and independently of the time since the last event.
- the oils and surfactants used to create the libraries prevents the exchange of the contents of the library between droplets.
- the present invention provides another emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first antibody, and a single element linked to at least a second antibody, wherein said first and second antibodies are different.
- each library element comprises a different bead, wherein each bead is attached to a number of antibodies and the bead is encapsulated within a droplet that contains a different antibody in solution.
- ELISA sandwiches can then be allowed to form “ELISA sandwiches,” which can be washed and prepared for a ELISA assay. Further, these contents of the droplets can be altered to be specific for the antibody contained therein to maximize the results of the assay.
- a specific example of an ELSA assay is shown in Example 5 and in FIG. 3 .
- the present invention also provides another emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first element linked to at least a first antibody, and at least a second element linked to at least a second antibody, wherein said first and second antibodies are different.
- a Protein-Fragment Complementation Assay PCA
- library droplets are prepared to contain a mixture of two different antibodies. Wherein the two antibodies bind with strong affinity to different epitopes of the antigen molecule that is to be detected.
- Detection is achieved by tethering protein fragments to the each of the antibodies such that when held in proximity the two fragments create an active enzyme capable of turning over a fluorogenic substrate, only in the presence of the antigen.
- the cell is not secreting any antigen hence the fluorogenic substrate is not converted into a fluorescent product.
- Panel B the cell is secreting the antigen.
- the antibodies bind to it the two protein fragments are held in close enough proximity to form an active enzyme.
- the intensity of the fluorescence signal generated from these sandwiches is indicative of the antigen concentration in the droplet.
- the library begins with a certain number of library elements, which may contain proteins, enzymes, small molecules and PCR primers, among other reagents.
- each library is added to a droplet in a specific concentration.
- the reagent contained within the droplets.
- each library element can be the same small molecule chemical compound at different concentrations or be completely different small molecule chemical compound per element.
- Labels can be used for identification of the library elements of the various types of droplet libraries. Libraries can be labeled for unique identification of each library element by any means known in the art.
- the label can be an optical label, an enzymatic label or a radioactive label.
- the label can be any detectable label, e.g., a protein, a DNA tag, a dye, a quantum dot or a radio frequency identification tag, or combinations thereof.
- the label is an optical label.
- the label can be detected by any means known in the art.
- the label is detected by fluorescence polarization, fluorescence intensity, fluorescence lifetime, fluorescence energy transfer, pH, ionic content, temperature or combinations thereof.
- Various labels and means for detection are described in greater detail herein.
- each of the various library elements contains a unique label so that the library elements may be identified.
- the elements are then encapsulated and each of the droplets contains a unique label so that the library elements may be identified.
- Optical labels are also utilized in quality control in order to ensure that the droplet libraries are well controlled, and that equal number of each library elements are contained within uniform volumes in each droplet library. After 120 minutes of mixing, using 8-labels in a 96-member library, the average number of droplets is 13,883 for each of the library elements. As Table 1 shows below, there is very little variation between the number of droplets for each library element, i.e., between ⁇ 0.8% to +1.1%. The slight variation in the number of droplets allows the pooled droplet libraries to be used in any number of assays.
- 384-member libraries were prepared with eight optical labels; typically 5 to 20 micro-liters of each library element are emulsified into approximately 10 picoliter volume droplets so there are about 1 million droplets of each library element and 384 million droplets in the library.
- the eight optical labels are a dye at concentrations that increase by a factor of c (where c ranges from about 1.2 to 1.4) from one optical label to the next so that the nth optical label has (c)(n ⁇ 1) the dye concentration of the lowest concentration.
- Optical labels are used with concentrations between 10 nM and 1 uM.
- the range of optical label concentrations for one series of labels is 1 order of magnitude (e.g., 10 nM to 100 nM with a multiplier of 1.43 for each increasing label concentration).
- a larger range of droplet label concentrations can also be used.
- multiplexed two-color labels can be used as well.
- Plates are prepared with 384 separate library elements in separate wells of the 384-well plates; 8 of which have optical labels.
- the library elements are made into droplets, collected in a vial, (also known as a creaming tower) and the collection is mixed on the mixer for several hours.
- the mixer works by flipping the vial over about once every 30 seconds and then allowing the droplets to rise. Multiple plates can be emulsified and pooled or collected sequentially into the same vial.
- a small fraction of the droplets are taken out of the vial to verify 1) that the droplets are present in the correct predetermined ratio and 2) that the droplets are of uniform size.
- 1,000 to 10,000 droplets of each library element are removed from the vial through a PEEK line in the center opening in the vial cap by positive displacement with a drive oil infused through the side opening in vial cap.
- the PEEK line takes the droplets into a port on a microfluidic chip at a rate of several thousand droplets/second; for 10 picoliter droplets at a rate of 3000 droplets/s corresponds to a typical infusion rate of roughly 110 micro-liters/hr.
- the droplets are spaced out by adding oil before they are imaged and pass one droplet at a time through a laser excitation spot.
- Maximum fluorescence intensity data from individual droplets is collected for all of the QC-droplets and histograms are built to show the number of droplets within a given fluorescence intensity range.
- the relative number of droplets in each peak is used as a quality metric to validate that the libraries were prepared with the expected relative representation. In this example, the percent variation is determined to be only 2.7% demonstrating that all library elements have uniform representation.
- Osmotic pressure e.g., two member library prepared with a small difference in buffer concentration
- Osmotic pressure can effect droplets. Specifically, droplets with a lower salt concentration shrink over time and droplets with higher salt concentration grow over time, until uniform salt concentrations are achieved. Thus it.
- Image analysis can also be utilizes for quality control of the library reformatting process. After the various library elements are generated, pooled and mixed, optical labels can be used to verify uniform representation of all library elements. Additionally, image analysis is used to verify uniform volume for all droplets.
- image analysis can be used for shelf life testing by quantifying the materials performance. Droplets are stored in vials under a variety of conditions to test droplets stability against droplet-droplet coalescence events. Conditions tested include temperature, vibration, presence of air in vials, surfactant type, and surfactant concentration. A Quality Score of percent coalescence is calculated by image analysis. Shelf-life for the droplet libraries of the present invention exceed 90 days.
- Reagents can be reformatted as droplet libraries utilizing automated devices.
- the library elements can be placed onto plates containing any number of wells, i.e. 96, 384, etc.
- the plates can then be placed in an Automated Droplet Library Production machine (or other such automated device known in the art), which forms the droplets and puts them into a vial or other such container, containing the ready to use droplet library.
- the process aspirates each of the library elements from the well plates through tubing connected to a microfluidic device (described in greater detail herein) which can be used to form the droplets.
- the tubing that aspirates the library elements can be rinsed at a wash station and then the process can be repeated for the next library element.
- a collection vial can be used to contain the droplets made using the Automated Droplet Library Production.
- the collection vial has two holes, a first hole in the center of the vial cap and a second hole part way to the edge of the vial cap.
- the vial is first filled with oil through the second hole to purge air out first hole, the emulsion is then introduced to the vial through the first hole, typically this is done sequentially one library element at a time at low volume fraction, and oil is displaced and goes out through the second hole.
- the collected droplets can be stored in the vial for periods of time in excess of 3 months.
- oil is introduced through the second opening to displace the emulsion and drive out the first opening.
- the droplet libraries of the present invention are preferably formed by utilizing microfluidic devices and are preferably utilized to perform various biological and chemical assays on microfluidic devices, as described in detail herein.
- the present invention also provides embedded microfluidic nozzles.
- a nozzle can be formed directly into the fitting used to connect the storage well/reservoir (e.g. syringe) to a syringe tip (e.g. capillary tubing). Examples of suitable nozzles to create the droplet libraries of the instant invention are described in WO 2007/081385 and WO 2008/063227.
- the nozzle can be made from one or two oil lines providing constant flow of oil into the nozzle, a connection to the capillary tubing, and a connection to the storage well/reservoir (e.g. syringe).
- the high resolution part of the nozzle can be made out of a small bore tubing or a small, simple part molded or stamped from an appropriate material (Teflon®, plastic, metal, etc). If necessary, the nozzle itself could be formed into the tip of the ferrule using post mold processing such as laser ablation or drilling.
- This nozzle design eliminates the surface wetting issues surrounding the quasi-2D flow associated with typical microfluidic nozzles made using soft lithography or other standard microfluidic chip manufacturing techniques. This is because the nozzle design is fully 3-dimensional, resulting is a complete isolation of the nozzle section from the continuous aqueous phase. This same design can also be used for generation of emulsions required for immediate use, where the aqueous line would be attached directly to a syringe and the outlet of the nozzle would be used to transport the emulsion to the point of use (e.g. into a microfluidic PCR chip, delay line, etc).
- the present invention provides compositions and methods to directly emulsify library elements from standard library storage geometries (e.g. 96 well plates, etc).
- standard library storage geometries e.g. 96 well plates, etc.
- this invention would include microfluidic based nozzles manufactured simultaneously with an appropriately designed fluidic interconnect or well.
- microfluidic devices and methods described herein are based on the creation and electrical manipulation of aqueous phase droplets (e.g., droplet libraries) completely encapsulated by an inert immiscible oil stream.
- aqueous phase droplets e.g., droplet libraries
- the microfluidic devices include one or more channels and modules.
- a schematic illustrating one example of interacting modules of a microfluidic substrate is shown in FIG. 1 .
- the integration of these modules is an essential enabling technology for a droplet based, high-throughput microfluidic reactor system and provides an ideal system for utilizing the droplet libraries provided herein for numerous biological, chemical, or diagnostic applications.
- the microfluidic device of the present invention includes one or more analysis units.
- An “analysis unit” is a microsubstrate, e.g., a microchip.
- the terms microsubstrate, substrate, microchip, and chip are used interchangeably herein.
- the analysis unit includes at least one inlet channel, at least one main channel and at least one inlet module.
- the analysis unit can further include at least one coalescence module.
- the sorting module can be in fluid communication with branch channels which are in fluid communication with one or more outlet modules (collection module or waste module). For sorting applications, at least one detection module cooperates with at least one sorting module to divert flow via a detector-originated signal.
- modules and channels are in fluid communication with each other and therefore may overlap; i.e., there may be no clear boundary where a module or channel begins or ends.
- a plurality of analysis units of the invention may be combined in one device.
- the dimensions of the substrate are those of typical microchips, ranging between about 0.5 cm to about 15 cm per side and about 1 micron to about 1 cm in thickness.
- the analysis unit and specific modules are described in further detail in WO 2006/040551; WO 2006/040554; WO 2004/002627; WO 2004/091763; WO 2005/021151; WO 2006/096571; WO 2007/089541; WO 2007/081385 and WO 2008/063227.
- various components of the invention can be formed from solid materials, in which the channels can be formed via molding, micromachining, film deposition processes such as spin coating and chemical vapor deposition, laser fabrication, photolithographic techniques, etching methods including wet chemical or plasma processes, and the like. See, for example, Angell, et al., Scientific American, 248:44-55, 1983. At least a portion of the fluidic system can be formed of silicone by molding a silicone chip. Technologies for precise and efficient formation of various fluidic systems and devices of the invention from silicone are known.
- Various components of the systems and devices of the invention can also be formed of a polymer, for example, an elastomeric polymer such as polydimethylsiloxane (“PDMS”), polytetrafluoroethylene (“PTFE”) or Teflon®, or the like.
- PDMS polydimethylsiloxane
- PTFE polytetrafluoroethylene
- Teflon® Teflon®
- Silicone polymers are preferred, for example, the silicone elastomer polydimethylsiloxane.
- Non-limiting examples of POMS polymers include those sold under the trademark Sylgard by Dow Chemical Co., Midland, Mich., and particularly Sylgard 182, Sylgard 184, and Sylgard 186, Silicone polymers including PDMS have several beneficial properties simplifying formation of the microfluidic structures of the invention. For instance, such materials are inexpensive, readily available, and can be solidified from a prepolymeric liquid via curing with heat.
- PDMSs are typically curable by exposure of the prepolymeric liquid to temperatures of about, for example, about 65° C. to about 75° C. for exposure times of, for example, about an hour.
- silicone polymers such as PDMS
- PDMS polymethyl methacrylate copolymer
- flexible (e.g., elastomeric) molds or masters can be advantageous in this regard.
- One advantage of forming structures such as microfluidic structures of the invention from silicone polymers, such as PDMS, is the ability of such polymers to be oxidized, for example by exposure to an oxygen-containing plasma such as an air plasma, so that the oxidized structures contain, at their surface, chemical groups capable of cross-linking to other oxidized silicone polymer surfaces or to the oxidized surfaces of a variety of other polymeric and non-polymeric materials.
- an oxygen-containing plasma such as an air plasma
- oxidized silicone such as oxidized PDMS can also be sealed irreversibly to a range of oxidized materials other than itself including, for example, glass, silicon, silicon oxide, quartz, silicon nitride, polyethylene, polystyrene, glassy carbon, and epoxy polymers, which have been oxidized in a similar fashion to the PDMS surface (for example, via exposure to an oxygen-containing plasma).
- Oxidation and sealing methods useful in the context of the present invention, as well as overall molding techniques, are described in the art, for example, in Duffy et al., “Rapid Prototyping of Microfluidic Systems and Polydimethylsiloxane,” Anal. Chem., 70:474-480, 1998.
- microfluidic structures of the invention or interior, fluid-contacting surfaces
- these surfaces can be much more hydrophilic than the surfaces of typical elastomeric polymers (where a hydrophilic interior surface is desired).
- Such hydrophilic channel surfaces can thus be more easily filled and wetted with aqueous solutions than can structures comprised of typical, unoxidized elastomeric polymers or other hydrophobic materials.
- the microfluidic substrates of the present invention include channels that form the boundary for a fluid.
- a “channel,” as used herein, means a feature on or in a substrate that at least partially directs the flow of a fluid.
- the channel may be formed, at least in part, by a single component, e.g., an etched substrate or molded unit.
- the channel can have any cross-sectional shape, for example, circular, oval, triangular, irregular, square or rectangular (having any aspect ratio), or the like, and can be covered or uncovered (i.e., open to the external environment surrounding the channel).
- at least one portion of the channel can have a cross-section that is completely enclosed, and/or the entire channel may be completely enclosed along its entire length with the exception of its inlet and outlet.
- the channels of the invention can be formed, for example by etching a silicon chip using conventional photolithography techniques, or using a micromachining technology called “soft lithography” as described by Whitesides and Xia, Angewandte Chemie International Edition 37, 550 (1998).
- An open channel generally will include characteristics that facilitate control over fluid transport, e.g., structural characteristics (an elongated indentation) and/or physical or chemical characteristics (hydrophobicity vs. hydrophilicity) and/or other characteristics that can exert a force (e.g., a containing force) on a fluid.
- the fluid within the channel may partially or completely fill the channel.
- the fluid may be held or confined within the channel or a portion of the channel in some fashion, for example, using surface tension (e.g., such that the fluid is held within the channel within a meniscus, such as a concave or convex meniscus).
- some (or all) of the channels may be of a particular size or less, for example, having a largest dimension perpendicular to fluid flow of less than about 5 mm, less than about 2 mm, less than about 1 mm, less than about 500 microns, less than about 200 microns, less than about 100 microns, less than about 60 microns, less than about 50 microns, less than about 40 microns, less than about 30 microns, less than about 25 microns, less than about 10 microns, less than about 3 microns, less than about 1 micron, less than about 300 nm, less than about 100 nm, less than about 30 nm, or less than about 10 mm or less in some cases.
- a “main channel” is a channel of the device of the invention which permits the flow of molecules, cells, small molecules or particles past a coalescence module for coalescing one or more droplets, and, if present, a detection module for detection (identification) or measurement of a droplet and a sorting module for sorting a droplet based on the detection in the detection module.
- the main channel is typically in fluid communication with the coalescence, detection and/or sorting modules, as well as, an inlet channel of the inlet module.
- the main channel is also typically in fluid communication with an outlet module and optionally with branch channels, each of which may have a collection module or waste module. These channels permit the flow of molecules, cells, small molecules or particles out of the main channel.
- An “inlet channel” permits the flow of molecules, cells, small molecules or particles into the main channel.
- One or more inlet channels communicate with one or more means for introducing a sample into the device of the present invention.
- the inlet channel communicates with the main channel at an inlet module.
- the microfluidic substrate can also comprise one or more fluid channels to inject or remove fluid in between droplets in a droplet stream for the purpose of changing the spacing between droplets.
- the channels of the device of the present invention can be of any geometry as described.
- the channels of the device can comprise a specific geometry such that the contents of the channel are manipulated, e.g., sorted, mixed, prevent clogging, etc.
- a microfluidic substrate can also include a specific geometry designed in such a manner as to prevent the aggregation of biological/chemical material and keep the biological/chemical material separated from each other prior to encapsulation in droplets.
- the geometry of channel dimension can be changed to disturb the aggregates and break them apart by various methods, that can include, but is not limited to, geometric pinching (to force cells through a (or a series of) narrow region(s), whose dimension is smaller or comparable to the dimension of a single cell) or a barricade (place a series of barricades on the way of the moving cells to disturb the movement and break up the aggregates of cells).
- the channels may have a coating which minimizes adhesion.
- the surface of the channels of the microfluidic device can be coated with any anti-wetting or blocking agent for the dispersed phase.
- the channel can be coated with any protein to prevent adhesion of the biological/chemical sample.
- Channels can be coated by any means known in the art. For example, the channels are coated with Teflon®, BSA, PEG-silane and/or fluorosilane in an amount sufficient to prevent attachment and prevent clogging.
- the channels can be coated with a cyclized transparent optical polymer obtained by copolymerization of perfluoro (alkenyl vinyl ethers), such as the type sold by Asahi Glass Co. under the trademark Cytop.
- the coating is applied from a 0.1-0.5 wt % solution of Cytop CTL-809M in CT-Solv 180. This solution can be injected into the channels of a microfluidic device via a plastic syringe. The device can then be heated to about 90° C. for 2 hours, followed by heating at 200° C. for an additional 2 hours.
- the channels can be coated with a hydrophobic coating of the type sold by PPG Industries, Inc.
- Aquapel e.g., perfluoroalkylalkylsilane surface treatment of plastic and coated plastic substrate surfaces in conjunction with the use of a silica primer layer
- Aquapel e.g., perfluoroalkylalkylsilane surface treatment of plastic and coated plastic substrate surfaces in conjunction with the use of a silica primer layer
- U.S. Pat. No. 5,523,162 By fluorinating the surfaces of the channels, the continuous phase preferentially wets the channels and allows for the stable generation and movement of droplets through the device.
- the low surface tension of the channel walls thereby minimizes the accumulation of channel clogging particulates.
- the surface of the channels in the microfluidic device can be also fluorinated by any means known in the art to prevent undesired wetting behaviors.
- a microfluidic device can be placed in a polycarbonate dessicator with an open bottle of (tridecafluoro-1,1,2,2-tetrahydrooctyl)trichlorosilane. The dessicator is evacuated for 5 minutes, and then sealed for 20-40 minutes. The dessicator is then backfilled with air and removed.
- This approach uses a simple diffusion mechanism to enable facile infiltration of channels of the microfluidic device with the fluorosilane and can be readily scaled up for simultaneous device fluorination.
- the fluids described herein are related to the fluids within the droplet libraries and to the fluids within a microfluidic device.
- the microfluidic device of the present invention is capable of controlling the direction and flow of fluids and entities within the device.
- flow means any movement of liquid or solid through a device or in a method of the invention, and encompasses without limitation any fluid stream, and any material moving with, within or against the stream, whether or not the material is carried by the stream.
- the movement of molecules, beads, cells or virions through a device or in a method of the invention, e.g. through channels of a microfluidic chip of the invention comprises a flow.
- any force may be used to provide a flow, including without limitation, pressure, capillary action, electro-osmosis, electrophoresis, dielectrophoresis, optical tweezers, and combinations thereof, without regard for any particular theory or mechanism of action, so long as molecules, cells or virions are directed for detection, measurement or sorting according to the invention. Specific flow forces are described in further detail herein.
- the flow stream in the main channel is typically, but not necessarily, continuous and may be stopped and started, reversed or changed in speed.
- a liquid that does not contain sample molecules, cells or particles can be introduced into a sample inlet well or channel and directed through the inlet module, e.g., by capillary action, to hydrate and prepare the device for use.
- buffer or oil can also be introduced into a main inlet region that communicates directly with the main channel to purge the device (e.g., or “dead” air) and prepare it for use.
- the pressure can be adjusted or equalized, for example, by adding buffer or oil to an outlet module.
- fluid stream or “fluidic stream” refers to the flow of a fluid, typically generally in a specific direction.
- the fluidic stream may be continuous and/or discontinuous.
- a “continuous” fluidic stream is a fluidic stream that is produced as a single entity, e.g., if a continuous fluidic stream is produced from a channel, the fluidic stream, after production, appears to be contiguous with the channel outlet.
- the continuous fluidic stream is also referred to as a continuous phase fluid or carrier fluid.
- the continuous fluidic stream may be laminar, or turbulent in some cases.
- a “discontinuous” fluidic stream is a fluidic stream that is not produced as a single entity.
- the discontinuous fluidic stream is also referred to as the dispersed phase fluid or sample fluid.
- a discontinuous fluidic stream may have the appearance of individual droplets, optionally surrounded by a second fluid.
- the dispersed phase fluid can include a biological/chemical material.
- the biological/chemical material can be tissues, cells, particles, proteins, antibodies, amino acids, nucleotides, small molecules, and pharmaceuticals.
- the biological/chemical material can include one or more labels known in the art.
- the label can be an optical label, an enzymatic label or a radioactive label.
- the label can be any detectable label, e.g., a protein, a DNA tag, a dye, a quantum dot or a radio frequency identification tag, or combinations thereof.
- the label is an optical label.
- the label can be detected by any means known in the art.
- the label is detected by fluorescence polarization, fluorescence intensity, fluorescence lifetime, fluorescence energy transfer, pH, ionic content, temperature or combinations thereof.
- fluorescence polarization fluorescence intensity, fluorescence lifetime, fluorescence energy transfer, pH, ionic content, temperature or combinations thereof.
- emulsion refers to a preparation of one liquid distributed in small globules (also referred to herein as drops, droplets or NanoReactors) in the body of a second liquid.
- the first and second fluids are immiscible with each other.
- the discontinuous phase can be an aqueous solution and the continuous phase can a hydrophobic fluid such as an oil. This is termed a water in oil emulsion.
- the emulsion may be a oil in water emulsion.
- the first liquid, which is dispersed in globules is referred to as the discontinuous phase
- the second liquid is referred to as the continuous phase or the dispersion medium.
- the continuous phase can be an aqueous solution and the discontinuous phase is a hydrophobic fluid, such as an oil (e.g., decane, tetradecane, or hexadecane).
- a hydrophobic fluid such as an oil (e.g., decane, tetradecane, or hexadecane).
- the droplets or globules of oil in an oil in water emulsion are also referred to herein as “micelles”, whereas globules of water in a water in oil emulsion may be referred to as “reverse micelles”.
- the fluidic droplets may each be substantially the same shape and/or size.
- the droplets may be uniform in size.
- the shape and/or size can be determined, for example, by measuring the average diameter or other characteristic dimension of the droplets.
- the “average diameter” of a plurality or series of droplets is the arithmetic average of the average diameters of each of the droplets. Those of ordinary skill in the art will be able to determine the average diameter (or other characteristic dimension) of a plurality or series of droplets, for example, using laser light scattering, microscopic examination, or other known techniques.
- the diameter of a droplet, in a non-spherical droplet is the mathematically-defined average diameter of the droplet, integrated across the entire surface.
- the average diameter of a droplet may be, for example, less than about 1 mm, less than about 500 micrometers, less than about 200 micrometers, less than about 100 micrometers, less than about 75 micrometers, less than about 50 micrometers, less than about 25 micrometers, less than about 10 micrometers, or less than about 5 micrometers in some cases.
- the average diameter may also be at least about 1 micrometer, at least about 2 micrometers, at least about 3 micrometers, at least about 5 micrometers, at least about 10 micrometers, at least about 15 micrometers, or at least about 20 micrometers in certain cases.
- NanoReactor and its plural encompass the terms “droplet”, “nanodrop”, “nanodroplet”, “microdrop” or “microdroplet” as defined herein, as well as an integrated system for the manipulation and probing of droplets, as described in detail herein.
- Nanoreactors as described herein can be 0.1-1000 ⁇ m (e.g., 0.1, 0.2 . . . 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 . . . 1000), or any size within this range. Droplets at these dimensions tend to conform to the size and shape of the channels, while maintaining their respective volumes. Thus, as droplets move from a wider channel to a narrower channel they become longer and thinner, and vice versa.
- the microfluidic substrate of this invention most preferably generate round, highly uniform, monodisperse droplets ( ⁇ 1.5% polydispersity).
- Droplets and methods of forming monodisperse droplets in microfluidic channels is described in WO 2006/040551; WO 2006/040554; WO 2004/002627; WO 2004/091763; WO 2005/021151; WO 2006/096571; WO 2007/089541; WO 2007/081385 and WO 2008/063227.
- the droplet forming liquid is typically an aqueous buffer solution, such as ultrapure water (e.g., 18 mega-ohm resistivity, obtained, for example by column chromatography), 10 mM Tris HCl and 1 mM EDTA (TE) buffer, phosphate buffer saline (PBS) or acetate buffer. Any liquid or buffer that is physiologically compatible with the population of molecules, cells or particles to be analyzed and/or sorted can be used.
- the fluid passing through the main channel and in which the droplets are formed is one that is immiscible with the droplet forming fluid.
- the fluid passing through the main channel can be a non-polar solvent, decane (e.g., tetradecane or hexadecane), fluorocarbon oil, silicone oil or another oil (for example, mineral oil).
- the droplet may also contain biological/chemical material (e.g., molecules, cells, or other particles) for combination, analysis and/or sorting in the device.
- biological/chemical material e.g., molecules, cells, or other particles
- the droplets of the dispersed phase fluid can contain more than one particle or can contain no more than one particle.
- Droplets of a sample fluid can be formed within the inlet module on the microfluidic device or droplets (or droplet libraries) can be formed before the sample fluid is introduced to the microfluidic device (“off chip” droplet formation).
- the droplets comprising each sample to be analyzed must be monodisperse.
- Droplet size must be highly controlled to ensure that droplets containing the correct contents for analysis and coalesced properly.
- the present invention provides devices and methods for forming droplets and droplet libraries.
- the fluids used in the invention may contain one or more additives, such as agents which reduce surface tensions (surfactants).
- Surfactants can include Tween, Span, fluorosurfactants, and other agents that are soluble in oil relative to water.
- performance is improved by adding a second surfactant to the aqueous phase.
- Surfactants can aid in controlling or optimizing droplet size, flow and uniformity, for example by reducing the shear force needed to extrude or inject droplets into an intersecting channel. This can affect droplet volume and periodicity, or the rate or frequency at which droplets break off into an intersecting channel.
- the surfactant can serve to stabilize aqueous emulsions in fluorinated oils from coalescing.
- the present invention provides compositions and methods to stabilize aqueous droplets in a fluorinated oil and minimize the transport of positively charged reagents (particularly, fluorescent dyes) from the aqueous phase to the oil phase.
- the droplets may be coated with a surfactant.
- Preferred surfactants that may be added to the continuous phase fluid include, but are not limited to, surfactants such as sorbitan-based carboxylic acid esters (e.g., the “Span” surfactants, Fluka Chemika), including sorbitan monolaurate (Span 20), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60) and sorbitan monooleate (Span 80), and perfluorinated polyethers (e.g., DuPont Krytox 157 FSL, FSM, and/or ESH).
- surfactants such as sorbitan-based carboxylic acid esters (e.g., the “Span” surfactants, Fluka Chemika), including sorbitan monolaurate (Span 20), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60) and sorbitan monooleate (Span 80), and perfluorin
- non-ionic surfactants which may be used include polyoxyethylenated alkylphenols (for example, nonyl-, p-dodecyl-, and dinonylphenols), polyoxyethylenated straight chain alcohols, polyoxyethylenated polyoxypropylene glycols, polyoxyethylenated mercaptans, long chain carboxylic acid esters (for example, glyceryl and polyglycerl esters of natural fatty acids, propylene glycol, sorbitol, polyoxyethylenated sorbitol esters, polyoxyethylene glycol esters, etc.) and alkanolamines (e.g., diethanolamine-fatty acid condensates and isopropanolamine-fatty acid condensates).
- alkylphenols for example, nonyl-, p-dodecyl-, and dinonylphenols
- polyoxyethylenated straight chain alcohols poly
- ionic surfactants such as sodium dodecyl sulfate (SDS) may also be used.
- SDS sodium dodecyl sulfate
- surfactants are generally less preferably for many embodiments of the invention.
- a water soluble surfactant such as SDS may denature or inactivate the contents of the droplet.
- the carrier fluid can be an oil (e.g., decane, tetradecane or hexadecane) or fluorocarbon oil that contains a surfactant (e.g., a non-ionic surfactant such as a Span surfactant) as an additive (preferably between about 0.2 and 5% by volume, more preferably about 2%).
- a surfactant e.g., a non-ionic surfactant such as a Span surfactant
- a user can preferably cause the carrier fluid to flow through channels of the microfluidic device so that the surfactant in the carrier fluid coats the channel walls.
- Fluorocarbon oil continuous phases are well-suited as the continuous phase for aqueous droplet libraries for a number of reasons. Fluorous oils are both hydrophobic and lipophobic. Therefore, they have low solubility for components of the aqueous phase and they limit molecular diffusion between droplets. Also, fluorous oils present an inert interface for chemistry and biology within droplets. In contrast to hydrocarbon or silicone oils, fluorous oils do not swell PDMS materials, which is a convenient material for constructing microfluidic channels. Finally, fluorocarbon oils have good solubility for gases, which is necessary for the viability of encapsulated cells.
- Combinations of surfactant(s) and oils must be developed to facilitate generation, storage, and manipulation of droplets to maintain the unique chemical/biochemical/biological environment within each droplet of a diverse library. Therefore, the surfactant and oil combination must (1) stabilize droplets against uncontrolled coalescence during the drop forming process and subsequent collection and storage, (2) minimize transport of any droplet contents to the oil phase and/or between droplets, and (3) maintain chemical and biological inertness with contents of each droplet (e.g., no adsorption or reaction of encapsulated contents at the oil-water interface, and no adverse effects on biological or chemical constituents in the droplets).
- the surfactant-in-oil solution must be coupled with the fluid physics and materials associated with the platform. Specifically, the oil solution must not swell, dissolve, or degrade the materials used to construct the microfluidic chip, and the physical properties of the oil (e.g., viscosity, boiling point, etc.) must be suited for the flow and operating conditions of the platform.
- the oil solution must not swell, dissolve, or degrade the materials used to construct the microfluidic chip, and the physical properties of the oil (e.g., viscosity, boiling point, etc.) must be suited for the flow and operating conditions of the platform.
- surfactant molecules are amphiphilic part of the molecule is oil soluble, and part of the molecule is water soluble.
- surfactant molecules that are dissolved in the oil phase adsorb to the interface.
- the hydrophilic portion of the molecule resides inside the droplet and the fluorophilic portion of the molecule decorates the exterior of the droplet.
- the surface tension of a droplet is reduced when the interface is populated with surfactant, so the stability of an emulsion is improved.
- the surfactant should be inert to the contents of each droplet and the surfactant should not promote transport of encapsulated components to the oil or other droplets.
- surfactants with short fluorotelomer-tails are available, but they do not provide sufficient long-term emulsion stability.
- Fluorosurfactants with longer fluorocarbon tails such as perfluoropolyether (PFPE), are limited to molecules with ionic headgroups.
- oils are available from wide variety of fluorinated oils and are available from commercial sources.
- the requirements for the oil are (1) immiscibility with the aqueous phase, (2) solubility of emulsion stabilizing surfactants in the oil, and (3) compatibility and/or insolubility of reagents from the droplet phase.
- Oils include hydrofluoroethers, which are fluorinated alkyl chains coupled with hydrocarbon chemistry through and ether bond.
- One supplier of this type of oil is 3M.
- the products are marketed as Novec Engineered Fluids or HFE-series oils. This oils include but are not limited to, HFE-7500, which is a preferred embodiment as it provides superior droplet stability seems to be higher.
- HFE-7100, -7200, -7600 which are examples of other HFEs available from 3M. These can be used as stand-alone oils or components of oil mixtures to optimize emulsion properties and performance.
- Other hydrofluoroethers are also available from other producers, distributors, or resellers may offer hydrofluoroethers.
- FC-oils Fluorinert Electronic Liquids
- FC-oils Fluorinert Electronic Liquids
- FC-oils Fluorinert products differ by variations in alkyl chain length, branch structure, and combinations of different structures or pure oils. Many of them offer the potential for stand-alone oils or components of oil mixtures to optimize emulsion properties and performance. Specific examples are Fluorinert FC-3283, Fluorinert FC-40, which are a preferred embodiments. Higher viscosity and boiling point useful for applications requiring elevated temperature (e.g., thermocyling for PCR).
- Fluorinert series can be used for stand-alone oils or components of oil mixtures to optimize emulsion properties and performance.
- other perfluoroalkylamines are available from other producers, distributors, or resellers may offer perfluoroalkylamines.
- Fluorinated organics/solvents offer a number of perfluorinated or partially fluorinated solvents are available from a variety of producers, distributors, and/or resellers. Many of them offer the potential for stand-alone oils or components of oil mixtures to optimize emulsion properties and performance.
- fluorinated organic reagents utilized included (but not limited to) trifluoroacetic acid and hexafluoroisopropanol, to improve droplet stability in other fluorinated oil systems.
- fluoropolymers may also be used within a microfluidic system. Examples of fluoropolymers include, Krytox GPL oils, Solvay Galden oils, and other liquid fluoropolymers.
- oils selected are based upon their chemical properties, such as, among others molecular structure, fluorine content and solvating strength. Physical properties of oils examined include viscosity, boiling point, thermal expansion coefficient, oil-in-water solubility, water-in-oil solubility, dielectric constant, polarity, and oil-in-water surface tension.
- Classes of surfactants include fluorosurfactants that can be categorized by the type of fluorophilic portion of the molecule, the type of hydrophilic, or polar, portion, and the chemistry used to link the different parts of the molecule. Materials developed are capable of stabilizing an emulsion or droplet library.
- the preferred embodiment is the EA surfactant.
- the EA surfactant is a Krytox-PFG-Krytox.
- the EA surfactant is a nonionic tri-block copolymer surfactant was developed to avoid issues that the ionic surfactants (e.g., RR, see below) which result from the use of some other ionic surfactant.
- ionic surfactants interact with charged species in the droplets and can sequester ions (e.g., magnesium required for the PCR reaction) or other reagents to the oil phase.
- the structure of the EA surfactant comprises a PEG—approximately 600 Da with amine end functionality, PFPE—Mn is ⁇ 5000-8000 from a Krytox FSH starting material and the linker is an amide coupling.
- Another surfactant includes the R R surfactant, which is a Krytox ammonium carboxylate.
- Alternative materials are alternative fluorophilic portion, i.e., PFPE (Solvay or Demnum), Poly(fluoroalkylacrylate) and other non-polymeric and partially fluorinated materials.
- Alternative head-group chemistry for the hydrophilic portion includes, non-ionic head groups like PEG (Mw, Mw/Mn (PDI)) and functionality (i.e., diblock, triblock and dendritic). Others include morpholino.
- Ionic head groups for the hydrophilic portion include anionic, such as elemental and amine salts and further cationic head portions.
- head group chemistries include zwitterionic, hybrid (e.g., PEG-ionic and zonyl FSO/FSN), lipophilic (e.g, lipophilic to promote bilayer and lipophilic spacer to hydrophile).
- zwitterionic hybrid
- zonyl FSO/FSN lipophilic
- Another alternative is alternative coupling chemistry such as, phosphoryl/Friedel-Crafts, spacer to organic handle and others.
- Characteristics of surfactants are their molecular structure, determined by NMR, chromatography (e.g., HPLC, GPC/SEC), FTIR, mass spectrometry, and titrations. Purity of surfactants is another characteristic examined in addition to the fluorophile-hydrophile balance.
- a preferred embodiment includes oil-surfactant formulation for the application of library emulsions is R-oil (HFE-7500) mixed with 2 wt % EA surfactant (“REA20”). Concentrations of EA or RR surfactant at 0.1 wt % or lower to 5% or greater. Other formulations of oils and surfactants and other components added to the aqueous phase are used to improved and optimized the performance of the droplets performance. Those properties of the oil-surfactant mixture include simple mixtures (i.e., one oil and one surfactant, with varied surface concentration), co-surfactants, oil mixtures and additives, such as zonyl and TFA.
- Oil and surfactant mixture properties include surfactant solubility, critical micelle concentration (CMC), surfactant diffusivity, and interfacial tension, i.e., dynamic and equilibrium. Emulsion properties are also accounted for, those properties include size (absolute and size distribution), stability, transport, and biocompatibility. Stability relates directly to the coalesced droplets and their deformability/breaking and shredding ability. More particularly, the stability of the droplets in their generation, storage and shipping.
- CMC critical micelle concentration
- Emulsion properties are also accounted for, those properties include size (absolute and size distribution), stability, transport, and biocompatibility. Stability relates directly to the coalesced droplets and their deformability/breaking and shredding ability. More particularly, the stability of the droplets in their generation, storage and shipping.
- surfactant and oils begins with the synthesis of surfactants and starting materials, such as PEG-diamine, EA and RR and also accounts for the purification processes, characterization, quality control, mixing and packaging.
- the fluorosurfactant can be prepared by reacting the perflourinated polyether DuPont Krytox 157 FSL, FSM, or FSH with aqueous ammonium hydroxide in a volatile fluorinated solvent.
- the solvent and residual water and ammonia can be removed with a rotary evaporator.
- the surfactant can then be dissolved (e.g., 2.5 wt %) in a fluorinated oil (e.g., Flourinert (3M)), which then serves as the continuous phase of the emulsion.
- a fluorinated oil e.g., Flourinert (3M)
- quaternary ammonium salt at the terminus of a hydrophilic oligomer is linked to a perfluoropolyether tail as shown in the following formula:
- PFPE chain is sufficiently long for molecule to be soluble in perfluorinated oils
- amide linker provides hydrolytic stability and hydrogen bonding site
- a combination of PEG and quaternary ammonium cation provide high anchoring strength to the aqueous phase as well as electrostatic repulsion and steric hindrance to minimize reagent transport.
- Variables in the molecular structure include, but are not limited to, PFPE molecular weight and polydispersity, PFPE structure, alternative perfluorinated tail chemistries, PEG molecular weight and polydispersity, shorter hydrocarbon linkers (ethyl or methyl versus propyl), longer hydrocarbon spacers (C4 or higher), alternative counterions, such as monovalent anions, monovalent, polyatomic anions and di- or tri-valent counterions (to produce two or more tail fluorosurfactants).
- linker chemistries e.g., ether, ester, etc
- hydrophilic oligomers e.g., polyalcohol, polyacrylamide, etc.
- alternative quaternary ammonium cations e.g., anionic terminus—carboxylate etc.; alternative cations.
- the present invention is also directed to the coupling of PEG-diamines with carboxylic acid-terminated perfluoropolyether (Krytox 157) to form surfactants.
- the present invention is directed to a fluorosurfactant molecule made by the ionic coupling of amine-terminated polyethyleneglycol (PEG-amine) with the carboxylic acid of DuPont Krytox perfluoropolyether (PFPE).
- PEG-amine polyethyleneglycol
- PFPE DuPont Krytox perfluoropolyether
- Examples of specific surfactants are shown in Examples 1 and 2.
- Preferred surfactants are also described in WO 2008/021123.
- the present invention provides droplets with a fluorosurfactant interface separating the aqueous droplet and its contents from the surrounding immiscible fluorocarbon oil.
- DNA amplification reactions occurring inside these droplets generate material that does not interact with the channel walls, and collection of the DNA-containing droplets for subsequent manipulation and sequencing is straightforward.
- This technology provides a solution for amplification of DNA from single cells, allowing for both genotyping and whole genome amplification.
- use within a microfluidic device or platform as described herein achieves very high throughput, with droplets processed at rates in excess of 5000 droplets per second, enabling greater than 1 ⁇ 10 6 single-cell droplets to be formed and manipulated per hour.
- materials related to this invention include the formation of salts made by combination of various primary, secondary, or tertiary amines with PFPE carboxylic acid.
- the resulting amphiphilic structure could be useful as a stand-alone surfactant or a cosurfactant.
- fluorinated materials with carboxylic acids other than Krytox PFPE could be used to form ionic fluorosurfactants with various amine containing compounds.
- Alternative amine-containing compounds for use with the present invention include, but are not limited to, PEG-monoamine (molecular weights range from 200 to 1,000,000 or more), PEG-diamine (molecular weights range from 200 to 1,000,000 or more), Multifunctional PEG amines (e.g., branched or dendritic structures), other hydrophilic polymers terminated with amines.
- Sugars include, but are not limited to, Sugars, Peptides, Biomolecules, Ethanolamine or Alkyl amines—primary, secondary, or tertiary (e.g., triethylamine, trimethylamine, methylamine, ethylamine, butylamine)
- Alternative fluorinated groups for use with the present invention include, but are not limited to, Krytox FSL and FSM (alternative molecular weights), Demnum PFPE materials, Fluolink PFPE materials or Fluorinated small molecules with carboxylic acids.
- fluorosurfactants comprised of PEG amine salts provide better performance (compared to other fluorosurfactants) for stabilization of aqueous droplets in fluorinated oils in droplet-based microfluidics applications.
- novel surfactants are useful either in combination with other surfactants or as a stand-alone surfactant system.
- the invention can use pressure drive flow control, e.g., utilizing valves and pumps, to manipulate the flow of cells, particles, molecules, enzymes or reagents in one or more directions and/or into one or more channels of a microfluidic device.
- pressure drive flow control e.g., utilizing valves and pumps
- other methods may also be used, alone or in combination with pumps and valves, such as electro-osmotic flow control, electrophoresis and dielectrophoresis as described in Fulwyer, Science 156, 910 (1974); Li and Harrison, Analytical Chemistry 69, 1564 (1997); Fiedler, et al. Analytical Chemistry 70, 1909-1915 (1998) and U.S. Pat. No. 5,656,155.
- Positive displacement pressure driven flow is a preferred way of controlling fluid flow and dielectrophoresis is a preferred way of manipulating droplets within that flow.
- the pressure at the inlet module can also be regulated by adjusting the pressure on the main and sample inlet channels, for example, with pressurized syringes feeding into those inlet channels. By controlling the pressure difference between the oil and water sources at the inlet module, the size and periodicity of the droplets generated may be regulated.
- a valve may be placed at or coincident to either the inlet module or the sample inlet channel connected thereto to control the flow of solution into the inlet module, thereby controlling the size and periodicity of the droplets.
- Periodicity and droplet volume may also depend on channel diameter, the viscosity of the fluids, and shear pressure.
- Examples of driving pressures and methods of modulating flow are as described in WO 2006/040551; WO 2006/040554; WO 2004/002627; WO 2004/091763; WO 2005/021151; WO 2006/096571; WO 2007/089541; WO 2007/081385 and WO 2008/063227; U.S. Pat. No. 6,540,895 and U.S. Patent Application Publication Nos. 20010029983 and 20050226742
- the microfluidic device of the present invention includes one or more inlet modules.
- An “inlet module” is an area of a microfluidic substrate device that receives molecules, cells, small molecules or particles for additional coalescence, detection and/or sorting.
- the inlet module can contain one or more inlet channels, wells or reservoirs, openings, and other features which facilitate the entry of molecules, cells, small molecules or particles into the substrate.
- a substrate may contain more than one inlet module if desired. Different sample inlet channels can communicate with the main channel at different inlet modules. Alternately, different sample inlet channels can communication with the main channel at the same inlet module.
- the inlet module is in fluid communication with the main channel.
- the inlet module generally comprises a junction between the sample inlet channel and the main channel such that a solution of a sample (i.e., a fluid containing a sample such as molecules, cells, small molecules (organic or inorganic) or particles) is introduced to the main channel and forms a plurality of droplets.
- a sample i.e., a fluid containing a sample such as molecules, cells, small molecules (organic or inorganic) or particles
- the sample solution can be pressurized.
- the sample inlet channel can intersect the main channel such that the sample solution is introduced into the main channel at an angle perpendicular to a stream of fluid passing through the main channel.
- the sample inlet channel and main channel intercept at a T-shaped junction; i.e., such that the sample inlet channel is perpendicular (90 degrees) to the main channel.
- the sample inlet channel can intercept the main channel at any angle, and need not introduce the sample fluid to the main channel at an angle that is perpendicular to that flow.
- the angle between intersecting channels is in the range of from about 60 to about 120 degrees. Particular exemplary angles are 45, 60, 90, and 120 degrees.
- Embodiments of the invention are also provided in which there are two or more inlet modules introducing droplets of samples into the main channel.
- a first inlet module may introduce droplets of a first sample into a flow of fluid in the main channel and a second inlet module may introduce droplets of a second sample into the flow of fluid in main channel, and so forth.
- the second inlet module is preferably downstream from the first inlet module (e.g., about 30 ⁇ m).
- the fluids introduced into the two or more different inlet modules can comprise the same fluid or the same type of fluid (e.g., different aqueous solutions).
- droplets of an aqueous solution containing an enzyme are introduced into the main channel at the first inlet module and droplets of aqueous solution containing a substrate for the enzyme are introduced into the main channel at the second inlet module.
- the droplets introduced at the different inlet modules may be droplets of different fluids which may be compatible or incompatible.
- the different droplets may be different aqueous solutions, or droplets introduced at a first inlet module may be droplets of one fluid (e.g., an aqueous solution) whereas droplets introduced at a second inlet module may be another fluid (e.g., alcohol or oil).
- An important element in making libraries utilizing the microfluidic device of the present invention is to include features in the channels of the device to remove particles that may effect the microfluidic system.
- emulsions When emulsions are injected or re-injected onto a microfluidic device, they carry contaminants that collect at the nozzle and either clog the nozzle and/or induce uncontrolled coalescence up to the complete shredding of the emulsion.
- Debris/contaminants include small debris, such as dust or TCS, fibers, goop (glue and/or surfactant) and large debris such as PDMS skins/shavings.
- the present invention provides a post trap for large debris, a pocket trap for small debris, a serpentine trap for fibers and a step trap for large droplets/debris. EAP filters work well to filter out the contaminants.
- the filter system filters out these contaminants and most importantly traps the contaminants out of the main pathway and allow the droplets to pass by so the contaminants cannot induce uncontrolled coalescence.
- the present invention comprises two distinct parts that specifically address two different scales. The first filters contaminants that are larger than the droplet size. The second filters contaminants that are smaller than the droplet and nozzle sizes. The large contaminants are easily trapped but are responsible for inducing uncontrolled coalescence, the small contaminants tend to stick to the nozzle and most probably induce wetting that results in the shredding of the emulsion.
- a triangular shape filter that contains an internal-collection channel and smaller lateral channels connected to the internal-collection channel with a specific angle.
- the collection pockets are connected to a channel of high hydrodynamic resistance so that some of the flow will still go through and maintain the contaminants in the collection pockets.
- the lateral collection channels are located at a stepwise transition between a shallow layer and a deep layer. In one example, he droplets are collected in the Droplet Collection Channel through the lateral angled channels.
- the contaminants are deflected toward the Contaminant Collection Pocket because of the triangular shape and the droplet flow. Because of the use of high resistance channel for the Contaminants Collection Pockets, the droplets go through them only marginally, but enough to force the trapped contaminants to stay there.
- a series of posts are used, each one being offset by a half-period to the adjacent ones.
- This geometry intends to create a region of null-recirculation flow at the tip of each post due to the symmetry and contaminants are trapped in that region.
- the posts have an indentation to both increase the effect of the flow pattern described above and to trap the contaminants so that they are out of the way of the droplets.
- the posts can be designed just with an indentation or with a flow-through restriction of high hydrodynamic resistance so that the contaminants will be directed and trapped deep in the structure.
- the symmetrical design creates a region where there is almost no flow, in this region creates the conditions to trap the contaminants that are smaller than the droplets.
- the droplets follow the main flow because of the high hydrodynamic resistance conditions.
- the posts on one side of the channel have a flow-through to ensure that the contaminants stay trapped there; on the other side the posts have only an indentation.
- Several series of these posts, offset by half of a period are used to increase both the filter capacity and the odds of trapping any given contaminant.
- the droplet pairs can contain liquids of different compositions and/or volumes, which would then combine to allow for a specific reaction to be investigated.
- the pair of droplets can come from any of the following: (i) two continuous aqueous streams and an oil stream; (ii) a continuous aqueous stream, an emulsion stream, and an oil stream, or (iii) two emulsion streams and an oil stream.
- interdigitation means pairing of droplets from separate aqueous streams, or from two separate inlet nozzles, for eventual coalescence.
- Various nozzle designs enhance the interdigitation of droplets and further improves coalescence of droplets due to the better control of the interdigitation and smaller distance between pairs of droplets.
- the greater control over interdigitation allows for a perfect control over the frequency of either of the droplets.
- the spacing between droplets and coupling of the droplets can be adjusted by adjusting flow of any of the streams, viscosity of the streams, nozzle design (including orifice diameter, the channel angle, and post-orifice neck of the nozzle). Examples of preferred nozzle designs are as described in WO 2007/081385 and WO 2008/063227.
- a device of the invention can include a sample solution reservoir or well or other apparatus for introducing a sample to the device, at the inlet module, which is typically in fluid communication with an inlet channel.
- Reservoirs and wells used for loading one or more samples onto the microfluidic device of the present invention include but are not limited to, syringes, cartridges, vials, eppendorf tubes and cell culture materials (e.g., 96 well plates).
- a reservoir may facilitate introduction of molecules or cells into the device and into the sample inlet channel of each analysis unit.
- the microfluidic device of the present invention also includes one or more coalescence modules.
- a “coalescence module” is within or coincident with at least a portion of the main channel at or downstream of the inlet module where molecules, cells, small molecules or particles comprised within droplets are brought within proximity of other droplets comprising molecules, cells, small molecules or particles and where the droplets in proximity fuse, coalesce or combine their contents.
- the coalescence module can also include an apparatus, for generating an electric force.
- the electric force exerted on the fluidic droplet may be large enough to cause the droplet to move within the liquid.
- the electric force exerted on the fluidic droplet may be used to direct a desired motion of the droplet within the liquid, for example, to or within a channel or a microfluidic channel (e.g., as further described herein), etc.
- the electric field can be generated from an electric field generator, i.e., a device or system able to create an electric field that can be applied to the fluid.
- the electric field generator may produce an AC field (i.e., one that varies periodically with respect to time, for example, sinusoidally, sawtooth, square, etc.), a DC field (i.e., one that is constant with respect to time), a pulsed field, etc.
- the electric field generator may be constructed and arranged to create an electric field within a fluid contained within a channel or a microfluidic channel.
- the electric field generator may be integral to or separate from the fluidic system containing the channel or microfluidic channel, according to some embodiments.
- integrated means that portions of the components integral to each other are joined in such a way that the components cannot be in manually separated from each other without cutting or breaking at least one of the components.
- an electric field is produced by applying voltage across a pair of electrodes, which may be positioned on or embedded within the fluidic system (for example, within a substrate defining the channel or microfluidic channel), and/or positioned proximate the fluid such that at least a portion of the electric field interacts with the fluid.
- the electrodes can be fashioned from any suitable electrode material or materials known to those of ordinary skill in the art, including, but not limited to, silver, gold, copper, carbon, platinum, copper, tungsten, tin, cadmium, nickel, indium tin oxide (“ITO”), etc., as well as combinations thereof.
- Preferred electrodes and patterned electrically conductive layers are described in WO 2007/081385 and WO 2008/063227 and can be associated with any module of the device (inlet module, coalescence module, mixing module, delay module, detection module and sorting module) to generate dielectric or electric forces to manipulate and control the droplets and their contents.
- the microfluidic device according to the present invention can include placing a fluidic channel between two parallel electrodes, which can result in a steep electric field gradient at the entrance to the electrodes due to edge effects at the ends of the electrode pair. Placing these pairs of electrodes at a symmetric channel split can allow precise bi-directional control of droplet within a device. Using the same principle, only with asymmetric splits, can allow single ended control of the droplet direction in the same manner. Alternatively, a variation on this geometry will allow precise control of the droplet phase by shifting.
- Dielectrophoresis is believed to produce movement of dielectric objects, which have no net charge, but have regions that are positively or negatively charged in relation to each other.
- dielectric polarizability of the particles and the suspending medium dielectric particles will move either toward the regions of high field strength or low field strength.
- the polarizability of living cells depends on their composition, morphology, and phenotype and is highly dependent on the frequency of the applied electrical field.
- cells of different types and in different physiological states generally possess distinctly different dielectric properties, which may provide a basis for cell separation, e.g., by differential dielectrophoretic forces.
- the polarizability of droplets also depends upon their size, shape and composition. For example, droplets that contain salts can be polarized. According to formulas provided in Fiedler, et al. Analytical Chemistry 70, 1909-1915 (1998), individual manipulation of single droplets requires field differences (inhomogeneities) with dimensions close to the droplets.
- dielectrophoretic force gradient means a dielectrophoretic force is exerted on an object in an electric field provided that the object has a different dielectric constant than the surrounding media. This force can either pull the object into the region of larger field or push it out of the region of larger field. The force is attractive or repulsive depending respectively on whether the object or the surrounding media has the larger dielectric constant.
- Manipulation is also dependent on permittivity (a dielectric property) of the droplets and/or particles with the suspending medium.
- permittivity a dielectric property
- polymer particles, living cells show negative dielectrophoresis at high-field frequencies in water.
- dielectrophoretic forces experienced by a latex sphere in a 0.5 MV/m field (10 V for a 20 micron electrode gap) in water are predicted to be about 0.2 piconewtons (pN) for a 3.4 micron latex sphere to 15 pN for a 15 micron latex sphere (Fiedler, et al. Analytical Chemistry, 70, 1909-1915 (1998)).
- the electric field generator can be constructed and arranged (e.g., positioned) to create an electric field applicable to the fluid of at least about 0.01 V/micrometer, and, in some cases, at least about 0.03 V/micrometer, at least about 0.05 V/micrometer, at least about 0.08 V/micrometer, at least about 0.1 V/micrometer, at least about 0.3 V/micrometer, at least about 0.5 V/micrometer, at least about 0.7 V/micrometer, at least about 1 V/micrometer, at least about 1.2 V/micrometer, at least about 1.4 V/micrometer, at least about 1.6 V/micrometer, or at least about 2 V/micrometer.
- even higher electric field intensities may be used, for example, at least about 2 V/micrometer, at least about 3 V/micrometer, at least about 5 V/micrometer, at least about 7 V/micrometer, or at least about 10 V/micrometer or more.
- an electric field may be applied to fluidic droplets to cause the droplets to experience an electric force.
- the electric force exerted on the fluidic droplets may be, in some cases, at least about 10 ⁇ 16 N/micrometer 3 .
- the electric force exerted on the fluidic droplets may be greater, e.g., at least about 10 ⁇ 15 N/micrometer, at least about 10 ⁇ 14 N/micrometer 3 , at least about 10 ⁇ 13 N/micrometer 3 , at least about 10 ⁇ 12 N/micrometer 3 , at least about 10 ⁇ 11 N/micrometer 3 , at least about 10 ⁇ 10 N/micrometer 3 , at least about 10 ⁇ 9 N/micrometer 3 , at least about 10 ⁇ 8 N/micrometer 3 , or at least about 10 ⁇ 7 N/micrometer 3 or more.
- the electric force exerted on the fluidic droplets, relative to the surface area of the fluid may be at least about 10 ⁇ 15 N/micrometer 2 , and in some cases, at least about 10 ⁇ 14 N/micrometer 2 , at least about 10 ⁇ 13 N/micrometer 2 , at least about 10 ⁇ 12 N/micrometer 2 , at least about 10 ⁇ 11 N/micrometer ⁇ 2 , at least about 10 ⁇ 10 N/micrometer 2 , at least about 10 ⁇ 9 N/micrometer 2 , at least about 10 ⁇ 8 N/micrometer 2 , at least about 10 ⁇ 7 N/micrometer 2 , or at least about 10 ⁇ 6 N/micrometer 2 or more.
- the electric force exerted on the fluidic droplets may be at least about 10 ⁇ 9 N, at least about 10 ⁇ 8 N, at least about 10 ⁇ 7 N, at least about 10 ⁇ 6 N, at least about 10 ⁇ 5 N, or at least about 10 ⁇ 4 N or more in some cases.
- droplet coalescence is presently carried out by having two droplet forming nozzles emitting droplets into the same main channel.
- the size of the nozzles allow for one nozzle to form a large drop that fills the exhaust line while the other nozzle forms a drop that is smaller than the first.
- the smaller droplet is formed at a rate that is less than the larger droplet rate, which insures that at most one small droplet is between big droplets.
- the small droplet will catch up to the larger one over a relatively short distance, but sometimes the recirculation zone behind the large drop causes the small drop to separate from the large drop cyclically.
- the small drop occasionally does not catch up with the large one over the distance between the nozzles and the coalescing electrodes. Thus, in some situations is a need for a more robust coalescence scheme.
- Geometric alterations in the coalescence module can create a more robust, reliable coalescence or fusing of droplets over a wider range of sizes and flows.
- the solution to inprove the performance is to place an expansion in the main channel between the electrodes.
- a small constriction (neckdown) just before this expansion can be used to better align the droplets on their way into the coalescence point. This optional neckdown can help center the small droplet in the channel stream lines, reducing the chance that it will flow around the larger droplet prior to coalescing in the expansion.
- the electrode pair may be placed on either one side of the channel or on both sides.
- the expansion in the coalescing region allows for a dramatic catching up of the small drop to the large drop, as shown through micrographs taken on an operating device.
- the volume of the expansion is big enough to slow the large droplet down so that the small drop always catches up to the large drop, but doesn't allow the next large drop to catch up and make contact with the pair to be coalesced.
- the electrodes allow for coalescence to take place when the drops are in contact with each other and passing through the field gradient.
- the microfluidic device of the present invention can also include one or more detection modules.
- a “detection module” is a location within the device, typically within the main channel where molecules, cells, small molecules or particles are to be detected, identified, measured or interrogated on the basis of at least one predetermined characteristic.
- the molecules, cells, small molecules or particles can be examined one at a time, and the characteristic is detected or measured optically, for example, by testing for the presence or amount of a reporter.
- the detection module is in communication with one or more detection apparatuses.
- the detection apparatuses can be optical or electrical detectors or combinations thereof.
- detection apparatuses include optical waveguides, microscopes, diodes, light stimulating devices, (e.g., lasers), photo multiplier tubes, and processors (e.g., computers and software), and combinations thereof, which cooperate to detect a signal representative of a characteristic, marker, or reporter, and to determine and direct the measurement or the sorting action at the sorting module.
- light stimulating devices e.g., lasers
- photo multiplier tubes e.g., computers and software
- processors e.g., computers and software
- detecting generally refers to the analysis or measurement of a species, for example, quantitatively or qualitatively, and/or the detection of the presence or absence of the species. “Detecting or “determining” may also refer to the analysis or measurement of an interaction between two or more species, for example, quantitatively or qualitatively, or by detecting the presence or absence of the interaction.
- spectroscopy such as infrared, absorption, fluorescence, UV/visible, FTIR (“Fourier Transform Infrared Spectroscopy”), or Raman
- gravimetric techniques such as infrared, absorption, fluorescence, UV/visible, FTIR (“Fourier Transform Infrared Spectroscopy”), or Raman
- gravimetric techniques such as ellipsometry; piezoelectric measurements; immunoassays; electrochemical measurements; optical measurements such as optical density measurements; circular dichromism; light scattering measurements such as quasielectric light scattering; polarimetry; refractometry; or turbidity measurements as described further herein.
- a detection module is within, communicating or coincident with a portion of the main channel at or downstream of the inlet module and, in sorting embodiments, at, proximate to, or upstream of, the sorting module or branch point.
- the sorting module may be located immediately downstream of the detection module or it may be separated by a suitable distance consistent with the size of the molecules, the channel dimensions and the detection system. Precise boundaries for the detection module are not required, but are preferred.
- One or more detections sensors and/or processors may be positioned to be in sensing communication with the fluidic droplet.
- Sensing communication means that the sensor may be positioned anywhere such that the fluidic droplet within the fluidic system (e.g., within a channel), and/or a portion of the fluidic system containing the fluidic droplet may be sensed and/or determined in some fashion.
- the sensor may be in sensing communication with the fluidic droplet and/or the portion of the fluidic system containing the fluidic droplet fluidly, optically or visually, thermally, pneumatically, electronically, or the like.
- the sensor can be positioned proximate the fluidic system, for example, embedded within or integrally connected to a wall of a channel, or positioned separately from the fluidic system but with physical, electrical, and/or optical communication with the fluidic system so as to be able to sense and/or determine the fluidic droplet and/or a portion of the fluidic system containing the fluidic droplet (e.g., a channel or a microchannel, a liquid containing the fluidic droplet, etc.).
- a sensor may be free of any physical connection with a channel containing a droplet, but may be positioned so as to detect electromagnetic radiation arising from the droplet or the fluidic system, such as infrared, ultraviolet, or visible light.
- the electromagnetic radiation may be produced by the droplet, and/or may arise from other portions of the fluidic system (or externally of the fluidic system) and interact with the fluidic droplet and/or the portion of the fluidic system containing the fluidic droplet in such as a manner as to indicate one or more characteristics of the fluidic droplet, for example, through absorption, reflection, diffraction, refraction, fluorescence, phosphorescence, changes in polarity, phase changes, changes with respect to time, etc.
- a laser may be directed towards the fluidic droplet and/or the liquid surrounding the fluidic droplet, and the fluorescence of the fluidic droplet and/or the surrounding liquid may be determined.
- “Sensing communication,” as used herein may also be direct or indirect.
- light from the fluidic droplet may be directed to a sensor, or directed first through a fiber optic system, a waveguide, etc., before being directed to a sensor.
- Non-limiting examples of detection sensors useful in the invention include optical or electromagnetically-based systems.
- the sensor may be a fluorescence sensor (e.g., stimulated by a laser), a microscopy system (which may include a camera or other recording device), or the like.
- the sensor may be an electronic sensor, e.g., a sensor able to determine an electric field or other electrical characteristic.
- the sensor may detect capacitance, inductance, etc., of a fluidic droplet and/or the portion of the fluidic system containing the fluidic droplet.
- the sensor may be connected to a processor, which in turn, cause an operation to be performed on the fluidic droplet, for example, by sorting the droplet.
- Characteristics determinable with respect to the droplet and usable in the invention can be identified by those of ordinary skill in the art. Non-limiting examples of such characteristics include fluorescence, spectroscopy (e.g., optical, infrared, ultraviolet, etc.), radioactivity, mass, volume, density, temperature, viscosity, pH, concentration of a substance, such as a biological substance (e.g., a protein, a nucleic acid, etc.), or the like.
- a corresponding signal is then produced, for example indicating that “yes” the characteristic is present, or “no” it is not.
- the signal may correspond to a characteristic qualitatively or quantitatively. That is, the amount of the signal can be measured and can correspond to the degree to which a characteristic is present.
- the strength of the signal may indicate the size of a molecule, or the potency or amount of an enzyme expressed by a cell, or a positive or negative reaction such as binding or hybridization of one molecule to another, or a chemical reaction of a substrate catalyzed by an enzyme.
- data can be collected and/or a control system in the sorting module, if present, can be activated to divert a droplet into one branch channel or another for delivery to the collection module or waste module.
- a control system in the sorting module if present, can be activated to divert a droplet into one branch channel or another for delivery to the collection module or waste module.
- molecules or cells within a droplet at a sorting module can be sorted into an appropriate branch channel according to a signal produced by the corresponding examination at a detection module.
- the means of changing the flow path can be accomplished through mechanical, electrical, optical, or some other technique as described herein.
- a preferred detector is an optical detector, such as a microscope, which may be coupled with a computer and/or other image processing or enhancement devices to process images or information produced by the microscope using known techniques.
- molecules can be analyzed and/or sorted by size or molecular weight.
- Enzymes can be analyzed and/or sorted by the extent to which they catalyze chemical reaction of a substrate (conversely, substrate can be analyzed and/or sorted by the level of chemical reactivity catalyzed by an enzyme).
- Cells can be sorted according to whether they contain or produce a particular protein, by using an optical detector to examine each cell for an optical indication of the presence or amount of that protein.
- the protein may itself be detectable, for example by a characteristic fluorescence, or it may be labeled or associated with a reporter that produces a detectable signal when the desired protein is present, or is present in at least a threshold amount.
- a characteristic fluorescence or it may be labeled or associated with a reporter that produces a detectable signal when the desired protein is present, or is present in at least a threshold amount.
- characteristics that can be identified or measured using the techniques of the invention, which include without limitation surface characteristics of the cell and intracellular characteristics, provided only that the characteristic or characteristics of interest for sorting can be sufficiently identified and detected or measured to distinguish cells having the desired characteristic(s) from those which do not.
- any label or reporter as described herein can be used as the basis for analyzing and/or sorting molecules or cells, i.e. detecting molecules or cells to be collected.
- the biological/chemical entity to be analyzed may itself be detectable, for example by a characteristic fluorescence, or it may be labeled or associated with a reporter that produces a detectable signal when the desired protein is present, or is present in at least a threshold amount.
- Luminescent colloidal semiconductor nanocrystals called quantum dots or q-dots (QD) are inorganic fluorophores that have the potential to circumvent some of the functional limitations encountered by organic dyes.
- CdSe—ZnS core-shell QDs exhibit size-dependent tunable photoluminescence (PL) with narrow emission bandwidths (FWHM ⁇ 30 to 45 nm) that span the visible spectrum and broad absorption bands. These allow simultaneous excitation of several particle sizes (colors) at a common wavelength. This, in turn, allows simultaneous resolution of several colors using standard instrumentation.
- CdSe—ZnS QDs also have high quantum yields, are resistant to photodegradation, and can be detected optically at concentrations comparable to organic dyes.
- Quantum dots are nano-scale semiconductors typically consisting of materials such as crystalline cadmium selenide.
- the term ‘q-dot’ emphasizes the quantum confinement effect of these materials, and typically refers to fluorescent nanocrystals in the quantum confined size range.
- Quantum confinement refers to the light emission from bulk (macroscopic) semiconductors such as LEDs which results from exciting the semiconductor either electrically or by shining light on it, creating electron-hole pairs which, when they recombine, emit light. The energy, and therefore the wavelength, of the emitted light is governed by the composition of the semiconductor material.
- the physical size of the semiconductor is considerably reduced to be much smaller than the natural radius of the electron-hole pair (Bohr radius)
- additional energy is required to “confine” this excitation within the nanoscopic semiconductor structure leading to a shift in the emission to shorter wavelengths.
- Three different q-dots in several concentrations each can be placed in a microdroplet, and can then be used with a microfluidic device to decode what is in the drop.
- the Q-dot readout extension to the fluorescence station can be incorporated into the design of the microfluidic device.
- a series of dichroic beamsplitters, emission filters, and detectors can be stacked onto the system, allowing measurement of the required five emission channels (two fluorescence polarization signals and three q-dot bands).
- Fluorescence Polarization (FP) detection technology enables homogeneous assays suitable for high throughput screening assays in the Drug Discovery field.
- the most common label in the assays is fluorescein.
- FP-assay the fluorophore is excited with polarized light. Only fluorophores parallel to the light absorb and are excited. The excited state has a lifetime before the light emission occurs. During this time the labeled fluorophore molecule rotates and the polarization of the light emitted differs from the excitation plane.
- S-plane a polarized emission filter parallel to the excitation filter
- P-plane a polarized emission filter perpendicular to the excitation filter
- S and P are background subtracted fluorescence count rates and G (grating) is an instrument and assay dependent factor.
- the rotational speed of a molecule is dependent on the size of the molecule, temperature and viscosity of the solution.
- Fluorescein has a fluorescence lifetime suitable for the rotation speeds of molecules in bio-affinity assays like receptor-ligand binding assays or immunoassays of haptens.
- the basic principle is that the labeled compound is small and rotates rapidly (low polarization). When the labeled compound binds to the larger molecule, its rotation slows down considerably (polarization changes from low to high polarization).
- FP provides a direct readout of the extent of tracer binding to protein, nucleic acids, and other biopolymers.
- Fluorescence polarization technology has been used in basic research and commercial diagnostic assays for many decades, but has begun to be widely used in drug discovery only in the past six years.
- FP assays for drug discovery were developed for single-tube analytical instruments, but the technology was rapidly converted to high-throughput screening assays when commercial plate readers with equivalent sensitivity became available.
- These assays include such well-known pharmaceutical targets such as kinases, phosphatases, proteases, G-protein coupled receptors, and nuclear receptors.
- Other homogeneous technologies based on fluorescence intensity have been developed. These include energy transfer, quenching, and enhancement assays.
- FP offers several advantages over these. The assays are usually easier to construct, since the tracers do not have to respond to binding by intensity changes.
- FP is independent of intensity, it is relatively immune to colored solutions and cloudy suspensions. FP offers several advantages in the area of instrumentation. Because FP is a fundamental property of the molecule, and the reagents are stable, little or no standardization is required. FP is relatively insensitive to drift in detector gain settings and laser power.
- the dyes chosen for FP are commonly used in most cell- and enzyme-based assays and are designed not to overlap significantly with the q-dots.
- the dyes are evaluated both independently and together with the q-dots (at first off-instrument) to assess the cross-talk.
- the liquid q-dot labels are read outside a spectral wavelength band currently used in FACS analysis and sorting (i.e., the dyes flourescein, Cy3, Cy5, etc). This permits the use of currently-available assays (dependent on these dyes). Using specific q-dots, crosstalk is minimized.
- the present invention provides methods to label droplets and/or nanoreactors formed on a microfluidic device by using only a single dye code to avoid cross-talk with other dyes during FP. Additionally, the present invention provides methods to create FP dye codes to label compounds contained within liquids (including droplets and/or nanoreactors) where the compound is designed to be differentiated by FP on a microfluidic device. In this manner, dye codes having the same color, absorption, and emission could be used to label compounds within liquids.
- the present invention is directed to the use of fluorescence polarization to label liquids.
- Droplets can be labeled using several means. These labeling means include, but are not limited to, the use of different dyes, quantum dots, capacitance, opacity, light scattering, fluorescence intensity (FI), fluorescence lifetime (FL), fluorescence polarization (FP), circular dichroism (CD), fluorescence correlation and combinations of all of these previous labeling means.
- the following disclosure describes the use of FP and FI as a means to label droplets on a microfluidic device.
- FL as a means to adjust the overall FP of a solution, and by varying the concentration of the total FI, to create a 2-dimensional encoding scheme is demonstrated.
- FP is independent of the concentration of the dye; liquids can have vastly different concentrations of FITC in them yet still have identical FP measurements.
- a FP dye is an organic dye that does not interfere with the assay dye is used. Furthermore, since the total intensity of the FP dye can be quantified, a second dimension in which to label the droplet is provided. Thus, one can exploit the differences in FP to create an encoding scheme of dye within a liquid solution, including droplets. Examples of ways to exploit the differences in FP are described in WO 2007/081385 and WO 2008/063227. In a single dimension, FP can be used to create an encoding scheme. However, the present invention can also use Fluorescence Intensity (FI) of the overall solution to create even more labels in a second dimension. Interestingly, the differences of the fluorescence lifetime (FL) of two dyes with spectral overlap in the detected emission wavelength to change the overall FP of the combined solution can also be exploited.
- FI Fluorescence Intensity
- a dye can be attached to a large compound (for example streptavidin) and kept at a fixed concentration, to which a smaller compound (for example, a free dye molecule) would be titrated into the same solution.
- the FP of the solution can be adjusted to be in discernable increments from the value of the large molecule to somewhere slightly greater than the FP of the smaller molecule.
- the [total] dye intensity can be varied by varying the concentration of the mixture of the two dye-attached compounds. By varying total dye concentration and the FP, two dimensions can be used to generate the FP dye codes (FPcodes). Accordingly, many FPcodes can be generated using only two compounds.
- the present invention is directed labeling solids using properties other than dye emission and dye concentration.
- the solid can include, for example, a bead or location on a solid support or chip.
- FI and FL can be two of many dimensions of characteristics used as labels.
- a linker can be used to couple the dye to the bead.
- the linker can be varied so as to allow the dye to have differing degrees of freedom in which to rotate (i.e., tumble). Varying the linker in this manner can change the FP of the attached dye, which in unique combinations can be used as a label.
- the beads can be swollen in organic solvent and the dyes held in place by hydrophobic forces.
- the FP, FI, FL methods described above for liquid labeling can also be used as a means for labeling the beads.
- a quenching molecule can also be used to change the characteristics of a dye.
- Such quenching can be continuous or brought about through the interaction of a molecule, such as a peptide or nucleic acid linker, with differing means of bringing molecules together depending on the strength of linker-internal interaction (e.g., a nucleotide stem loop structure of varying lengths).
- a molecule such as a peptide or nucleic acid linker
- the reactions analyzed on the virtual, random and non-random arrays can be also increased beyond the two (cy3 and cy5 intensities) commonly used for multiplexing.
- different FP, FI, etc can be used as a read-out.
- Random array decoding Beads of the prior art use one or more pre-attached oligonucleotide-coupled beads that are held in place in a fiber-optic faceplate (for example, those used by Illiumina). The oligos on the beads are decoded using sequential hybridization of a labeled complementary oligo.
- the assay of the prior art uses a separate oligonucleotide complementary zipcode (‘Illumacode’) attached to each type of bead.
- the invention described herein is superior to the methods of the prior art in that the FP, FI, FL-labeled bead or mobile solid support can be placed into a random array (e.g., a chip as manufactured by Illumina) and the FP, FI, FL used to decode the bead.
- the FP, FI, FL of the bead can be decoded before using the chip and the different beads ‘mapped’ as to their specific locations.
- the bead can be decoded during attachment of the assay read-out.
- the methods described by the present invention can be used to pre-determine the location of each bead-type either before, or during analysis.
- Virtual array decoding Methods of the prior art use 2 lasers and 3 detectors to differentiate a set of 100 bead-types.
- the beads-types are differentiated by the FI of two different dyes present in 1 of 10 concentrations (per dye) contained within the bead, and the assay detector is used to measure fluorescein concentration on the bead.
- the dyes which are added to organic-solvent swollen beads, are not directly attached to the beads, but remain held within the bead by hydrophobic forces.
- a second detector to the machines of the prior art used to measure FP can be added, thereby adding a third dimension and extending the encoding scheme beyond the 100 available in the prior art.
- Non-random array decoding In chips of the prior art (such as those used by Affymetrix) oligonucleotides are synthesized directly on the chip. Decoding is simply a matter of knowing the location of the assay on the chip.
- the methods as described herein can be advantageously used in conjunction with such chips to increase the number of things that can be simultaneously analyzed (i.e., multiplexed) on the chip.
- Cy3, Cy5, FL and FP can be used as analysis markers for hybridization reactions.
- the present invention also provides methods for labeling micro or nano-sized droplets using Radio Frequency Identification (RFID).
- RFID tags can improve the identification of the contents within the droplets.
- the droplets are utilized within a microfluidic device.
- RFID is an automatic identification method, relying on storing and remotely retrieving data using devices called RFID tags or transponders.
- An RFID tag is an object that can be attached to or incorporated into a product, animal, or person for the purpose of identification using radio waves.
- Chip-based RFID tags contain silicon chips and antennae. Passive tags require no internal power source, whereas active tags require a power source.
- Hitachi has “powder” 0.05 mm ⁇ 0.05 mm RFID chips. The new chips are 64 times smaller than the previous record holder, the 0.4 mm ⁇ 0.4 mm mu-chips, and nine times smaller than Hitachi's last year prototype, and have room for a 128-bit ROM that can store a unique 38-digit ID number.
- a solution containing RFID tags are emulsified into droplets and are used as a label for the identification of the material within the droplet solution.
- Applications include, but are not limited to; genetics, genomics, proteomics, chemical synthesis, biofuels, and others.
- the detection module may include an apparatus for stimulating a reporter for that characteristic to emit measurable light energy, e.g., a light source such as a laser, laser diode, light emitting diode (LED), high-intensity lamp, (e.g., mercury lamp), and the like.
- a lamp e.g., the channels are preferably shielded from light in all regions except the detection module.
- the laser can be set to scan across a set of detection modules from different analysis units.
- laser diodes or LED's may be microfabricated into the same chip that contains the analysis units.
- laser diodes or LED's may be incorporated into a second chip (i.e., a laser diode chip) that is placed adjacent to the analysis or microchip such that the laser light from the diodes shines on the detection module(s).
- An integrated semiconductor laser and/or an integrated photodiode detector can be included on the substrate in the vicinity of the detection module. This design provides the advantages of compactness and a shorter optical path for exciting and/or emitted radiation, thus minimizing distortion and losses.
- Fluorescence produced by a reporter is excited using a laser beam focused on molecules (e.g., DNA, protein, enzyme or substrate) or cells passing through a detection region.
- Fluorescent reporters can include, but are not limited to, rhodamine, fluorescein, Texas red, Cy 3, Cy 5, phycobiliprotein (e.g., phycoerythrin), green fluorescent protein (GFP), YOYO-1 and PicoGreen.
- the reporter labels can be fluorescently labeled single nucleotides, such as fluorescein-dNTP, rhodamine-dNTP, Cy3-dNTP, etc.; where dNTP represents dATP, dTTP, dUTP or dCTP.
- the reporter can also be chemically-modified single nucleotides, such as biotin-dNTP.
- the reporter can be fluorescently or chemically labeled amino acids or antibodies (which bind to a particular antigen, or fragment thereof, when expressed or displayed by a cell or virus).
- the device can analyze and/or sort cells based on the level of expression of selected cell markers, such as cell surface markers, which have a detectable reporter bound thereto, in a manner similar to that currently employed using fluorescence-activated cell sorting (FACS) machines. Proteins or other characteristics within a cell, and which do not necessarily appear on the cell surface, can also be identified and used as a basis for sorting.
- the device can also determine the size or molecular weight of molecules such as polynucleotides or polypeptides (including enzymes and other proteins) or fragments thereof passing through the detection module. Alternatively, the device can determine the presence or degree of some other characteristic indicated by a reporter. If desired, the cells, particles or molecules can be sorted based on this analysis.
- the sorted cells, particles or molecules can be collected from the outlet channels in collection modules (or discarded in wasted modules) and used as needed.
- the collected cells, particles or molecules can be removed from the device or reintroduced to the device for additional coalescence, analysis and sorting.
- a “processor” or a “microprocessor” is any component or device able to receive a signal from one or more sensors, store the signal, and/or direct one or more responses (e.g., as described above), for example, by using a mathematical formula or an electronic or computational circuit.
- the signal may be any suitable signal indicative of the environmental factor determined by the sensor, for example a pneumatic signal, an electronic signal, an optical signal, a mechanical signal, etc.
- the device of the present invention can comprise features, such as integrated metal alloy components and/or features patterned in an electrically conductive layer, for detecting droplets by broadcasting a signal around a droplet and picking up an electrical signal in proximity to the droplet.
- the device of the present invention also comprises the use of beads and methods for analyzing and sorting beads (i.e., bead reader device).
- the device can read and either sort or not sort droplets containing one or more of a set of two or more beads. Each bead can be differentiated from each other bead within a set. Beads can be separated by several tags including, but not limited to, quantum dyes, fluorescent dyes, ratios of fluorescent dyes, radioactivity, radio-tags, etc.
- a set of beads containing a ratio of two dyes in discrete amounts with an apparatus for detecting and differentiating beads containing one discrete ratio from the other beads in this set having a different ratio of the two dyes.
- the microfluidic device can include paramagnetic beads. The paramagnetic beads can introduce and remove chemical components from droplets using droplet coalescence and breakup events. The paramagnetic beads can also be used for sorting droplets.
- the present invention provides methods of screening molecular libraries on beads through limited-dilution-loading and then chemical or optical release inside of droplets.
- a releasing means chemical, UV light, heat, etc
- tea-bag synthesis of chemicals on a bead simultaneously with a means for identifying said bead (using, for example, a mass spec tag).
- a means for identifying said bead using, for example, a mass spec tag.
- the device of the present invention can comprise column separation prior to bead sorting.
- Such separating means could include size, charge, hydrophobicity, atomic mass, etc.
- the separating can be done isocratic or by use of a means for generating a gradient chemically, (for example using salt or hydrophobicity), electrically, by pressure, or etc.
- a channel is preloaded with Sepharose size exclusion media.
- a sample is loaded at one end, and the droplets are formed at an opposing end. The sample separates by size prior to becoming incorporated within a droplet.
- the microfluidic device of the present invention can further include one or more sorting modules.
- a “sorting module” is a junction of a channel where the flow of molecules, cells, small molecules or particles can change direction to enter one or more other channels, e.g., a branch channel for delivery to an outlet module (i.e., collection or waste module), depending on a signal received in connection with an examination in the detection module.
- a sorting module is monitored and/or under the control of a detection module, and therefore a sorting module may “correspond” to such detection module.
- the sorting region is in communication with and is influenced by one or more sorting apparatuses.
- a sorting apparatus comprises techniques or control systems, e.g., dielectric, electric, electro-osmotic, (micro-) valve, etc.
- a control system can employ a variety of sorting techniques to change or direct the flow of molecules, cells, small molecules or particles into a predetermined branch channel.
- a “branch channel” is a channel which is in communication with a sorting region and a main channel. The main channel can communicate with two or more branch channels at the sorting module or “branch point”, forming, for example, a T-shape or a Y-shape. Other shapes and channel geometries may be used as desired.
- a branch channel receives molecules, cells, small molecules or particles depending on the molecule, cells, small molecules or particles characteristic of interest as detected by the detection module and sorted at the sorting module.
- a branch channel can have an outlet module and/or terminate with a well or reservoir to allow collection or disposal (collection module or waste module, respectively) of the molecules, cells, small molecules or particles.
- a branch channel may be in communication with other channels to permit additional sorting.
- the device of the present invention can further include one or more outlet modules.
- An “outlet module” is an area of the device that collects or dispenses molecules, cells, small molecules or particles after coalescence, detection and/or sorting.
- the outlet module can include a collection module and/or a waste module.
- the collection module can be connected to a means for storing a sample.
- the collection module can be a well or reservoir for collecting and containing droplets detected to have a specific predetermined characteristic in the detection module.
- the collection module can be temperature controlled.
- the waste module can be connected to a means for discarding a sample.
- the waste module can be a well or reservoir for collecting and containing droplets detected to not have a specific predetermined characteristic in the detection module.
- the outlet module is downstream from a sorting module, if present, or downstream from the detection module if a sorting module is not present.
- the outlet module may contain branch channels or outlet channels for connection to a collection module or waste module.
- a device can contain more than one outlet module.
- a characteristic of a fluidic droplet may be sensed and/or determined in some fashion, for example, as described herein (e.g., fluorescence of the fluidic droplet may be determined), and, in response, an electric field may be applied or removed from the fluidic droplet to direct the fluidic droplet to a particular region (e.g. a channel).
- a fluidic droplet is preferably sorted or steered by inducing a dipole in the uncharged fluidic droplet (which may be initially charged or uncharged), and sorting or steering the droplet using an applied electric field.
- the electric field may be an AC field, a DC field, etc.
- Methods of sorting or steering droplets in an electric field are as described in WO 2006/040551; WO 2006/040554; WO 2004/002627; WO 2004/091763; WO 2005/021151; WO 2006/096571; WO 2007/089541; WO 2007/081385 and WO 2008/063227. Improvements in the efficiency, accuracy, and reliability of the preferred dielectric droplet sorting technique described above are possibly by utilizing additional channel and electrode geometries, as described in WO 2007/081385 and WO 2008/063227.
- a fluidic droplet may be directed by creating an electric charge (e.g., as previously described) on the droplet, and steering the droplet using an applied electric field, which may be an AC field, a DC field, etc.
- an electric field maybe selectively applied and removed (or a different electric field may be applied) as needed to direct the fluidic droplet to a particular region.
- the electric field may be selectively applied and removed as needed, in some embodiments, without substantially altering the flow of the liquid containing the fluidic droplet.
- a liquid may flow on a substantially steady-state basis (i.e., the average flowrate of the liquid containing the fluidic droplet deviates by less than 20% or less than 15% of the steady-state flow or the expected value of the flow of liquid with respect to time, and in some cases, the average flowrate may deviate less than 10% or less than 5%) or other predetermined basis through a fluidic system of the invention (e.g., through a channel or a microchannel), and fluidic droplets contained within the liquid may be directed to various regions, e.g., using an electric field, without substantially altering the flow of the liquid through the fluidic system.
- a substantially steady-state basis i.e., the average flowrate of the liquid containing the fluidic droplet deviates by less than 20% or less than 15% of the steady-state flow or the expected value of the flow of liquid with respect to time, and in some cases, the average flowrate may deviate less than 10% or less than 5%
- a fluidic system of the invention e.g.
- the fluidic droplets may be sorted into more than two channels. Alternately, a fluidic droplet may be sorted and/or split into two or more separate droplets, for example, depending on the particular application. Any of the above-described techniques may be used to spilt and/or sort droplets.
- a fluidic droplet may be directed to a first region or channel; by applying (or removing) a second electric field to the device (or a portion thereof), the droplet may be directed to a second region or channel; by applying a third electric field to the device (or a portion thereof), the droplet may be directed to a third region or channel; etc., where the electric fields may differ in some way, for example, in intensity, direction, frequency, duration, etc.
- each droplet may be independently sorted and/or split; for example, some droplets may be directed to one location or another, while other droplets may be split into multiple droplets directed to two or more locations.
- At least about 1 droplet per second may be determined and/or sorted in some cases, and in other cases, at least about 10 droplets per second, at least about 20 droplets per second, at least about 30 droplets per second, at least about 100 droplets per second, at least about 200 droplets per second, at least about 300 droplets per second, at least about 500 droplets per second, at least about 750 droplets per second, at least about 1000 droplets per second, at least about 1500 droplets per second, at least about 2000 droplets per second, at least about 3000 droplets per second, at least about 5000 droplets per second, at least about 7500 droplets per second, at least about 10,000 droplets per second, at least about 15,000 droplets per second, at least about 20,000 droplets per second, at least about 30,000 droplets per second, at least about 50,000 droplets per second, at least about 75,000 droplets per second, at least about 100,000 droplets per second, at least about 150,000 droplets per second,
- the present invention proposes methods for recovering aqueous phase components from aqueous emulsions that have been collected on a microfluidic device in a minimum number of steps and in a gentle manner so as to minimize potential damage to cell viability.
- a stable aqueous sample droplet emulsion containing aqueous phase components in a continuous phase carrier fluid is allowed to cream to the top of the continuous phase carrier oil.
- the continuous phase carrier fluid can include a perfluorocarbon oil that can have one or more stabilizing surfactants.
- the aqueous emulsion rises to the top or separates from the continuous phase carrier fluid by virtue of the density of the continuous phase fluid being greater than that of the aqueous phase emulsion.
- the perfluorocarbon oil used in one embodiment of the device is 1.8, compared to the density of the aqueous emulsion, which is 1.0.
- the creamed emulsion is then placed onto a second continuous phase carrier fluid which contains a de-stabilizing surfactant, such as a perfluorinated alcohol (e.g., 1H,1H,2H,2H-Perfluoro-1-octanol).
- a de-stabilizing surfactant such as a perfluorinated alcohol (e.g., 1H,1H,2H,2H-Perfluoro-1-octanol).
- the second continuous phase carrier fluid can also be a perfluorocarbon oil.
- Additional destabilizing surfactants and/or oil combinations can be identified or synthesized to be useful with this invention.
- microfluidic devices of the present invention can further include one or more mixing modules, one or more delay modules, one or more acoustic actuators and/or UV-release modules, as described in WO 2007/081385 and WO 2008/063227.
- the droplet generation rate, spacing and size of the water droplets made on a microfluidic device are tuned to the desired size, such as picoliter to nanoliter volumes.
- droplet libraries of the present invention can be introduced back onto a medium for additional processing.
- Multicomponent droplets can easily be generated by bringing together streams of materials at the point where droplets are made (co-flow).
- An electric field is then used to induce dipoles in the droplet pairs, forcing them to combine into a single droplet and permitting them to intermix the contents.
- Optics for fluorescence detection capable of measuring fluorophores within the aqueous droplets, while simultaneously permitting visual monitoring via a high speed video microscope.
- three separate lasers provide excitation at 405 nm, 488 nm, and 561 nm wavelengths focused to a spot approximately 17 microns in diameter, illuminating each droplet as it enters the detection zone.
- the system is configured to detect emitted light using a series of photomultiplier tubes, and is able to detect less than 10,000 FITC molecule equivalents at a 5 kHz droplet rate.
- a critical component for isolating sub-populations or rare cells from a heterogeneous cell mixture is a fluorescence-activated microfluidic droplet sorter as described in greater detail herein. Sorting in microfluidic devices can be done using a dielectrophoretic force on neutral droplets. Providing an alternate means that can be precisely controlled, can be switched at high frequencies, and requires no moving parts. After the contents of individual droplets are probed in the fluorescence detection zone, selected droplets can be sorted into discreet streams for recovery and further processing.
- a key feature for improving genomic characterization of the heterogeneous mixture of cell types present in a typical tissue or biopsy would be the ability to fractionate the initial cell population into sub-populations, permitting analysis of rare cells and enabling molecular correlation studies.
- the microfluidic device provides the ability to sort cell-containing droplets based on fluorescent signals.
- a number of immediate uses for this capability include: 1) sorting cell-containing droplets away from empty droplets; 2) sorting sub-populations based on specific nucleic acid hybridization; 3) sorting sub-populations based on cell surface binding properties; 4) sorting sub-populations based on secreted activities or reporter enzyme products.
- a number of these approaches have already been tested in preliminary experiments, using either bacterial or mammalian cells.
- Sort-on-Generation is a combination of modules that generates single cell containing-droplets (along with approximately 10 times more empty droplets, from Poisson distribution as described herein and subsequently sorts the cell-containing droplets away from the empty droplets, based on fluorescent signals.
- Determining the volume of an individual drop from a 2-D image in a microfluidic channel can be accomplished relatively easily with tools typically associated with microfluidics.
- the basic equipment needed are; simple optics with a camera, a fluorescent laser detector, a microfluidic device, and pumps.
- a 10 pt calibration is done by plotting the average projected area vs. the average volume of a drop.
- the average projected area is determined by real-time image analysis of droplets during emulsion generation in a specific region of the chip. This region is clearly marked and called the calibration region.
- Calibration is accomplished by simultaneously logging the projected area of individual droplets for 60 s and calculating the average, and using a laser is to count the total number of droplets that pass through the channel at the calibration region. From this count, one can determine the average frequency and the average volume of a droplet.
- V _ F Buffer ⁇ [ uL hr ] * 10 6 ⁇ [ pL uL ] f ⁇ [ Drops s ] * 3600 ⁇ [ s hr ]
- the microfluidic device of the present invention can be utilized to conduct numerous chemical and biological assays, including but not limited to, creating emulsion libraries, flow cytometry, gene amplification, isothermal gene amplification, DNA sequencing, SNP analysis, drug screening, RNAi analysis, karyotyping, creating microbial strains with improved biomass conversion, moving cells using optical tweezer/cell trapping, transformation of cells by electroporation, ⁇ TAS, and DNA hybridization.
- chemical and biological assays including but not limited to, creating emulsion libraries, flow cytometry, gene amplification, isothermal gene amplification, DNA sequencing, SNP analysis, drug screening, RNAi analysis, karyotyping, creating microbial strains with improved biomass conversion, moving cells using optical tweezer/cell trapping, transformation of cells by electroporation, ⁇ TAS, and DNA hybridization.
- An emulsion library comprising at least a first aqueous droplet and at least a second aqueous droplet within a fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and wherein at least first droplet comprises at least a first pair or oligonucleotides and the at least second droplet comprises at least a second pair or oligonucleotides, wherein the first and second pair of oligonucleotides is different.
- the oligonucleotide is DNA; in another embodiment, the oligonucleotide is RNA. In a further embodiment, the oligonucleotide has at least 5 nucleotides, e.g., 5 to 100, 10 to 90, 12 to 80, 14 to 70, 15 to 60, 15 to 50, 15 to 40, 15 to 35, 15 to 30, 15 to 28, 15 to 25, 15 to 23, and 15 to 20 nucleotides. In one embodiment, the two oligonucleotides in the pair of oligonucleotides have the same number of nucleotides; in another embodiment, the two oligonucleotides in the pair of oligonucleotides have different number of nucleotides.
- the present invention provides a method for amplifying a genomic DNA, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising at least a first aqueous droplet and at least a second aqueous droplet within a fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and wherein at least first droplet comprises at least a first pair or oligonucleotides and the at least second droplet comprises at least a second pair or oligonucleotides, wherein the first and second pair of oligonucleotides is different; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets comprising said genomic DNA within an immiscible fluorocarbon oil comprising at least one fluorosurfactant; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed
- a unique feature of the described droplet-based microfluidic approach for working with nucleic acids is that it uses immiscible oil-encapsulated aqueous droplets to shield the DNA from the inner surfaces of the microfluidic chip, with a surfactant interface separating the aqueous droplet and its contents from the surrounding immiscible fluorocarbon oil. Therefore, DNA amplification reactions occurring inside these droplets generate material that does not interact with the channel walls, and collection of the DNA-containing droplets for subsequent manipulation and sequencing is straightforward.
- This technology provides a solution for amplification of DNA from single cells, allowing for both genotyping and whole genome amplification.
- PCR in droplets generated on the microfluidic device either by performing PCR on-chip (with droplets moving through a serpentine channel across several different temperatures under microfluidic control), or by placing the collected droplets into a standard thermocycler.
- Droplets generated containing DNA and reagents required for PCR-based amplification have been demonstrated to be extremely robust, showing high stability for both on-chip and off-chip (standard thermocycler) amplification.
- a microfluidic device as described herein fuses droplets with individual primer pairs for PCR amplification and preparation of many exons in parallel for high throughput re-sequencing.
- the present invention provides a method for performing an ELISA assay, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first antibody, and a single element linked to at least a second antibody, wherein said first and second antibodies are different; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising a test fluid; (c) providing a third sample fluid wherein said third sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one enzyme; (d) providing a fourth sample fluid wherein said fourth
- the present invention also provides a method for performing an ELISA assay, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first element linked to at least a first antibody, and at least a second element linked to at least a second antibody, wherein said first and second antibodies are different; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising a test fluid (c) providing a third sample fluid wherein said third sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one substrate; (d)
- ELISA assays Small sample volumes are needed in performing immunoassays.
- Non-limiting examples include cases where the sample is precious or limited, i.e., serum archives, tissue banks, and tumor biopsies. Immunoassays would ideally be run in droplets where only 10 to 100 pL of sample were consumed for each assay. Specifically, the lack of a robust convenient wash step has prevented the development of ELISA assays in droplets.
- the present invention provides for methods in which beads can be used to perform ELISA assays in aqueous droplets within channels on a microfluidic device. The advantage of utilizing microfluidic devices is it greatly reduces the size of the sample volume needed. Moreover, a benefit of droplet based microfluidic methods is the ability to run numerous assays in parallel and in separate micro-compartments.
- amplification methods include enzyme amplification and rolling circle amplification of signal that uses a nucleic-acid intermediate.
- a non-enzymatic means for signal amplification can also be used.
- the present invention provides a method for generating an enzyme library, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one cell transformed with at least one nucleic acid molecule encoding for an enzyme, wherein said cells replicate within said droplets thereby secreting produced enzymes within the droplets; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one substrate; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (d) flowing the first sample fluid through a first inlet channel which is in fluid communication
- microfluidic system to emulsify a library of 3-5 bacteria strains that encode a single protease with a known range of activity against a designated substrate in microdroplets, and sort via a fluorescence assay to demonstrate the ability to identify and sort one of the cell strains that expresses a protease that is more active against a specified substrate than the other strains.
- a microfluidic system to emulsify a library of mutagenized bacteria cells in microdroplets, identify and sort via a fluorescence assay a subpopulation of cells to produce a 10 4 fold enrichment of cells expressing a designated enzyme variant, and recover viable cells and enriched library.
- the present invention provides a method for sorting a plurality of cells, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one cell labeled with an enzyme; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one substrate; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (d) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a first fluidic nozzle designed for flow focusing such that said
- WGA Whole Genome Amplification
- DOP-PCR degenerate oligonucleotide primed PCR
- PEP-PCR primer extension pre-amplification
- MDA multiple displacement amplification
- Non-specific DNA synthesis due to contaminating DNA and non-template amplification are characteristic problems associated with WGA.
- NTA non-template amplification
- Recent evidence demonstrates that NTA and also amplification bias are reduced when using very small reaction volumes, with one group using 60 nanoliter microfluidic chambers for single cell WGA reactions. Based on these findings, the use of picoliter-volume droplets in a microfluidic system reduces NTA even further.
- amplification from contaminating DNA templates will be constrained to individual compartments (droplets), minimizing the overwhelming effects of contamination in bulk WGA reactions.
- Next generation sequencing instruments offer two distinct advantages in the pursuit of microbiome characterization. First, they do not require conventional clone-based approaches to DNA sequencing, and thus ensure that the commonly experienced biasing against specific sequences in the E. coli host system does not impact the representation of genomes being sequenced. Second, they offer a streamlined and robust workflow for preparing DNA for sequencing that has far fewer steps than conventional workflows. Hence, a library can be prepared for sequencing in about 2 days.
- the Roche/454 FLX pyrosequencer was the first “next generation”, massively parallel sequencer to achieve commercial introduction (in 2004) and uses a sequencing reaction type known as “pyrosequencing” to read out nucleotide sequences.
- each incorporation of a nucleotide by DNA polymerase results in the release of pyrophosphate, which initiates a series of downstream reactions that ultimately produce light by the firefly enzyme luciferase.
- the light amount produced is proportional to the number of nucleotides incorporated (up to the point of detector saturation).
- the DNA fragments to be sequenced first have specific A and B adapter oligos ligated to their ends, and then are mixed with a population of agarose beads whose surfaces carry oligonucleotides complementary to 454-specific adapter sequences on the DNA fragments, such that each bead is associated with a single DNA fragment.
- the PTP acts as a flow cell, into which each pure nucleotide solution is introduced in a stepwise fashion, with an imaging step after each nucleotide incorporation step. Because the PTP is seated opposite a CCD camera, the light emitted at each bead that is being actively sequenced is recorded.
- the first four nucleotides (TCGA) on the adapter fragment adjacent to the sequencing primer added in library construction are first to be sequenced, and this sequence corresponds to the sequential flow of nucleotides into the flow cell.
- This strategy allows the 454 base calling software to calibrate the light emitted by a single nucleotide incorporation, which then enables the software to call novel bases downstream according to the light emission levels.
- the present invention provides a method for screening for an enzyme inhibitor, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one compound; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one enzyme and substrate; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (d) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a first fluidic nozzle designed for flow focusing such that said first sample fluid forms a pluralit
- the present invention provides compositions and methods for generating, manipulating, and analyzing aqueous droplets of precisely defined size and composition. These microfluidic device-generated droplets can encapsulate a wide variety of components, including those that are used in enzymatic assays.
- Kinases are a therapeutically important class of enzymes, and this collaboration examines the feasibility of performing analysis and interrogation of kinases with potentially inhibitory compounds using the described microfluidic platform and systems.
- the present invention provides a method for screening for a live cell, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one cell; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one cell-membrane-permeable fluorescent dye and at least one cell-membrane-impermeable fluorescent dye; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (d) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction,
- Microfluidic technologies have the potential to enhance the precision and throughput of these single-cell assays by integrating and automating the cell handling, processing, and analysis steps.
- major limitations in microfluidic systems hinder the development of high-throughput screening platforms.
- One challenge is to achieve sufficiently short mixing times. Mixing under the laminar flow conditions typically found in microfluidic devices occurs by diffusion, a relatively slow process for biological material and biochemical reactants.
- the confinement of reagents in droplets in an immiscible carrier fluid overcomes these limitations.
- the droplet technology is an essential enabling technology for a high-throughput microfluidic screening platform.
- Droplet isolation allows the cells to be exposed to discrete concentrations of chemicals or factors.
- the droplet format ensures that the sample materials never touch the walls of the microfluidic channels and thus eliminates the risk of contamination.
- the reagents can be mixed within a droplet and sample dispersion is simultaneously minimized.
- the advantages of this technique include the physical and chemical isolation of droplets from one another and the ability to digitally manipulate these droplets at very high-throughput. Finally, the absence of any moving parts and in particular valves brings the degree of robustness required for screening applications.
- Possible cell applications include screen for combinatorial cell assays, cloning, FACS-like assays, and polymer encapsulation for cell-based therapies. As a small number of cells are consumed per sample, this technology is particularly suitable for working with cells of limited availability, like primary cells. In addition, for rare cell sorting, the dilution factor in the collection droplets can be orders of magnitude smaller than for a standard bench-scale flow cytometer. Finally, the use of fluorocarbons that can dissolve large amount of oxygen as carrier fluids is regarded as a key feature for long-term survival of encapsulated cells.
- Droplets can be fused or coalesced, their content mixed, incubated on-chip, and their incubation time tuned with an oil-extractor, their fluorescent content can be interrogated, and finally they can be sorted.
- Example 9 illustrates some examples of live-dead assays.
- the device has been designed to sequentially accomplish six different functions.
- encapsulated cells can be collected into a syringe and re-inject the emulsion for on-chip scoring.
- kits also typically include instructions for carrying out the subject assay, and may optionally include the fluid receptacle, e.g., the cuvette, multiwell plate, microfluidic device, etc. in which the reaction is to be carried out.
- the fluid receptacle e.g., the cuvette, multiwell plate, microfluidic device, etc. in which the reaction is to be carried out.
- reagents included within the kit are uniquely labeled emulsions containing tissues, cells, particles, proteins, antibodies, amino acids, nucleotides, small molecules, substrates, and/or pharmaceuticals.
- These reagents may be provided in pre-measured container (e.g., vials or ampoules) which are co-packaged in a single box, pouch or the like that is ready for use.
- the container holding the reagents can be configured so as to readily attach to the fluid receptacle of the device in which the reaction is to be carried out (e.g., the inlet module of the microfluidic device as described herein).
- the kit can include an RNAi kit.
- the kit can include a chemical synthesis kit. It will be appreciated by persons of ordinary skill in the art that these embodiments are merely illustrative and that other kits are also within the scope of the present invention.
- “about” or “approximately” shall generally mean within 20 percent, preferably within 10 percent, and more preferably within 5 percent of a given value or range.
- molecule means any distinct or distinguishable structural unit of matter comprising one or more atoms, and includes for example polypeptides and polynucleotides.
- polymer means any substance or compound that is composed of two or more building blocks (‘mers’) that are repetitively linked to each other.
- a “dimer” is a compound in which two building blocks have been joined together.
- polynucleotide refers to a polymeric molecule having a backbone that supports bases capable of hydrogen bonding to typical polynucleotides, where the polymer backbone presents the bases in a manner to permit such hydrogen bonding in a sequence specific fashion between the polymeric molecule and a typical polynucleotide (e.g., single-stranded DNA).
- bases are typically inosine, adenosine, guanosine, cytosine, uracil and thymidine.
- Polymeric molecules include double and single stranded RNA and DNA, and backbone modifications thereof, for example, methylphosphonate linkages.
- nucleotide sequence is a series of nucleotide bases (also called “nucleotides”) generally in DNA and RNA, and means any chain of two or more nucleotides.
- a nucleotide sequence typically carries genetic information, including the information used by cellular machinery to make proteins and enzymes. These terms include double or single stranded genomic and cDNA, RNA, any synthetic and genetically manipulated polynucleotide, and both sense and anti-sense polynucleotide (although only sense stands are being represented herein).
- PNA protein nucleic acids
- the polynucleotides herein may be flanked by natural regulatory sequences, or may be associated with heterologous sequences, including promoters, enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5′- and 3′-non-coding regions, and the like.
- the nucleic acids may also be modified by many means known in the art.
- Non-limiting examples of such modifications include methylation, “caps”, substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.).
- uncharged linkages e.g., methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.
- charged linkages e.g., phosphorothioates, phosphorodithioates, etc.
- Polynucleotides may contain one or more additional covalently linked moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive metals, iron, oxidative metals, etc.), and alkylators.
- the polynucleotides may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoramidate linkage.
- the polynucleotides herein may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.
- dielectrophoretic force gradient means a dielectrophoretic force is exerted on an object in an electric field provided that the object has a different dielectric constant than the surrounding media. This force can either pull the object into the region of larger field or push it out of the region of larger field. The force is attractive or repulsive depending respectively on whether the object or the surrounding media has the larger dielectric constant.
- DNA deoxyribonucleic acid
- DNA means any chain or sequence of the chemical building blocks adenine (A), guanine (G), cytosine (C) and thymine (T), called nucleotide bases, that are linked together on a deoxyribose sugar backbone.
- DNA can have one strand of nucleotide bases, or two complimentary strands which may form a double helix structure.
- RNA ribonucleic acid
- RNA ribonucleic acid
- RNA typically has one strand of nucleotide bases.
- a “polypeptide” (one or more peptides) is a chain of chemical building blocks called amino acids that are linked together by chemical bonds called peptide bonds.
- a “protein” is a polypeptide produced by a living organism.
- a protein or polypeptide may be “native” or “wild-type”, meaning that it occurs in nature; or it may be a “mutant”, “variant” or “modified”, meaning that it has been made, altered, derived, or is in some way different or changed from a native protein, or from another mutant.
- an “enzyme” is a polypeptide molecule, usually a protein produced by a living organism, that catalyzes chemical reactions of other substances. The enzyme is not itself altered or destroyed upon completion of the reaction, and can therefore be used repeatedly to catalyze reactions.
- a “substrate” refers to any substance upon which an enzyme acts.
- particles means any substance that may be encapsulated within a droplet for analysis, reaction, sorting, or any operation according to the invention.
- Particles are not only objects such as microscopic beads (e.g., chromatographic and fluorescent beads), latex, glass, silica or paramagnetic beads, but also includes other encapsulating porous and/or biomaterials such as liposomes, vesicles and other emulsions. Beads ranging in size from 0.1 micron to 1 mm can be used in the devices and methods of the invention and are therefore encompassed with the term “particle” as used herein.
- the term particle also encompasses biological cells, as well as beads and other microscopic objects of similar size (e.g., from about 0.1 to 120 microns, and typically from about 1 to 50 microns) or smaller (e.g., from about 0.1 to 150 nm).
- the devices and methods of the invention are also directed to sorting and/or analyzing molecules of any kind, including polynucleotides, polypeptides and proteins (including enzymes) and their substrates and small molecules (organic or inorganic).
- the term particle further encompasses these materials.
- the particles are sorted and/or analyzed by encapsulating the particles into individual droplets (e.g., droplets of aqueous solution in oil), and these droplets are then sorted, combined and/or analyzed in a microfabricated device.
- droplets generally includes anything that is or can be contained within a droplet.
- a “small molecule” or “small molecule chemical compound” as used herein, is meant to refer to a composition that has a molecular weight of less than 500 Daltons. Small molecules are distinguished from polynucleotides, polypeptides, carbohydrates and lipids.
- cell means any cell or cells, as well as viruses or any other particles having a microscopic size, e.g. a size that is similar to or smaller than that of a biological cell, and includes any prokaryotic or eukaryotic cell, e.g., bacteria, fungi, plant and animal cells.
- Cells are typically spherical, but can also be elongated, flattened, deformable and asymmetrical, i.e., non-spherical.
- the size or diameter of a cell typically ranges from about 0.1 to 120 microns, and typically is from about 1 to 50 microns.
- a cell may be living or dead.
- the microfabricated device of the invention is directed to sorting materials having a size similar to a biological cell (e.g. about 0.1 to 120 microns) or smaller (e.g., about 0.1 to 150 nm) any material having a size similar to or smaller than a biological cell can be characterized and sorted using the microfabricated device of the invention.
- the term cell shall further include microscopic beads (such as chromatographic and fluorescent beads), liposomes, emulsions, or any other encapsulating biomaterials and porous materials.
- Non-limiting examples include latex, glass, or paramagnetic beads; and vesicles such as emulsions and liposomes, and other porous materials such as silica beads.
- Beads ranging in size from 0.1 micron to 1 mm can also be used, for example in sorting a library of compounds produced by combinatorial chemistry.
- a cell may be charged or uncharged.
- charged beads may be used to facilitate flow or detection, or as a reporter.
- Biological cells, living or dead may be charged for example by using a surfactant, such as SDS (sodium dodecyl sulfate).
- SDS sodium dodecyl sulfate
- the term cell further encompasses “virions”, whether or not virions are expressly mentioned.
- a “virion”, “virus particle” is the complete particle of a virus.
- Viruses typically comprise a nucleic acid core (comprising DNA or RNA) and, in certain viruses, a protein coat or “capsid”. Certain viruses may have an outer protein covering called an “envelope”.
- a virion may be either living (i.e., “viable”) or dead (i.e., “non-viable”).
- a living or “viable” virus is one capable of infecting a living cell.
- Viruses are generally smaller than biological cells and typically range in size from about 20-25 nm diameter or less (parvoviridae, picornoviridae) to approximately 200-450 nm (poxyiridae).
- filamentous viruses may reach lengths of 2000 nm (closterviruses) and are therefore larger than some bacterial cells.
- the microfabricated device of the invention is particularly suited for sorting materials having a size similar to a virus (i.e., about 0.1 to 150 nm)
- any material having a size similar to a virion can be characterized and sorted using the microfabricated device of the invention.
- Non-limiting examples include latex, glass or paramagnetic beads; vesicles such as emulsions and liposomes; and other porous materials such as silica beads. Beads ranging in size from 0.1 to 150 nm can also be used, for example, in sorting a library of compounds produced by combinatorial chemistry.
- a virion may be charged or uncharged.
- charged beads may be used to facilitate flow or detection, or as a reporter.
- Biological viruses whether viable or non-viable, may be charged, for example, by using a surfactant, such as SDS.
- a “reporter” is any molecule, or a portion thereof that is detectable, or measurable, for example, by optical detection.
- the reporter associates with a molecule, cell or virion or with a particular marker or characteristic of the molecule, cell or virion, or is itself detectable to permit identification of the molecule, cell or virion's, or the presence or absence of a characteristic of the molecule, cell or virion.
- characteristics include size, molecular weight, the presence or absence of particular constituents or moieties (such as particular nucleotide sequences or restrictions sites).
- reporter In the case of cells, characteristics which may be marked by a reporter includes antibodies, proteins and sugar moieties, receptors, polynucleotides, and fragments thereof.
- label can be used interchangeably with “reporter”.
- the reporter is typically a dye, fluorescent, ultraviolet, or chemiluminescent agent, chromophore, or radio-label, any of which may be detected with or without some kind of stimulatory event, e.g., fluoresce with or without a reagent.
- the reporter is a protein that is optically detectable without a device, e.g. a laser, to stimulate the reporter, such as horseradish peroxidase (HRP).
- HRP horseradish peroxidase
- a protein reporter can be expressed in the cell that is to be detected, and such expression may be indicative of the presence of the protein or it can indicate the presence of another protein that may or may not be coexpressed with the reporter.
- a reporter may also include any substance on or in a cell that causes a detectable reaction, for example by acting as a starting material, reactant or a catalyst for a reaction which produces a detectable product. Cells may be sorted, for example, based on the presence of the substance, or on the ability of the cell to produce the detectable product when the reporter substance is provided.
- a “marker” is a characteristic of a molecule, cell or virion that is detectable or is made detectable by a reporter, or which may be coexpressed with a reporter.
- a marker can be particular constituents or moieties, such as restrictions sites or particular nucleic acid sequences in the case of polynucleotides.
- characteristics may include a protein, including enzyme, receptor and ligand proteins, sacchamides, polynucleotides, and combinations thereof, or any biological material associated with a cell or virion.
- the product of an enzymatic reaction may also be used as a marker.
- the marker may be directly or indirectly associated with the reporter or can itself be a reporter.
- a marker is generally a distinguishing feature of a molecule, cell or virion
- a reporter is generally an agent which directly or indirectly identifies or permits measurement of a marker.
- Example 1 shows methods of surfactant syntheses.
- Reagent Table is as follows:
- the procedure includes, adding 10.0 g (1.54 mmol; 1 eq) of Krytox acid FSH in 50 mL HFE 7100 (not anhydrous) at right under Ar was added 1.95 g (15.4 mmol; 10 eq) of Oxalyl Chloride dropwise. Stirred 10 min, then the reaction was warmed to gentle reflux (note boiling points of solvent and reagent). Some bubbling was noted, even before reaction had reached reflux. Continued overnight.
- the reagent table is as follows:
- the procedure includes, drying the amine was by placing under hivac rotovap at a bath temp of 60° C. for 4 hrs.
- a solution of 0.441 g (0.77 mmol; 1 eq) of PEG; 600 diamine J and 0.325 mL (2.33 mmol; 3 eq) of Et 3 N in 20 mL anhydrous THF at rt under Ar was added a solution of 10.14 g (1.55 mmol; 2 eq) of crude JSJ 73-019 in 40 mL FC 3283.
- a white precipitate (Et 3 N.HCl) was noted to form in the reaction and on the flask walls. The milky-white two-phase suspension was stirred well overnight.
- the reagent table is as follows:
- the reagent table includes:
- the procedure includes adding to a solution of 92.75 g (102 mmol; 1 eq) of JSJ 73-078 in 600 mL anhydrous DMF at rt under Ar was added 41.5 g (224 mmol; 2.2 eq) of Potassium phthalimide as a solid in 2 portions.
- the heterogeneous solution was then warmed slowly to 85-90° C. (internal temp) and the r ⁇ n stirred overnight.
- the phthalimide slowly went into solution and the color became more yellow. A small amount of the phthalimide wasn't consumed, remaining a solid dispersed in the reaction.
- the reagent table includes:
- the procedure includes adding to a solution of 57.93 g (67 mmol; 1 eq) of crude JSJ 73-081 in 300 mL anhydrous MeOH and 300 mL anhydrous THF at rt under Ar was added 15 mL (471 mmol; 7 eq) of Hydrazine and the reaction stirred (mechanical stirring used) at rt for 1.5 hrs. After 45 min, white solid began to form from the homogeneous solution. This was thought to be the byproduct of the hydrazine-phthalimide reaction. The reaction was warmed to 40° C. and stirred overnight under Ar. The stirring became slightly more difficult as more solid formed, so the stirring was increased slightly.
- This oil was placed under hivac rotovap at ⁇ 70° C. for several hours to remove residual solvents, Hydrazine, and also possibly any residual DMF brought from the SM in the previous step.
- Example 2 shows PEG-Amine derived fluorosurfactant syntheses
- a PEG-amine derived fluorosurfactant can be made by the following process: 10.0 g of Kytox 157 FSH (PFPE, 6500 g/mol, 0.00154 mole) was dissolved in 25.0-mL of FC-3283 (521 g/mol, 45.5 g, 0.0873 mole). 0.567 g PEG 600 Diamine (566.7 g/mol, 0.001 mole, 0.65 mol eq.) was dissolved in 10.0-mL of THF (72.11 g/mol, 8.9 g, 0.1234 mole). The resulting solutions were then combined and emulsified. The resulting emulsion was spun on a BUCHI rota-vap.
- FIG. 5 shows Ammonium Carboxylate Salt of Krytox 157 FSH 2 Wt % in FC 3283 without PEG amine salt (Panel A) and with PEG 600 Diammonium Carboxylate Salt of Krytox 157 FSH at 4.0% by volume (Panel B) (Flow Rates: 2000 ul/hr (FC oil), 500 ul/hr (aq)). The difference in the number of coalesced drops in the right image indicates that the PEG amine salt is effective in stabilizing emulsions.
- Emulsions made with the Ammonium Carboxylate Salt of Krytox 157 FSH 2 Wt % in FC 3283 with PEG 600 Diammonium Carboxylate Salt of Krytox 157 FSH co-surfactant added at 4.0% by volume were shown to remain stable when reinjected into a microfluidic channel.
- the primer droplet library generation is a Type IV library generation.
- FIG. 6 shows a schematic of the primer library generation.
- Step 1 of the library formation is to design primers for loci of interest. There are no constraints on primer design associated with traditional multiplex PCR.
- Step 2 requires synthesis of the primer pairs using standard oligo synthesis.
- the primer pairs are reformatted as droplets, where only one primer pair present in each droplet. Each droplet contains multiple copies of the single primer pair directed to a single target of interest.
- the emulsions are pooled as primer library. The droplet stability prevents cross-contamination of primer pairs.
- a pooled primer library can be placed onto a microfluidic device as provided by the instant invention.
- Each primer library droplet follows an inlet channel that intersects with another inlet channel, which has droplets containing gDNA, Taq, dNTPs and any other materials needed to perform PCR.
- the two inlet channels merge into a single main channel where the two different types of droplets, i.e., the primer library droplet and the PCR component droplets travel singularly until they are coalesced.
- the droplets are coalesced within the main channel in which they are traveling, at a widened portion of the main channel.
- electrodes are used to coalesce the droplets containing the primer libraries and the droplets containing the PCR components.
- the coalesced droplets then continue along the same main channel and are collected onto well containing plates.
- the droplets in the plates are subjected to thermocycling to permit PCR amplification.
- the amplified DNA can then be sequenced by any means known in the art.
- the relative number of sequencing reads from each of 20 targeted exons can be plotted using primer libraries against human genomic DNA.
- Disposable PDMS/glass microfluidic devices were designed with regions maintained at 95° C., and regions maintained at 67° C. and further including interrogation neckdowns.
- Aqueous fluid was infused into the microfluidic device perpendicularly to two channels flowing immiscible oil which generated 65 pL (50 um) droplets.
- the aqueous fluid contained the following reagents:
- the concentrations of the diluted DNA were verified by qPCR using a traditional real-time thermocycler.
- PCR primers and probe were designed to detect a 245 bp region of the Adenovirus genome.
- Droplets were generated at a rate of 500 per second.
- the channels on the microfluidic device conveyed the droplets through of 2 thermal zones at a 95° C. and 67° C. for 34 passes which were the equivalent of 34 cycles of two step PCR with the following cycling parameters:
- PCR droplets were interrogated at specific “neckdowns” which were 100 micron long regions of the microfluidic device where the channel width and depth decreased forcing droplets into a single file.
- a two wavelength laser excitation and detection system was used to interrogate the fluorescence at each of the neckdowns at cycles 4, 8, 11, 14, 17, 20, 23, 26, 29, 32, and 34.
- a fluorescent dye, Alexa Fluor 594 provided a constant signal in each droplet that was used for droplet detection without inhibiting PCR amplification efficiency or yield.
- the distribution of fluorescence signal among droplets was determined as the droplets pass through the excitation lasers (488 nm and 561 nm) at the last interrogation neckdown (cycle 34).
- a bimodal distribution of FAM fluorescence was observed for droplets with starting template concentrations of less than one molecule per droplet, indicating the presence of two populations corresponding to empty droplets and droplets that supported amplification.
- a time trace of fluorescence signals from those droplets is readily plotted as those droplets pass one-by-one through the excitation lasers.
- the percentage of PCR positive droplets was plotted versus cycle number.
- Type TI library droplets which encapsulate a library element, e.g., cell or bead, follow a Poisson Distribution.
- a library element e.g., cell or bead
- the primer droplet library generation is a Type II library generation.
- FIG. 3 shows a schematic of the antibody pair library generation.
- Reagent solutions 1 through n where n is the number of parallel ELISA assays to be performed, are prepared in separate vials. Each solution contains two antibodies, one bound to beads and one free in solution. It is often desirable, but not essential, for the unbound antibody to be biotinylated or for it to be conjugated to an enzyme.
- the beads are optically labeled using dyes, quantum dots or other distinguishing characteristics that make each of the n bead types uniquely identifiable, these characteristics can be also geometrical shape or features or fluorescence intensity or fluorescence polarization.
- emulsion library preparation in separate locations, beads of each type are encapsulated in reagent droplets; the reagent contains an unbound second antibody matched for a specific immunoassay. It is often desirable, but not essential to have exactly one bead in a droplet. Droplets having exactly one bead are collected by sorting on droplet generation in a microfluidic device.
- the emulsion library consists of a pooled collection of the n different droplet types. The droplet stability prevents cross-contamination of antibody pairs.
- FIG. 3 shows the test fluid is the sample fluid used to analyze one or more immunoassays.
- Example test fluids include serum, sputum, urine or tumor biopsies.
- the test fluid is dispersed into droplets of uniform volume and combined with a single droplet from the library. There may be unpaired droplets of the library material.
- the beads are recovered, washed in bulk, a readout enzyme is introduced.
- Non-limiting examples of readout enzymes could include a conjugate streptavidin-enzyme (typical enzymes are, for example but not limited to: ⁇ -Galactasidase, alkaline phosphatase, horseradish peroxidase), or conjugate antibody-enzyme (for example the same list of enzymes), followed by a final wash.
- a conjugate streptavidin-enzyme typically enzymes are, for example but not limited to: ⁇ -Galactasidase, alkaline phosphatase, horseradish peroxidase
- conjugate antibody-enzyme for example the same list of enzymes
- a fluorogenic substrate is added to the droplets under co-flow conditions at the time of droplet generation.
- the substrate is enzymatically turned-over to make a fluorescent product proportional to the concentration of analyte (and readout enzyme) in the sample fluid.
- An optical signal indicating the bead type and immunoassay number information is read on the beads simultaneously with the fluorescence signal from the product. This is done at one or more time points after the droplet is generated. Bead handling may benefit from using magnetic beads.
- step one it may be advantageous to enhance step one with a sort procedure to remove the droplets containing excess beads that have not had the test fluid added to them.
- the sort can be triggered either by droplet size or through the introduction of a fluorescent dye to the test fluid.
- Beads can then be washed, introduced to additional reagents, and subsequently followed by a final wash. By performing all of the previous steps all on-chip, the need for bulk processing of beads is eliminated.
- the substrate is added in bulk and the diffusion of the product around the bead is measured.
- methods that could also be applied in a microfluidic device. For example, one could use a tyramide amplification assay.
- Test fluids can be run sequentially using conventional auto-loaders and sample injection loops. Each sample would need to be separated by a rinse fluid and the off-chip processing of beads would require that the beads from each test fluid be collected separately.
- reporter enzyme bound to single positive beads (anti-m-biotin) or single negative beads in 30 um droplets can be assayed with HorseRadish Peroxidase (HRP) enzyme.
- HRP horseRadish Peroxidase
- the beads were injected at a final concentration 10 million/ml, HRP readout at 10 minute time point—Amplex Ultra Red 100 uM, hydrogen peroxide 1 mM. HRP allows for adequate separation of bead containing droplets from empty droplets. Additionally, a linear response is seen down to 10 molecules in a 30 um drop (at 10 minutes).
- Serum concentration can be measured accurately and is able to be reproduced, generally within a CV of less that 6% as shown in the Table below that shows the results of serum sample replicates ( ⁇ 60,000 droplets/run)
- the droplet based screening is high-throughput, highly accurate and has low reagents costs.
- the droplets provide an accurate high-throughput screen versus a halo assay.
- the DNA enzyme contained within the bacterial host is encapsulated within a droplet that also contains a fluorogenic substance, creating a droplet library of the bacteria, where only a single bacteria is contained with the droplets. All droplets, however, contain the fluorogenic substrate.
- the bacteria are allowed to replicate for a set time period, i.e., overnight. Using a green filter shows the discrete bacteria, within particular droplets, and using a red filter shows the secreted enzyme.
- Droplet libraries can also be used in enzyme activity detection with single cell growth and enzyme secretion.
- a droplet library can include a number of droplets containing a single cell, where other droplets do not contain any cells. The cells remain in the droplets overnight and grow into clonal populations. Both the discrete bacteria and the secreted enzyme are detected with an overlay of assay and cell fluorescence. The droplet library is then sorted, such that the droplets all contain a clonal population of bacteria having secreted the desired enzyme.
- the droplet library enables a single cell generation to result in clonal populations within single droplets to be used in assays and or to be sorted.
- Cell droplet libraries enable the sorting of the most active stain from a mixed cell library.
- droplets were generated with four individual strains and optical labeling using specific fluorescein concentrations (labeling plotted on y-axis). All of the droplets were collected into the same syringe and the mixed droplets were re-injected onto a microfluidic device after overnight growth at 30° C.
- a scatter plot shows the four labeled populations of droplets starting with no assay signal (on generation), and droplets having growing cells secreting protease showing assay activity moving to the right (after 16 hrs). The origin of each droplet is clearly identified, with the assay signal strength for each droplet type matching the appropriate strain ranking. Starting from a dilution of 1 positive in 100 Negatives viable bacteria can be recovered from sorted droplets to achieve sorted population.
- a 5-member library sorting can be achieved.
- a starting ratio of one Pos #4-containing droplet to 30 cell-containing droplets was used.
- Pos#3 cells only are kanamycin resistant. After recovering and plating out the contents of the sorted droplets, there were 19 kanamycin-resistant colonies out of 1131 total colonies. This is equivalent to an apparent false positive rate of 1.7%.
- Sorting the most active strain can also be done with large (i.e., 2 million members) mixed cell libraries. Further exemplified is a parent library of 2 ⁇ 10 6 discrete cell types (bacteria secreting mutagenized enzyme library) was placed into droplets for growth and screening. Two levels of sorting threshold stringency were used to recover either the top 100 cells or the top 10K cell. After re-growth, each population was placed in droplets for an enriched library analytical run. Three populations were optically labeled, and five minutes of data were collected after cell growth and assay development in droplets. Clear enrichment of the parent library is seen in the Top 10K-Enriched Library. Validation of Test Library#1 enrichment is seen. White and red filtered microscope images of the Parent Library (Test Library #1) in droplets after growth are observed. Similar images of the Top 110K-Enriched Library are seen. Clear enrichment for active clones are also observed.
- bacteria secreting mutagenized enzyme library Two levels of sorting threshold stringency were used to recover either the top
- FIG. 7 shows a schematic of the encapsulation of enzyme labeled individual cells in a substrate containing droplets.
- traditional flow cytometry utilizes fluor-labeled antibodies.
- the contents of the droplets are then amplified, such that the contents of the droplet produce a labeled product.
- the contents are then put onto the inicrofluidic device in order to sort/recover the desired products.
- a particular example is the U937 Monocyte Droplets, where cell library of an antibody, reporter enzyme and cell stain is prepared and co-flowed into droplets with the assay substrate.
- a different signal is produced and the number of cells per droplet follows a Poisson distribution, where 8.4% of the droplets have a single cell, i.e., 25356 single cell droplets out of 300943 total droplets.
- the enzyme amplified signal increases over time.
- the droplet libraries also enable multiplexed assays with optical labeling. Various labels can be utilized and overlayed. In a comparison of FACS and droplet sorting, droplet sorting provides improved cell population fractionation.
- Screen libraries of bacterially produced scFv's can also be developed.
- transformed bacteria are encapsulated and incubated at 37° C. After incubation the droplets are combined with droplets that contain beads, antigens and a detection antibody. After the two different droplets are combined they are collected and sorted. The positive droplets are then broken and the contents are recovered and sequenced. The process is able to screen for scFv's in droplets at a rate of about 1 ⁇ 10 6 per hour.
- the droplet based binding assays utilize localized fluorescence detection of scFV binding. Specifically, the diffuse signal becomes bright and localized on the capture bead.
- the present invention provides Immobilized Metal-Ion Affinity Partitioning (IMAP) FP detection of kinase reaction progress.
- IMAP Immobilized Metal-Ion Affinity Partitioning
- reaction components are encapsulated inside droplets generated by a microfluidic device and collected into a syringe.
- the refrigerated syringe is brought up to the reaction temperature, and the ‘emulsified’ reaction mixture proceeds to react for a defined amount of time.
- the reaction emulsion is re-injected and each individual droplet is analyzed when it flows past a laser detector.
- detection of the phosphorylated reaction product is via measurement of its Fluorescence Polarization (FP) after binding to the commercially available Immobilized Metal-Ion Affinity Partitioning (IMAP) kit reagents (Molecular Probes).
- IMAP Immobilized Metal-Ion Affinity Partitioning
- the fluorescence polarization is measured for each droplet and changes upon binding. Specifically, the phosphorylated product binds to IMAP and increases its FP. Compound/DMSO dilution and encapsulation of the reaction reagents into droplets is formulated on the microfluidic device.
- two sets of droplets are initially generated, one from an aqueous stream made of compound (provided in 70% DMSO) and ATP (nozzle 1 ), and the other from an aqueous stream containing the kinase and substrate in a reaction buffer (nozzle 2 ).
- nozzle 1 aqueous stream made of compound (provided in 70% DMSO) and ATP
- nozzle 2 aqueous stream containing the kinase and substrate in a reaction buffer
- fluid flow rates are set such that the compound that is initially in 70% DMSO is diluted to a concentration of 10% DMSO in the droplets generated by nozzle 1 .
- the volume ratio of droplets generated at nozzle 1 vs. nozzle 2 is 1 to 3, therefore when droplets from nozzle 1 are coalesced with droplets from nozzle 2 (containing the kinase and substrate) there is another 4 fold dilution of DMSO is therefore 28-fold (the concentration of DMSO in the final reaction mix is 2.5%).
- IMAP particles are encapsulated inside droplets which are subsequently coalesced with the emulsified reaction mixture droplets as they are being re-injected.
- the droplets enter a delay line which provides sufficient time for each droplet to be interrogated using an FP readout as it moves from left to right through the microfluidic channel shown.
- a combined microfluidic device design was also developed in order to improve emulsion stability (by reducing microfluidic device connection manipulations) and to reduce the time required for switching microfluidic devices and re-equilibrating fluid pressures.
- this design the same channel is used for both emulsion collection and re-injection, allowing for emulsion generation, IMAP coalescence and FP readout all on one microfluidic device.
- This design provides for a higher degree of automation and reproducibility by reducing operator manipulations of the inicrofluidic devices and optics, reducing opportunities for contaminants to be introduced into the microfluidic system, and provides better control of the operation time.
- Optical components have been defined and developed to enable FP detection. Optical components were assembled, using a 25-milliwatt solid-state laser to generate a 10 micron focused laser spot in the microfluidic channel, allowing a fluorescence signal to be measured for each droplet.
- the prototype instrument used in this study is able to detect approximately 10,000 FITC molecules encapsulated in a 30 micron droplet passing through the detection point at a rate of up to 10,000 per second.
- Binding of the IMAP particle to the phosphorylated peptide substrate can be directly observed using the microfluidic device. As each droplet moves at a defined flow rate through the circuitry, observation at different positions after IMAP coalescence defines specific times after binding. A delay line allows measurements over approximately 20 seconds after binding IMAP. Binding of the Akt positive control phospho-peptide to IMAP and the reaction of Abl-tide substrate with AbI kinase are seen. Binding of the IMAP reagent to both of these phospho-peptides reaches equilibrium within 10 seconds. Further, a comparison of on-chip and plate reader assays using 3 compounds where % inhibition time courses for AbI kinase and compounds E, A, and 11 show improved resolution for on-chip assays.
- one nozzle is used to encapsulate U937 mammalian cells that are cultivated in RPMI supplemented with fetal calf serum (10% v/v) under saturated CO 2 atmosphere (5%).
- Flow-focusing geometry to form the droplets was used.
- a water stream is infused from one channel through a narrow constriction; oil streams hydrodynamically focus the water stream and reduce its size as it passes through the constriction resulting in a “geometry-controlled” breakup of the droplet.
- the size of the water droplets is controlled in part by the relative flow rates of the oil and the water and in part by the nozzle section dimensions.
- the fluorinated oil contains a fluorocarbon surfactant (Ammonium Carboxylate Salt of Perfluoropolyether, 1% w/w) to stabilize the droplets.
- a fluorocarbon surfactant Ammonium Carboxylate Salt of Perfluoropolyether, 1% w/w
- Pluronic F-68 (0.1% final solution) a shear-protectant, is added to the cells just prior the injection to minimize the effect of shear-stress.
- the other nozzle generates droplets containing the Calcein-AM and Sytox Orange (Invitrogen) dyes that are used to respectively score live and dead cells.
- Calcein-AM is membrane permeant, non-fluorescent and diffuses into cells where the acetoxy groups are hydrolyzed by nonspecific esterases.
- the hydrolyzed dye (Calcein) is both cell membrane impermeant and fluorescent.
- Sytox Orange is impermeant and excluded from viable cells, but is able to enter cells with compromised membranes. In this case, it binds to DNA by intercalating between the bases with little sequence specificity and its fluorescence is greatly enhanced.
- a fluoro-surfactant Zonyl-FSO, 1.3%, Dupont was added in the dye solution to prevent the interaction of the dyes with the carboxylate group of the main surfactant.
- the droplet streams are interdigitated so that each cell droplet pairs with a dye droplet before entering the coalescence module.
- the expansion in the coalescing region allows for a dramatic catching up of the small droplet to the large droplet and accounts for a very robust coalescence (fewer than 0.1% misses).
- the volume of the expansion is big enough to slow the large droplet down so that the small droplet always catches up to the large droplet, but doesn't allow the next droplet to catch up and make contact with the pair to be coalesced.
- their content i.e. cells and dyes
- the Calcein-AM dye has to be processed enzymatically by the cells to become fluorescent, the droplets need to be incubated on-chip for tens of minutes.
- the cross-section 600 ⁇ m ⁇ 250 ⁇ m
- the length of the channel (1,550 mm) was increased so that the flow sweeps through a large volume.
- This design results in a significant residence time on the microfluidic device.
- oil extractor consists of a series of T-junction whose sections are much smaller than the droplet size, which are used to specifically extract oil and reduce the overall flowrate and hence the droplet velocity. The combined use of the incubation line and the oil extractor results in a significant on-chip residency time of the droplets.
- the live-dead assay experiments are carried out with an incubation time of 70 minutes on the microfluidic device.
- all the cells are illuminated in the same conditions by confining them through a constriction and by using a slit geometry for the excitation spot.
- a confocal optical set-up is used and the signal is collected with a set of photomultipliers at a rate of 100 kHz.
- a typical fluorescent readout is provided, over a timescale of 100 ms.
- the cell growth medium gives a dim fluorescent background which is much lower than the live-dead assay signals.
- some fluorescein (10 ⁇ M) (Invitrogen) was added into the dye solution to get a clear fluorescent signature of the droplets which is characterized by an approximately rectangular cross-section. Peak signals corresponding to cell staining are characterized by higher maximum signal and narrower Forward Half Maximum. They can be clearly distinguished on top of the homogeneous signal.
- Data processing software has been developed to extract different parameters (height, integrated area . . . ) after interpolation and curve fitting from each droplet signal. After scoring the cells retain a normal morphology without any apparent sign of shearing. Cell density upon injection with discussion on Poisson's distribution and single cell analysis % drop size.
- the assay was test to see whether it was able to score all the injected cells disregarding their cell state (either alive or dead). To this purpose all the cells with a red dye (Qdot® 655 wheat germ agglutinin, Invitrogen) were identified and checked that they were all scored. Again, live cells and dead cells were scored separately. It is noteworthy that these numbers are the result of the combined efficiencies of all the modules used for the live-dead assay, demonstrating the robustness of this assay and technology.
- the droplet microfluidic technology will facilitate an expansive list of microfluidic applications.
- high-throughput cell screening and combinatorial screening at the single cell level will greatly benefit from this technology platform.
- the major advantages of this technology are the absence of contact between the sample and the channel walls eliminating contamination, and high-throughput manipulation.
- the toxicity assay with droplets requires encapsulating cells determining the difference between live cells and dead cells. In order to get a reading of the droplet and fluorescent level therein, the droplet is elongated for detection. The cell viability does not significantly change over time (>3 days) in the droplets.
Abstract
Description
- The present application claims priority to, and the benefit of, U.S. Provisional Application No. 61/081,930, filed Jul. 18, 2008. The contents of this application is herein incorporated by reference in its entirety.
- The present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets. The present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.
- The manipulation of fluids to form fluid streams of desired configuration, discontinuous fluid streams, droplets, particles, dispersions, etc., for purposes of fluid delivery, product manufacture, analysis, and the like, is a relatively well-studied art. Microfluidic systems have been described in a variety of contexts, typically in the context of miniaturized laboratory (e.g., clinical) analysis. Other uses have been described as well. For example, International Patent Application Publication Nos. WO 01/89788; WO 2006/040551; WO 2006/040554; WO 2004/002627; WO 2008/063227; WO 2004/091763; WO 2005/021151; WO 2006/096571; WO 2007/089541; WO 2007/081385 and WO 2008/063227.
- Precision manipulation of streams of fluids with microfluidic devices is revolutionizing many fluid-based technologies. Networks of small channels are a flexible platform for the precision manipulation of small amounts of fluids. However, virtually all microfluidic devices are based on flows of streams of fluids; this sets a limit on the smallest volume of reagent that can effectively be used because of the contaminating effects of diffusion and surface adsorption. As the dimensions of small volumes shrink, diffusion becomes the dominant mechanism for mixing, leading to dispersion of reactants; moreover, surface adsorption of reactants, while small, can be highly detrimental when the concentrations are low and volumes are small. As a result, current microfluidic technologies cannot be reliably used for applications involving minute quantities of reagent; for example, bioassays on single cells or library searches involving single beads are not easily performed. An alternate approach that overcomes these limitations is the use of aqueous droplets in an immiscible carrier fluid; these provide a well defined, encapsulated microenvironment that eliminates cross contamination or changes in concentration due to diffusion or surface interactions. Droplets provide the ideal microcapsule that can isolate reactive materials, cells, or small particles for further manipulation and study. However, essentially all enabling technology for microfluidic systems developed thus far has focused on single phase fluid flow and there are few equivalent active means to manipulate droplets requiring the development of droplet handling technology. While significant advances have been made in dynamics at the macro- or microfluidic scale, improved techniques and the results of these techniques are still needed. For example, as the scale of these reactors shrinks, contamination effects due to surface adsorption and diffusion limit the smallest quantities that can be used. Confinement of reagents in droplets in an immiscible carrier fluid overcomes these limitations, but demands new fluid-handling technology.
- The present invention overcomes the current limitations in the field by providing precise, well-defined, droplet libraries which can be utilized alone, or within microfluidic channels and devices, to perform various biological and chemical assays efficiently and effectively, especially at high speeds.
- The present invention provides for droplet libraries useful to perform large numbers of assays while consuming only limited amounts of reagents.
- The present invention provides an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises the same aqueous fluid and comprises a different library element. The present invention also provides a method for forming the emulsion library comprising providing a single aqueous fluid comprising different library elements, encapsulating each library element into an aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises the same aqueous fluid and comprises a different library element and pooling the aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, thereby forming an emulsion library.
- The present invention also provides an emulsion library comprising at least a first aqueous droplet and at least a second aqueous droplet within a fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and comprise a different aqueous fluid and a different library element. The present invention also provides a method for forming the emulsion library comprising providing at least a first aqueous fluid comprising at least a first library of elements, providing at least a second aqueous fluid comprising at least a second library of elements, encapsulating each element of said at least first library into at least a first aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, encapsulating each element of said at least second library into at least a second aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and comprise a different aqueous fluid and a different library element and pooling the at least first aqueous droplet and the at least second aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant thereby forming an emulsion library.
- The present invention provides another emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first antibody, and a single element linked to at least a second antibody, wherein said first and second antibodies are different.
- The present invention provides another emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first element linked to at least a first antibody, and at least a second element linked to at least a second antibody, wherein said first and second antibodies are different.
- In some embodiments, each droplet within each library comprises no more than one library element. In other embodiments, each droplet within each library comprises a plurality of library elements.
- In some embodiments, the fluorosurfactant comprised within immiscible fluorocarbon oil is a block copolymer consisting of one or more perfluorinated polyether (PFPE) blocks and one or more polyethylene glycol (PEG) blocks. In other embodiments, the fluorosurfactant is a triblock copolymer consisting of a PEG center block covalently bound to two PFPE blocks by amide linking groups.
- The droplets within each are 10 microns to 100 micros in size. The emulsion library is stable for long term storage. Preferably, the emulsion library is stable at least 30 days.
- The droplets within each emulsion library can include any library element. Preferably, the library element is a cell, virus, bacteria, yeast, bead, protein, polypeptide, nucleic acid, polynucleotide or small molecule chemical compound. The emulsion library can include any number of library elements.
- The emulsion libraries can be labeled for unique identification of each library element by any means known in the art. The label can be an optical label, an enzymatic label or a radioactive label. The label can be any detectable label, e.g., a protein, a DNA tag, a dye, a quantum dot or a radio frequency identification tag. Preferably the label is an optical label. The label can be detected by any means known in the art. Preferably, the label is detected by fluorescence polarization, fluorescence intensity, fluorescence lifetime, fluorescence energy transfer, pH, ionic content, temperature or combinations thereof.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
- Other features and advantages of the invention will be apparent from the following detailed description and claims.
- Non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying drawings, which are schematic and are not intended to be drawn to scale. In the drawings, each identical or nearly identical component illustrated is typically represented by a single numeral. For the purposes of clarity, not every component is labeled in every drawing, nor is every component of each embodiment of the invention shown where illustration is not necessary to allow those of ordinary skill in the art to understand the invention. In the drawings;
-
FIG. 1 is an schematic illustrating the interacting modules of a microfluidic device of the present invention. -
FIG. 2 is a schematic illustrating a one emulsion library. -
FIG. 3 is a schematic illustrating an antibody pair library for ELISA Application. -
FIG. 4 Panel A is a schematic illustrating that the cell in the Protein-Fragment Complementation Assay is not secreting any antigen hence the fluorogenic substrate is not converted into a fluorescent product. Panel B is a schematic showing the conversion to a fluorescent product. -
FIG. 5 Panel A is a photograph showing droplets containing Ammonium Carboxylate Salt of Krytox 157FSH 2 Wt % in FC 3283 without PEG amine salt. Panel B is a photograph showing droplets containing PEG 600 Diainmonium Carboxylate Salt of Krytox 157 FSH at 4.0% by volume. -
FIG. 6 is a schematic illustrating a primer library generation. -
FIG. 7 is a schematic illustrating enzyme amplified flow cytometry. - Droplet libraries are useful to perform large numbers of assays while consuming only limited amounts of reagents. A “droplet,” as used herein, is an isolated portion of a first fluid that completely surrounded by a second fluid. In some cases, the droplets may be spherical or substantially spherical; however, in other cases, the droplets may be non-spherical, for example, the droplets may have the appearance of “blobs” or other irregular shapes, for instance, depending on the external environment. As used herein, a first entity is “surrounded” by a second entity if a closed loop can be drawn or idealized around the first entity through only the second entity.
- In general, a droplet library is made up of a number of library elements that are pooled together in a single collection. Libraries may vary in complexity from a single library element to 1015 library elements or more. Each library element is one or more given components at a fixed concentration. The element may be, but is not limited to, cells, virus, bacteria, yeast, beads, amino acids, proteins, polypeptides, nucleic acids, polynucleotides or small molecule chemical compounds. The element may contain an identifier such as a label. The terms “droplet library” or “droplet libraries” are also referred to herein as an “emulsion library” or “emulsion libraries.” These terms are used interchangeably throughout the specification.
- A cell library element can include, but is not limited to, hybridomas, B-cells, primary cells, cultured cell lines, cancer cells, stem cells, or any other cell type. Cellular library elements are prepared by encapsulating a number of cells from one to tens of thousands in individual droplets. The number of cells encapsulated is usually given by Poisson statistics from the number density of cells and volume of the droplet. However, in some cases the number deviates from Poisson statistics as described in Edd et al., “Controlled encapsulation of single-cells into monodisperse picolitre drops.” Lab Chip, 8(8): 1262-1264, 2008. The discreet nature of cells allows for libraries to be prepared in mass with a plurality of cellular variants all present in a single starting media and then that media is broken up into individual droplet capsules that contain at most one cell. These individual droplets capsules are then combined or pooled to form a library consisting of unique library elements. Cell division subsequent to, or in some embodiments following, encapsulation produces a clonal library element.
- A bead based library element contains one or more beads, of a given type and may also contain other reagents, such as antibodies, enzymes or other proteins. In the case where all library elements contain different types of beads, but the same surrounding media, the library elements can all be prepared from a single starting fluid or have a variety of starting fluids. In the case of cellular libraries prepared in mass from a collection of variants, such as genomically modified, yeast or bacteria cells, the library elements will be prepared from a variety of starting fluids.
- Often it is desirable to have exactly one cell per droplet with only a few droplets containing more than one cell when starting with a plurality of cells or yeast or bacteria, engineered to produce variants on a protein. In some cases, variations from Poisson statistics can be achieved to proved an enhanced loading of droplets such that there are more droplets with exactly one cell per droplet and few exceptions of empty droplets or droplets containing more than one cell.
- Examples of droplet libraries are collections of droplets that have different contents, ranging from beads, cells, small molecules, DNA, primers, antibodies. The droplets range in size from roughly 0.5 micron to 500 micron in diameter, which corresponds to about 1 pico liter to 1 nano liter. However, droplets can be as small as 5 microns and as large as 500 microns. Preferably, the droplets are at less than 100 microns, about 1 micron to about 100 microns in diameter. The most preferred size is about 20 to 40 microns in diameter (10 to 100 picoliters). The preferred properties examined of droplet libraries include osmotic pressure balance, uniform size, and size ranges.
- The droplets comprised within the droplet library provided by the instant invention are uniform in size. That is, the diameter of any droplet within the library will vary less than 5%, 4%, 3%, 2%, 1% or 0.5% when compared to the diameter of other droplets within the same library. The uniform size of the droplets in the library is critical to maintain the stability and integrity of the droplets and is also essential for the subsequent use of the droplets within the library for the various biological and chemical assays described herein.
- The droplets comprised within the emulsion libraries of the present invention are contained within an immiscible fluorocarbon oil comprising at least one fluorosurfactant. In some embodiments, the fluorosurfactant comprised within immiscible fluorocarbon oil is a block copolymer consisting of one or more perfluorinated polyether (PFPE) blocks and one or more polyethylene glycol (PEG) blocks. In other embodiments, the fluorosurfactant is a triblock copolymer consisting of a PEG center block covalently bound to two PFPE blocks by amide linking groups. The presence of the fluorosurfactant (similar to uniform size of the droplets in the library) is critical to maintain the stability and integrity of the droplets and is also essential for the subsequent use of the droplets within the library for the various biological and chemical assays described herein. Fluids (e.g., aqueous fluids, immiscible oils, etc.) and other surfactants that can be utilized in the droplet libraries of the present invention are described in greater detail herein.
- The droplet libraries of the present invention are very stable and are capable of long-term storage. The droplet libraries are determined to be stable if the droplets comprised within the libraries maintain their structural integrity, that is the droplets do not rupture and elements do not diffuse from the droplets. The droplets libraries are also determined to be stable if the droplets comprised within the libraries do not coalesce spontaneously (without additional energy input, such as electrical fields described in detail herein). Stability can be measured at any temperature. For example, the droplets are very stable and are capable of long-term storage at any temperature; for example, e.g., −70° C., 0° C., 4° C., 37° C., room temperature, 75° C. and 95° C. Specifically, the droplet libraries of the present invention are stable for at least 30 days. More preferably, the droplets are stable for at least 60 days. Most preferably, the droplets are stable for at least 90 days.
- The present invention provides an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises the same aqueous fluid and comprises a different library element. The present invention also provides a method for forming the emulsion library comprising providing a single aqueous fluid comprising different library elements, encapsulating each library element into an aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises the same aqueous fluid and comprises a different library element, and pooling the aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, thereby forming an emulsion library.
- For example, in one type of emulsion library, all different types of elements (e.g., cells or beads), are pooled in a single source contained in the same medium. After the initial pooling, the cells or beads are then encapsulated in droplets to generate a library of droplets wherein each droplet with a different type of bead or cell is a different library element. The dilution of the initial solution enables the encapsulation process. In some embodiments, the droplets formed will either contain a single cell or bead or will not contain anything, i.e., be empty. In other embodiments, the droplets formed will contain multiple copies of a library element. The cells or beads being encapsulated are generally variants on the same type of cell or bead. In one example, the cells can comprise cancer cells of a tissue biopsy, and each cell type is encapsulated to be screened for genomic data or against different drug therapies. Another example is that 1011 or 1015 different type of bacteria; each having a different plasmid spliced therein, are encapsulated. One example is a bacterial library where each library element grows into a clonal population that secretes a variant on an enzyme.
- In another example, the emulsion library comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil, wherein a single molecule is encapsulated, such that there is a single molecule contained within a droplet for every 20-60 droplets produced (e.g., 20, 25, 30, 35, 40, 45, 50, 55, 60 droplets, or any integer in between). Single molecules are encapsulated by diluting the solution containing the molecules to such a low concentration that the encapsulation of single molecules is enabled. In one specific example, a LacZ plasmid DNA was encapsulated at a concentration of 20 fM after two hours of incubation such that there was about one gene in 40 droplets, where 10 μm droplets were made at 10 kHz per second. Formation of these libraries rely on limiting dilutions.
- The present invention also provides an emulsion library comprising at least a first aqueous droplet and at least a second aqueous droplet within a fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and comprise a different aqueous fluid and a different library element. The present invention also provides a method for forming the emulsion library comprising providing at least a first aqueous fluid comprising at least a first library of elements, providing at least a second aqueous fluid comprising at least a second library of elements, encapsulating each element of said at least first library into at least a first aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, encapsulating each element of said at least second library into at least a second aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and comprise a different aqueous fluid and a different library element, and pooling the at least first aqueous droplet and the at least second aqueous droplet within an immiscible fluorocarbon oil comprising at least one fluorosurfactant thereby forming an emulsion library.
- For example, in one type of emulsion library, there are library elements that have different particles, i.e., cells or beads in a different medium and are encapsulated prior to pooling. As exemplified in
FIG. 2 , a specified number of library of elements, i.e., n number of different cells or beads, are contained within different mediums. Each of the library elements are separately emulsified and pooled, at which point each of the n number of pooled different library elements are combined and pooled into a single pool. The resultant pool contains a plurality of water-in-oil emulsion droplets each containing a different type of particle. - In some embodiments, the droplets formed will either contain a single library element or will not contain anything, i.e., be empty. In other embodiments, the droplets formed will contain multiple copies of a library element. The contents of the beads follow a Poisson distribution, where there is a discrete probability distribution that expresses the probability of a number of events occurring in a fixed period of time if these events occur with a known average rate and independently of the time since the last event. The oils and surfactants used to create the libraries prevents the exchange of the contents of the library between droplets.
- Examples of assays that utilize these emulsion libraries are ELISA assays. The present invention provides another emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first antibody, and a single element linked to at least a second antibody, wherein said first and second antibodies are different. In one example, each library element comprises a different bead, wherein each bead is attached to a number of antibodies and the bead is encapsulated within a droplet that contains a different antibody in solution. These antibodies can then be allowed to form “ELISA sandwiches,” which can be washed and prepared for a ELISA assay. Further, these contents of the droplets can be altered to be specific for the antibody contained therein to maximize the results of the assay. A specific example of an ELSA assay is shown in Example 5 and in
FIG. 3 . - The present invention also provides another emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first element linked to at least a first antibody, and at least a second element linked to at least a second antibody, wherein said first and second antibodies are different. In one example of a Protein-Fragment Complementation Assay (PCA), library droplets are prepared to contain a mixture of two different antibodies. Wherein the two antibodies bind with strong affinity to different epitopes of the antigen molecule that is to be detected. Detection is achieved by tethering protein fragments to the each of the antibodies such that when held in proximity the two fragments create an active enzyme capable of turning over a fluorogenic substrate, only in the presence of the antigen. For example, as shown in
FIG. 4 Panel A, the cell is not secreting any antigen hence the fluorogenic substrate is not converted into a fluorescent product. By contrast, in Panel B, the cell is secreting the antigen. Hence when the antibodies bind to it the two protein fragments are held in close enough proximity to form an active enzyme. The intensity of the fluorescence signal generated from these sandwiches is indicative of the antigen concentration in the droplet. - In another example, of the emulsion library, the library begins with a certain number of library elements, which may contain proteins, enzymes, small molecules and PCR primers, among other reagents. However, there is no Poisson distribution in these droplet libraries, Rather, each library is added to a droplet in a specific concentration. In these droplet libraries, there are a large number of the reagent contained within the droplets. With small molecule chemical compounds, each library element can be the same small molecule chemical compound at different concentrations or be completely different small molecule chemical compound per element. When encapsulating PCR primers there are any number of a single type of primer pairs contained within each droplet.
- Labels can be used for identification of the library elements of the various types of droplet libraries. Libraries can be labeled for unique identification of each library element by any means known in the art. The label can be an optical label, an enzymatic label or a radioactive label. The label can be any detectable label, e.g., a protein, a DNA tag, a dye, a quantum dot or a radio frequency identification tag, or combinations thereof. Preferably the label is an optical label. The label can be detected by any means known in the art. Preferably, the label is detected by fluorescence polarization, fluorescence intensity, fluorescence lifetime, fluorescence energy transfer, pH, ionic content, temperature or combinations thereof. Various labels and means for detection are described in greater detail herein.
- Specifically, after a label is added to each of the various library elements, the elements are then encapsulated and each of the droplets contains a unique label so that the library elements may be identified. In one example, by using various combinations of labels and detection methods, it is possible to use two different colors with different intensities or to use a single color at a different intensity and different florescence anisotropy.
- Optical labels are also utilized in quality control in order to ensure that the droplet libraries are well controlled, and that equal number of each library elements are contained within uniform volumes in each droplet library. After 120 minutes of mixing, using 8-labels in a 96-member library, the average number of droplets is 13,883 for each of the library elements. As Table 1 shows below, there is very little variation between the number of droplets for each library element, i.e., between −0.8% to +1.1%. The slight variation in the number of droplets allows the pooled droplet libraries to be used in any number of assays.
-
TABLE 1 Element G1 G2 G3 G4 G5 G6 G7 G8 # drops 13913 13898 14036 13898 13834 13927 13788 13769 % variation +0.2% 0% +1.1% 0% −0.4% +0.3% −0.7% −0.8% - In some quality control examples, 384-member libraries were prepared with eight optical labels; typically 5 to 20 micro-liters of each library element are emulsified into approximately 10 picoliter volume droplets so there are about 1 million droplets of each library element and 384 million droplets in the library.
- The eight optical labels are a dye at concentrations that increase by a factor of c (where c ranges from about 1.2 to 1.4) from one optical label to the next so that the nth optical label has (c)(n−1) the dye concentration of the lowest concentration. Optical labels are used with concentrations between 10 nM and 1 uM. Typically, the range of optical label concentrations for one series of labels is 1 order of magnitude (e.g., 10 nM to 100 nM with a multiplier of 1.43 for each increasing label concentration). A larger range of droplet label concentrations can also be used. Further, multiplexed two-color labels can be used as well.
- Plates are prepared with 384 separate library elements in separate wells of the 384-well plates; 8 of which have optical labels. The library elements are made into droplets, collected in a vial, (also known as a creaming tower) and the collection is mixed on the mixer for several hours. The mixer works by flipping the vial over about once every 30 seconds and then allowing the droplets to rise. Multiple plates can be emulsified and pooled or collected sequentially into the same vial.
- A small fraction of the droplets are taken out of the vial to verify 1) that the droplets are present in the correct predetermined ratio and 2) that the droplets are of uniform size. Typically, 1,000 to 10,000 droplets of each library element (0.384 to 3.84 million QC-droplets) are removed from the vial through a PEEK line in the center opening in the vial cap by positive displacement with a drive oil infused through the side opening in vial cap. The PEEK line takes the droplets into a port on a microfluidic chip at a rate of several thousand droplets/second; for 10 picoliter droplets at a rate of 3000 droplets/s corresponds to a typical infusion rate of roughly 110 micro-liters/hr. Once on chip the droplets are spaced out by adding oil before they are imaged and pass one droplet at a time through a laser excitation spot. Maximum fluorescence intensity data from individual droplets is collected for all of the QC-droplets and histograms are built to show the number of droplets within a given fluorescence intensity range. As expected, if eight of the library elements have optical labels, then there are eight peaks in the histograms. The increasing concentration factor c=1.38 results in uniformly separated peaks across one decade when plotted on a log scale. The relative number of droplets in each peak is used as a quality metric to validate that the libraries were prepared with the expected relative representation. In this example, the percent variation is determined to be only 2.7% demonstrating that all library elements have uniform representation.
- Image analysis can be utilized to determine and monitor osmotic pressure within the droplets. Osmotic pressure (e.g., two member library prepared with a small difference in buffer concentration) can effect droplets. Specifically, droplets with a lower salt concentration shrink over time and droplets with higher salt concentration grow over time, until uniform salt concentrations are achieved. Thus it.
- Image analysis can also be utilizes for quality control of the library reformatting process. After the various library elements are generated, pooled and mixed, optical labels can be used to verify uniform representation of all library elements. Additionally, image analysis is used to verify uniform volume for all droplets.
- Further, image analysis can be used for shelf life testing by quantifying the materials performance. Droplets are stored in vials under a variety of conditions to test droplets stability against droplet-droplet coalescence events. Conditions tested include temperature, vibration, presence of air in vials, surfactant type, and surfactant concentration. A Quality Score of percent coalescence is calculated by image analysis. Shelf-life for the droplet libraries of the present invention exceed 90 days.
- Reagents can be reformatted as droplet libraries utilizing automated devices. Specifically, the library elements can be placed onto plates containing any number of wells, i.e. 96, 384, etc. The plates can then be placed in an Automated Droplet Library Production machine (or other such automated device known in the art), which forms the droplets and puts them into a vial or other such container, containing the ready to use droplet library. In general, the process aspirates each of the library elements from the well plates through tubing connected to a microfluidic device (described in greater detail herein) which can be used to form the droplets. The tubing that aspirates the library elements can be rinsed at a wash station and then the process can be repeated for the next library element.
- A collection vial can be used to contain the droplets made using the Automated Droplet Library Production. In one example, the collection vial has two holes, a first hole in the center of the vial cap and a second hole part way to the edge of the vial cap. The vial is first filled with oil through the second hole to purge air out first hole, the emulsion is then introduced to the vial through the first hole, typically this is done sequentially one library element at a time at low volume fraction, and oil is displaced and goes out through the second hole. The collected droplets can be stored in the vial for periods of time in excess of 3 months. To remove the emulsion for use or to make smaller aliquots, oil is introduced through the second opening to displace the emulsion and drive out the first opening.
- The droplet libraries of the present invention are preferably formed by utilizing microfluidic devices and are preferably utilized to perform various biological and chemical assays on microfluidic devices, as described in detail herein. The present invention also provides embedded microfluidic nozzles. In order to create a monodisperse (<1.5% polydispersity) emulsion directly from a library well, a nozzle can be formed directly into the fitting used to connect the storage well/reservoir (e.g. syringe) to a syringe tip (e.g. capillary tubing). Examples of suitable nozzles to create the droplet libraries of the instant invention are described in WO 2007/081385 and WO 2008/063227.
- Since the flow is three dimensional, under this design surface wetting effects are minimized.
- The nozzle can be made from one or two oil lines providing constant flow of oil into the nozzle, a connection to the capillary tubing, and a connection to the storage well/reservoir (e.g. syringe). The high resolution part of the nozzle can be made out of a small bore tubing or a small, simple part molded or stamped from an appropriate material (Teflon®, plastic, metal, etc). If necessary, the nozzle itself could be formed into the tip of the ferrule using post mold processing such as laser ablation or drilling.
- This nozzle design eliminates the surface wetting issues surrounding the quasi-2D flow associated with typical microfluidic nozzles made using soft lithography or other standard microfluidic chip manufacturing techniques. This is because the nozzle design is fully 3-dimensional, resulting is a complete isolation of the nozzle section from the continuous aqueous phase. This same design can also be used for generation of emulsions required for immediate use, where the aqueous line would be attached directly to a syringe and the outlet of the nozzle would be used to transport the emulsion to the point of use (e.g. into a microfluidic PCR chip, delay line, etc).
- In another embodiment, the present invention provides compositions and methods to directly emulsify library elements from standard library storage geometries (e.g. 96 well plates, etc). In order to create a monodisperse emulsion from fluids contained in a library well plate, this invention would include microfluidic based nozzles manufactured simultaneously with an appropriately designed fluidic interconnect or well.
- Specifically, the microfluidic devices and methods described herein are based on the creation and electrical manipulation of aqueous phase droplets (e.g., droplet libraries) completely encapsulated by an inert immiscible oil stream. This combination enables precise droplet generation, highly efficient, electrically addressable, droplet coalescence, and controllable, electrically addressable single droplet sorting. The microfluidic devices include one or more channels and modules. A schematic illustrating one example of interacting modules of a microfluidic substrate is shown in
FIG. 1 . The integration of these modules is an essential enabling technology for a droplet based, high-throughput microfluidic reactor system and provides an ideal system for utilizing the droplet libraries provided herein for numerous biological, chemical, or diagnostic applications. - Substrates
- The microfluidic device of the present invention includes one or more analysis units. An “analysis unit” is a microsubstrate, e.g., a microchip. The terms microsubstrate, substrate, microchip, and chip are used interchangeably herein. The analysis unit includes at least one inlet channel, at least one main channel and at least one inlet module. The analysis unit can further include at least one coalescence module. at least one detection module and one or more sorting modules. The sorting module can be in fluid communication with branch channels which are in fluid communication with one or more outlet modules (collection module or waste module). For sorting applications, at least one detection module cooperates with at least one sorting module to divert flow via a detector-originated signal. It shall be appreciated that the “modules” and “channels” are in fluid communication with each other and therefore may overlap; i.e., there may be no clear boundary where a module or channel begins or ends. A plurality of analysis units of the invention may be combined in one device. The dimensions of the substrate are those of typical microchips, ranging between about 0.5 cm to about 15 cm per side and about 1 micron to about 1 cm in thickness. The analysis unit and specific modules are described in further detail in WO 2006/040551; WO 2006/040554; WO 2004/002627; WO 2004/091763; WO 2005/021151; WO 2006/096571; WO 2007/089541; WO 2007/081385 and WO 2008/063227.
- A variety of materials and methods can be used to form any of the described components of the systems and devices of the invention. For example, various components of the invention can be formed from solid materials, in which the channels can be formed via molding, micromachining, film deposition processes such as spin coating and chemical vapor deposition, laser fabrication, photolithographic techniques, etching methods including wet chemical or plasma processes, and the like. See, for example, Angell, et al., Scientific American, 248:44-55, 1983. At least a portion of the fluidic system can be formed of silicone by molding a silicone chip. Technologies for precise and efficient formation of various fluidic systems and devices of the invention from silicone are known. Various components of the systems and devices of the invention can also be formed of a polymer, for example, an elastomeric polymer such as polydimethylsiloxane (“PDMS”), polytetrafluoroethylene (“PTFE”) or Teflon®, or the like.
- Silicone polymers are preferred, for example, the silicone elastomer polydimethylsiloxane. Non-limiting examples of POMS polymers include those sold under the trademark Sylgard by Dow Chemical Co., Midland, Mich., and particularly Sylgard 182, Sylgard 184, and Sylgard 186, Silicone polymers including PDMS have several beneficial properties simplifying formation of the microfluidic structures of the invention. For instance, such materials are inexpensive, readily available, and can be solidified from a prepolymeric liquid via curing with heat. For example, PDMSs are typically curable by exposure of the prepolymeric liquid to temperatures of about, for example, about 65° C. to about 75° C. for exposure times of, for example, about an hour. Also, silicone polymers, such as PDMS, can be elastomeric and thus may be useful for forming very small features with relatively high aspect ratios, necessary in certain embodiments of the invention. Flexible (e.g., elastomeric) molds or masters can be advantageous in this regard.
- One advantage of forming structures such as microfluidic structures of the invention from silicone polymers, such as PDMS, is the ability of such polymers to be oxidized, for example by exposure to an oxygen-containing plasma such as an air plasma, so that the oxidized structures contain, at their surface, chemical groups capable of cross-linking to other oxidized silicone polymer surfaces or to the oxidized surfaces of a variety of other polymeric and non-polymeric materials. Thus, components can be formed and then oxidized and essentially irreversibly sealed to other silicone polymer surfaces, or to the surfaces of other substrates reactive with the oxidized silicone polymer surfaces, without the need for separate adhesives or other sealing means. In most cases, sealing can be completed simply by contacting an oxidized silicone surface to another surface without the need to apply auxiliary pressure to form the seat. That is, the pre-oxidized silicone surface acts as a contact adhesive against suitable mating surfaces. Specifically, in addition to being irreversibly sealable to itself, oxidized silicone such as oxidized PDMS can also be sealed irreversibly to a range of oxidized materials other than itself including, for example, glass, silicon, silicon oxide, quartz, silicon nitride, polyethylene, polystyrene, glassy carbon, and epoxy polymers, which have been oxidized in a similar fashion to the PDMS surface (for example, via exposure to an oxygen-containing plasma). Oxidation and sealing methods useful in the context of the present invention, as well as overall molding techniques, are described in the art, for example, in Duffy et al., “Rapid Prototyping of Microfluidic Systems and Polydimethylsiloxane,” Anal. Chem., 70:474-480, 1998.
- Another advantage to forming microfluidic structures of the invention (or interior, fluid-contacting surfaces) from oxidized silicone polymers is that these surfaces can be much more hydrophilic than the surfaces of typical elastomeric polymers (where a hydrophilic interior surface is desired). Such hydrophilic channel surfaces can thus be more easily filled and wetted with aqueous solutions than can structures comprised of typical, unoxidized elastomeric polymers or other hydrophobic materials.
- Channels
- The microfluidic substrates of the present invention include channels that form the boundary for a fluid. A “channel,” as used herein, means a feature on or in a substrate that at least partially directs the flow of a fluid. In some cases, the channel may be formed, at least in part, by a single component, e.g., an etched substrate or molded unit. The channel can have any cross-sectional shape, for example, circular, oval, triangular, irregular, square or rectangular (having any aspect ratio), or the like, and can be covered or uncovered (i.e., open to the external environment surrounding the channel). In embodiments where the channel is completely covered, at least one portion of the channel can have a cross-section that is completely enclosed, and/or the entire channel may be completely enclosed along its entire length with the exception of its inlet and outlet.
- The channels of the invention can be formed, for example by etching a silicon chip using conventional photolithography techniques, or using a micromachining technology called “soft lithography” as described by Whitesides and Xia, Angewandte Chemie International Edition 37, 550 (1998).
- An open channel generally will include characteristics that facilitate control over fluid transport, e.g., structural characteristics (an elongated indentation) and/or physical or chemical characteristics (hydrophobicity vs. hydrophilicity) and/or other characteristics that can exert a force (e.g., a containing force) on a fluid. The fluid within the channel may partially or completely fill the channel. In some cases the fluid may be held or confined within the channel or a portion of the channel in some fashion, for example, using surface tension (e.g., such that the fluid is held within the channel within a meniscus, such as a concave or convex meniscus). In an article or substrate, some (or all) of the channels may be of a particular size or less, for example, having a largest dimension perpendicular to fluid flow of less than about 5 mm, less than about 2 mm, less than about 1 mm, less than about 500 microns, less than about 200 microns, less than about 100 microns, less than about 60 microns, less than about 50 microns, less than about 40 microns, less than about 30 microns, less than about 25 microns, less than about 10 microns, less than about 3 microns, less than about 1 micron, less than about 300 nm, less than about 100 nm, less than about 30 nm, or less than about 10 mm or less in some cases.
- A “main channel” is a channel of the device of the invention which permits the flow of molecules, cells, small molecules or particles past a coalescence module for coalescing one or more droplets, and, if present, a detection module for detection (identification) or measurement of a droplet and a sorting module for sorting a droplet based on the detection in the detection module. The main channel is typically in fluid communication with the coalescence, detection and/or sorting modules, as well as, an inlet channel of the inlet module. The main channel is also typically in fluid communication with an outlet module and optionally with branch channels, each of which may have a collection module or waste module. These channels permit the flow of molecules, cells, small molecules or particles out of the main channel. An “inlet channel” permits the flow of molecules, cells, small molecules or particles into the main channel. One or more inlet channels communicate with one or more means for introducing a sample into the device of the present invention. The inlet channel communicates with the main channel at an inlet module.
- The microfluidic substrate can also comprise one or more fluid channels to inject or remove fluid in between droplets in a droplet stream for the purpose of changing the spacing between droplets.
- The channels of the device of the present invention can be of any geometry as described. However, the channels of the device can comprise a specific geometry such that the contents of the channel are manipulated, e.g., sorted, mixed, prevent clogging, etc.
- A microfluidic substrate can also include a specific geometry designed in such a manner as to prevent the aggregation of biological/chemical material and keep the biological/chemical material separated from each other prior to encapsulation in droplets. The geometry of channel dimension can be changed to disturb the aggregates and break them apart by various methods, that can include, but is not limited to, geometric pinching (to force cells through a (or a series of) narrow region(s), whose dimension is smaller or comparable to the dimension of a single cell) or a barricade (place a series of barricades on the way of the moving cells to disturb the movement and break up the aggregates of cells).
- To prevent material (e.g., cells and other particles or molecules) from adhering to the sides of the channels, the channels (and coverslip, if used) may have a coating which minimizes adhesion. The surface of the channels of the microfluidic device can be coated with any anti-wetting or blocking agent for the dispersed phase. The channel can be coated with any protein to prevent adhesion of the biological/chemical sample. Channels can be coated by any means known in the art. For example, the channels are coated with Teflon®, BSA, PEG-silane and/or fluorosilane in an amount sufficient to prevent attachment and prevent clogging. In another example, the channels can be coated with a cyclized transparent optical polymer obtained by copolymerization of perfluoro (alkenyl vinyl ethers), such as the type sold by Asahi Glass Co. under the trademark Cytop. In such an example, the coating is applied from a 0.1-0.5 wt % solution of Cytop CTL-809M in CT-Solv 180. This solution can be injected into the channels of a microfluidic device via a plastic syringe. The device can then be heated to about 90° C. for 2 hours, followed by heating at 200° C. for an additional 2 hours. In another embodiment, the channels can be coated with a hydrophobic coating of the type sold by PPG Industries, Inc. under the trademark Aquapel (e.g., perfluoroalkylalkylsilane surface treatment of plastic and coated plastic substrate surfaces in conjunction with the use of a silica primer layer) and disclosed in U.S. Pat. No. 5,523,162. By fluorinating the surfaces of the channels, the continuous phase preferentially wets the channels and allows for the stable generation and movement of droplets through the device. The low surface tension of the channel walls thereby minimizes the accumulation of channel clogging particulates.
- The surface of the channels in the microfluidic device can be also fluorinated by any means known in the art to prevent undesired wetting behaviors. For example, a microfluidic device can be placed in a polycarbonate dessicator with an open bottle of (tridecafluoro-1,1,2,2-tetrahydrooctyl)trichlorosilane. The dessicator is evacuated for 5 minutes, and then sealed for 20-40 minutes. The dessicator is then backfilled with air and removed. This approach uses a simple diffusion mechanism to enable facile infiltration of channels of the microfluidic device with the fluorosilane and can be readily scaled up for simultaneous device fluorination.
- Fluids
- The fluids described herein are related to the fluids within the droplet libraries and to the fluids within a microfluidic device.
- The microfluidic device of the present invention is capable of controlling the direction and flow of fluids and entities within the device. The term “flow” means any movement of liquid or solid through a device or in a method of the invention, and encompasses without limitation any fluid stream, and any material moving with, within or against the stream, whether or not the material is carried by the stream. For example, the movement of molecules, beads, cells or virions through a device or in a method of the invention, e.g. through channels of a microfluidic chip of the invention, comprises a flow. This is so, according to the invention, whether or not the molecules, beads, cells or virions are carried by a stream of fluid also comprising a flow, or whether the molecules, cells or virions are caused to move by some other direct or indirect force or motivation, and whether or not the nature of any motivating force is known or understood. The application of any force may be used to provide a flow, including without limitation, pressure, capillary action, electro-osmosis, electrophoresis, dielectrophoresis, optical tweezers, and combinations thereof, without regard for any particular theory or mechanism of action, so long as molecules, cells or virions are directed for detection, measurement or sorting according to the invention. Specific flow forces are described in further detail herein.
- The flow stream in the main channel is typically, but not necessarily, continuous and may be stopped and started, reversed or changed in speed. A liquid that does not contain sample molecules, cells or particles can be introduced into a sample inlet well or channel and directed through the inlet module, e.g., by capillary action, to hydrate and prepare the device for use. Likewise, buffer or oil can also be introduced into a main inlet region that communicates directly with the main channel to purge the device (e.g., or “dead” air) and prepare it for use. If desired, the pressure can be adjusted or equalized, for example, by adding buffer or oil to an outlet module.
- As used herein, the term “fluid stream” or “fluidic stream” refers to the flow of a fluid, typically generally in a specific direction. The fluidic stream may be continuous and/or discontinuous. A “continuous” fluidic stream is a fluidic stream that is produced as a single entity, e.g., if a continuous fluidic stream is produced from a channel, the fluidic stream, after production, appears to be contiguous with the channel outlet. The continuous fluidic stream is also referred to as a continuous phase fluid or carrier fluid. The continuous fluidic stream may be laminar, or turbulent in some cases.
- Similarly, a “discontinuous” fluidic stream is a fluidic stream that is not produced as a single entity. The discontinuous fluidic stream is also referred to as the dispersed phase fluid or sample fluid. A discontinuous fluidic stream may have the appearance of individual droplets, optionally surrounded by a second fluid. The dispersed phase fluid can include a biological/chemical material. The biological/chemical material can be tissues, cells, particles, proteins, antibodies, amino acids, nucleotides, small molecules, and pharmaceuticals. The biological/chemical material can include one or more labels known in the art. The label can be an optical label, an enzymatic label or a radioactive label. The label can be any detectable label, e.g., a protein, a DNA tag, a dye, a quantum dot or a radio frequency identification tag, or combinations thereof. Preferably the label is an optical label. The label can be detected by any means known in the art. Preferably, the label is detected by fluorescence polarization, fluorescence intensity, fluorescence lifetime, fluorescence energy transfer, pH, ionic content, temperature or combinations thereof. Various labels and means for detection are described in greater detail herein.
- The term “emulsion” refers to a preparation of one liquid distributed in small globules (also referred to herein as drops, droplets or NanoReactors) in the body of a second liquid. The first and second fluids are immiscible with each other. For example, the discontinuous phase can be an aqueous solution and the continuous phase can a hydrophobic fluid such as an oil. This is termed a water in oil emulsion. Alternatively, the emulsion may be a oil in water emulsion. In that example, the first liquid, which is dispersed in globules, is referred to as the discontinuous phase, whereas the second liquid is referred to as the continuous phase or the dispersion medium. The continuous phase can be an aqueous solution and the discontinuous phase is a hydrophobic fluid, such as an oil (e.g., decane, tetradecane, or hexadecane). The droplets or globules of oil in an oil in water emulsion are also referred to herein as “micelles”, whereas globules of water in a water in oil emulsion may be referred to as “reverse micelles”.
- The fluidic droplets may each be substantially the same shape and/or size. The droplets may be uniform in size. The shape and/or size can be determined, for example, by measuring the average diameter or other characteristic dimension of the droplets. The “average diameter” of a plurality or series of droplets is the arithmetic average of the average diameters of each of the droplets. Those of ordinary skill in the art will be able to determine the average diameter (or other characteristic dimension) of a plurality or series of droplets, for example, using laser light scattering, microscopic examination, or other known techniques. The diameter of a droplet, in a non-spherical droplet, is the mathematically-defined average diameter of the droplet, integrated across the entire surface. The average diameter of a droplet (and/or of a plurality or series of droplets) may be, for example, less than about 1 mm, less than about 500 micrometers, less than about 200 micrometers, less than about 100 micrometers, less than about 75 micrometers, less than about 50 micrometers, less than about 25 micrometers, less than about 10 micrometers, or less than about 5 micrometers in some cases. The average diameter may also be at least about 1 micrometer, at least about 2 micrometers, at least about 3 micrometers, at least about 5 micrometers, at least about 10 micrometers, at least about 15 micrometers, or at least about 20 micrometers in certain cases.
- As used herein, the term “NanoReactor” and its plural encompass the terms “droplet”, “nanodrop”, “nanodroplet”, “microdrop” or “microdroplet” as defined herein, as well as an integrated system for the manipulation and probing of droplets, as described in detail herein. Nanoreactors as described herein can be 0.1-1000 μm (e.g., 0.1, 0.2 . . . 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 . . . 1000), or any size within this range. Droplets at these dimensions tend to conform to the size and shape of the channels, while maintaining their respective volumes. Thus, as droplets move from a wider channel to a narrower channel they become longer and thinner, and vice versa.
- The microfluidic substrate of this invention most preferably generate round, highly uniform, monodisperse droplets (<1.5% polydispersity). Droplets and methods of forming monodisperse droplets in microfluidic channels is described in WO 2006/040551; WO 2006/040554; WO 2004/002627; WO 2004/091763; WO 2005/021151; WO 2006/096571; WO 2007/089541; WO 2007/081385 and WO 2008/063227.
- The droplet forming liquid is typically an aqueous buffer solution, such as ultrapure water (e.g., 18 mega-ohm resistivity, obtained, for example by column chromatography), 10 mM Tris HCl and 1 mM EDTA (TE) buffer, phosphate buffer saline (PBS) or acetate buffer. Any liquid or buffer that is physiologically compatible with the population of molecules, cells or particles to be analyzed and/or sorted can be used. The fluid passing through the main channel and in which the droplets are formed is one that is immiscible with the droplet forming fluid. The fluid passing through the main channel can be a non-polar solvent, decane (e.g., tetradecane or hexadecane), fluorocarbon oil, silicone oil or another oil (for example, mineral oil).
- The droplet may also contain biological/chemical material (e.g., molecules, cells, or other particles) for combination, analysis and/or sorting in the device. The droplets of the dispersed phase fluid can contain more than one particle or can contain no more than one particle.
- Droplets of a sample fluid can be formed within the inlet module on the microfluidic device or droplets (or droplet libraries) can be formed before the sample fluid is introduced to the microfluidic device (“off chip” droplet formation). To permit effective interdigitation, coalescence and detection, the droplets comprising each sample to be analyzed must be monodisperse. As described in more detail herein, in many applications, different samples to be analyzed are contained within droplets of different sizes. Droplet size must be highly controlled to ensure that droplets containing the correct contents for analysis and coalesced properly. As such, the present invention provides devices and methods for forming droplets and droplet libraries.
- Surfactants
- The fluids used in the invention may contain one or more additives, such as agents which reduce surface tensions (surfactants). Surfactants can include Tween, Span, fluorosurfactants, and other agents that are soluble in oil relative to water. In some applications, performance is improved by adding a second surfactant to the aqueous phase. Surfactants can aid in controlling or optimizing droplet size, flow and uniformity, for example by reducing the shear force needed to extrude or inject droplets into an intersecting channel. This can affect droplet volume and periodicity, or the rate or frequency at which droplets break off into an intersecting channel. Furthermore, the surfactant can serve to stabilize aqueous emulsions in fluorinated oils from coalescing. The present invention provides compositions and methods to stabilize aqueous droplets in a fluorinated oil and minimize the transport of positively charged reagents (particularly, fluorescent dyes) from the aqueous phase to the oil phase.
- The droplets may be coated with a surfactant. Preferred surfactants that may be added to the continuous phase fluid include, but are not limited to, surfactants such as sorbitan-based carboxylic acid esters (e.g., the “Span” surfactants, Fluka Chemika), including sorbitan monolaurate (Span 20), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60) and sorbitan monooleate (Span 80), and perfluorinated polyethers (e.g., DuPont Krytox 157 FSL, FSM, and/or ESH). Other non-limiting examples of non-ionic surfactants which may be used include polyoxyethylenated alkylphenols (for example, nonyl-, p-dodecyl-, and dinonylphenols), polyoxyethylenated straight chain alcohols, polyoxyethylenated polyoxypropylene glycols, polyoxyethylenated mercaptans, long chain carboxylic acid esters (for example, glyceryl and polyglycerl esters of natural fatty acids, propylene glycol, sorbitol, polyoxyethylenated sorbitol esters, polyoxyethylene glycol esters, etc.) and alkanolamines (e.g., diethanolamine-fatty acid condensates and isopropanolamine-fatty acid condensates). In addition, ionic surfactants such as sodium dodecyl sulfate (SDS) may also be used. However, such surfactants are generally less preferably for many embodiments of the invention. For instance, in those embodiments where aqueous droplets are used as nanoreactors for chemical reactions (including biochemical reactions) or are used to analyze and/or sort biomaterials, a water soluble surfactant such as SDS may denature or inactivate the contents of the droplet.
- The carrier fluid can be an oil (e.g., decane, tetradecane or hexadecane) or fluorocarbon oil that contains a surfactant (e.g., a non-ionic surfactant such as a Span surfactant) as an additive (preferably between about 0.2 and 5% by volume, more preferably about 2%). A user can preferably cause the carrier fluid to flow through channels of the microfluidic device so that the surfactant in the carrier fluid coats the channel walls.
- Fluorocarbon oil continuous phases are well-suited as the continuous phase for aqueous droplet libraries for a number of reasons. Fluorous oils are both hydrophobic and lipophobic. Therefore, they have low solubility for components of the aqueous phase and they limit molecular diffusion between droplets. Also, fluorous oils present an inert interface for chemistry and biology within droplets. In contrast to hydrocarbon or silicone oils, fluorous oils do not swell PDMS materials, which is a convenient material for constructing microfluidic channels. Finally, fluorocarbon oils have good solubility for gases, which is necessary for the viability of encapsulated cells.
- Combinations of surfactant(s) and oils must be developed to facilitate generation, storage, and manipulation of droplets to maintain the unique chemical/biochemical/biological environment within each droplet of a diverse library. Therefore, the surfactant and oil combination must (1) stabilize droplets against uncontrolled coalescence during the drop forming process and subsequent collection and storage, (2) minimize transport of any droplet contents to the oil phase and/or between droplets, and (3) maintain chemical and biological inertness with contents of each droplet (e.g., no adsorption or reaction of encapsulated contents at the oil-water interface, and no adverse effects on biological or chemical constituents in the droplets). In addition to the requirements on the droplet library function and stability, the surfactant-in-oil solution must be coupled with the fluid physics and materials associated with the platform. Specifically, the oil solution must not swell, dissolve, or degrade the materials used to construct the microfluidic chip, and the physical properties of the oil (e.g., viscosity, boiling point, etc.) must be suited for the flow and operating conditions of the platform.
- Droplets formed in oil without surfactant are not stable to permit coalescence, so surfactants must be dissolved in the fluorous oil that is used as the continuous phase for the emulsion library. Surfactant molecules are amphiphilic part of the molecule is oil soluble, and part of the molecule is water soluble. When a water-oil interface is formed at the nozzle of a microfluidic chip for example in the inlet module described herein, surfactant molecules that are dissolved in the oil phase adsorb to the interface. The hydrophilic portion of the molecule resides inside the droplet and the fluorophilic portion of the molecule decorates the exterior of the droplet. The surface tension of a droplet is reduced when the interface is populated with surfactant, so the stability of an emulsion is improved. In addition to stabilizing the droplets against coalescence, the surfactant should be inert to the contents of each droplet and the surfactant should not promote transport of encapsulated components to the oil or other droplets.
- A very large body of fundamental research and commercial application development exists for non-fluorous surfactants and emulsions ranging from sub-micron droplets to very large, macroscopic emulsions. In contrast, fundamental knowledge and commercial practice with fluorinated oils and surfactants is much less common. More specifically, testing and development of fluorosurfactants and fluorous oil formulations for the application of creating large libraries of micron-scale droplets with unique composition is limited to only a few groups throughout the world. Only a few commercially-available fluorosurfactants that stabilize water-in-fluorocarbon oil emulsions exist. For instance, surfactants with short fluorotelomer-tails (typically perfluorinated C6 to C10) are available, but they do not provide sufficient long-term emulsion stability. Fluorosurfactants with longer fluorocarbon tails, such as perfluoropolyether (PFPE), are limited to molecules with ionic headgroups.
- Classes of oils are available from wide variety of fluorinated oils and are available from commercial sources. The requirements for the oil are (1) immiscibility with the aqueous phase, (2) solubility of emulsion stabilizing surfactants in the oil, and (3) compatibility and/or insolubility of reagents from the droplet phase. Oils include hydrofluoroethers, which are fluorinated alkyl chains coupled with hydrocarbon chemistry through and ether bond. One supplier of this type of oil is 3M. The products are marketed as Novec Engineered Fluids or HFE-series oils. This oils include but are not limited to, HFE-7500, which is a preferred embodiment as it provides superior droplet stability seems to be higher. Other oils include HFE-7100, -7200, -7600, which are examples of other HFEs available from 3M. These can be used as stand-alone oils or components of oil mixtures to optimize emulsion properties and performance. Other hydrofluoroethers are also available from other producers, distributors, or resellers may offer hydrofluoroethers.
- Another class of oil is perfluoroalkylamines, which are perfluorinated oils based on perfluoroalkyl amine structures. 3M produces these oils as Fluorinert Electronic Liquids (FC-oils). Fluorinert products differ by variations in alkyl chain length, branch structure, and combinations of different structures or pure oils. Many of them offer the potential for stand-alone oils or components of oil mixtures to optimize emulsion properties and performance. Specific examples are Fluorinert FC-3283, Fluorinert FC-40, which are a preferred embodiments. Higher viscosity and boiling point useful for applications requiring elevated temperature (e.g., thermocyling for PCR). Other Fluorinert series can be used for stand-alone oils or components of oil mixtures to optimize emulsion properties and performance. Again, other perfluoroalkylamines are available from other producers, distributors, or resellers may offer perfluoroalkylamines.
- Fluorinated organics/solvents offer a number of perfluorinated or partially fluorinated solvents are available from a variety of producers, distributors, and/or resellers. Many of them offer the potential for stand-alone oils or components of oil mixtures to optimize emulsion properties and performance. Examples of fluorinated organic reagents utilized, included (but not limited to) trifluoroacetic acid and hexafluoroisopropanol, to improve droplet stability in other fluorinated oil systems. Additionally, fluoropolymers may also be used within a microfluidic system. Examples of fluoropolymers include, Krytox GPL oils, Solvay Galden oils, and other liquid fluoropolymers. Other fluorinated materials find widespread use in a variety of industries, but they are generally not well-known in the disciplines of interfacial, colloidal, physical, or synthetic organic chemistry. Therefore, a number of other candidates for oils exist in specialty and niche market applications. As such, new oils have been targeted partially that are per-fluorinated materials, which are not widely recognized.
- The properties of oils selected are based upon their chemical properties, such as, among others molecular structure, fluorine content and solvating strength. Physical properties of oils examined include viscosity, boiling point, thermal expansion coefficient, oil-in-water solubility, water-in-oil solubility, dielectric constant, polarity, and oil-in-water surface tension.
- Classes of surfactants include fluorosurfactants that can be categorized by the type of fluorophilic portion of the molecule, the type of hydrophilic, or polar, portion, and the chemistry used to link the different parts of the molecule. Materials developed are capable of stabilizing an emulsion or droplet library. The preferred embodiment is the EA surfactant. Specifically, the EA surfactant is a Krytox-PFG-Krytox. The EA surfactant is a nonionic tri-block copolymer surfactant was developed to avoid issues that the ionic surfactants (e.g., RR, see below) which result from the use of some other ionic surfactant. Specifically, ionic surfactants interact with charged species in the droplets and can sequester ions (e.g., magnesium required for the PCR reaction) or other reagents to the oil phase. The structure of the EA surfactant comprises a PEG—approximately 600 Da with amine end functionality, PFPE—Mn is ˜5000-8000 from a Krytox FSH starting material and the linker is an amide coupling. Another surfactant includes the R R surfactant, which is a Krytox ammonium carboxylate.
- Alternative materials are alternative fluorophilic portion, i.e., PFPE (Solvay or Demnum), Poly(fluoroalkylacrylate) and other non-polymeric and partially fluorinated materials. Alternative head-group chemistry for the hydrophilic portion includes, non-ionic head groups like PEG (Mw, Mw/Mn (PDI)) and functionality (i.e., diblock, triblock and dendritic). Others include morpholino. Ionic head groups for the hydrophilic portion include anionic, such as elemental and amine salts and further cationic head portions. Other head group chemistries include zwitterionic, hybrid (e.g., PEG-ionic and zonyl FSO/FSN), lipophilic (e.g, lipophilic to promote bilayer and lipophilic spacer to hydrophile). Another alternative is alternative coupling chemistry such as, phosphoryl/Friedel-Crafts, spacer to organic handle and others.
- Characteristics of surfactants are their molecular structure, determined by NMR, chromatography (e.g., HPLC, GPC/SEC), FTIR, mass spectrometry, and titrations. Purity of surfactants is another characteristic examined in addition to the fluorophile-hydrophile balance.
- A preferred embodiment includes oil-surfactant formulation for the application of library emulsions is R-oil (HFE-7500) mixed with 2 wt % EA surfactant (“REA20”). Concentrations of EA or RR surfactant at 0.1 wt % or lower to 5% or greater. Other formulations of oils and surfactants and other components added to the aqueous phase are used to improved and optimized the performance of the droplets performance. Those properties of the oil-surfactant mixture include simple mixtures (i.e., one oil and one surfactant, with varied surface concentration), co-surfactants, oil mixtures and additives, such as zonyl and TFA.
- Oil and surfactant mixture properties include surfactant solubility, critical micelle concentration (CMC), surfactant diffusivity, and interfacial tension, i.e., dynamic and equilibrium. Emulsion properties are also accounted for, those properties include size (absolute and size distribution), stability, transport, and biocompatibility. Stability relates directly to the coalesced droplets and their deformability/breaking and shredding ability. More particularly, the stability of the droplets in their generation, storage and shipping.
- In general, production of surfactant and oils begins with the synthesis of surfactants and starting materials, such as PEG-diamine, EA and RR and also accounts for the purification processes, characterization, quality control, mixing and packaging.
- In one embodiment, the fluorosurfactant can be prepared by reacting the perflourinated polyether DuPont Krytox 157 FSL, FSM, or FSH with aqueous ammonium hydroxide in a volatile fluorinated solvent. The solvent and residual water and ammonia can be removed with a rotary evaporator. The surfactant can then be dissolved (e.g., 2.5 wt %) in a fluorinated oil (e.g., Flourinert (3M)), which then serves as the continuous phase of the emulsion.
- In another embodiment, a quaternary ammonium salt at the terminus of a hydrophilic oligomer is linked to a perfluoropolyether tail as shown in the following formula:
- PFPE-(O)NH—H2CH2CH2CH2—(OCH2CH2)3O—CH2CH2CH2—N(CH3)3+I-Some specific molecular features of the present invention include, but are not limited to, PFPE is from Krytox 157 FSH (Mn˜6500), amide bond linking PFPE to hydrophile, propyl group immediately adjacent to the amide, propyl group immediately adjacent to the trimethylamino terminus. Specific structural formations can alter performance relationships, for example, PFPE chain is sufficiently long for molecule to be soluble in perfluorinated oils, amide linker provides hydrolytic stability and hydrogen bonding site, and a combination of PEG and quaternary ammonium cation provide high anchoring strength to the aqueous phase as well as electrostatic repulsion and steric hindrance to minimize reagent transport.
- Variables in the molecular structure include, but are not limited to, PFPE molecular weight and polydispersity, PFPE structure, alternative perfluorinated tail chemistries, PEG molecular weight and polydispersity, shorter hydrocarbon linkers (ethyl or methyl versus propyl), longer hydrocarbon spacers (C4 or higher), alternative counterions, such as monovalent anions, monovalent, polyatomic anions and di- or tri-valent counterions (to produce two or more tail fluorosurfactants). Further variables in the molecule structure include alternative linker chemistries (e.g., ether, ester, etc), alternative hydrophilic oligomers (e.g., polyalcohol, polyacrylamide, etc.), alternative quaternary ammonium cations, and alternative ionic groups (e.g., anionic terminus—carboxylate etc.; alternative cations).
- The present invention is also directed to the coupling of PEG-diamines with carboxylic acid-terminated perfluoropolyether (Krytox 157) to form surfactants. Specifically, the present invention is directed to a fluorosurfactant molecule made by the ionic coupling of amine-terminated polyethyleneglycol (PEG-amine) with the carboxylic acid of DuPont Krytox perfluoropolyether (PFPE). The resulting structure conveys good performance in the stabilization of aqueous droplets in fluorinated oil in a microfluidic system. Examples of specific surfactants are shown in Examples 1 and 2. Preferred surfactants are also described in WO 2008/021123.
- The present invention provides droplets with a fluorosurfactant interface separating the aqueous droplet and its contents from the surrounding immiscible fluorocarbon oil. In one example, DNA amplification reactions occurring inside these droplets generate material that does not interact with the channel walls, and collection of the DNA-containing droplets for subsequent manipulation and sequencing is straightforward. This technology provides a solution for amplification of DNA from single cells, allowing for both genotyping and whole genome amplification. In addition, use within a microfluidic device or platform as described herein achieves very high throughput, with droplets processed at rates in excess of 5000 droplets per second, enabling greater than 1×106 single-cell droplets to be formed and manipulated per hour.
- Other examples of materials related to this invention include the formation of salts made by combination of various primary, secondary, or tertiary amines with PFPE carboxylic acid. The resulting amphiphilic structure could be useful as a stand-alone surfactant or a cosurfactant. Similarly, fluorinated materials with carboxylic acids other than Krytox PFPE could be used to form ionic fluorosurfactants with various amine containing compounds.
- Alternative amine-containing compounds for use with the present invention include, but are not limited to, PEG-monoamine (molecular weights range from 200 to 1,000,000 or more), PEG-diamine (molecular weights range from 200 to 1,000,000 or more), Multifunctional PEG amines (e.g., branched or dendritic structures), other hydrophilic polymers terminated with amines. Sugars include, but are not limited to, Sugars, Peptides, Biomolecules, Ethanolamine or Alkyl amines—primary, secondary, or tertiary (e.g., triethylamine, trimethylamine, methylamine, ethylamine, butylamine)
- Alternative fluorinated groups for use with the present invention include, but are not limited to, Krytox FSL and FSM (alternative molecular weights), Demnum PFPE materials, Fluolink PFPE materials or Fluorinated small molecules with carboxylic acids.
- The data described herein show that the fluorosurfactants comprised of PEG amine salts provide better performance (compared to other fluorosurfactants) for stabilization of aqueous droplets in fluorinated oils in droplet-based microfluidics applications. These novel surfactants are useful either in combination with other surfactants or as a stand-alone surfactant system.
- Driving Forces
- The invention can use pressure drive flow control, e.g., utilizing valves and pumps, to manipulate the flow of cells, particles, molecules, enzymes or reagents in one or more directions and/or into one or more channels of a microfluidic device. However, other methods may also be used, alone or in combination with pumps and valves, such as electro-osmotic flow control, electrophoresis and dielectrophoresis as described in Fulwyer, Science 156, 910 (1974); Li and Harrison, Analytical Chemistry 69, 1564 (1997); Fiedler, et al. Analytical Chemistry 70, 1909-1915 (1998) and U.S. Pat. No. 5,656,155. Application of these techniques according to the invention provides more rapid and accurate devices and methods for analysis or sorting, for example, because the sorting occurs at or in a sorting module that can be placed at or immediately after a detection module. This provides a shorter distance for molecules or cells to travel, they can move more rapidly and with less turbulence, and can more readily be moved, examined, and sorted in single file, i.e., one at a time.
- Positive displacement pressure driven flow is a preferred way of controlling fluid flow and dielectrophoresis is a preferred way of manipulating droplets within that flow. The pressure at the inlet module can also be regulated by adjusting the pressure on the main and sample inlet channels, for example, with pressurized syringes feeding into those inlet channels. By controlling the pressure difference between the oil and water sources at the inlet module, the size and periodicity of the droplets generated may be regulated. Alternatively, a valve may be placed at or coincident to either the inlet module or the sample inlet channel connected thereto to control the flow of solution into the inlet module, thereby controlling the size and periodicity of the droplets. Periodicity and droplet volume may also depend on channel diameter, the viscosity of the fluids, and shear pressure. Examples of driving pressures and methods of modulating flow are as described in WO 2006/040551; WO 2006/040554; WO 2004/002627; WO 2004/091763; WO 2005/021151; WO 2006/096571; WO 2007/089541; WO 2007/081385 and WO 2008/063227; U.S. Pat. No. 6,540,895 and U.S. Patent Application Publication Nos. 20010029983 and 20050226742
- Inlet Module
- The microfluidic device of the present invention includes one or more inlet modules. An “inlet module” is an area of a microfluidic substrate device that receives molecules, cells, small molecules or particles for additional coalescence, detection and/or sorting. The inlet module can contain one or more inlet channels, wells or reservoirs, openings, and other features which facilitate the entry of molecules, cells, small molecules or particles into the substrate. A substrate may contain more than one inlet module if desired. Different sample inlet channels can communicate with the main channel at different inlet modules. Alternately, different sample inlet channels can communication with the main channel at the same inlet module. The inlet module is in fluid communication with the main channel. The inlet module generally comprises a junction between the sample inlet channel and the main channel such that a solution of a sample (i.e., a fluid containing a sample such as molecules, cells, small molecules (organic or inorganic) or particles) is introduced to the main channel and forms a plurality of droplets. The sample solution can be pressurized. The sample inlet channel can intersect the main channel such that the sample solution is introduced into the main channel at an angle perpendicular to a stream of fluid passing through the main channel. For example, the sample inlet channel and main channel intercept at a T-shaped junction; i.e., such that the sample inlet channel is perpendicular (90 degrees) to the main channel. However, the sample inlet channel can intercept the main channel at any angle, and need not introduce the sample fluid to the main channel at an angle that is perpendicular to that flow. The angle between intersecting channels is in the range of from about 60 to about 120 degrees. Particular exemplary angles are 45, 60, 90, and 120 degrees.
- Embodiments of the invention are also provided in which there are two or more inlet modules introducing droplets of samples into the main channel. For example, a first inlet module may introduce droplets of a first sample into a flow of fluid in the main channel and a second inlet module may introduce droplets of a second sample into the flow of fluid in main channel, and so forth. The second inlet module is preferably downstream from the first inlet module (e.g., about 30 μm). The fluids introduced into the two or more different inlet modules can comprise the same fluid or the same type of fluid (e.g., different aqueous solutions). For example, droplets of an aqueous solution containing an enzyme are introduced into the main channel at the first inlet module and droplets of aqueous solution containing a substrate for the enzyme are introduced into the main channel at the second inlet module. Alternatively, the droplets introduced at the different inlet modules may be droplets of different fluids which may be compatible or incompatible. For example, the different droplets may be different aqueous solutions, or droplets introduced at a first inlet module may be droplets of one fluid (e.g., an aqueous solution) whereas droplets introduced at a second inlet module may be another fluid (e.g., alcohol or oil).
- Filters
- An important element in making libraries utilizing the microfluidic device of the present invention is to include features in the channels of the device to remove particles that may effect the microfluidic system. When emulsions are injected or re-injected onto a microfluidic device, they carry contaminants that collect at the nozzle and either clog the nozzle and/or induce uncontrolled coalescence up to the complete shredding of the emulsion. Debris/contaminants include small debris, such as dust or TCS, fibers, goop (glue and/or surfactant) and large debris such as PDMS skins/shavings. In one example, the present invention provides a post trap for large debris, a pocket trap for small debris, a serpentine trap for fibers and a step trap for large droplets/debris. EAP filters work well to filter out the contaminants.
- The filter system filters out these contaminants and most importantly traps the contaminants out of the main pathway and allow the droplets to pass by so the contaminants cannot induce uncontrolled coalescence. The present invention comprises two distinct parts that specifically address two different scales. The first filters contaminants that are larger than the droplet size. The second filters contaminants that are smaller than the droplet and nozzle sizes. The large contaminants are easily trapped but are responsible for inducing uncontrolled coalescence, the small contaminants tend to stick to the nozzle and most probably induce wetting that results in the shredding of the emulsion.
- To address the issue of large contaminants, a triangular shape filter is used that contains an internal-collection channel and smaller lateral channels connected to the internal-collection channel with a specific angle. On each side of the triangle are pockets to collect the contaminants that have been deflected by the triangle and directed there by the flow of the droplets due to the specific angle of the filter. In addition, the collection pockets are connected to a channel of high hydrodynamic resistance so that some of the flow will still go through and maintain the contaminants in the collection pockets. The lateral collection channels are located at a stepwise transition between a shallow layer and a deep layer. In one example, he droplets are collected in the Droplet Collection Channel through the lateral angled channels. The contaminants are deflected toward the Contaminant Collection Pocket because of the triangular shape and the droplet flow. Because of the use of high resistance channel for the Contaminants Collection Pockets, the droplets go through them only marginally, but enough to force the trapped contaminants to stay there.
- To address the issue of the small contaminants, a series of posts are used, each one being offset by a half-period to the adjacent ones. This geometry intends to create a region of null-recirculation flow at the tip of each post due to the symmetry and contaminants are trapped in that region. In addition, the posts have an indentation to both increase the effect of the flow pattern described above and to trap the contaminants so that they are out of the way of the droplets. The posts can be designed just with an indentation or with a flow-through restriction of high hydrodynamic resistance so that the contaminants will be directed and trapped deep in the structure. The symmetrical design creates a region where there is almost no flow, in this region creates the conditions to trap the contaminants that are smaller than the droplets. The droplets follow the main flow because of the high hydrodynamic resistance conditions. The posts on one side of the channel have a flow-through to ensure that the contaminants stay trapped there; on the other side the posts have only an indentation. Several series of these posts, offset by half of a period are used to increase both the filter capacity and the odds of trapping any given contaminant.
- Droplet Interdigitation
- Particular design embodiments of the microfluidic device described herein allow for a more reproducible and controllable interdigitation of droplets of specific liquids followed by pair-wise coalescence of these droplets, described in further detail herein. The droplet pairs can contain liquids of different compositions and/or volumes, which would then combine to allow for a specific reaction to be investigated. The pair of droplets can come from any of the following: (i) two continuous aqueous streams and an oil stream; (ii) a continuous aqueous stream, an emulsion stream, and an oil stream, or (iii) two emulsion streams and an oil stream. The term “interdigitation” as used herein means pairing of droplets from separate aqueous streams, or from two separate inlet nozzles, for eventual coalescence.
- Various nozzle designs enhance the interdigitation of droplets and further improves coalescence of droplets due to the better control of the interdigitation and smaller distance between pairs of droplets. The greater control over interdigitation allows for a perfect control over the frequency of either of the droplets. To obtain the optimum operation, the spacing between droplets and coupling of the droplets can be adjusted by adjusting flow of any of the streams, viscosity of the streams, nozzle design (including orifice diameter, the channel angle, and post-orifice neck of the nozzle). Examples of preferred nozzle designs are as described in WO 2007/081385 and WO 2008/063227.
- Reservoir/Well
- A device of the invention can include a sample solution reservoir or well or other apparatus for introducing a sample to the device, at the inlet module, which is typically in fluid communication with an inlet channel. Reservoirs and wells used for loading one or more samples onto the microfluidic device of the present invention, include but are not limited to, syringes, cartridges, vials, eppendorf tubes and cell culture materials (e.g., 96 well plates). A reservoir may facilitate introduction of molecules or cells into the device and into the sample inlet channel of each analysis unit.
- Coalescence Module
- The microfluidic device of the present invention also includes one or more coalescence modules. A “coalescence module” is within or coincident with at least a portion of the main channel at or downstream of the inlet module where molecules, cells, small molecules or particles comprised within droplets are brought within proximity of other droplets comprising molecules, cells, small molecules or particles and where the droplets in proximity fuse, coalesce or combine their contents. The coalescence module can also include an apparatus, for generating an electric force.
- The electric force exerted on the fluidic droplet may be large enough to cause the droplet to move within the liquid. In some cases, the electric force exerted on the fluidic droplet may be used to direct a desired motion of the droplet within the liquid, for example, to or within a channel or a microfluidic channel (e.g., as further described herein), etc.
- The electric field can be generated from an electric field generator, i.e., a device or system able to create an electric field that can be applied to the fluid. The electric field generator may produce an AC field (i.e., one that varies periodically with respect to time, for example, sinusoidally, sawtooth, square, etc.), a DC field (i.e., one that is constant with respect to time), a pulsed field, etc. The electric field generator may be constructed and arranged to create an electric field within a fluid contained within a channel or a microfluidic channel. The electric field generator may be integral to or separate from the fluidic system containing the channel or microfluidic channel, according to some embodiments. As used herein, “integral” means that portions of the components integral to each other are joined in such a way that the components cannot be in manually separated from each other without cutting or breaking at least one of the components.
- Techniques for producing a suitable electric field (which may be AC, DC, etc.) are known to those of ordinary skill in the art. For example, in one embodiment, an electric field is produced by applying voltage across a pair of electrodes, which may be positioned on or embedded within the fluidic system (for example, within a substrate defining the channel or microfluidic channel), and/or positioned proximate the fluid such that at least a portion of the electric field interacts with the fluid. The electrodes can be fashioned from any suitable electrode material or materials known to those of ordinary skill in the art, including, but not limited to, silver, gold, copper, carbon, platinum, copper, tungsten, tin, cadmium, nickel, indium tin oxide (“ITO”), etc., as well as combinations thereof.
- Preferred electrodes and patterned electrically conductive layers are described in WO 2007/081385 and WO 2008/063227 and can be associated with any module of the device (inlet module, coalescence module, mixing module, delay module, detection module and sorting module) to generate dielectric or electric forces to manipulate and control the droplets and their contents.
- Effective control of uncharged droplets within microfluidic devices can require the generation of extremely strong dielectric field gradients. The fringe fields from the edges of a parallel plate capacitor can provide an excellent topology to form these gradients. The microfluidic device according to the present invention can include placing a fluidic channel between two parallel electrodes, which can result in a steep electric field gradient at the entrance to the electrodes due to edge effects at the ends of the electrode pair. Placing these pairs of electrodes at a symmetric channel split can allow precise bi-directional control of droplet within a device. Using the same principle, only with asymmetric splits, can allow single ended control of the droplet direction in the same manner. Alternatively, a variation on this geometry will allow precise control of the droplet phase by shifting.
- Dielectrophoresis is believed to produce movement of dielectric objects, which have no net charge, but have regions that are positively or negatively charged in relation to each other. Alternating, non-homogeneous electric fields in the presence of droplets and/or particles, such as cells or molecules, cause the droplets and/or particles to become electrically polarized and thus to experience dielectrophoretic forces. Depending on the dielectric polarizability of the particles and the suspending medium, dielectric particles will move either toward the regions of high field strength or low field strength. For example, the polarizability of living cells depends on their composition, morphology, and phenotype and is highly dependent on the frequency of the applied electrical field. Thus, cells of different types and in different physiological states generally possess distinctly different dielectric properties, which may provide a basis for cell separation, e.g., by differential dielectrophoretic forces. Likewise, the polarizability of droplets also depends upon their size, shape and composition. For example, droplets that contain salts can be polarized. According to formulas provided in Fiedler, et al. Analytical Chemistry 70, 1909-1915 (1998), individual manipulation of single droplets requires field differences (inhomogeneities) with dimensions close to the droplets.
- The term “dielectrophoretic force gradient” means a dielectrophoretic force is exerted on an object in an electric field provided that the object has a different dielectric constant than the surrounding media. This force can either pull the object into the region of larger field or push it out of the region of larger field. The force is attractive or repulsive depending respectively on whether the object or the surrounding media has the larger dielectric constant.
- Manipulation is also dependent on permittivity (a dielectric property) of the droplets and/or particles with the suspending medium. Thus, polymer particles, living cells show negative dielectrophoresis at high-field frequencies in water. For example, dielectrophoretic forces experienced by a latex sphere in a 0.5 MV/m field (10 V for a 20 micron electrode gap) in water are predicted to be about 0.2 piconewtons (pN) for a 3.4 micron latex sphere to 15 pN for a 15 micron latex sphere (Fiedler, et al. Analytical Chemistry, 70, 1909-1915 (1998)). These values are mostly greater than the hydrodynamic forces experienced by the sphere in a stream (about 0.3 pN for a 3.4 micron sphere and 1.5 pN for a 15 micron sphere). Therefore, manipulation of individual cells or particles can be accomplished in a streaming fluid, such as in a cell sorter device, using dielectrophoresis. Using conventional semiconductor technologies, electrodes can be microfabricated onto a substrate to control the force fields in a microfabricated sorting device of the invention. Dielectrophoresis is particularly suitable for moving objects that are electrical conductors. The use of AC current is preferred, to prevent permanent alignment of ions. Megahertz frequencies are suitable to provide a net alignment, attractive force, and motion over relatively long distances. See U.S. Pat. No. 5,454,472. The electric field generator can be constructed and arranged (e.g., positioned) to create an electric field applicable to the fluid of at least about 0.01 V/micrometer, and, in some cases, at least about 0.03 V/micrometer, at least about 0.05 V/micrometer, at least about 0.08 V/micrometer, at least about 0.1 V/micrometer, at least about 0.3 V/micrometer, at least about 0.5 V/micrometer, at least about 0.7 V/micrometer, at least about 1 V/micrometer, at least about 1.2 V/micrometer, at least about 1.4 V/micrometer, at least about 1.6 V/micrometer, or at least about 2 V/micrometer. In some embodiments, even higher electric field intensities may be used, for example, at least about 2 V/micrometer, at least about 3 V/micrometer, at least about 5 V/micrometer, at least about 7 V/micrometer, or at least about 10 V/micrometer or more.
- As described, an electric field may be applied to fluidic droplets to cause the droplets to experience an electric force. The electric force exerted on the fluidic droplets may be, in some cases, at least about 10−16 N/micrometer3. In certain cases, the electric force exerted on the fluidic droplets may be greater, e.g., at least about 10−15 N/micrometer, at least about 10−14 N/micrometer3, at least about 10−13 N/micrometer3, at least about 10−12 N/micrometer3, at least about 10−11 N/micrometer3, at least about 10−10 N/micrometer3, at least about 10−9 N/micrometer3, at least about 10−8 N/micrometer3, or at least about 10−7 N/micrometer3 or more. The electric force exerted on the fluidic droplets, relative to the surface area of the fluid, may be at least about 10−15 N/micrometer2, and in some cases, at least about 10−14 N/micrometer2, at least about 10−13 N/micrometer2, at least about 10−12 N/micrometer2, at least about 10−11 N/micrometer−2, at least about 10−10 N/micrometer2, at least about 10−9 N/micrometer2, at least about 10−8 N/micrometer2, at least about 10−7 N/micrometer2, or at least about 10−6 N/micrometer2 or more. In yet other embodiments, the electric force exerted on the fluidic droplets may be at least about 10−9 N, at least about 10−8 N, at least about 10−7 N, at least about 10−6 N, at least about 10−5 N, or at least about 10−4 N or more in some cases.
- Channel Expansion Geometries
- In preferred embodiments described herein, droplet coalescence is presently carried out by having two droplet forming nozzles emitting droplets into the same main channel. The size of the nozzles allow for one nozzle to form a large drop that fills the exhaust line while the other nozzle forms a drop that is smaller than the first. The smaller droplet is formed at a rate that is less than the larger droplet rate, which insures that at most one small droplet is between big droplets. Normally, the small droplet will catch up to the larger one over a relatively short distance, but sometimes the recirculation zone behind the large drop causes the small drop to separate from the large drop cyclically. In addition, the small drop occasionally does not catch up with the large one over the distance between the nozzles and the coalescing electrodes. Thus, in some situations is a need for a more robust coalescence scheme.
- Geometric alterations in the coalescence module can create a more robust, reliable coalescence or fusing of droplets over a wider range of sizes and flows. The solution to inprove the performance is to place an expansion in the main channel between the electrodes. Optionally, a small constriction (neckdown) just before this expansion can be used to better align the droplets on their way into the coalescence point. This optional neckdown can help center the small droplet in the channel stream lines, reducing the chance that it will flow around the larger droplet prior to coalescing in the expansion. The electrode pair may be placed on either one side of the channel or on both sides.
- The expansion in the coalescing region allows for a dramatic catching up of the small drop to the large drop, as shown through micrographs taken on an operating device. The volume of the expansion is big enough to slow the large droplet down so that the small drop always catches up to the large drop, but doesn't allow the next large drop to catch up and make contact with the pair to be coalesced. The electrodes allow for coalescence to take place when the drops are in contact with each other and passing through the field gradient.
- Detection Module
- The microfluidic device of the present invention can also include one or more detection modules. A “detection module” is a location within the device, typically within the main channel where molecules, cells, small molecules or particles are to be detected, identified, measured or interrogated on the basis of at least one predetermined characteristic. The molecules, cells, small molecules or particles can be examined one at a time, and the characteristic is detected or measured optically, for example, by testing for the presence or amount of a reporter. For example, the detection module is in communication with one or more detection apparatuses. The detection apparatuses can be optical or electrical detectors or combinations thereof. Examples of suitable detection apparatuses include optical waveguides, microscopes, diodes, light stimulating devices, (e.g., lasers), photo multiplier tubes, and processors (e.g., computers and software), and combinations thereof, which cooperate to detect a signal representative of a characteristic, marker, or reporter, and to determine and direct the measurement or the sorting action at the sorting module. However, other detection techniques can also be employed
- The terms “detecting” or “determining,” as used herein, generally refers to the analysis or measurement of a species, for example, quantitatively or qualitatively, and/or the detection of the presence or absence of the species. “Detecting or “determining” may also refer to the analysis or measurement of an interaction between two or more species, for example, quantitatively or qualitatively, or by detecting the presence or absence of the interaction. Examples of suitable techniques include, but are not limited to, spectroscopy such as infrared, absorption, fluorescence, UV/visible, FTIR (“Fourier Transform Infrared Spectroscopy”), or Raman; gravimetric techniques; ellipsometry; piezoelectric measurements; immunoassays; electrochemical measurements; optical measurements such as optical density measurements; circular dichromism; light scattering measurements such as quasielectric light scattering; polarimetry; refractometry; or turbidity measurements as described further herein.
- A detection module is within, communicating or coincident with a portion of the main channel at or downstream of the inlet module and, in sorting embodiments, at, proximate to, or upstream of, the sorting module or branch point. The sorting module may be located immediately downstream of the detection module or it may be separated by a suitable distance consistent with the size of the molecules, the channel dimensions and the detection system. Precise boundaries for the detection module are not required, but are preferred.
- Sensors
- One or more detections sensors and/or processors may be positioned to be in sensing communication with the fluidic droplet. “Sensing communication,” as used herein, means that the sensor may be positioned anywhere such that the fluidic droplet within the fluidic system (e.g., within a channel), and/or a portion of the fluidic system containing the fluidic droplet may be sensed and/or determined in some fashion. For example, the sensor may be in sensing communication with the fluidic droplet and/or the portion of the fluidic system containing the fluidic droplet fluidly, optically or visually, thermally, pneumatically, electronically, or the like. The sensor can be positioned proximate the fluidic system, for example, embedded within or integrally connected to a wall of a channel, or positioned separately from the fluidic system but with physical, electrical, and/or optical communication with the fluidic system so as to be able to sense and/or determine the fluidic droplet and/or a portion of the fluidic system containing the fluidic droplet (e.g., a channel or a microchannel, a liquid containing the fluidic droplet, etc.). For example, a sensor may be free of any physical connection with a channel containing a droplet, but may be positioned so as to detect electromagnetic radiation arising from the droplet or the fluidic system, such as infrared, ultraviolet, or visible light. The electromagnetic radiation may be produced by the droplet, and/or may arise from other portions of the fluidic system (or externally of the fluidic system) and interact with the fluidic droplet and/or the portion of the fluidic system containing the fluidic droplet in such as a manner as to indicate one or more characteristics of the fluidic droplet, for example, through absorption, reflection, diffraction, refraction, fluorescence, phosphorescence, changes in polarity, phase changes, changes with respect to time, etc. As an example, a laser may be directed towards the fluidic droplet and/or the liquid surrounding the fluidic droplet, and the fluorescence of the fluidic droplet and/or the surrounding liquid may be determined. “Sensing communication,” as used herein may also be direct or indirect. As an example, light from the fluidic droplet may be directed to a sensor, or directed first through a fiber optic system, a waveguide, etc., before being directed to a sensor.
- Non-limiting examples of detection sensors useful in the invention include optical or electromagnetically-based systems. For example, the sensor may be a fluorescence sensor (e.g., stimulated by a laser), a microscopy system (which may include a camera or other recording device), or the like. As another example, the sensor may be an electronic sensor, e.g., a sensor able to determine an electric field or other electrical characteristic. For example, the sensor may detect capacitance, inductance, etc., of a fluidic droplet and/or the portion of the fluidic system containing the fluidic droplet. In some cases, the sensor may be connected to a processor, which in turn, cause an operation to be performed on the fluidic droplet, for example, by sorting the droplet.
- Characteristics
- Characteristics determinable with respect to the droplet and usable in the invention can be identified by those of ordinary skill in the art. Non-limiting examples of such characteristics include fluorescence, spectroscopy (e.g., optical, infrared, ultraviolet, etc.), radioactivity, mass, volume, density, temperature, viscosity, pH, concentration of a substance, such as a biological substance (e.g., a protein, a nucleic acid, etc.), or the like.
- A corresponding signal is then produced, for example indicating that “yes” the characteristic is present, or “no” it is not. The signal may correspond to a characteristic qualitatively or quantitatively. That is, the amount of the signal can be measured and can correspond to the degree to which a characteristic is present. For example, the strength of the signal may indicate the size of a molecule, or the potency or amount of an enzyme expressed by a cell, or a positive or negative reaction such as binding or hybridization of one molecule to another, or a chemical reaction of a substrate catalyzed by an enzyme. In response to the signal, data can be collected and/or a control system in the sorting module, if present, can be activated to divert a droplet into one branch channel or another for delivery to the collection module or waste module. Thus, in sorting embodiments, molecules or cells within a droplet at a sorting module can be sorted into an appropriate branch channel according to a signal produced by the corresponding examination at a detection module. The means of changing the flow path can be accomplished through mechanical, electrical, optical, or some other technique as described herein.
- A preferred detector is an optical detector, such as a microscope, which may be coupled with a computer and/or other image processing or enhancement devices to process images or information produced by the microscope using known techniques. For example, molecules can be analyzed and/or sorted by size or molecular weight. Enzymes can be analyzed and/or sorted by the extent to which they catalyze chemical reaction of a substrate (conversely, substrate can be analyzed and/or sorted by the level of chemical reactivity catalyzed by an enzyme). Cells can be sorted according to whether they contain or produce a particular protein, by using an optical detector to examine each cell for an optical indication of the presence or amount of that protein. The protein may itself be detectable, for example by a characteristic fluorescence, or it may be labeled or associated with a reporter that produces a detectable signal when the desired protein is present, or is present in at least a threshold amount. There is no limit to the kind or number of characteristics that can be identified or measured using the techniques of the invention, which include without limitation surface characteristics of the cell and intracellular characteristics, provided only that the characteristic or characteristics of interest for sorting can be sufficiently identified and detected or measured to distinguish cells having the desired characteristic(s) from those which do not. For example, any label or reporter as described herein can be used as the basis for analyzing and/or sorting molecules or cells, i.e. detecting molecules or cells to be collected.
- Fluorescence Polarization and Fluorescence Intensity
- As described herein, the biological/chemical entity to be analyzed may itself be detectable, for example by a characteristic fluorescence, or it may be labeled or associated with a reporter that produces a detectable signal when the desired protein is present, or is present in at least a threshold amount.
- Luminescent colloidal semiconductor nanocrystals called quantum dots or q-dots (QD) are inorganic fluorophores that have the potential to circumvent some of the functional limitations encountered by organic dyes. In particular, CdSe—ZnS core-shell QDs exhibit size-dependent tunable photoluminescence (PL) with narrow emission bandwidths (FWHM ˜30 to 45 nm) that span the visible spectrum and broad absorption bands. These allow simultaneous excitation of several particle sizes (colors) at a common wavelength. This, in turn, allows simultaneous resolution of several colors using standard instrumentation. CdSe—ZnS QDs also have high quantum yields, are resistant to photodegradation, and can be detected optically at concentrations comparable to organic dyes.
- Quantum dots are nano-scale semiconductors typically consisting of materials such as crystalline cadmium selenide. The term ‘q-dot’ emphasizes the quantum confinement effect of these materials, and typically refers to fluorescent nanocrystals in the quantum confined size range. Quantum confinement refers to the light emission from bulk (macroscopic) semiconductors such as LEDs which results from exciting the semiconductor either electrically or by shining light on it, creating electron-hole pairs which, when they recombine, emit light. The energy, and therefore the wavelength, of the emitted light is governed by the composition of the semiconductor material. If, however, the physical size of the semiconductor is considerably reduced to be much smaller than the natural radius of the electron-hole pair (Bohr radius), additional energy is required to “confine” this excitation within the nanoscopic semiconductor structure leading to a shift in the emission to shorter wavelengths. Three different q-dots in several concentrations each can be placed in a microdroplet, and can then be used with a microfluidic device to decode what is in the drop. The Q-dot readout extension to the fluorescence station can be incorporated into the design of the microfluidic device. A series of dichroic beamsplitters, emission filters, and detectors can be stacked onto the system, allowing measurement of the required five emission channels (two fluorescence polarization signals and three q-dot bands).
- Fluorescence Polarization (FP) detection technology enables homogeneous assays suitable for high throughput screening assays in the Drug Discovery field. The most common label in the assays is fluorescein. In FP-assay the fluorophore is excited with polarized light. Only fluorophores parallel to the light absorb and are excited. The excited state has a lifetime before the light emission occurs. During this time the labeled fluorophore molecule rotates and the polarization of the light emitted differs from the excitation plane. To evaluate the polarization two measurements are needed: the first using a polarized emission filter parallel to the excitation filter (S-plane) and the second with a polarized emission filter perpendicular to the excitation filter (P-plane). The Fluorescence Polarization response is given as mP (milli-Polarization level) and is obtained from the equation:
-
Polarization (mP)=1000*(S−G*P)/(S+G*P) - Where S and P are background subtracted fluorescence count rates and G (grating) is an instrument and assay dependent factor.
- The rotational speed of a molecule is dependent on the size of the molecule, temperature and viscosity of the solution. Fluorescein has a fluorescence lifetime suitable for the rotation speeds of molecules in bio-affinity assays like receptor-ligand binding assays or immunoassays of haptens. The basic principle is that the labeled compound is small and rotates rapidly (low polarization). When the labeled compound binds to the larger molecule, its rotation slows down considerably (polarization changes from low to high polarization). Thus, FP provides a direct readout of the extent of tracer binding to protein, nucleic acids, and other biopolymers.
- Fluorescence polarization technology has been used in basic research and commercial diagnostic assays for many decades, but has begun to be widely used in drug discovery only in the past six years. Originally, FP assays for drug discovery were developed for single-tube analytical instruments, but the technology was rapidly converted to high-throughput screening assays when commercial plate readers with equivalent sensitivity became available. These assays include such well-known pharmaceutical targets such as kinases, phosphatases, proteases, G-protein coupled receptors, and nuclear receptors. Other homogeneous technologies based on fluorescence intensity have been developed. These include energy transfer, quenching, and enhancement assays. FP offers several advantages over these. The assays are usually easier to construct, since the tracers do not have to respond to binding by intensity changes. In addition, only one tracer is required and crude receptor preparations may be utilized. Furthermore, since FP is independent of intensity, it is relatively immune to colored solutions and cloudy suspensions. FP offers several advantages in the area of instrumentation. Because FP is a fundamental property of the molecule, and the reagents are stable, little or no standardization is required. FP is relatively insensitive to drift in detector gain settings and laser power.
- The dyes chosen for FP are commonly used in most cell- and enzyme-based assays and are designed not to overlap significantly with the q-dots. The dyes are evaluated both independently and together with the q-dots (at first off-instrument) to assess the cross-talk. Preferably, the liquid q-dot labels are read outside a spectral wavelength band currently used in FACS analysis and sorting (i.e., the dyes flourescein, Cy3, Cy5, etc). This permits the use of currently-available assays (dependent on these dyes). Using specific q-dots, crosstalk is minimized.
- Accordingly, the present invention provides methods to label droplets and/or nanoreactors formed on a microfluidic device by using only a single dye code to avoid cross-talk with other dyes during FP. Additionally, the present invention provides methods to create FP dye codes to label compounds contained within liquids (including droplets and/or nanoreactors) where the compound is designed to be differentiated by FP on a microfluidic device. In this manner, dye codes having the same color, absorption, and emission could be used to label compounds within liquids.
- In one aspect, the present invention is directed to the use of fluorescence polarization to label liquids. Droplets can be labeled using several means. These labeling means include, but are not limited to, the use of different dyes, quantum dots, capacitance, opacity, light scattering, fluorescence intensity (FI), fluorescence lifetime (FL), fluorescence polarization (FP), circular dichroism (CD), fluorescence correlation and combinations of all of these previous labeling means. The following disclosure describes the use of FP and FI as a means to label droplets on a microfluidic device. In addition, the use of FL as a means to adjust the overall FP of a solution, and by varying the concentration of the total FI, to create a 2-dimensional encoding scheme is demonstrated.
- In general, molecules that take up more volume will tumble slower than a smaller molecule coupled to the same fluorophore. FP is independent of the concentration of the dye; liquids can have vastly different concentrations of FITC in them yet still have identical FP measurements.
- In a preferred embodiment, a FP dye is an organic dye that does not interfere with the assay dye is used. Furthermore, since the total intensity of the FP dye can be quantified, a second dimension in which to label the droplet is provided. Thus, one can exploit the differences in FP to create an encoding scheme of dye within a liquid solution, including droplets. Examples of ways to exploit the differences in FP are described in WO 2007/081385 and WO 2008/063227. In a single dimension, FP can be used to create an encoding scheme. However, the present invention can also use Fluorescence Intensity (FI) of the overall solution to create even more labels in a second dimension. Interestingly, the differences of the fluorescence lifetime (FL) of two dyes with spectral overlap in the detected emission wavelength to change the overall FP of the combined solution can also be exploited.
- Although the use of multiple compounds to which a dye molecule is attached to span a range of FP can be utilized, it is also possible to span the range using a high and low molecular weight compound set. For example, a dye can be attached to a large compound (for example streptavidin) and kept at a fixed concentration, to which a smaller compound (for example, a free dye molecule) would be titrated into the same solution. The FP of the solution can be adjusted to be in discernable increments from the value of the large molecule to somewhere slightly greater than the FP of the smaller molecule. The [total] dye intensity can be varied by varying the concentration of the mixture of the two dye-attached compounds. By varying total dye concentration and the FP, two dimensions can be used to generate the FP dye codes (FPcodes). Accordingly, many FPcodes can be generated using only two compounds.
- This could also include use of large fluorescent proteins such as GFP and the phycobiliproteins combined with a smaller molecule.
- Examples of dyes commonly used in biological dyes are listed in Table 2 below.
-
TABLE 2 Examples of Excitation Wavelength Emission Wavelength Compatible Dyes 450 500 Cyan 500 483 533 SYBR Green, FAM 523 568 HEX, VIC 558 610 RED 610 615 640 RED 640 650 670 CY5 - In another aspect, the present invention is directed labeling solids using properties other than dye emission and dye concentration. In one embodiment the solid can include, for example, a bead or location on a solid support or chip. As demonstrated above for liquids, FI and FL can be two of many dimensions of characteristics used as labels. By way of non-limiting example, it is possible to use two dyes with different FL to change the overall FP for a solid such as a bead or other mobile solid support.
- In another embodiment, a linker can be used to couple the dye to the bead. The linker can be varied so as to allow the dye to have differing degrees of freedom in which to rotate (i.e., tumble). Varying the linker in this manner can change the FP of the attached dye, which in unique combinations can be used as a label. In some embodiments, the beads can be swollen in organic solvent and the dyes held in place by hydrophobic forces. In this case, the FP, FI, FL methods described above for liquid labeling can also be used as a means for labeling the beads. A quenching molecule can also be used to change the characteristics of a dye. Such quenching can be continuous or brought about through the interaction of a molecule, such as a peptide or nucleic acid linker, with differing means of bringing molecules together depending on the strength of linker-internal interaction (e.g., a nucleotide stem loop structure of varying lengths).
- The reactions analyzed on the virtual, random and non-random arrays (discussed briefly below) can be also increased beyond the two (cy3 and cy5 intensities) commonly used for multiplexing. For example, different FP, FI, etc can be used as a read-out.
- Random array decoding: Beads of the prior art use one or more pre-attached oligonucleotide-coupled beads that are held in place in a fiber-optic faceplate (for example, those used by Illiumina). The oligos on the beads are decoded using sequential hybridization of a labeled complementary oligo. The assay of the prior art uses a separate oligonucleotide complementary zipcode (‘Illumacode’) attached to each type of bead.
- The invention described herein is superior to the methods of the prior art in that the FP, FI, FL-labeled bead or mobile solid support can be placed into a random array (e.g., a chip as manufactured by Illumina) and the FP, FI, FL used to decode the bead. The FP, FI, FL of the bead can be decoded before using the chip and the different beads ‘mapped’ as to their specific locations. Alternatively, the bead can be decoded during attachment of the assay read-out. Significantly, the methods described by the present invention can be used to pre-determine the location of each bead-type either before, or during analysis.
- Virtual array decoding: Methods of the
prior art use 2 lasers and 3 detectors to differentiate a set of 100 bead-types. The beads-types are differentiated by the FI of two different dyes present in 1 of 10 concentrations (per dye) contained within the bead, and the assay detector is used to measure fluorescein concentration on the bead. The dyes, which are added to organic-solvent swollen beads, are not directly attached to the beads, but remain held within the bead by hydrophobic forces. - Using the methods of the present invention as described herein, a second detector to the machines of the prior art used to measure FP can be added, thereby adding a third dimension and extending the encoding scheme beyond the 100 available in the prior art.
- Non-random array decoding: In chips of the prior art (such as those used by Affymetrix) oligonucleotides are synthesized directly on the chip. Decoding is simply a matter of knowing the location of the assay on the chip.
- The methods as described herein can be advantageously used in conjunction with such chips to increase the number of things that can be simultaneously analyzed (i.e., multiplexed) on the chip. By way of non-limiting example, Cy3, Cy5, FL and FP can be used as analysis markers for hybridization reactions.
- The present invention also provides methods for labeling micro or nano-sized droplets using Radio Frequency Identification (RFID). RID tags can improve the identification of the contents within the droplets. Preferably, the droplets are utilized within a microfluidic device.
- RFID is an automatic identification method, relying on storing and remotely retrieving data using devices called RFID tags or transponders. An RFID tag is an object that can be attached to or incorporated into a product, animal, or person for the purpose of identification using radio waves. Chip-based RFID tags contain silicon chips and antennae. Passive tags require no internal power source, whereas active tags require a power source. Hitachi has “powder” 0.05 mm×0.05 mm RFID chips. The new chips are 64 times smaller than the previous record holder, the 0.4 mm×0.4 mm mu-chips, and nine times smaller than Hitachi's last year prototype, and have room for a 128-bit ROM that can store a unique 38-digit ID number.
- In one embodiment, a solution containing RFID tags are emulsified into droplets and are used as a label for the identification of the material within the droplet solution. Applications include, but are not limited to; genetics, genomics, proteomics, chemical synthesis, biofuels, and others.
- To detect a reporter or determine whether a molecule, cell or particle has a desired characteristic, the detection module may include an apparatus for stimulating a reporter for that characteristic to emit measurable light energy, e.g., a light source such as a laser, laser diode, light emitting diode (LED), high-intensity lamp, (e.g., mercury lamp), and the like. Where a lamp is used, the channels are preferably shielded from light in all regions except the detection module. Where a laser is used, the laser can be set to scan across a set of detection modules from different analysis units. In addition, laser diodes or LED's may be microfabricated into the same chip that contains the analysis units. Alternatively, laser diodes or LED's may be incorporated into a second chip (i.e., a laser diode chip) that is placed adjacent to the analysis or microchip such that the laser light from the diodes shines on the detection module(s).
- An integrated semiconductor laser and/or an integrated photodiode detector can be included on the substrate in the vicinity of the detection module. This design provides the advantages of compactness and a shorter optical path for exciting and/or emitted radiation, thus minimizing distortion and losses.
- Fluorescence produced by a reporter is excited using a laser beam focused on molecules (e.g., DNA, protein, enzyme or substrate) or cells passing through a detection region. Fluorescent reporters can include, but are not limited to, rhodamine, fluorescein, Texas red,
Cy 3,Cy 5, phycobiliprotein (e.g., phycoerythrin), green fluorescent protein (GFP), YOYO-1 and PicoGreen. In molecular fingerprinting applications, the reporter labels can be fluorescently labeled single nucleotides, such as fluorescein-dNTP, rhodamine-dNTP, Cy3-dNTP, etc.; where dNTP represents dATP, dTTP, dUTP or dCTP. The reporter can also be chemically-modified single nucleotides, such as biotin-dNTP. The reporter can be fluorescently or chemically labeled amino acids or antibodies (which bind to a particular antigen, or fragment thereof, when expressed or displayed by a cell or virus). - The device can analyze and/or sort cells based on the level of expression of selected cell markers, such as cell surface markers, which have a detectable reporter bound thereto, in a manner similar to that currently employed using fluorescence-activated cell sorting (FACS) machines. Proteins or other characteristics within a cell, and which do not necessarily appear on the cell surface, can also be identified and used as a basis for sorting. The device can also determine the size or molecular weight of molecules such as polynucleotides or polypeptides (including enzymes and other proteins) or fragments thereof passing through the detection module. Alternatively, the device can determine the presence or degree of some other characteristic indicated by a reporter. If desired, the cells, particles or molecules can be sorted based on this analysis. The sorted cells, particles or molecules can be collected from the outlet channels in collection modules (or discarded in wasted modules) and used as needed. The collected cells, particles or molecules can be removed from the device or reintroduced to the device for additional coalescence, analysis and sorting.
- Processors
- As used herein, a “processor” or a “microprocessor” is any component or device able to receive a signal from one or more sensors, store the signal, and/or direct one or more responses (e.g., as described above), for example, by using a mathematical formula or an electronic or computational circuit. The signal may be any suitable signal indicative of the environmental factor determined by the sensor, for example a pneumatic signal, an electronic signal, an optical signal, a mechanical signal, etc.
- The device of the present invention can comprise features, such as integrated metal alloy components and/or features patterned in an electrically conductive layer, for detecting droplets by broadcasting a signal around a droplet and picking up an electrical signal in proximity to the droplet.
- Beads
- The device of the present invention also comprises the use of beads and methods for analyzing and sorting beads (i.e., bead reader device). The device can read and either sort or not sort droplets containing one or more of a set of two or more beads. Each bead can be differentiated from each other bead within a set. Beads can be separated by several tags including, but not limited to, quantum dyes, fluorescent dyes, ratios of fluorescent dyes, radioactivity, radio-tags, etc. For example, a set of beads containing a ratio of two dyes in discrete amounts with an apparatus for detecting and differentiating beads containing one discrete ratio from the other beads in this set having a different ratio of the two dyes. The microfluidic device can include paramagnetic beads. The paramagnetic beads can introduce and remove chemical components from droplets using droplet coalescence and breakup events. The paramagnetic beads can also be used for sorting droplets.
- The present invention provides methods of screening molecular libraries on beads through limited-dilution-loading and then chemical or optical release inside of droplets. Provided are methods for chemical synthesis on a bead and releasing said chemical attached to the bead using a releasing means (chemical, UV light, heat, etc) within a droplet, and then combining a second droplet to the first droplet for further manipulation. For example, tea-bag synthesis of chemicals on a bead simultaneously with a means for identifying said bead (using, for example, a mass spec tag). Using the resulting mixed-chemistry beads in a droplet within a fluid flow, and exposing the beads to UV light to release the chemical synthesized from the bead into the droplet environment. Combining the droplet containing the released chemical with a droplet containing a cell, and performing a cell-based assay. Sorting droplets having the desired characteristics (for example, turn on of a reporter gene), and then analyzing the sorted beads using mass spectroscopy.
- The device of the present invention can comprise column separation prior to bead sorting. A device containing a channel loaded with a separating means for chromatographically sorting the sample prior to droplet formation. Such separating means could include size, charge, hydrophobicity, atomic mass, etc. The separating can be done isocratic or by use of a means for generating a gradient chemically, (for example using salt or hydrophobicity), electrically, by pressure, or etc. For example, a channel is preloaded with Sepharose size exclusion media. A sample is loaded at one end, and the droplets are formed at an opposing end. The sample separates by size prior to becoming incorporated within a droplet.
- Sorting Module
- The microfluidic device of the present invention can further include one or more sorting modules. A “sorting module” is a junction of a channel where the flow of molecules, cells, small molecules or particles can change direction to enter one or more other channels, e.g., a branch channel for delivery to an outlet module (i.e., collection or waste module), depending on a signal received in connection with an examination in the detection module. Typically, a sorting module is monitored and/or under the control of a detection module, and therefore a sorting module may “correspond” to such detection module. The sorting region is in communication with and is influenced by one or more sorting apparatuses. A sorting apparatus comprises techniques or control systems, e.g., dielectric, electric, electro-osmotic, (micro-) valve, etc. A control system can employ a variety of sorting techniques to change or direct the flow of molecules, cells, small molecules or particles into a predetermined branch channel. A “branch channel” is a channel which is in communication with a sorting region and a main channel. The main channel can communicate with two or more branch channels at the sorting module or “branch point”, forming, for example, a T-shape or a Y-shape. Other shapes and channel geometries may be used as desired. Typically, a branch channel receives molecules, cells, small molecules or particles depending on the molecule, cells, small molecules or particles characteristic of interest as detected by the detection module and sorted at the sorting module. A branch channel can have an outlet module and/or terminate with a well or reservoir to allow collection or disposal (collection module or waste module, respectively) of the molecules, cells, small molecules or particles. Alternatively, a branch channel may be in communication with other channels to permit additional sorting.
- The device of the present invention can further include one or more outlet modules. An “outlet module” is an area of the device that collects or dispenses molecules, cells, small molecules or particles after coalescence, detection and/or sorting. The outlet module can include a collection module and/or a waste module. The collection module can be connected to a means for storing a sample. The collection module can be a well or reservoir for collecting and containing droplets detected to have a specific predetermined characteristic in the detection module. The collection module can be temperature controlled. The waste module can be connected to a means for discarding a sample. The waste module can be a well or reservoir for collecting and containing droplets detected to not have a specific predetermined characteristic in the detection module. The outlet module is downstream from a sorting module, if present, or downstream from the detection module if a sorting module is not present. The outlet module may contain branch channels or outlet channels for connection to a collection module or waste module. A device can contain more than one outlet module.
- A characteristic of a fluidic droplet may be sensed and/or determined in some fashion, for example, as described herein (e.g., fluorescence of the fluidic droplet may be determined), and, in response, an electric field may be applied or removed from the fluidic droplet to direct the fluidic droplet to a particular region (e.g. a channel). A fluidic droplet is preferably sorted or steered by inducing a dipole in the uncharged fluidic droplet (which may be initially charged or uncharged), and sorting or steering the droplet using an applied electric field. The electric field may be an AC field, a DC field, etc. Methods of sorting or steering droplets in an electric field are as described in WO 2006/040551; WO 2006/040554; WO 2004/002627; WO 2004/091763; WO 2005/021151; WO 2006/096571; WO 2007/089541; WO 2007/081385 and WO 2008/063227. Improvements in the efficiency, accuracy, and reliability of the preferred dielectric droplet sorting technique described above are possibly by utilizing additional channel and electrode geometries, as described in WO 2007/081385 and WO 2008/063227.
- Alternately, a fluidic droplet may be directed by creating an electric charge (e.g., as previously described) on the droplet, and steering the droplet using an applied electric field, which may be an AC field, a DC field, etc. As an example, an electric field maybe selectively applied and removed (or a different electric field may be applied) as needed to direct the fluidic droplet to a particular region. The electric field may be selectively applied and removed as needed, in some embodiments, without substantially altering the flow of the liquid containing the fluidic droplet. For example, a liquid may flow on a substantially steady-state basis (i.e., the average flowrate of the liquid containing the fluidic droplet deviates by less than 20% or less than 15% of the steady-state flow or the expected value of the flow of liquid with respect to time, and in some cases, the average flowrate may deviate less than 10% or less than 5%) or other predetermined basis through a fluidic system of the invention (e.g., through a channel or a microchannel), and fluidic droplets contained within the liquid may be directed to various regions, e.g., using an electric field, without substantially altering the flow of the liquid through the fluidic system.
- In some embodiments, the fluidic droplets may be sorted into more than two channels. Alternately, a fluidic droplet may be sorted and/or split into two or more separate droplets, for example, depending on the particular application. Any of the above-described techniques may be used to spilt and/or sort droplets. As a non-limiting example, by applying (or removing) a first electric field to a device (or a portion thereof), a fluidic droplet may be directed to a first region or channel; by applying (or removing) a second electric field to the device (or a portion thereof), the droplet may be directed to a second region or channel; by applying a third electric field to the device (or a portion thereof), the droplet may be directed to a third region or channel; etc., where the electric fields may differ in some way, for example, in intensity, direction, frequency, duration, etc. In a series of droplets, each droplet may be independently sorted and/or split; for example, some droplets may be directed to one location or another, while other droplets may be split into multiple droplets directed to two or more locations.
- In some cases, high sorting speeds may be achievable using certain systems and methods of the invention. For instance, at least about 1 droplet per second may be determined and/or sorted in some cases, and in other cases, at least about 10 droplets per second, at least about 20 droplets per second, at least about 30 droplets per second, at least about 100 droplets per second, at least about 200 droplets per second, at least about 300 droplets per second, at least about 500 droplets per second, at least about 750 droplets per second, at least about 1000 droplets per second, at least about 1500 droplets per second, at least about 2000 droplets per second, at least about 3000 droplets per second, at least about 5000 droplets per second, at least about 7500 droplets per second, at least about 10,000 droplets per second, at least about 15,000 droplets per second, at least about 20,000 droplets per second, at least about 30,000 droplets per second, at least about 50,000 droplets per second, at least about 75,000 droplets per second, at least about 100,000 droplets per second, at least about 150,000 droplets per second, at least about 200,000 droplets per second, at least about 300,000 droplets per second, at least about 500,000 droplets per second, at least about 750,000 droplets per second, at least about 1,000,000 droplets per second may be determined and/or sorted in such a fashion.
- Sample Recovery
- The present invention proposes methods for recovering aqueous phase components from aqueous emulsions that have been collected on a microfluidic device in a minimum number of steps and in a gentle manner so as to minimize potential damage to cell viability.
- In one aspect, a stable aqueous sample droplet emulsion containing aqueous phase components in a continuous phase carrier fluid is allowed to cream to the top of the continuous phase carrier oil. By way of nonlimiting example, the continuous phase carrier fluid can include a perfluorocarbon oil that can have one or more stabilizing surfactants. The aqueous emulsion rises to the top or separates from the continuous phase carrier fluid by virtue of the density of the continuous phase fluid being greater than that of the aqueous phase emulsion. For example, the perfluorocarbon oil used in one embodiment of the device is 1.8, compared to the density of the aqueous emulsion, which is 1.0.
- The creamed emulsion is then placed onto a second continuous phase carrier fluid which contains a de-stabilizing surfactant, such as a perfluorinated alcohol (e.g., 1H,1H,2H,2H-Perfluoro-1-octanol). The second continuous phase carrier fluid can also be a perfluorocarbon oil. Upon mixing, the aqueous emulsion begins to coalesce, and coalescence is completed by brief centrifugation at low speed (e.g., 1 minute at 2000 rpm in a microcentrifuge). The coalesced aqueous phase can now be removed (cells can be placed in an appropriate environment for further analysis).
- Additional destabilizing surfactants and/or oil combinations can be identified or synthesized to be useful with this invention.
- Additional Modules
- The microfluidic devices of the present invention can further include one or more mixing modules, one or more delay modules, one or more acoustic actuators and/or UV-release modules, as described in WO 2007/081385 and WO 2008/063227.
- The droplet generation rate, spacing and size of the water droplets made on a microfluidic device are tuned to the desired size, such as picoliter to nanoliter volumes. Additionally, droplet libraries of the present invention can be introduced back onto a medium for additional processing. Multicomponent droplets can easily be generated by bringing together streams of materials at the point where droplets are made (co-flow). Alternatively, one can combine different droplets, each containing individual reactants. This is achieved by selecting droplet sizes such that one droplet is roughly wider than the channel width and the other droplet is smaller so that the small droplets rapidly catch up to the larger droplets. An electric field is then used to induce dipoles in the droplet pairs, forcing them to combine into a single droplet and permitting them to intermix the contents.
- Optics for fluorescence detection capable of measuring fluorophores within the aqueous droplets, while simultaneously permitting visual monitoring via a high speed video microscope. Specifically, three separate lasers provide excitation at 405 nm, 488 nm, and 561 nm wavelengths focused to a spot approximately 17 microns in diameter, illuminating each droplet as it enters the detection zone. The system is configured to detect emitted light using a series of photomultiplier tubes, and is able to detect less than 10,000 FITC molecule equivalents at a 5 kHz droplet rate.
- A critical component for isolating sub-populations or rare cells from a heterogeneous cell mixture is a fluorescence-activated microfluidic droplet sorter as described in greater detail herein. Sorting in microfluidic devices can be done using a dielectrophoretic force on neutral droplets. Providing an alternate means that can be precisely controlled, can be switched at high frequencies, and requires no moving parts. After the contents of individual droplets are probed in the fluorescence detection zone, selected droplets can be sorted into discreet streams for recovery and further processing.
- A key feature for improving genomic characterization of the heterogeneous mixture of cell types present in a typical tissue or biopsy would be the ability to fractionate the initial cell population into sub-populations, permitting analysis of rare cells and enabling molecular correlation studies. The microfluidic device provides the ability to sort cell-containing droplets based on fluorescent signals. A number of immediate uses for this capability include: 1) sorting cell-containing droplets away from empty droplets; 2) sorting sub-populations based on specific nucleic acid hybridization; 3) sorting sub-populations based on cell surface binding properties; 4) sorting sub-populations based on secreted activities or reporter enzyme products. A number of these approaches have already been tested in preliminary experiments, using either bacterial or mammalian cells.
- For example, Sort-on-Generation is a combination of modules that generates single cell containing-droplets (along with approximately 10 times more empty droplets, from Poisson distribution as described herein and subsequently sorts the cell-containing droplets away from the empty droplets, based on fluorescent signals.
- Also, it has been demonstrated the ability to sort-on-generation using DNA-intercalating dyes. This approach is enabled for any stained cell.
- Determining the volume of an individual drop from a 2-D image in a microfluidic channel can be accomplished relatively easily with tools typically associated with microfluidics. The basic equipment needed are; simple optics with a camera, a fluorescent laser detector, a microfluidic device, and pumps.
- A 10 pt calibration is done by plotting the average projected area vs. the average volume of a drop. The average projected area is determined by real-time image analysis of droplets during emulsion generation in a specific region of the chip. This region is clearly marked and called the calibration region. Calibration is accomplished by simultaneously logging the projected area of individual droplets for 60 s and calculating the average, and using a laser is to count the total number of droplets that pass through the channel at the calibration region. From this count, one can determine the average frequency and the average volume of a droplet. Where,
-
- Plotting this data for all points yields a calibration curve.
- During reinjection of an emulsion, using image analysis, one can log the projected area of each individual droplet and estimate the volume of each droplet by using the calibration curve. From this data, one can calculate the average volume and size distribution for a given population of droplets.
- The microfluidic device of the present invention can be utilized to conduct numerous chemical and biological assays, including but not limited to, creating emulsion libraries, flow cytometry, gene amplification, isothermal gene amplification, DNA sequencing, SNP analysis, drug screening, RNAi analysis, karyotyping, creating microbial strains with improved biomass conversion, moving cells using optical tweezer/cell trapping, transformation of cells by electroporation, μTAS, and DNA hybridization.
- PCR in Droplets
- An emulsion library comprising at least a first aqueous droplet and at least a second aqueous droplet within a fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and wherein at least first droplet comprises at least a first pair or oligonucleotides and the at least second droplet comprises at least a second pair or oligonucleotides, wherein the first and second pair of oligonucleotides is different.
- In an embodiment, the oligonucleotide is DNA; in another embodiment, the oligonucleotide is RNA. In a further embodiment, the oligonucleotide has at least 5 nucleotides, e.g., 5 to 100, 10 to 90, 12 to 80, 14 to 70, 15 to 60, 15 to 50, 15 to 40, 15 to 35, 15 to 30, 15 to 28, 15 to 25, 15 to 23, and 15 to 20 nucleotides. In one embodiment, the two oligonucleotides in the pair of oligonucleotides have the same number of nucleotides; in another embodiment, the two oligonucleotides in the pair of oligonucleotides have different number of nucleotides.
- The present invention provides a method for amplifying a genomic DNA, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising at least a first aqueous droplet and at least a second aqueous droplet within a fluorocarbon oil comprising at least one fluorosurfactant, wherein the at least first and the at least second droplets are uniform in size and wherein at least first droplet comprises at least a first pair or oligonucleotides and the at least second droplet comprises at least a second pair or oligonucleotides, wherein the first and second pair of oligonucleotides is different; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets comprising said genomic DNA within an immiscible fluorocarbon oil comprising at least one fluorosurfactant; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (d) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a first fluidic nozzle designed for flow focusing such that said first sample fluid forms a plurality of droplets of a first uniform size in said continuous phase; (e) flowing the second sample fluid through a second inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a second fluidic nozzle designed for flow focusing such that said second sample fluid forms a plurality of droplets of a second uniform size in said continuous phase, wherein the size of the droplets of the second sample fluid are smaller than the size of the droplets of the first sample fluid; (f) providing a flow and droplet formation rate of the first and second sample fluids wherein the droplets are interdigitized such that a first sample fluid droplet is followed by and paired with a second sample fluid droplet; (g) providing channel dimensions such that the paired first sample fluid and the second sample fluid droplet are brought into proximity; (h) coalescing the paired first and second sample droplets as the paired droplets pass through an electric field, and (i) amplifying said genomic DNA comprised within the coalesced droplets.
- A unique feature of the described droplet-based microfluidic approach for working with nucleic acids is that it uses immiscible oil-encapsulated aqueous droplets to shield the DNA from the inner surfaces of the microfluidic chip, with a surfactant interface separating the aqueous droplet and its contents from the surrounding immiscible fluorocarbon oil. Therefore, DNA amplification reactions occurring inside these droplets generate material that does not interact with the channel walls, and collection of the DNA-containing droplets for subsequent manipulation and sequencing is straightforward. This technology provides a solution for amplification of DNA from single cells, allowing for both genotyping and whole genome amplification.
- Evidence shows that specific loci can be amplified by PCR in droplets generated on the microfluidic device, either by performing PCR on-chip (with droplets moving through a serpentine channel across several different temperatures under microfluidic control), or by placing the collected droplets into a standard thermocycler. Droplets generated containing DNA and reagents required for PCR-based amplification (thermostable polymerase, dNTPs, Mg, appropriate buffer) have been demonstrated to be extremely robust, showing high stability for both on-chip and off-chip (standard thermocycler) amplification. Each droplet remains intact and separate during cycling, including during the denaturation steps at 98° C. In one embodiment, a microfluidic device as described herein, fuses droplets with individual primer pairs for PCR amplification and preparation of many exons in parallel for high throughput re-sequencing.
- Antibodies and ELISA
- The present invention provides a method for performing an ELISA assay, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first antibody, and a single element linked to at least a second antibody, wherein said first and second antibodies are different; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising a test fluid; (c) providing a third sample fluid wherein said third sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one enzyme; (d) providing a fourth sample fluid wherein said fourth sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one substrate; (e) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (f) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a first fluidic nozzle designed for flow focusing such that said first sample fluid forms a plurality of droplets of a first uniform size in said continuous phase; (g) flowing the second sample fluid through a second inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a second fluidic nozzle designed for flow focusing such that said second sample fluid forms a plurality of droplets of a second uniform size in said continuous phase, wherein the size of the droplets of the second sample fluid are smaller than the size of the droplets of the first sample fluid; (h) providing a flow and droplet formation rate of the first and second sample fluids wherein the droplets are interdigitized such that a first sample fluid droplet is followed by and paired with a second sample fluid droplet; (i) providing channel dimensions such that the paired first sample fluid and the second sample fluid droplet are brought into proximity; (j) coalescing the paired first and second sample droplets as the paired droplets pass through an electric field, forming at least a first coalesced droplet; (k) flowing the third sample fluid through a third inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a third fluidic nozzle designed for flow focusing such that said third sample fluid forms a plurality of droplets of a third uniform size in said continuous phase, wherein the size of the droplets of the third sample fluid are smaller than the size of the droplets of at least first coalesced droplet; (l) providing a flow and droplet formation rate of the third sample fluid wherein the third sample fluid droplet and at least first coalesced droplet are interdigitized such that the at least first coalesced droplet is followed by and paired with the third sample fluid droplet; (m) providing channel dimensions such that the paired at least first coalesced droplet and the third sample fluid droplet are brought into proximity; (n) coalescing the paired at least first coalesced droplet and third sample droplets as the paired droplets pass through an electric field, forming at least a second coalesced droplet; (o) flowing the fourth sample fluid through a fourth inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a fourth fluidic nozzle designed for flow focusing such that said fourth sample fluid forms a plurality of droplets of a fourth uniform size in said continuous phase, wherein the size of the droplets of the fourth sample fluid are smaller than the size of the droplets of at least second coalesced droplet; (p) providing a flow and droplet formation rate of the fourth sample fluid wherein the fourth sample fluid droplet and at least second coalesced droplet are interdigitized such that the at least second coalesced droplet is followed by and paired with the fourth sample fluid droplet; (q) providing channel dimensions such that the paired at least second coalesced droplet and the fourth sample fluid droplet are brought into proximity; (r) coalescing the paired at least second coalesced droplet and fourth sample droplets as the paired droplets pass through an electric field, forming at least a third coalesced droplet, and (s) detecting the conversion of said substrate to a product by said enzyme within the at least a third coalesced droplet.
- The present invention also provides a method for performing an ELISA assay, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, wherein each droplet is uniform in size and comprises at least a first element linked to at least a first antibody, and at least a second element linked to at least a second antibody, wherein said first and second antibodies are different; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising a test fluid (c) providing a third sample fluid wherein said third sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one substrate; (d) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (e) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a first fluidic nozzle designed for flow focusing such that said first sample fluid forms a plurality of droplets of a first uniform size in said continuous phase; (f) flowing the second sample fluid through a second inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a second fluidic nozzle designed for flow focusing such that said second sample fluid forms a plurality of droplets of a second uniform size in said continuous phase, wherein the size of the droplets of the second sample fluid are smaller than the size of the droplets of the first sample fluid; (g) providing a flow and droplet formation rate of the first and second sample fluids wherein the droplets are interdigitized such that a first sample fluid droplet is followed by and paired with a second sample fluid droplet; (h) providing channel dimensions such that the paired first sample fluid and the second sample fluid droplet are brought into proximity; (i) coalescing the paired first and second sample droplets as the paired droplets pass through an electric field, forming at least a first coalesced droplet, wherein if the two antibodies bind an antigen in the test sample the at least first and at least second elements interact to form a functional enzyme; (j) flowing the third sample fluid through a third inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a third fluidic nozzle designed for flow focusing such that said third sample fluid forms a plurality of droplets of a third uniform size in said continuous phase, wherein the size of the droplets of the third sample fluid are smaller than the size of the droplets of at least first coalesced droplet; (k) providing a flow and droplet formation rate of the third sample fluid wherein the third sample fluid droplet and at least first coalesced droplet are interdigitized such that the at least first coalesced droplet is followed by and paired with the third sample fluid droplet; (l) providing channel dimensions such that the paired at least first coalesced droplet and the third sample fluid droplet are brought into proximity; (m) coalescing the paired at least first coalesced droplet and third sample droplets as the paired droplets pass through an electric field, forming at least a second coalesced droplet, and (n) detecting the conversion of said substrate to a product by said enzyme within the at least a second coalesced droplet.
- Small sample volumes are needed in performing immunoassays. Non-limiting examples include cases where the sample is precious or limited, i.e., serum archives, tissue banks, and tumor biopsies. Immunoassays would ideally be run in droplets where only 10 to 100 pL of sample were consumed for each assay. Specifically, the lack of a robust convenient wash step has prevented the development of ELISA assays in droplets. The present invention provides for methods in which beads can be used to perform ELISA assays in aqueous droplets within channels on a microfluidic device. The advantage of utilizing microfluidic devices is it greatly reduces the size of the sample volume needed. Moreover, a benefit of droplet based microfluidic methods is the ability to run numerous assays in parallel and in separate micro-compartments.
- In the examples shown herein, there are several non-limiting read-outs that can be applied to signal amplification in a microfluidic device. The amplification methods include enzyme amplification and rolling circle amplification of signal that uses a nucleic-acid intermediate. In addition, a non-enzymatic means for signal amplification can also be used.
- Cell Libraries
- The present invention provides a method for generating an enzyme library, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one cell transformed with at least one nucleic acid molecule encoding for an enzyme, wherein said cells replicate within said droplets thereby secreting produced enzymes within the droplets; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one substrate; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (d) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a first fluidic nozzle designed for flow focusing such that said first sample fluid forms a plurality of droplets of a first uniform size in said continuous phase; (e) flowing the second sample fluid through a second inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a second fluidic nozzle designed for flow focusing such that said second sample fluid forms a plurality of droplets of a second uniform size in said continuous phase, wherein the size of the droplets of the second sample fluid are smaller than the size of the droplets of the first sample fluid; (f) providing a flow and droplet formation rate of the first and second sample fluids wherein the droplets are interdigitized such that a first sample fluid droplet is followed by and paired with a second sample fluid droplet; (g) providing channel dimensions such that the paired first sample fluid and the second sample fluid droplet are brought into proximity; (h) coalescing the paired first and second sample droplets as the paired droplets pass through an electric field, and (i) detecting enzyme activity within the coalesced droplets, wherein the conversion of substrate to product indicates the presence of an enzyme library.
- In a small library, the use of microfluidic system to emulsify a library of 3-5 bacteria strains that encode a single protease with a known range of activity against a designated substrate in microdroplets, and sort via a fluorescence assay to demonstrate the ability to identify and sort one of the cell strains that expresses a protease that is more active against a specified substrate than the other strains.
- Further in a full library screen, the use of a microfluidic system to emulsify a library of mutagenized bacteria cells in microdroplets, identify and sort via a fluorescence assay a subpopulation of cells to produce a 104 fold enrichment of cells expressing a designated enzyme variant, and recover viable cells and enriched library.
- The present invention provides a method for sorting a plurality of cells, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one cell labeled with an enzyme; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one substrate; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (d) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a first fluidic nozzle designed for flow focusing such that said first sample fluid forms a plurality of droplets of a first uniform size in said continuous phase; (e) flowing the second sample fluid through a second inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a second fluidic nozzle designed for flow focusing such that said second sample fluid forms a plurality of droplets of a second uniform size in said continuous phase, wherein the size of the droplets of the second sample fluid are smaller than the size of the droplets of the first sample fluid; (f) providing a flow and droplet formation rate of the first and second sample fluids wherein the droplets are interdigitized such that a first sample fluid droplet is followed by and paired with a second sample fluid droplet; (g) providing channel dimensions such that the paired first sample fluid and the second sample fluid droplet are brought into proximity; (h) coalescing the paired first and second sample droplets as the paired droplets pass through an electric field; (i) detecting enzyme activity within the coalesced droplets, and (j) selecting cells where the enzyme has converted substrate to product.
- Whole Genome Amplification
- Whole Genome Amplification (WGA) is a method that amplifies genomic material from minute samples, even from a single cell, enabling genome sequencing. A number of commercially available WGA methodologies have been developed, including PCR-based methods like degenerate oligonucleotide primed PCR (DOP-PCR) and primer extension pre-amplification (PEP-PCR), and multiple displacement amplification (MDA) which uses random hexamers and using high fidelity Φ29 or Bst DNA polymerases to provide isothermal amplification. Several analyses have shown that MDA products generate the least amplification bias and produce a higher yield of amplified DNA. This method has been used recently to amplify genomic DNA for sequencing from single cells, with partial genome sequencing demonstrated. MDA-based WGA has also been performed on cell populations selected using flow-FISH.
- Non-specific DNA synthesis due to contaminating DNA and non-template amplification (NTA) are characteristic problems associated with WGA. Recent evidence demonstrates that NTA and also amplification bias are reduced when using very small reaction volumes, with one group using 60 nanoliter microfluidic chambers for single cell WGA reactions. Based on these findings, the use of picoliter-volume droplets in a microfluidic system reduces NTA even further. In addition, amplification from contaminating DNA templates will be constrained to individual compartments (droplets), minimizing the overwhelming effects of contamination in bulk WGA reactions.
- Next Generation Sequencing
- Next generation sequencing instruments offer two distinct advantages in the pursuit of microbiome characterization. First, they do not require conventional clone-based approaches to DNA sequencing, and thus ensure that the commonly experienced biasing against specific sequences in the E. coli host system does not impact the representation of genomes being sequenced. Second, they offer a streamlined and robust workflow for preparing DNA for sequencing that has far fewer steps than conventional workflows. Hence, a library can be prepared for sequencing in about 2 days. The Roche/454 FLX pyrosequencer was the first “next generation”, massively parallel sequencer to achieve commercial introduction (in 2004) and uses a sequencing reaction type known as “pyrosequencing” to read out nucleotide sequences. In pyrosequencing, each incorporation of a nucleotide by DNA polymerase results in the release of pyrophosphate, which initiates a series of downstream reactions that ultimately produce light by the firefly enzyme luciferase. The light amount produced is proportional to the number of nucleotides incorporated (up to the point of detector saturation). In the Roche/454 instrument, the DNA fragments to be sequenced first have specific A and B adapter oligos ligated to their ends, and then are mixed with a population of agarose beads whose surfaces carry oligonucleotides complementary to 454-specific adapter sequences on the DNA fragments, such that each bead is associated with a single DNA fragment. By isolating each of these fragment:bead complexes into individual oil:water micelles that also contain PCR reactants, thermal cycling (“emulsion PCR”) of the micelles produces approximately one million copies of each DNA fragment on the surface of each bead. These amplified single molecules are then sequenced en masse by first arraying them into a PicoTiter Plate (PTP-a fused silica capillary structure), that holds a single bead in each of several hundred thousand single wells, providing a fixed location at which each sequencing reaction can be monitored. Enzyme-containing beads that catalyze the downstream pyrosequencing reaction steps then are added to the PTP, and centrifuged to surround the agarose beads. On instrument, the PTP acts as a flow cell, into which each pure nucleotide solution is introduced in a stepwise fashion, with an imaging step after each nucleotide incorporation step. Because the PTP is seated opposite a CCD camera, the light emitted at each bead that is being actively sequenced is recorded. In practice, the first four nucleotides (TCGA) on the adapter fragment adjacent to the sequencing primer added in library construction are first to be sequenced, and this sequence corresponds to the sequential flow of nucleotides into the flow cell. This strategy allows the 454 base calling software to calibrate the light emitted by a single nucleotide incorporation, which then enables the software to call novel bases downstream according to the light emission levels. However, the calibrated base calling cannot properly interpret long stretches (>6) of the same nucleotides occurring in a stretch (“homopolymer” run), due to detector saturation, so these stretches are prone to base insertion and deletion errors during base calling. By contrast, since each incorporation step is nucleotide specific, substitution errors are rarely encountered in Roche/454 sequence reads.
- Enzyme Inhibitor Screening
- The present invention provides a method for screening for an enzyme inhibitor, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one compound; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one enzyme and substrate; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (d) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a first fluidic nozzle designed for flow focusing such that said first sample fluid forms a plurality of droplets of a first uniform size in said continuous phase; (e) flowing the second sample fluid through a second inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a second fluidic nozzle designed for flow focusing such that said second sample fluid forms a plurality of droplets of a second uniform size in said continuous phase, wherein the size of the droplets of the second sample fluid are smaller than the size of the droplets of the first sample fluid; (f) providing a flow and droplet formation rate of the first and second sample fluids wherein the droplets are interdigitized such that a first sample fluid droplet is followed by and paired with a second sample fluid droplet; (g) providing channel dimensions such that the paired first sample fluid and the second sample fluid droplet are brought into proximity; (h) coalescing the paired first and second sample droplets as the paired droplets pass through an electric field, and (i) detecting enzyme activity within the coalesced droplets, wherein the failure of the enzyme to convert the substrate to product indicates the compound is an enzyme inhibitor.
- The present invention provides compositions and methods for generating, manipulating, and analyzing aqueous droplets of precisely defined size and composition. These microfluidic device-generated droplets can encapsulate a wide variety of components, including those that are used in enzymatic assays. Kinases are a therapeutically important class of enzymes, and this collaboration examines the feasibility of performing analysis and interrogation of kinases with potentially inhibitory compounds using the described microfluidic platform and systems.
- High-Throughput Droplet Live-Dead Assay Screening
- The present invention provides a method for screening for a live cell, comprising (a) providing a first sample fluid wherein said first sample fluid comprises an emulsion library comprising a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one cell; (b) providing a second sample fluid wherein said second sample fluid comprises a plurality of aqueous droplets within an immiscible fluorocarbon oil comprising at least one fluorosurfactant, said droplets comprising at least one cell-membrane-permeable fluorescent dye and at least one cell-membrane-impermeable fluorescent dye; (c) providing a microfluidic substrate comprising at least two inlet channels adapted to carry at least two dispersed phase sample fluids and at least one main channel adapted to carry at least one continuous phase fluid; (d) flowing the first sample fluid through a first inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a first fluidic nozzle designed for flow focusing such that said first sample fluid forms a plurality of droplets of a first uniform size in said continuous phase; (e) flowing the second sample fluid through a second inlet channel which is in fluid communication with said main channel at a junction, wherein said junction comprises a second fluidic nozzle designed for flow focusing such that said second sample fluid forms a plurality of droplets of a second uniform size in said continuous phase, wherein the size of the droplets of the second sample fluid are smaller than the size of the droplets of the first sample fluid; (f) providing a flow and droplet formation rate of the first and second sample fluids wherein the droplets are interdigitized such that a first sample fluid droplet is followed by and paired with a second sample fluid droplet; (g) providing channel dimensions such that the paired first sample fluid and the second sample fluid droplet are brought into proximity; (h) coalescing the paired first and second sample droplets as the paired droplets pass through an electric field, and (i) detecting fluorescence within the coalesced droplets, wherein the detection of fluorescence of cell-membrane-permeable dye indicates a droplet comprising a dead cell and the detection of fluorescence of cell-membrane-impermeable dye indicates a droplet comprising a live cell.
- Single-cell analysis in the context of cell populations avoids the loss of information on cellular systems that is inherent with averaged analysis. In recent years, this type of analysis has been aided by the development of sophisticated instrumentation. Microfluidic technologies have the potential to enhance the precision and throughput of these single-cell assays by integrating and automating the cell handling, processing, and analysis steps. However, major limitations in microfluidic systems hinder the development of high-throughput screening platforms. One challenge is to achieve sufficiently short mixing times. Mixing under the laminar flow conditions typically found in microfluidic devices occurs by diffusion, a relatively slow process for biological material and biochemical reactants. Most importantly, as the scale of these reactors shrinks, contamination effects due to surface adsorption and diffusion limit both the smallest sample size and the repeated use of channels for screening different conditions. These limitations are major hurdles when this technology is to be applied for screening libraries containing thousands of different compounds each corresponding to different experimental conditions.
- The confinement of reagents in droplets in an immiscible carrier fluid overcomes these limitations. The droplet technology is an essential enabling technology for a high-throughput microfluidic screening platform. Droplet isolation allows the cells to be exposed to discrete concentrations of chemicals or factors. Most importantly, the droplet format ensures that the sample materials never touch the walls of the microfluidic channels and thus eliminates the risk of contamination. The reagents can be mixed within a droplet and sample dispersion is simultaneously minimized. The advantages of this technique include the physical and chemical isolation of droplets from one another and the ability to digitally manipulate these droplets at very high-throughput. Finally, the absence of any moving parts and in particular valves brings the degree of robustness required for screening applications.
- Possible cell applications include screen for combinatorial cell assays, cloning, FACS-like assays, and polymer encapsulation for cell-based therapies. As a small number of cells are consumed per sample, this technology is particularly suitable for working with cells of limited availability, like primary cells. In addition, for rare cell sorting, the dilution factor in the collection droplets can be orders of magnitude smaller than for a standard bench-scale flow cytometer. Finally, the use of fluorocarbons that can dissolve large amount of oxygen as carrier fluids is regarded as a key feature for long-term survival of encapsulated cells.
- Numerous modules have been developed for performing a variety of key tasks on droplets, They include the generation of monodisperse aqueous droplets and its use for cell encapsulation. Droplets can be fused or coalesced, their content mixed, incubated on-chip, and their incubation time tuned with an oil-extractor, their fluorescent content can be interrogated, and finally they can be sorted.
- The assembly of such modules into complete systems provides a convenient and robust way to construct droplet microfluidic devices that would fulfill the promises of the droplet technology as a screening platform.
- Example 9 illustrates some examples of live-dead assays. The device has been designed to sequentially accomplish six different functions. (i) separated cell and dye encapsulations, (ii) fusion of droplets containing cells and droplets containing dyes, (iii) mixing of cell with dyes in each fused droplet, (iv) oil-extraction to modulate on-chip incubation of droplets, (v) droplet incubation on-chip and (vi) interrogation of the fluorescent signal of each droplet. Furthermore, encapsulated cells can be collected into a syringe and re-inject the emulsion for on-chip scoring.
- As a matter of convenience, predetermined amounts of the reagents, compound libraries, and/or emulsions described herein and employed in the present invention can be optionally provided in a kit in packaged combination to facilitate the application of the various assays and methods described herein. Such kits also typically include instructions for carrying out the subject assay, and may optionally include the fluid receptacle, e.g., the cuvette, multiwell plate, microfluidic device, etc. in which the reaction is to be carried out.
- Typically, reagents included within the kit are uniquely labeled emulsions containing tissues, cells, particles, proteins, antibodies, amino acids, nucleotides, small molecules, substrates, and/or pharmaceuticals. These reagents may be provided in pre-measured container (e.g., vials or ampoules) which are co-packaged in a single box, pouch or the like that is ready for use. The container holding the reagents can be configured so as to readily attach to the fluid receptacle of the device in which the reaction is to be carried out (e.g., the inlet module of the microfluidic device as described herein). In one embodiment, the kit can include an RNAi kit. In another embodiment, the kit can include a chemical synthesis kit. It will be appreciated by persons of ordinary skill in the art that these embodiments are merely illustrative and that other kits are also within the scope of the present invention.
- The terms used in this specification generally have their ordinary meanings in the art, within the context of this invention and in the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the devices and methods of the invention and how to make and use them. It will be appreciated that the same thing can typically be described in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein. Synonyms for certain terms are provided. However, a recital of one or more synonyms does not exclude the use of other synonyms, nor is any special significance to be placed upon whether or not a term is elaborated or discussed herein. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.
- The invention is also described by means of particular examples. However, the use of such examples anywhere in the specification, including examples of any terms discussed herein, is illustrative only and in no way limits the scope and meaning of the invention or of any exemplified term. Likewise, the invention is not limited to any particular preferred embodiments described herein. Indeed, many modifications and variations of the invention will be apparent to those skilled in the art upon reading this specification and can be made without departing from its spirit and scope. The invention is therefore to be limited only by the terms of the appended claims along with the full scope of equivalents to which the claims are entitled.
- As used herein, “about” or “approximately” shall generally mean within 20 percent, preferably within 10 percent, and more preferably within 5 percent of a given value or range.
- The term “molecule” means any distinct or distinguishable structural unit of matter comprising one or more atoms, and includes for example polypeptides and polynucleotides.
- The term “polymer” means any substance or compound that is composed of two or more building blocks (‘mers’) that are repetitively linked to each other. For example, a “dimer” is a compound in which two building blocks have been joined together.
- The term “polynucleotide” as used herein refers to a polymeric molecule having a backbone that supports bases capable of hydrogen bonding to typical polynucleotides, where the polymer backbone presents the bases in a manner to permit such hydrogen bonding in a sequence specific fashion between the polymeric molecule and a typical polynucleotide (e.g., single-stranded DNA). Such bases are typically inosine, adenosine, guanosine, cytosine, uracil and thymidine. Polymeric molecules include double and single stranded RNA and DNA, and backbone modifications thereof, for example, methylphosphonate linkages.
- Thus, a “polynucleotide” or “nucleotide sequence” is a series of nucleotide bases (also called “nucleotides”) generally in DNA and RNA, and means any chain of two or more nucleotides. A nucleotide sequence typically carries genetic information, including the information used by cellular machinery to make proteins and enzymes. These terms include double or single stranded genomic and cDNA, RNA, any synthetic and genetically manipulated polynucleotide, and both sense and anti-sense polynucleotide (although only sense stands are being represented herein). This includes single- and double-stranded molecules, i.e., DNA-DNA, DNA-RNA and RNA-RNA hybrids, as well as “protein nucleic acids” (PNA) formed by conjugating bases to an amino acid backbone. This also includes nucleic acids containing modified bases, for example thio-uracil, thio-guanine and fluoro-uracil.
- The polynucleotides herein may be flanked by natural regulatory sequences, or may be associated with heterologous sequences, including promoters, enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5′- and 3′-non-coding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, “caps”, substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.). Polynucleotides may contain one or more additional covalently linked moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive metals, iron, oxidative metals, etc.), and alkylators. The polynucleotides may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoramidate linkage. Furthermore, the polynucleotides herein may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.
- The term “dielectrophoretic force gradient” means a dielectrophoretic force is exerted on an object in an electric field provided that the object has a different dielectric constant than the surrounding media. This force can either pull the object into the region of larger field or push it out of the region of larger field. The force is attractive or repulsive depending respectively on whether the object or the surrounding media has the larger dielectric constant.
- “DNA” (deoxyribonucleic acid) means any chain or sequence of the chemical building blocks adenine (A), guanine (G), cytosine (C) and thymine (T), called nucleotide bases, that are linked together on a deoxyribose sugar backbone. DNA can have one strand of nucleotide bases, or two complimentary strands which may form a double helix structure. “RNA” (ribonucleic acid) means any chain or sequence of the chemical building blocks adenine (A), guanine (G), cytosine (C) and uracil (U), called nucleotide bases, that are linked together on a ribose sugar backbone. RNA typically has one strand of nucleotide bases.
- A “polypeptide” (one or more peptides) is a chain of chemical building blocks called amino acids that are linked together by chemical bonds called peptide bonds. A “protein” is a polypeptide produced by a living organism. A protein or polypeptide may be “native” or “wild-type”, meaning that it occurs in nature; or it may be a “mutant”, “variant” or “modified”, meaning that it has been made, altered, derived, or is in some way different or changed from a native protein, or from another mutant.
- An “enzyme” is a polypeptide molecule, usually a protein produced by a living organism, that catalyzes chemical reactions of other substances. The enzyme is not itself altered or destroyed upon completion of the reaction, and can therefore be used repeatedly to catalyze reactions. A “substrate” refers to any substance upon which an enzyme acts.
- As used herein, “particles” means any substance that may be encapsulated within a droplet for analysis, reaction, sorting, or any operation according to the invention. Particles are not only objects such as microscopic beads (e.g., chromatographic and fluorescent beads), latex, glass, silica or paramagnetic beads, but also includes other encapsulating porous and/or biomaterials such as liposomes, vesicles and other emulsions. Beads ranging in size from 0.1 micron to 1 mm can be used in the devices and methods of the invention and are therefore encompassed with the term “particle” as used herein. The term particle also encompasses biological cells, as well as beads and other microscopic objects of similar size (e.g., from about 0.1 to 120 microns, and typically from about 1 to 50 microns) or smaller (e.g., from about 0.1 to 150 nm). The devices and methods of the invention are also directed to sorting and/or analyzing molecules of any kind, including polynucleotides, polypeptides and proteins (including enzymes) and their substrates and small molecules (organic or inorganic). Thus, the term particle further encompasses these materials.
- The particles (including, e.g., cells and molecules) are sorted and/or analyzed by encapsulating the particles into individual droplets (e.g., droplets of aqueous solution in oil), and these droplets are then sorted, combined and/or analyzed in a microfabricated device. Accordingly, the term “droplet” generally includes anything that is or can be contained within a droplet.
- A “small molecule” or “small molecule chemical compound” as used herein, is meant to refer to a composition that has a molecular weight of less than 500 Daltons. Small molecules are distinguished from polynucleotides, polypeptides, carbohydrates and lipids.
- As used herein, “cell” means any cell or cells, as well as viruses or any other particles having a microscopic size, e.g. a size that is similar to or smaller than that of a biological cell, and includes any prokaryotic or eukaryotic cell, e.g., bacteria, fungi, plant and animal cells. Cells are typically spherical, but can also be elongated, flattened, deformable and asymmetrical, i.e., non-spherical. The size or diameter of a cell typically ranges from about 0.1 to 120 microns, and typically is from about 1 to 50 microns. A cell may be living or dead. Since the microfabricated device of the invention is directed to sorting materials having a size similar to a biological cell (e.g. about 0.1 to 120 microns) or smaller (e.g., about 0.1 to 150 nm) any material having a size similar to or smaller than a biological cell can be characterized and sorted using the microfabricated device of the invention. Thus, the term cell shall further include microscopic beads (such as chromatographic and fluorescent beads), liposomes, emulsions, or any other encapsulating biomaterials and porous materials. Non-limiting examples include latex, glass, or paramagnetic beads; and vesicles such as emulsions and liposomes, and other porous materials such as silica beads. Beads ranging in size from 0.1 micron to 1 mm can also be used, for example in sorting a library of compounds produced by combinatorial chemistry. As used herein, a cell may be charged or uncharged. For example, charged beads may be used to facilitate flow or detection, or as a reporter. Biological cells, living or dead, may be charged for example by using a surfactant, such as SDS (sodium dodecyl sulfate). The term cell further encompasses “virions”, whether or not virions are expressly mentioned.
- A “virion”, “virus particle” is the complete particle of a virus. Viruses typically comprise a nucleic acid core (comprising DNA or RNA) and, in certain viruses, a protein coat or “capsid”. Certain viruses may have an outer protein covering called an “envelope”. A virion may be either living (i.e., “viable”) or dead (i.e., “non-viable”). A living or “viable” virus is one capable of infecting a living cell. Viruses are generally smaller than biological cells and typically range in size from about 20-25 nm diameter or less (parvoviridae, picornoviridae) to approximately 200-450 nm (poxyiridae). However, some filamentous viruses may reach lengths of 2000 nm (closterviruses) and are therefore larger than some bacterial cells. Since the microfabricated device of the invention is particularly suited for sorting materials having a size similar to a virus (i.e., about 0.1 to 150 nm), any material having a size similar to a virion can be characterized and sorted using the microfabricated device of the invention. Non-limiting examples include latex, glass or paramagnetic beads; vesicles such as emulsions and liposomes; and other porous materials such as silica beads. Beads ranging in size from 0.1 to 150 nm can also be used, for example, in sorting a library of compounds produced by combinatorial chemistry. As used herein, a virion may be charged or uncharged. For example, charged beads may be used to facilitate flow or detection, or as a reporter. Biological viruses, whether viable or non-viable, may be charged, for example, by using a surfactant, such as SDS.
- A “reporter” is any molecule, or a portion thereof that is detectable, or measurable, for example, by optical detection. In addition, the reporter associates with a molecule, cell or virion or with a particular marker or characteristic of the molecule, cell or virion, or is itself detectable to permit identification of the molecule, cell or virion's, or the presence or absence of a characteristic of the molecule, cell or virion. In the case of molecules such as polynucleotides such characteristics include size, molecular weight, the presence or absence of particular constituents or moieties (such as particular nucleotide sequences or restrictions sites). In the case of cells, characteristics which may be marked by a reporter includes antibodies, proteins and sugar moieties, receptors, polynucleotides, and fragments thereof. The term “label” can be used interchangeably with “reporter”. The reporter is typically a dye, fluorescent, ultraviolet, or chemiluminescent agent, chromophore, or radio-label, any of which may be detected with or without some kind of stimulatory event, e.g., fluoresce with or without a reagent. In one embodiment, the reporter is a protein that is optically detectable without a device, e.g. a laser, to stimulate the reporter, such as horseradish peroxidase (HRP). A protein reporter can be expressed in the cell that is to be detected, and such expression may be indicative of the presence of the protein or it can indicate the presence of another protein that may or may not be coexpressed with the reporter. A reporter may also include any substance on or in a cell that causes a detectable reaction, for example by acting as a starting material, reactant or a catalyst for a reaction which produces a detectable product. Cells may be sorted, for example, based on the presence of the substance, or on the ability of the cell to produce the detectable product when the reporter substance is provided.
- A “marker” is a characteristic of a molecule, cell or virion that is detectable or is made detectable by a reporter, or which may be coexpressed with a reporter. For molecules, a marker can be particular constituents or moieties, such as restrictions sites or particular nucleic acid sequences in the case of polynucleotides. For cells and virions, characteristics may include a protein, including enzyme, receptor and ligand proteins, sacchamides, polynucleotides, and combinations thereof, or any biological material associated with a cell or virion. The product of an enzymatic reaction may also be used as a marker. The marker may be directly or indirectly associated with the reporter or can itself be a reporter. Thus, a marker is generally a distinguishing feature of a molecule, cell or virion, and a reporter is generally an agent which directly or indirectly identifies or permits measurement of a marker. These terms may, however, be used interchangeably.
- The invention is further described below, by way of the following examples. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.
- Example 1 shows methods of surfactant syntheses.
- Below of the reaction scheme for creating the surfactants utilized in stabilizing the droplet libraries provided by the instant invention.
- Reagent Table is as follows:
-
Other (density, purity, safety, Name MW Moles/Equiv. Amount used misc.) Krytox FSH 6500 1.54 mmol (1 eq) 10.0 g Oxalyl 126.93 15.4 mmol 1.3 mL d = 1.5 g/mL; Chloride (10 eq) (1.95 g) b.p. 62-65° C. HFE 7100 250.06 50 mL b.p. 61° C. - The procedure includes, adding 10.0 g (1.54 mmol; 1 eq) of Krytox acid FSH in 50 mL HFE 7100 (not anhydrous) at right under Ar was added 1.95 g (15.4 mmol; 10 eq) of Oxalyl Chloride dropwise. Stirred 10 min, then the reaction was warmed to gentle reflux (note boiling points of solvent and reagent). Some bubbling was noted, even before reaction had reached reflux. Continued overnight.
- The following day, the reaction was very slightly cloudy, and contained a very small amount of a yellow solid. Cooled, HFE and excess Oxalyl chloride evaporated. Residue dissolved in 40 mL fresh HFE, then filtered to remove the solid. HFE evaporated again, residue placed under hivac for 1 hr. Yield of a cloudy white oil 10.14 g. Used without further purification.
- The reagent table is as follows:
-
Name MW Moles/Equiv. Amount used Other (density, purity, safety, misc.) JSJ 73-019 6518 1.55 mmol (2 eq) 10.14 g used crude JSJ 73-006 568 0.77 mmol (1 eq) 0.441 g Triethylamine 101.19 2.33 mmol (3 eq) 0.325 mL d = 0.726; b.p. 88° C. Tetrahydrofuran 20 mL b.p. 66° C. FC 3283 521 40 mL b.p. 123-33° C.; dried over CaSO4 - The procedure includes, drying the amine was by placing under hivac rotovap at a bath temp of 60° C. for 4 hrs. To a solution of 0.441 g (0.77 mmol; 1 eq) of PEG; 600 diamine J and 0.325 mL (2.33 mmol; 3 eq) of Et3N in 20 mL anhydrous THF at rt under Ar was added a solution of 10.14 g (1.55 mmol; 2 eq) of crude JSJ 73-019 in 40 mL FC 3283. A white precipitate (Et3N.HCl) was noted to form in the reaction and on the flask walls. The milky-white two-phase suspension was stirred well overnight.
- The THF and most FC was evaporated. This left a solid residue dispersed in the FC solvent (Et3N.HCl). Oil residue diluted with 50 mL FC 3283, then filtered through Celite. Celite washed with 2×30 mL FC 3283. The solid left in the flask was found to be water soluble, suggesting that it was Et3N.HCl. The filtrate was cloudy white. FC 3283 evaporated using hivac and 60° C. bath. Kept as such for ˜1.5 hrs to evaporate all solvent.
- Sample submitted for 19F NMR. Peak for the CF was in the correct position, indicating amide had formed
- The reagent table is as follows:
-
Other (density, Amount purity, safety, Name MW Moles/Equiv. used misc.) PEG 600 (Fluka) 600 0.125 (1 eq) 75.0 g Avg. MW 600; CAS 25322-65-3; m.p. 17-22° C. p-Toluene 190.65 0.283 (2.3 eq) 53.93 g Sulfonyl chloride Tetrahydrofuran 525 mL b.p. 66° C., Sodium 40.00 0.506 (4.05 20.25 g not anhydrous Hydroxide eq) Water 156 mL - The procedure included adding to a solution of 20.25 g (0.506 mol; 4.05 eq) of NaOH in 156 mL water cooled in an ice-bath to ˜0° C. (not under inert atmosphere) was added a solution of 75.0 g (0.125 mol; 1 eq, 2 eq of hydroxyl) of PEG 600 in 300 mL of THF dropwise via addition funnel. Internal temp was kept 5° C. during the addition. After complete addition, the slightly cloudy reaction was stirred while warming to rt over 1 hr. Following this, the reaction was again cooled to ˜0° C. and a solution of 53.93 g (0.283 mol; 2.3 eq) of Tosyl chloride in 225 mL THF was added dropwise via addition funnel, again keeping the internal temp ˜10° C. during the addition. Reaction allowed to stir overnight while warming to rt.
- Layers allowed to separate in an addition funnel, THF separated from aqueous layer and evaporated. Residue dissolved in 600 mL EtOAc and recombined w/aqueous from above. Shaken, separated. Organic washed 3×125 mL water, then with brine, dried over MgSO4. Stirred over the weekend.
- Filtered, solvent evaporated to give a colorless oil, which was dried under
hivac rotovap 3 hrs at ˜60° C. This gave 91.95 g of a colorless oil (81% yield). This was a typical yield for this reaction. - The reagent table includes:
-
Other (density, Moles/ Amount purity, safety, Name MW Equiv. used misc.) JSJ 73-078 910 102 mmol 92.75 g used crude (1 eq) Potassium 185.22 224 mmol 41.5 g Phthalimide (2.2 eq) Dimethylformamide 73.09 600 mL b.p. 153° C. - The procedure includes adding to a solution of 92.75 g (102 mmol; 1 eq) of JSJ 73-078 in 600 mL anhydrous DMF at rt under Ar was added 41.5 g (224 mmol; 2.2 eq) of Potassium phthalimide as a solid in 2 portions. The heterogeneous solution was then warmed slowly to 85-90° C. (internal temp) and the r×n stirred overnight. The phthalimide slowly went into solution and the color became more yellow. A small amount of the phthalimide wasn't consumed, remaining a solid dispersed in the reaction.
- While still warm, the reaction was poured into a separate flask and most of the DMF was evaporated (hivac at 80° C.). Any remaining solution was kept warm while the DMF was being evaporated. The resulting sludgy solid was diluted EtOAc (˜1 L in total) and filtered. The sludge was triturated in a smaller portion of EtOAc (200 mL) and filtered again to ensure all product was recovered. Solid was triturated w/another 200 mL EtOAc. Filtrate was then concentrated to give a yellow oil. Continued pumping on oil under hivac at 80° C. for several hours to remove residual DMF. This gave 57.93 g of orange-yellow oil. This was typical yield for this reaction.
- The reagent table includes:
-
Other (density, Moles/ Amount purity, safety, Name MW Equiv. used misc.) JSJ 73-081 860 67 mmol 57.93 g used crude (1 eq) Hydrazine, 32.05 471 mmol 15 g (15 mL) d = 1.021 g/mL, anhydrous (7 eq) b.p. 113° C. Tetrahydrofuran 300 mL b.p. 66° C. Methanol 300 mL b.p. 65° C. - The procedure includes adding to a solution of 57.93 g (67 mmol; 1 eq) of crude JSJ 73-081 in 300 mL anhydrous MeOH and 300 mL anhydrous THF at rt under Ar was added 15 mL (471 mmol; 7 eq) of Hydrazine and the reaction stirred (mechanical stirring used) at rt for 1.5 hrs. After 45 min, white solid began to form from the homogeneous solution. This was thought to be the byproduct of the hydrazine-phthalimide reaction. The reaction was warmed to 40° C. and stirred overnight under Ar. The stirring became slightly more difficult as more solid formed, so the stirring was increased slightly.
- The reaction appeared the same, very thick with the solid. Rxn cooled, THF and MeOH evaporated. The residue was diluted w/EtOAc (300 mL) then filtered. Filtration was relatively easy, solid washed well w/EtOAc (200 mL). Filtrate concentrated, upon which additional solid was noted. Residue diluted back in EtOAc (300 mL), giving a slightly cloudy solution (diamine may not be completely soluble in this volume of EtOAc). Filtered, solvent evaporated, giving a yellow oil.
- This oil was placed under hivac rotovap at ˜70° C. for several hours to remove residual solvents, Hydrazine, and also possibly any residual DMF brought from the SM in the previous step.
- Example 2 shows PEG-Amine derived fluorosurfactant syntheses
- A PEG-amine derived fluorosurfactant can be made by the following process: 10.0 g of Kytox 157 FSH (PFPE, 6500 g/mol, 0.00154 mole) was dissolved in 25.0-mL of FC-3283 (521 g/mol, 45.5 g, 0.0873 mole). 0.567 g PEG 600 Diamine (566.7 g/mol, 0.001 mole, 0.65 mol eq.) was dissolved in 10.0-mL of THF (72.11 g/mol, 8.9 g, 0.1234 mole). The resulting solutions were then combined and emulsified. The resulting emulsion was spun on a BUCHI rota-vap. at ˜75% for ˜20 hours. The crude reaction mixture was then placed in centrifuge tubes with equal volumes of DI H2O, emulsified and centrifuged at 15,000 rpm for 15-minutes. Once the emulsion was broken, the oil layer was extracted, dried with anhydrous sodium sulfate and filtered over a 0.45-um disposable nylon filter. The filtered oil was then evaporated on a BUCHI rota-vap. model R-200 fitted with a B-490 water bath for =2-hours at 70° C.
- The procedure is depicted in Scheme 1:
-
FIG. 5 shows Ammonium Carboxylate Salt of Krytox 157FSH 2 Wt % in FC 3283 without PEG amine salt (Panel A) and with PEG 600 Diammonium Carboxylate Salt of Krytox 157 FSH at 4.0% by volume (Panel B) (Flow Rates: 2000 ul/hr (FC oil), 500 ul/hr (aq)). The difference in the number of coalesced drops in the right image indicates that the PEG amine salt is effective in stabilizing emulsions. Emulsions made with the Ammonium Carboxylate Salt of Krytox 157FSH 2 Wt % in FC 3283 with PEG 600 Diammonium Carboxylate Salt of Krytox 157 FSH co-surfactant added at 4.0% by volume were shown to remain stable when reinjected into a microfluidic channel. - The primer droplet library generation is a Type IV library generation.
FIG. 6 shows a schematic of the primer library generation.Step 1 of the library formation is to design primers for loci of interest. There are no constraints on primer design associated with traditional multiplex PCR.Step 2 requires synthesis of the primer pairs using standard oligo synthesis. After the library elements are created, the primer pairs are reformatted as droplets, where only one primer pair present in each droplet. Each droplet contains multiple copies of the single primer pair directed to a single target of interest. After the droplets for each type of primer pair is created, the emulsions are pooled as primer library. The droplet stability prevents cross-contamination of primer pairs. - Primer Library for Genome Selection
- A pooled primer library can be placed onto a microfluidic device as provided by the instant invention. Each primer library droplet follows an inlet channel that intersects with another inlet channel, which has droplets containing gDNA, Taq, dNTPs and any other materials needed to perform PCR. At the intersection the two inlet channels merge into a single main channel where the two different types of droplets, i.e., the primer library droplet and the PCR component droplets travel singularly until they are coalesced. The droplets are coalesced within the main channel in which they are traveling, at a widened portion of the main channel. In addition to the widening in the channel, electrodes are used to coalesce the droplets containing the primer libraries and the droplets containing the PCR components. The coalesced droplets then continue along the same main channel and are collected onto well containing plates. The droplets in the plates are subjected to thermocycling to permit PCR amplification. The amplified DNA can then be sequenced by any means known in the art. The relative number of sequencing reads from each of 20 targeted exons can be plotted using primer libraries against human genomic DNA.
- Primer Library for Digital qPCR Method
- Disposable PDMS/glass microfluidic devices were designed with regions maintained at 95° C., and regions maintained at 67° C. and further including interrogation neckdowns. Aqueous fluid was infused into the microfluidic device perpendicularly to two channels flowing immiscible oil which generated 65 pL (50 um) droplets. The aqueous fluid contained the following reagents:
-
- 50 mM Tris/HCl (pH 8.3)
- 10 mM KCl
- 5 mM (NH4)2SO4
- 3.5 mM MgCl2
- 0.2 mM dNTP
- 0.5% Tetronics
- 0.1 mg/mlBSA
- 0.2 units per μL of FastStart Taq DNA polymerase
- 0.5 μM each of forward and reverse primers
- 0.25 μM FAM-labeled probe quenched with a 3′ BHQ1
- 1 μM Alexa Fluor 594
- Serial dilutions of the pAdeasy-1 vector (Stratagene, La Jolla, Calif.) were made from 60 to 0.0006 ng/uL or from 600 copies per/droplet to 0.006 copies per/droplet
- The concentrations of the diluted DNA were verified by qPCR using a traditional real-time thermocycler. PCR primers and probe were designed to detect a 245 bp region of the Adenovirus genome. Droplets were generated at a rate of 500 per second. The channels on the microfluidic device conveyed the droplets through of 2 thermal zones at a 95° C. and 67° C. for 34 passes which were the equivalent of 34 cycles of two step PCR with the following cycling parameters:
-
- 1 cycle-3 min hot start
- 34 cycles:
- 95° C. for 15 seconds
- 68° C. for 40 seconds
- PCR droplets were interrogated at specific “neckdowns” which were 100 micron long regions of the microfluidic device where the channel width and depth decreased forcing droplets into a single file. A two wavelength laser excitation and detection system was used to interrogate the fluorescence at each of the neckdowns at
cycles 4, 8, 11, 14, 17, 20, 23, 26, 29, 32, and 34. A fluorescent dye, Alexa Fluor 594, provided a constant signal in each droplet that was used for droplet detection without inhibiting PCR amplification efficiency or yield. - The distribution of fluorescence signal among droplets was determined as the droplets pass through the excitation lasers (488 nm and 561 nm) at the last interrogation neckdown (cycle 34). A bimodal distribution of FAM fluorescence was observed for droplets with starting template concentrations of less than one molecule per droplet, indicating the presence of two populations corresponding to empty droplets and droplets that supported amplification. A time trace of fluorescence signals from those droplets is readily plotted as those droplets pass one-by-one through the excitation lasers. For each of the Adenovirus dilutions examined, the percentage of PCR positive droplets was plotted versus cycle number.
- Successful amplification was detected at Adenovirus concentrations as low as 0.006 copies per drop (0.003 pg/μl). Following amplification, the droplets collected from the microfluidic device were broken and analyzed by automated electrophoresis to confirm a product of the appropriate size. Consistent with the fluorescence data, get analysis showed an increase in total product as the amount of starting material was increased. The observed titers were compared with the average percentage of positive reactions predicted for each starting template concentration by Poisson statistics and by MPN (most probable number) (see Table below).
-
TABLE 3 Comparison of Observed Amplification Distribution to Poisson Statistics and MPN. Template Concentration PCR Positive Droplets Copies per Droplet Expected Expected (Poisson, Copies per Droplet (MPN adjusted)a Observed (Poisson) MPN adjusted)a 0.006 0.0050 (±0.000082) 2.08% 0.60% 0.49-0.51% 0.06 0.050 (±0.00082) 11.7% 5.82% 4.76-4.95% 0.3 0.25 (±0.0041) 20.3% 25.9% 21.6-22.4% 0.6 0.50 (±0.0082) 32.6% 45.1% 38.6-39.8% 6 5.0 (±0.082) 89.0% 99.8% 99.2-99.4% 60 50 (±0.82) 95.9% 100% 100% 600 500 (±8.2) 98.2% 100% 100% aMPN calculation based on the 4 lowest dilutions was 0.83 ± 0.017. Adjusted values are within 95% confidence. - A percentage of droplets that supported amplification was plotted versus starting copy number compared to that predicted by Poisson. Very good agreement was seen between the percentage of droplets that supported amplification and the predicted Poisson distribution. Given the accuracy of the data for endpoint analysis this droplet-based strategy appears to be ideal for quantitative PCR applications that require single molecule detection.
- As described in detail herein, the formation of Type TI library droplets, which encapsulate a library element, e.g., cell or bead, follow a Poisson Distribution. Using the following, equation, the distributions were calculated based on theory using the following equation:
-
- and experimental results are based on beads that were injected at a concentration of 40 million/ml into 23 μm drops (6.37 pL); CV=0.2548. The results are shown in the following table:
-
Theoretical Poisson Experimental P (N) Distribution Distribution # of Drops Counted P (0) 77.5 79.8 1010 P (1) 19.7 17.3 219 P (2) 2.5 2.5 32 P (3 and more) 0.3 0.4 5 Total 100% 100% 1266 - The primer droplet library generation is a Type II library generation.
FIG. 3 shows a schematic of the antibody pair library generation.Reagent solutions 1 through n, where n is the number of parallel ELISA assays to be performed, are prepared in separate vials. Each solution contains two antibodies, one bound to beads and one free in solution. It is often desirable, but not essential, for the unbound antibody to be biotinylated or for it to be conjugated to an enzyme. The beads are optically labeled using dyes, quantum dots or other distinguishing characteristics that make each of the n bead types uniquely identifiable, these characteristics can be also geometrical shape or features or fluorescence intensity or fluorescence polarization. For the emulsion library preparation: in separate locations, beads of each type are encapsulated in reagent droplets; the reagent contains an unbound second antibody matched for a specific immunoassay. It is often desirable, but not essential to have exactly one bead in a droplet. Droplets having exactly one bead are collected by sorting on droplet generation in a microfluidic device. The emulsion library consists of a pooled collection of the n different droplet types. The droplet stability prevents cross-contamination of antibody pairs. -
FIG. 3 shows the test fluid is the sample fluid used to analyze one or more immunoassays. Example test fluids include serum, sputum, urine or tumor biopsies. Instep 1 the test fluid is dispersed into droplets of uniform volume and combined with a single droplet from the library. There may be unpaired droplets of the library material. Instep 2 the beads are recovered, washed in bulk, a readout enzyme is introduced. Non-limiting examples of readout enzymes could include a conjugate streptavidin-enzyme (typical enzymes are, for example but not limited to: β-Galactasidase, alkaline phosphatase, horseradish peroxidase), or conjugate antibody-enzyme (for example the same list of enzymes), followed by a final wash. Instep 3 the beads are put back on microfluidic device at a low concentration so that limiting dilution conditions result. Most droplets will contain zero beads and most bead-containing droplets will have only one bead. Droplets containing exactly one bead will be used for the remainder of the assay. Droplets with no beads or more than one bead are sorted and discarded as discussed above. A fluorogenic substrate is added to the droplets under co-flow conditions at the time of droplet generation. The substrate is enzymatically turned-over to make a fluorescent product proportional to the concentration of analyte (and readout enzyme) in the sample fluid. An optical signal indicating the bead type and immunoassay number information is read on the beads simultaneously with the fluorescence signal from the product. This is done at one or more time points after the droplet is generated. Bead handling may benefit from using magnetic beads. - In some cases it may be advantageous to enhance step one with a sort procedure to remove the droplets containing excess beads that have not had the test fluid added to them. The sort can be triggered either by droplet size or through the introduction of a fluorescent dye to the test fluid.
- In some cases it may be advantageous to collect all beads on-chip. This is achieved with a micro-fabricated bead filter. Beads can then be washed, introduced to additional reagents, and subsequently followed by a final wash. By performing all of the previous steps all on-chip, the need for bulk processing of beads is eliminated.
- In some cases it is difficult to re-space beads after the final wash of
step 1. In those cases it may be advantageous to capture beads in isolation on-chip. In the example, the substrate is added in bulk and the diffusion of the product around the bead is measured. There are several other non-limiting examples of methods that could also be applied in a microfluidic device. For example, one could use a tyramide amplification assay. - Auto-loading of sample fluids, injection loop and dispense techniques can be utilized to enhance efficiency. Test fluids can be run sequentially using conventional auto-loaders and sample injection loops. Each sample would need to be separated by a rinse fluid and the off-chip processing of beads would require that the beads from each test fluid be collected separately.
- Droplet ELISA Performance—Reported Enzyme
- The activity of reporter enzyme bound to single positive beads (anti-m-biotin) or single negative beads in 30 um droplets can be assayed with HorseRadish Peroxidase (HRP) enzyme. Under the assay conditions, the beads were injected at a final concentration 10 million/ml, HRP readout at 10 minute time point—Amplex Ultra Red 100 uM,
hydrogen peroxide 1 mM. HRP allows for adequate separation of bead containing droplets from empty droplets. Additionally, a linear response is seen down to 10 molecules in a 30 um drop (at 10 minutes). - Droplet ELISA Performance—Binding
- Similar binding kinetics are seen when performing ELISA in a tube when compared to performance in droplets. Specifically, similar binding kinetics and a linear calibration curve is seen using droplets.
- Droplet ELISA Performance—Full Assay
- Serum concentration can be measured accurately and is able to be reproduced, generally within a CV of less that 6% as shown in the Table below that shows the results of serum sample replicates (˜60,000 droplets/run)
-
t = 0 min t = 10 min Antigen pg/ml All drops Empty drops Bead drops Human serum 18.2 21.7 252 1:1600 Human serum 19.7 25.8 264 1:1600 Human serum 23.5 25.6 278 1:1600 Positive control 40.5 56.2 4272 beads - Sorting Cells for Secreted Enzymatic Activity
- Molecular biology methods allow for generation of large libraries of mutant enzymes, which can be cloned DNA, which can be developed into a mutagenized DNA library that is then put into a bacterial host. The droplet based screening is high-throughput, highly accurate and has low reagents costs. The droplets provide an accurate high-throughput screen versus a halo assay. Specifically, the DNA enzyme contained within the bacterial host is encapsulated within a droplet that also contains a fluorogenic substance, creating a droplet library of the bacteria, where only a single bacteria is contained with the droplets. All droplets, however, contain the fluorogenic substrate. After the droplet library is created the bacteria are allowed to replicate for a set time period, i.e., overnight. Using a green filter shows the discrete bacteria, within particular droplets, and using a red filter shows the secreted enzyme.
- Droplet libraries can also be used in enzyme activity detection with single cell growth and enzyme secretion. A droplet library can include a number of droplets containing a single cell, where other droplets do not contain any cells. The cells remain in the droplets overnight and grow into clonal populations. Both the discrete bacteria and the secreted enzyme are detected with an overlay of assay and cell fluorescence. The droplet library is then sorted, such that the droplets all contain a clonal population of bacteria having secreted the desired enzyme. The droplet library enables a single cell generation to result in clonal populations within single droplets to be used in assays and or to be sorted.
- Activity in droplets is similar to that seen in microtitre plates. Matching rank orders with microtiter plate assays and droplet assays show similar rank orders using either method.
- Cell droplet libraries enable the sorting of the most active stain from a mixed cell library. In one example, droplets were generated with four individual strains and optical labeling using specific fluorescein concentrations (labeling plotted on y-axis). All of the droplets were collected into the same syringe and the mixed droplets were re-injected onto a microfluidic device after overnight growth at 30° C. A scatter plot shows the four labeled populations of droplets starting with no assay signal (on generation), and droplets having growing cells secreting protease showing assay activity moving to the right (after 16 hrs). The origin of each droplet is clearly identified, with the assay signal strength for each droplet type matching the appropriate strain ranking. Starting from a dilution of 1 positive in 100 Negatives viable bacteria can be recovered from sorted droplets to achieve sorted population.
- In another example, a 5-member library sorting can be achieved. A starting ratio of one Pos #4-containing droplet to 30 cell-containing droplets was used.
Pos# 3 cells only are kanamycin resistant. After recovering and plating out the contents of the sorted droplets, there were 19 kanamycin-resistant colonies out of 1131 total colonies. This is equivalent to an apparent false positive rate of 1.7%. - Sorting the most active strain can also be done with large (i.e., 2 million members) mixed cell libraries. Further exemplified is a parent library of 2×106 discrete cell types (bacteria secreting mutagenized enzyme library) was placed into droplets for growth and screening. Two levels of sorting threshold stringency were used to recover either the top 100 cells or the top 10K cell. After re-growth, each population was placed in droplets for an enriched library analytical run. Three populations were optically labeled, and five minutes of data were collected after cell growth and assay development in droplets. Clear enrichment of the parent library is seen in the Top 10K-Enriched Library. Validation of
Test Library# 1 enrichment is seen. White and red filtered microscope images of the Parent Library (Test Library #1) in droplets after growth are observed. Similar images of the Top 110K-Enriched Library are seen. Clear enrichment for active clones are also observed. -
FIG. 7 shows a schematic of the encapsulation of enzyme labeled individual cells in a substrate containing droplets. In contrast, traditional flow cytometry utilizes fluor-labeled antibodies. The contents of the droplets are then amplified, such that the contents of the droplet produce a labeled product. The contents are then put onto the inicrofluidic device in order to sort/recover the desired products. - A particular example is the U937 Monocyte Droplets, where cell library of an antibody, reporter enzyme and cell stain is prepared and co-flowed into droplets with the assay substrate. Depending on the contents of the droplet, a different signal is produced and the number of cells per droplet follows a Poisson distribution, where 8.4% of the droplets have a single cell, i.e., 25356 single cell droplets out of 300943 total droplets. Additionally, the enzyme amplified signal increases over time. The droplet libraries also enable multiplexed assays with optical labeling. Various labels can be utilized and overlayed. In a comparison of FACS and droplet sorting, droplet sorting provides improved cell population fractionation.
- Screen libraries of bacterially produced scFv's can also be developed. In one example, transformed bacteria are encapsulated and incubated at 37° C. After incubation the droplets are combined with droplets that contain beads, antigens and a detection antibody. After the two different droplets are combined they are collected and sorted. The positive droplets are then broken and the contents are recovered and sequenced. The process is able to screen for scFv's in droplets at a rate of about 1×106 per hour. The droplet based binding assays utilize localized fluorescence detection of scFV binding. Specifically, the diffuse signal becomes bright and localized on the capture bead.
- The present invention provides Immobilized Metal-Ion Affinity Partitioning (IMAP) FP detection of kinase reaction progress. Significant achievements allowing the instant method include:
-
- Solving problems handling IMAP, such as precipitation and providing proper mixing.
- Fast mixing/equilibrium in droplets allows direct on-chip analysis.
Initially, a significant precipitation of the IMAP particles in the syringe, particularly when present at high concentrations was observed. A mechanical mixing device and protocols was utilized to minimize this problem. Subsequently, this problem was fully solved by varying the ratio of buffers provided in Molecular Devices' Progressive Binding Buffer system, with a final concentration of 50% A:B buffer used for all assays. Buffer B contains a high salt concentration which prevented aggregation, and in addition allows a single buffer system to be used for many different kinases (using different substrates with a range of acidity).
- There are several distinct steps in performing kinase assays within droplets. First the reaction components are encapsulated inside droplets generated by a microfluidic device and collected into a syringe. Next, the refrigerated syringe is brought up to the reaction temperature, and the ‘emulsified’ reaction mixture proceeds to react for a defined amount of time. Finally, the reaction emulsion is re-injected and each individual droplet is analyzed when it flows past a laser detector. In this scheme, detection of the phosphorylated reaction product is via measurement of its Fluorescence Polarization (FP) after binding to the commercially available Immobilized Metal-Ion Affinity Partitioning (IMAP) kit reagents (Molecular Probes). The scheme incorporates a formulation step allowing chemical compounds to be tested for their inhibitory properties towards kinases.
- The fluorescence polarization is measured for each droplet and changes upon binding. Specifically, the phosphorylated product binds to IMAP and increases its FP. Compound/DMSO dilution and encapsulation of the reaction reagents into droplets is formulated on the microfluidic device.
- In one example, two sets of droplets are initially generated, one from an aqueous stream made of compound (provided in 70% DMSO) and ATP (nozzle 1), and the other from an aqueous stream containing the kinase and substrate in a reaction buffer (nozzle 2). These two droplet types are subsequently coalesced via the application of voltage from the electrode, generating the final reaction mixture droplets which is collected into a glass syringe.
- When generating the compound/ATP droplets, fluid flow rates are set such that the compound that is initially in 70% DMSO is diluted to a concentration of 10% DMSO in the droplets generated by
nozzle 1. The volume ratio of droplets generated atnozzle 1 vs.nozzle 2 is 1 to 3, therefore when droplets fromnozzle 1 are coalesced with droplets from nozzle 2 (containing the kinase and substrate) there is another 4 fold dilution of DMSO is therefore 28-fold (the concentration of DMSO in the final reaction mix is 2.5%). - Coalescence of droplets with IMAP, IMAP binding, and timed readout of droplets are observed. Specifically, IMAP particles are encapsulated inside droplets which are subsequently coalesced with the emulsified reaction mixture droplets as they are being re-injected. The droplets enter a delay line which provides sufficient time for each droplet to be interrogated using an FP readout as it moves from left to right through the microfluidic channel shown.
- A combined microfluidic device design was also developed in order to improve emulsion stability (by reducing microfluidic device connection manipulations) and to reduce the time required for switching microfluidic devices and re-equilibrating fluid pressures. In this design, the same channel is used for both emulsion collection and re-injection, allowing for emulsion generation, IMAP coalescence and FP readout all on one microfluidic device. This design provides for a higher degree of automation and reproducibility by reducing operator manipulations of the inicrofluidic devices and optics, reducing opportunities for contaminants to be introduced into the microfluidic system, and provides better control of the operation time.
- In order to generate kinetic data on the kinase reaction progress, a collection of the reaction droplet emulsion at 4° C. was provided, to prevent the enzymatic reaction from proceeding until the temperature is raised. Once the emulsion has been generated, the syringe can be raised to any temperature desired (e.g. room temperature or 30° C.). All of the experiments shown in this report were performed at room temperature. Time course experiments were also performed by varying the time that the emulsion was kept at room temperature, before re-injection and coalescence with the IMAP detection reagent. Automated protocols were established allowing for time points to be collected every 10 minutes over a period up to 4 hours.
- Optical components have been defined and developed to enable FP detection. Optical components were assembled, using a 25-milliwatt solid-state laser to generate a 10 micron focused laser spot in the microfluidic channel, allowing a fluorescence signal to be measured for each droplet. The prototype instrument used in this study is able to detect approximately 10,000 FITC molecules encapsulated in a 30 micron droplet passing through the detection point at a rate of up to 10,000 per second.
- Binding of the IMAP particle to the phosphorylated peptide substrate can be directly observed using the microfluidic device. As each droplet moves at a defined flow rate through the circuitry, observation at different positions after IMAP coalescence defines specific times after binding. A delay line allows measurements over approximately 20 seconds after binding IMAP. Binding of the Akt positive control phospho-peptide to IMAP and the reaction of Abl-tide substrate with AbI kinase are seen. Binding of the IMAP reagent to both of these phospho-peptides reaches equilibrium within 10 seconds. Further, a comparison of on-chip and plate reader assays using 3 compounds where % inhibition time courses for AbI kinase and compounds E, A, and 11 show improved resolution for on-chip assays.
- Compound Libraries—Screening for Cytotoxic Drugs
- In one example, one nozzle is used to encapsulate U937 mammalian cells that are cultivated in RPMI supplemented with fetal calf serum (10% v/v) under saturated CO2 atmosphere (5%). Flow-focusing geometry to form the droplets was used. A water stream is infused from one channel through a narrow constriction; oil streams hydrodynamically focus the water stream and reduce its size as it passes through the constriction resulting in a “geometry-controlled” breakup of the droplet. The size of the water droplets is controlled in part by the relative flow rates of the oil and the water and in part by the nozzle section dimensions. The fluorinated oil contains a fluorocarbon surfactant (Ammonium Carboxylate Salt of Perfluoropolyether, 1% w/w) to stabilize the droplets. Cell density upon injection with discussion on Poisson's distribution and single cell analysis % drop size. Pluronic F-68 (0.1% final solution) a shear-protectant, is added to the cells just prior the injection to minimize the effect of shear-stress. The other nozzle generates droplets containing the Calcein-AM and Sytox Orange (Invitrogen) dyes that are used to respectively score live and dead cells. In brief, Calcein-AM is membrane permeant, non-fluorescent and diffuses into cells where the acetoxy groups are hydrolyzed by nonspecific esterases. The hydrolyzed dye (Calcein) is both cell membrane impermeant and fluorescent. Sytox Orange is impermeant and excluded from viable cells, but is able to enter cells with compromised membranes. In this case, it binds to DNA by intercalating between the bases with little sequence specificity and its fluorescence is greatly enhanced. Finally, a fluoro-surfactant (Zonyl-FSO, 1.3%, Dupont) was added in the dye solution to prevent the interaction of the dyes with the carboxylate group of the main surfactant. The droplet streams are interdigitated so that each cell droplet pairs with a dye droplet before entering the coalescence module. To this end, the fact that smaller droplets flow at higher velocities than larger droplets due to the parabolic flow velocity distribution in microfluidic channels was exploited. The small dye droplets catch up and come into contact with the larger cell droplets, but do not coalesce because they are stabilized with surfactant. In addition, in order to have each cell droplet paired with a dye droplet the formation rate of dye droplets is higher than the formation rate of cell droplets formation in a ratio close to 1:2. Coalescence is controllably induced when a pair of droplets passes through an alternative electric field (˜300V.cm−1, 100 kHz). The expansion in the coalescing region allows for a dramatic catching up of the small droplet to the large droplet and accounts for a very robust coalescence (fewer than 0.1% misses). The volume of the expansion is big enough to slow the large droplet down so that the small droplet always catches up to the large droplet, but doesn't allow the next droplet to catch up and make contact with the pair to be coalesced. After the droplet pairs are coalesced, their content, i.e. cells and dyes, is mixed by traveling through a passive serpentine mixer. Because the Calcein-AM dye has to be processed enzymatically by the cells to become fluorescent, the droplets need to be incubated on-chip for tens of minutes. To achieve this type of incubation on-chip the cross-section (600 μm×250 μm) and the length of the channel (1,550 mm) was increased so that the flow sweeps through a large volume. This design results in a significant residence time on the microfluidic device. In addition, to modulate with ease the incubation period without changing the flowrates used for generating the droplets oil from the flowing stream was extracted. The oil extractor consists of a series of T-junction whose sections are much smaller than the droplet size, which are used to specifically extract oil and reduce the overall flowrate and hence the droplet velocity. The combined use of the incubation line and the oil extractor results in a significant on-chip residency time of the droplets. Typically, the live-dead assay experiments are carried out with an incubation time of 70 minutes on the microfluidic device. For consistent fluorescent detection, all the cells are illuminated in the same conditions by confining them through a constriction and by using a slit geometry for the excitation spot. A confocal optical set-up is used and the signal is collected with a set of photomultipliers at a rate of 100 kHz.
- A typical fluorescent readout is provided, over a timescale of 100 ms. The cell growth medium gives a dim fluorescent background which is much lower than the live-dead assay signals. To compensate for this low signal, some fluorescein (10 μM) (Invitrogen) was added into the dye solution to get a clear fluorescent signature of the droplets which is characterized by an approximately rectangular cross-section. Peak signals corresponding to cell staining are characterized by higher maximum signal and narrower Forward Half Maximum. They can be clearly distinguished on top of the homogeneous signal. Data processing software has been developed to extract different parameters (height, integrated area . . . ) after interpolation and curve fitting from each droplet signal. After scoring the cells retain a normal morphology without any apparent sign of shearing. Cell density upon injection with discussion on Poisson's distribution and single cell analysis % drop size.
- To test the performances of the assay, a series of experiments were conducted to test its specificity and its sensitivity. First the signal specificity was checked by injecting and scoring with the live-dead assay either only live or dead cells. Dead cells were prepared by incubating fresh cells with 70% Ethanol for 5 minutes. The experiment demonstrates that the assay is very specific as all the cells are scored properly. In addition, it shows that the injection does not kill the cells over a short-term period, in agreement with other's observations.
- Second, the assay was test to see whether it was able to score all the injected cells disregarding their cell state (either alive or dead). To this purpose all the cells with a red dye (Qdot® 655 wheat germ agglutinin, Invitrogen) were identified and checked that they were all scored. Again, live cells and dead cells were scored separately. It is noteworthy that these numbers are the result of the combined efficiencies of all the modules used for the live-dead assay, demonstrating the robustness of this assay and technology.
- Third, to assess the usefulness of this assay for screening purpose a series of known ratios of live and dead cells were scored in the range of 0-10% dead cells. Indeed, the fraction of positive hits for a cytotoxicity large-scale screen is expected to be in the order of a few percent. For example, as little as 5% positive cells can be reproducibly detected in a sample population of 500-1,000 measured cells.
- Finally, it was demonstrated that encapsulated cells can be collected into a syringe and the emulsions re-injected for on-chip scoring. This ability is an essential feature of the technology for conducting screens, as the cells will have to be incubated with compounds for a much longer time than achievable on-chip.
- It was observed that the cell emulsion which is re-injected through the lower nozzle is still monodisperse. The stability depends critically on the use of the fluoro-surfactant and design of the microfluidic circuit to avoid uncontrolled coalescence. By the use of a scatter plot, it is determined that most of the cells are able to survive the collection-reinjection procedure.
- The droplet microfluidic technology will facilitate an expansive list of microfluidic applications. In particular high-throughput cell screening and combinatorial screening at the single cell level will greatly benefit from this technology platform. The major advantages of this technology are the absence of contact between the sample and the channel walls eliminating contamination, and high-throughput manipulation.
- The toxicity assay with droplets requires encapsulating cells determining the difference between live cells and dead cells. In order to get a reading of the droplet and fluorescent level therein, the droplet is elongated for detection. The cell viability does not significantly change over time (>3 days) in the droplets.
Claims (14)
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/504,764 US20100022414A1 (en) | 2008-07-18 | 2009-07-17 | Droplet Libraries |
US13/487,030 US10533998B2 (en) | 2008-07-18 | 2012-06-01 | Enzyme quantification |
US13/855,318 US9562837B2 (en) | 2006-05-11 | 2013-04-02 | Systems for handling microfludic droplets |
US15/290,378 US11534727B2 (en) | 2008-07-18 | 2016-10-11 | Droplet libraries |
US15/415,044 US9896722B2 (en) | 2006-05-11 | 2017-01-25 | Systems for handling microfluidic droplets |
US15/863,496 US10011865B2 (en) | 2006-05-11 | 2018-01-05 | Systems for handling microfluidic droplets |
US16/022,360 US10927407B2 (en) | 2006-05-11 | 2018-06-28 | Systems and methods for handling microfluidic droplets |
US16/105,042 US11596908B2 (en) | 2008-07-18 | 2018-08-20 | Droplet libraries |
US16/733,132 US20200225232A1 (en) | 2008-07-18 | 2020-01-02 | Enzyme quantification |
US17/081,220 US11187702B2 (en) | 2003-03-14 | 2020-10-27 | Enzyme quantification |
US17/174,519 US20210262020A1 (en) | 2006-05-11 | 2021-02-12 | Systems and methods for handling microfluidic droplets |
US17/510,092 US11511242B2 (en) | 2008-07-18 | 2021-10-25 | Droplet libraries |
US17/509,933 US20220042995A1 (en) | 2003-03-14 | 2021-10-25 | Enzyme quantification |
US17/513,437 US20220050108A1 (en) | 2008-07-18 | 2021-10-28 | Enzyme quantification |
US18/178,965 US20230219043A1 (en) | 2008-07-18 | 2023-03-06 | Droplet libraries |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8193008P | 2008-07-18 | 2008-07-18 | |
US12/504,764 US20100022414A1 (en) | 2008-07-18 | 2009-07-17 | Droplet Libraries |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/803,104 Continuation-In-Part US20080003142A1 (en) | 2006-05-11 | 2007-05-11 | Microfluidic devices |
US13/026,120 Continuation-In-Part US9074242B2 (en) | 2006-05-11 | 2011-02-11 | Digital analyte analysis |
Related Child Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/803,104 Continuation-In-Part US20080003142A1 (en) | 2006-05-11 | 2007-05-11 | Microfluidic devices |
US13/026,120 Continuation-In-Part US9074242B2 (en) | 2006-05-11 | 2011-02-11 | Digital analyte analysis |
US13/487,030 Continuation-In-Part US10533998B2 (en) | 2003-03-14 | 2012-06-01 | Enzyme quantification |
US13/855,318 Continuation-In-Part US9562837B2 (en) | 2006-05-11 | 2013-04-02 | Systems for handling microfludic droplets |
US15/290,378 Division US11534727B2 (en) | 2008-07-18 | 2016-10-11 | Droplet libraries |
US16/733,132 Continuation US20200225232A1 (en) | 2003-03-14 | 2020-01-02 | Enzyme quantification |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100022414A1 true US20100022414A1 (en) | 2010-01-28 |
Family
ID=41278485
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/504,764 Abandoned US20100022414A1 (en) | 2003-03-14 | 2009-07-17 | Droplet Libraries |
US15/290,378 Active US11534727B2 (en) | 2008-07-18 | 2016-10-11 | Droplet libraries |
US16/105,042 Active US11596908B2 (en) | 2008-07-18 | 2018-08-20 | Droplet libraries |
US17/510,092 Active US11511242B2 (en) | 2008-07-18 | 2021-10-25 | Droplet libraries |
US18/178,965 Pending US20230219043A1 (en) | 2008-07-18 | 2023-03-06 | Droplet libraries |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/290,378 Active US11534727B2 (en) | 2008-07-18 | 2016-10-11 | Droplet libraries |
US16/105,042 Active US11596908B2 (en) | 2008-07-18 | 2018-08-20 | Droplet libraries |
US17/510,092 Active US11511242B2 (en) | 2008-07-18 | 2021-10-25 | Droplet libraries |
US18/178,965 Pending US20230219043A1 (en) | 2008-07-18 | 2023-03-06 | Droplet libraries |
Country Status (3)
Country | Link |
---|---|
US (5) | US20100022414A1 (en) |
EP (2) | EP4047367A1 (en) |
WO (1) | WO2010009365A1 (en) |
Cited By (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060003439A1 (en) * | 2004-07-02 | 2006-01-05 | Ismagilov Rustem F | Microfluidic system |
US20060153924A1 (en) * | 2003-03-31 | 2006-07-13 | Medical Research Council | Selection by compartmentalised screening |
US20060163385A1 (en) * | 2003-04-10 | 2006-07-27 | Link Darren R | Formation and control of fluidic species |
US20070003442A1 (en) * | 2003-08-27 | 2007-01-04 | President And Fellows Of Harvard College | Electronic control of fluidic species |
US20070092914A1 (en) * | 2004-03-31 | 2007-04-26 | Medical Research Council, Harvard University | Compartmentalised screening by microfluidic control |
US20070172954A1 (en) * | 2002-05-09 | 2007-07-26 | The University Of Chicago | Device and method for pressure-driven plug transport and reaction |
US20090104637A1 (en) * | 2006-01-31 | 2009-04-23 | Ismagilov Rustem F | Method and Apparatus for Assaying Blood Clotting |
US20090197248A1 (en) * | 2004-10-08 | 2009-08-06 | President And Fellows Of Harvard College | Vitro evolution in microfluidic systems |
US20100078077A1 (en) * | 2006-12-19 | 2010-04-01 | Ismagilov Rustem F | Spacers for Microfluidic Channels |
US20100092987A1 (en) * | 2003-09-05 | 2010-04-15 | Stokes Bio Limited | Microfluidic analysis system |
US20100105112A1 (en) * | 2006-08-07 | 2010-04-29 | Christian Holtze | Fluorocarbon emulsion stabilizing surfactants |
US20100120635A1 (en) * | 2003-09-05 | 2010-05-13 | Stokes Bio Limited | Sample dispensing |
US20100136544A1 (en) * | 2007-03-07 | 2010-06-03 | Jeremy Agresti | Assays and other reactions involving droplets |
US20100163109A1 (en) * | 2007-02-06 | 2010-07-01 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US20100210479A1 (en) * | 2003-03-31 | 2010-08-19 | Medical Research Council | Method of synthesis and testing of cominatorial libraries using microcapsules |
US20100227767A1 (en) * | 2007-07-26 | 2010-09-09 | Boedicker James Q | Stochastic confinement to detect, manipulate, and utilize molecules and organisms |
US20100233026A1 (en) * | 2002-05-09 | 2010-09-16 | Ismagliov Rustem F | Device and method for pressure-driven plug transport and reaction |
US20100252118A1 (en) * | 2007-04-19 | 2010-10-07 | Seth Fraden | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US20100297685A1 (en) * | 2003-09-05 | 2010-11-25 | Stokes Bio Limited | Methods for culturing and analyzing cells |
US20110053798A1 (en) * | 2009-09-02 | 2011-03-03 | Quantalife, Inc. | System for mixing fluids by coalescence of multiple emulsions |
US20110086780A1 (en) * | 2008-09-23 | 2011-04-14 | Quantalife, Inc. | System for forming an array of emulsions |
US20110112503A1 (en) * | 2008-06-04 | 2011-05-12 | Ismagilov Rustem F | Chemistrode, a plug-based microfluidic device and method for stimulation and sampling with high temporal, spatial, and chemical resolution |
US20110165037A1 (en) * | 2010-01-07 | 2011-07-07 | Ismagilov Rustem F | Interfaces that eliminate non-specific adsorption, and introduce specific interactions |
US20110212516A1 (en) * | 2008-09-23 | 2011-09-01 | Ness Kevin D | Flow-based thermocycling system with thermoelectric cooler |
US20110218123A1 (en) * | 2008-09-19 | 2011-09-08 | President And Fellows Of Harvard College | Creation of libraries of droplets and related species |
US20110217711A1 (en) * | 2010-03-02 | 2011-09-08 | Quantalife, Inc. | Assays with droplets transformed into capsules |
WO2012022976A1 (en) | 2010-08-20 | 2012-02-23 | Sphere Fluidics Limited | Method of providing a chemical or biological material in quantised form and system therefor |
WO2012047324A2 (en) | 2010-06-10 | 2012-04-12 | President And Fellows Of Harvard College | Systems and methods for amplification and phage display |
WO2012045012A3 (en) * | 2010-09-30 | 2012-07-19 | Raindance Technologies, Inc. | Sandwich assays in droplets |
WO2012109604A1 (en) * | 2011-02-11 | 2012-08-16 | Raindance Technologies, Inc. | Thermocycling device for nucleic acid amplification and methods of use |
WO2012112804A1 (en) | 2011-02-18 | 2012-08-23 | Raindance Technoligies, Inc. | Compositions and methods for molecular labeling |
WO2012156744A2 (en) | 2011-05-17 | 2012-11-22 | Cambridge Enterprise Limited | Gel beads in microfluidic droplets |
WO2012167142A2 (en) | 2011-06-02 | 2012-12-06 | Raindance Technolgies, Inc. | Enzyme quantification |
WO2013116698A2 (en) | 2012-02-02 | 2013-08-08 | Invenra, Inc. | High throughput screen for biologically active polypeptides |
WO2013126741A1 (en) | 2012-02-24 | 2013-08-29 | Raindance Technologies, Inc. | Labeling and sample preparation for sequencing |
US8528589B2 (en) | 2009-03-23 | 2013-09-10 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
US8535889B2 (en) | 2010-02-12 | 2013-09-17 | Raindance Technologies, Inc. | Digital analyte analysis |
US20130345088A1 (en) * | 2011-03-08 | 2013-12-26 | Japan Science And Technology Agency | Bead sealing method, method for detecting target molecule, array, kit, and target molecule detection device |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
US8663920B2 (en) | 2011-07-29 | 2014-03-04 | Bio-Rad Laboratories, Inc. | Library characterization by digital assay |
US8709762B2 (en) | 2010-03-02 | 2014-04-29 | Bio-Rad Laboratories, Inc. | System for hot-start amplification via a multiple emulsion |
US20140120604A1 (en) * | 2011-04-08 | 2014-05-01 | Stokes Bio Limited | Biological Detection System and Method of Use |
US8730479B2 (en) | 2010-03-25 | 2014-05-20 | Bio-Rad Laboratories, Inc. | Detection system for droplet-based assays |
US8748094B2 (en) | 2008-12-19 | 2014-06-10 | President And Fellows Of Harvard College | Particle-assisted nucleic acid sequencing |
US20140203169A1 (en) * | 2011-06-17 | 2014-07-24 | Life Technologies Corporation | Flat-Field Imaging System and Methods of Use |
WO2014138711A1 (en) * | 2013-03-08 | 2014-09-12 | Bio-Rad Laboratories, Inc. | Compositions, methods and systems for polymerase chain reaction assays |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US20140303005A1 (en) * | 2013-04-05 | 2014-10-09 | Raindance Technologies, Inc. | Rare cell analysis after negative selection |
WO2014172288A2 (en) | 2013-04-19 | 2014-10-23 | Raindance Technologies, Inc. | Digital analyte analysis |
WO2014179596A1 (en) * | 2013-05-01 | 2014-11-06 | Advanced Liquid Logic, Inc. | Analysis of dna |
WO2014189898A1 (en) * | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Compositions for detecting cellular forces |
US20140355008A1 (en) * | 2013-05-28 | 2014-12-04 | Nasser Ashgriz | Spray Droplet Sizer |
US20150038344A1 (en) * | 2010-02-25 | 2015-02-05 | Advanced Liquid Logic, Inc. | Method of Preparing a Nucleic Acid Library |
US8951939B2 (en) | 2011-07-12 | 2015-02-10 | Bio-Rad Laboratories, Inc. | Digital assays with multiplexed detection of two or more targets in the same optical channel |
US8986628B2 (en) | 2002-06-28 | 2015-03-24 | President And Fellows Of Harvard College | Method and apparatus for fluid dispersion |
US9056289B2 (en) | 2009-10-27 | 2015-06-16 | President And Fellows Of Harvard College | Droplet creation techniques |
US9080208B2 (en) | 2010-07-22 | 2015-07-14 | Gencell Biosystems Ltd. | Composite liquid cells |
US9089844B2 (en) | 2010-11-01 | 2015-07-28 | Bio-Rad Laboratories, Inc. | System for forming emulsions |
US9132394B2 (en) | 2008-09-23 | 2015-09-15 | Bio-Rad Laboratories, Inc. | System for detection of spaced droplets |
US20150346201A1 (en) * | 2013-01-07 | 2015-12-03 | Tali Korny | System and method for picoliter volume microfluidic diagnostics |
US9222128B2 (en) | 2011-03-18 | 2015-12-29 | Bio-Rad Laboratories, Inc. | Multiplexed digital assays with combinatorial use of signals |
US9273308B2 (en) | 2006-05-11 | 2016-03-01 | Raindance Technologies, Inc. | Selection of compartmentalized screening method |
WO2016040476A1 (en) | 2014-09-09 | 2016-03-17 | The Broad Institute, Inc. | A droplet-based method and apparatus for composite single-cell nucleic acid analysis |
US9328344B2 (en) | 2006-01-11 | 2016-05-03 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9347059B2 (en) | 2011-04-25 | 2016-05-24 | Bio-Rad Laboratories, Inc. | Methods and compositions for nucleic acid analysis |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
US9364803B2 (en) | 2011-02-11 | 2016-06-14 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
US9388465B2 (en) | 2013-02-08 | 2016-07-12 | 10X Genomics, Inc. | Polynucleotide barcode generation |
EP2931259A4 (en) * | 2012-12-14 | 2016-07-13 | Gnubio Inc | Method for maintaining heterogeneous concentrations of molecules in emulsion droplets |
US9393560B2 (en) | 2010-03-25 | 2016-07-19 | Bio-Rad Laboratories, Inc. | Droplet transport system for detection |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
US9399215B2 (en) | 2012-04-13 | 2016-07-26 | Bio-Rad Laboratories, Inc. | Sample holder with a well having a wicking promoter |
US9410201B2 (en) | 2012-12-14 | 2016-08-09 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9417190B2 (en) | 2008-09-23 | 2016-08-16 | Bio-Rad Laboratories, Inc. | Calibrations and controls for droplet-based assays |
US9415392B2 (en) | 2009-03-24 | 2016-08-16 | The University Of Chicago | Slip chip device and methods |
US9427737B2 (en) | 2012-12-14 | 2016-08-30 | Bio-Rad Laboratories, Inc. | Methods and compositions for using oils for analysis and detection of molecules |
WO2016138490A1 (en) | 2015-02-27 | 2016-09-01 | Fluidigm Corporation | Single-cell nucleic acids for high-throughput studies |
WO2016138488A2 (en) | 2015-02-26 | 2016-09-01 | The Broad Institute Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
US9447461B2 (en) | 2009-03-24 | 2016-09-20 | California Institute Of Technology | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
US9464319B2 (en) | 2009-03-24 | 2016-10-11 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes |
US9492797B2 (en) | 2008-09-23 | 2016-11-15 | Bio-Rad Laboratories, Inc. | System for detection of spaced droplets |
US9500664B2 (en) | 2010-03-25 | 2016-11-22 | Bio-Rad Laboratories, Inc. | Droplet generation for droplet-based assays |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
WO2017075549A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute, Inc. | High-throughput dynamic reagent delivery system |
US20170151536A1 (en) * | 2009-03-13 | 2017-06-01 | President And Fellows Of Harvard College | Scale-up of microfluidic devices |
US9689024B2 (en) | 2012-08-14 | 2017-06-27 | 10X Genomics, Inc. | Methods for droplet-based sample preparation |
US9694361B2 (en) | 2014-04-10 | 2017-07-04 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
WO2017124101A2 (en) | 2016-01-15 | 2017-07-20 | The Broad Institute Inc. | Semi-permeable arrays for analyzing biological systems and methods of using same |
US9764322B2 (en) | 2008-09-23 | 2017-09-19 | Bio-Rad Laboratories, Inc. | System for generating droplets with pressure monitoring |
US9777269B2 (en) | 2012-01-25 | 2017-10-03 | Gencell Biosystems Ltd. | Biomolecule isolation |
US9776182B2 (en) | 2012-11-27 | 2017-10-03 | Gencell Biosystems Ltd. | Handling liquid samples |
US9797010B2 (en) | 2007-12-21 | 2017-10-24 | President And Fellows Of Harvard College | Systems and methods for nucleic acid sequencing |
EP3100045A4 (en) * | 2014-01-31 | 2017-10-25 | Carnegie Mellon University | Device and method for clinical data sampling and specimen banking |
US9816088B2 (en) | 2013-03-15 | 2017-11-14 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US9824068B2 (en) | 2013-12-16 | 2017-11-21 | 10X Genomics, Inc. | Methods and apparatus for sorting data |
US9910020B1 (en) | 2005-03-30 | 2018-03-06 | Copilot Ventures Fund Iii Llc | Methods and articles for identifying objects using encapsulated perfluorocarbon tracers |
US9921154B2 (en) | 2011-03-18 | 2018-03-20 | Bio-Rad Laboratories, Inc. | Multiplexed digital assays |
US9925504B2 (en) | 2004-03-31 | 2018-03-27 | President And Fellows Of Harvard College | Compartmentalised combinatorial chemistry by microfluidic control |
US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US20180112036A1 (en) * | 2015-04-21 | 2018-04-26 | Ran Biotechnologies, Inc | Novel fluorinated surfactants |
US9970052B2 (en) | 2012-08-23 | 2018-05-15 | Bio-Rad Laboratories, Inc. | Digital assays with a generic reporter |
US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
EP3333269A1 (en) | 2011-03-31 | 2018-06-13 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to enable multiplex cold-pcr |
US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10018627B2 (en) | 2011-03-08 | 2018-07-10 | Japan Science And Technology Agency | Method for sealing substances, method for detecting target molecule, array, kit, and target molecule detection device |
US20180223348A1 (en) * | 2013-12-12 | 2018-08-09 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
JP2018194318A (en) * | 2017-05-12 | 2018-12-06 | 国立大学法人東北大学 | Immunoassay in micro water droplet |
US10196700B2 (en) | 2009-03-24 | 2019-02-05 | University Of Chicago | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
US10221436B2 (en) | 2015-01-12 | 2019-03-05 | 10X Genomics, Inc. | Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same |
US10221442B2 (en) | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10287623B2 (en) | 2014-10-29 | 2019-05-14 | 10X Genomics, Inc. | Methods and compositions for targeted nucleic acid sequencing |
CN109863398A (en) * | 2016-04-15 | 2019-06-07 | 蒙彼利埃大学医疗中心 | For detecting and/or characterizing the method and relevant apparatus of tumour cell |
US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US10357771B2 (en) | 2017-08-22 | 2019-07-23 | 10X Genomics, Inc. | Method of producing emulsions |
US10384187B2 (en) | 2014-02-10 | 2019-08-20 | Gencell Biosystems Ltd | Composite liquid cell (CLC) mediated nucleic acid library preparation device, and methods for using the same |
US10395758B2 (en) | 2013-08-30 | 2019-08-27 | 10X Genomics, Inc. | Sequencing methods |
US10400235B2 (en) | 2017-05-26 | 2019-09-03 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
US10400280B2 (en) | 2012-08-14 | 2019-09-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10428326B2 (en) | 2017-01-30 | 2019-10-01 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
US10451619B2 (en) | 2014-07-08 | 2019-10-22 | Japan Science And Technology Agency | Substance sealing method and target molecule detecting method |
US10471016B2 (en) | 2013-11-08 | 2019-11-12 | President And Fellows Of Harvard College | Microparticles, methods for their preparation and use |
WO2019222562A1 (en) * | 2018-05-16 | 2019-11-21 | Catalog Technologies, Inc. | Printer-finisher system for data storage in dna |
US10501786B2 (en) | 2011-05-20 | 2019-12-10 | Fluidigm Corporation | Nucleic acid encoding reactions |
US10512910B2 (en) | 2008-09-23 | 2019-12-24 | Bio-Rad Laboratories, Inc. | Droplet-based analysis method |
US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10544413B2 (en) | 2017-05-18 | 2020-01-28 | 10X Genomics, Inc. | Methods and systems for sorting droplets and beads |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
CN110799679A (en) * | 2017-06-20 | 2020-02-14 | 10X基因组学有限公司 | Method and system for improving droplet stabilization |
US10590483B2 (en) | 2014-09-15 | 2020-03-17 | Abvitro Llc | High-throughput nucleotide library sequencing |
US10596541B2 (en) | 2014-04-21 | 2020-03-24 | President And Fellows Of Harvard College | Systems and methods for barcoding nucleic acids |
WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
US10650912B2 (en) | 2015-01-13 | 2020-05-12 | 10X Genomics, Inc. | Systems and methods for visualizing structural variation and phasing information |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
US10697000B2 (en) | 2015-02-24 | 2020-06-30 | 10X Genomics, Inc. | Partition processing methods and systems |
US10730051B2 (en) | 2006-02-07 | 2020-08-04 | Stokes Bio Ltd. | Liquid bridge and system |
US10745742B2 (en) | 2017-11-15 | 2020-08-18 | 10X Genomics, Inc. | Functionalized gel beads |
US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10774370B2 (en) | 2015-12-04 | 2020-09-15 | 10X Genomics, Inc. | Methods and compositions for nucleic acid analysis |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US10839939B2 (en) | 2014-06-26 | 2020-11-17 | 10X Genomics, Inc. | Processes and systems for nucleic acid sequence assembly |
US10854315B2 (en) | 2015-02-09 | 2020-12-01 | 10X Genomics, Inc. | Systems and methods for determining structural variation and phasing using variant call data |
US20200408747A1 (en) * | 2015-08-25 | 2020-12-31 | Bio-Rad Laboratories, Inc. | Digital immunoassay |
US10883102B2 (en) * | 2015-03-20 | 2021-01-05 | Novozymes A/S | Droplet-based selection by injection |
EP3799956A1 (en) * | 2019-10-04 | 2021-04-07 | ETH Zurich | Electrophoretic enrichment of analytes in droplets |
US11001883B2 (en) | 2012-03-05 | 2021-05-11 | The General Hospital Corporation | Systems and methods for epigenetic sequencing |
CN113167715A (en) * | 2018-10-08 | 2021-07-23 | 生物电子公司 | System and method for optically processing a sample |
US11072816B2 (en) | 2017-05-03 | 2021-07-27 | The Broad Institute, Inc. | Single-cell proteomic assay using aptamers |
US11072820B2 (en) | 2017-10-19 | 2021-07-27 | Bio-Rad Laboratories, Inc. | Digital amplification assays with unconventional and/or inverse changes in photoluminescence |
US11081208B2 (en) | 2016-02-11 | 2021-08-03 | 10X Genomics, Inc. | Systems, methods, and media for de novo assembly of whole genome sequence data |
US11084036B2 (en) | 2016-05-13 | 2021-08-10 | 10X Genomics, Inc. | Microfluidic systems and methods of use |
US11092607B2 (en) | 2015-10-28 | 2021-08-17 | The Board Institute, Inc. | Multiplex analysis of single cell constituents |
US11117113B2 (en) | 2015-12-16 | 2021-09-14 | Fluidigm Corporation | High-level multiplex amplification |
US11123297B2 (en) | 2015-10-13 | 2021-09-21 | President And Fellows Of Harvard College | Systems and methods for making and using gel microspheres |
US11130128B2 (en) | 2008-09-23 | 2021-09-28 | Bio-Rad Laboratories, Inc. | Detection method for a target nucleic acid |
US11155881B2 (en) | 2018-04-06 | 2021-10-26 | 10X Genomics, Inc. | Systems and methods for quality control in single cell processing |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
US11209440B2 (en) | 2014-02-27 | 2021-12-28 | The Broad Institute, Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
US11274343B2 (en) | 2015-02-24 | 2022-03-15 | 10X Genomics, Inc. | Methods and compositions for targeted nucleic acid sequence coverage |
US11471888B2 (en) * | 2015-06-05 | 2022-10-18 | Miroculus Inc. | Evaporation management in digital microfluidic devices |
US11511242B2 (en) | 2008-07-18 | 2022-11-29 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11524298B2 (en) | 2019-07-25 | 2022-12-13 | Miroculus Inc. | Digital microfluidics devices and methods of use thereof |
US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US11619631B2 (en) | 2010-03-01 | 2023-04-04 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
US11623219B2 (en) | 2017-04-04 | 2023-04-11 | Miroculus Inc. | Digital microfluidics apparatuses and methods for manipulating and processing encapsulated droplets |
US11629344B2 (en) | 2014-06-26 | 2023-04-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11639933B2 (en) * | 2017-09-27 | 2023-05-02 | Bio-Rad Laboratories, Inc. | Digital affinity linkage assay |
US11660601B2 (en) | 2017-05-18 | 2023-05-30 | 10X Genomics, Inc. | Methods for sorting particles |
US11738345B2 (en) | 2019-04-08 | 2023-08-29 | Miroculus Inc. | Multi-cartridge digital microfluidics apparatuses and methods of use |
US11746367B2 (en) | 2015-04-17 | 2023-09-05 | President And Fellows Of Harvard College | Barcoding systems and methods for gene sequencing and other applications |
US11773389B2 (en) | 2017-05-26 | 2023-10-03 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
US11772093B2 (en) | 2022-01-12 | 2023-10-03 | Miroculus Inc. | Methods of mechanical microfluidic manipulation |
US11795494B2 (en) | 2009-04-02 | 2023-10-24 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
US11833515B2 (en) | 2017-10-26 | 2023-12-05 | 10X Genomics, Inc. | Microfluidic channel networks for partitioning |
US11833516B2 (en) | 2016-12-28 | 2023-12-05 | Miroculus Inc. | Digital microfluidic devices and methods |
US11857969B2 (en) | 2017-07-24 | 2024-01-02 | Miroculus Inc. | Digital microfluidics systems and methods with integrated plasma collection device |
US11873483B2 (en) | 2015-03-11 | 2024-01-16 | The Broad Institute, Inc. | Proteomic analysis with nucleic acid identifiers |
US11898206B2 (en) | 2017-05-19 | 2024-02-13 | 10X Genomics, Inc. | Systems and methods for clonotype screening |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US11944974B2 (en) | 2015-06-05 | 2024-04-02 | Miroculus Inc. | Air-matrix digital microfluidics apparatuses and methods for limiting evaporation and surface fouling |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2826748C (en) | 2011-02-09 | 2020-08-04 | Bio-Rad Laboratories, Inc. | Method of detecting variations in copy number of a target nucleic acid |
KR20140122751A (en) * | 2012-02-08 | 2014-10-20 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Droplet formation using fluid breakup |
KR102334118B1 (en) | 2015-04-22 | 2021-12-01 | 버클리 라잇츠, 인크. | Freezing and archiving cells on a microfluidic device |
US10350573B2 (en) * | 2016-04-29 | 2019-07-16 | Saint-Gobain Performance Plastics Corporation | Radiation curable system and method for making a radiation curable article |
JP7071056B2 (en) | 2017-02-27 | 2022-05-18 | シスメックス株式会社 | Liquid delivery method and liquid delivery device |
GB2563577A (en) * | 2017-06-14 | 2018-12-26 | Cambridge Consultants | Methods and apparatus for selection and characterisation of genetically transformed cells |
EP3415140A1 (en) * | 2017-06-16 | 2018-12-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | A method for preparing a functional synthetic cell in form of a giant unilamellar vesicle |
US11391735B2 (en) * | 2017-09-06 | 2022-07-19 | AimPlex Biosciences, Inc. | Methods for improving the dynamic range of biological assays |
US11634757B2 (en) | 2017-10-20 | 2023-04-25 | Stilla Technologies | Emulsions with improved stability |
EP3752596A4 (en) * | 2018-02-15 | 2021-12-15 | enEvolv, Inc. | Sensor systems |
WO2019241710A1 (en) * | 2018-06-15 | 2019-12-19 | The Scripps Research Institute | Droplet ecosystem |
WO2020037031A1 (en) * | 2018-08-17 | 2020-02-20 | Becton, Dickinson And Company | Antimicrobial susceptibility testing using microdroplets |
GB201817321D0 (en) | 2018-10-24 | 2018-12-05 | Nanna Therapeutics Ltd | Microbeads for tagless encoded chemical library screening |
US20200289676A1 (en) * | 2019-03-15 | 2020-09-17 | Lahjavida, Llc | Near-Infrared Dyes And Conjugates For Targeting Tumors |
CN109894167B (en) * | 2019-03-25 | 2021-09-28 | 上海天马微电子有限公司 | Micro-fluidic chip |
CN110170343A (en) * | 2019-05-27 | 2019-08-27 | 天津大学 | A kind of Water-In-Oil microlayer model manufacture system and manufacturing method |
JP2022552194A (en) * | 2019-10-10 | 2022-12-15 | 1859,インク. | Methods and systems for microfluidic screening |
US11857981B2 (en) | 2019-12-23 | 2024-01-02 | 10X Genomics, Inc. | Magnetic separator for an automated single cell sequencing system |
CN115698284A (en) * | 2020-01-13 | 2023-02-03 | 福路伦特生物科学公司 | Reverse transcription during template emulsification |
US20230133186A1 (en) * | 2020-03-19 | 2023-05-04 | Mayo Foundation For Medical Education And Research | Point-of-care digital microfluidics for sepsis diagnosis |
EP3939699A1 (en) * | 2020-07-17 | 2022-01-19 | Biomillenia SAS | Growth modulation |
WO2022191727A2 (en) * | 2021-03-11 | 2022-09-15 | Qatar Foundation For Education, Science And Community Development | Systems, devices, and methods of high-throughput screening of microbial interactions |
WO2023136945A1 (en) * | 2022-01-13 | 2023-07-20 | Massachusetts Institute Of Technology | Analysis, screening, and selection for soluble protein function in secreted protein cell libraries |
WO2023215320A1 (en) * | 2022-05-02 | 2023-11-09 | The Brigham And Women’S Hospital, Inc. | Microfluidic platform for the study of molecular and/or cellular interactions |
CN115368576B (en) * | 2022-08-22 | 2023-06-16 | 苏州中科医疗器械产业发展有限公司 | Perfluoropolyether-adipic acid dihydrazide block copolymer and preparation method and application thereof |
Citations (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2971700A (en) * | 1957-07-22 | 1961-02-14 | Vilbiss Co | Apparatus for coating articles with chemically reactive liquids |
US4315754A (en) * | 1979-08-28 | 1982-02-16 | Bifok Ab | Flow injection analysis with intermittent flow |
US4801529A (en) * | 1985-06-18 | 1989-01-31 | Brandeis University | Methods for isolating mutant microoganisms using microcapsules coated with indicator material |
US4801086A (en) * | 1985-02-19 | 1989-01-31 | Imperial Chemical Industries Plc | Spraying apparatus |
US4981580A (en) * | 1989-05-01 | 1991-01-01 | Coulter Corporation | Coincidence arbitration in a flow cytomery sorting system |
US4996004A (en) * | 1982-08-14 | 1991-02-26 | Bayer Aktiengesellschaft | Preparation of pharmaceutical or cosmetic dispersions |
US5091652A (en) * | 1990-01-12 | 1992-02-25 | The Regents Of The University Of California | Laser excited confocal microscope fluorescence scanner and method |
US5180662A (en) * | 1988-01-05 | 1993-01-19 | The United States Of America As Represented By The Department Of Health And Human Services | Cytotoxic T lymphocyte activation assay |
US5185099A (en) * | 1988-04-20 | 1993-02-09 | Institut National De Recherche Chimique Appliquee | Visco-elastic, isotropic materials based on water, fluorinate sufactants and fluorinated oils, process for their preparation, and their use in various fields, such as optics, pharmacology and electrodynamics |
US5188290A (en) * | 1990-02-16 | 1993-02-23 | J. Wagner Gmbh | Electrostatic compressed air paint spray gun |
US5188291A (en) * | 1989-05-31 | 1993-02-23 | Her Majesty The Queen In Right Of New Zealand | Fluid distribution device |
US5378957A (en) * | 1989-11-17 | 1995-01-03 | Charged Injection Corporation | Methods and apparatus for dispersing a fluent material utilizing an electron beam |
US5480614A (en) * | 1993-03-16 | 1996-01-02 | Hitachi, Ltd. | Micro-reactor device for minute sample analysis |
US5486335A (en) * | 1992-05-01 | 1996-01-23 | Trustees Of The University Of Pennsylvania | Analysis based on flow restriction |
US5604097A (en) * | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
US5858655A (en) * | 1991-03-11 | 1999-01-12 | The General Hospital Corporation | Method for diagnosing neoplasia by detecting expression of PRAD1 cyclin |
US5858670A (en) * | 1990-07-02 | 1999-01-12 | The Arizona Board Of Regents | Bio-oligomer libraries and a method of use thereof |
US5858187A (en) * | 1996-09-26 | 1999-01-12 | Lockheed Martin Energy Systems, Inc. | Apparatus and method for performing electrodynamic focusing on a microchip |
US5863722A (en) * | 1994-10-13 | 1999-01-26 | Lynx Therapeutics, Inc. | Method of sorting polynucleotides |
US5868322A (en) * | 1996-01-31 | 1999-02-09 | Hewlett-Packard Company | Apparatus for forming liquid droplets having a mechanically fixed inner microtube |
US5872010A (en) * | 1995-07-21 | 1999-02-16 | Northeastern University | Microscale fluid handling system |
US5904933A (en) * | 1994-06-09 | 1999-05-18 | Alliance Pharmaceutical Corp. | Stable reverse and multiple fluorocarbon emulsions |
US6023540A (en) * | 1997-03-14 | 2000-02-08 | Trustees Of Tufts College | Fiber optic sensor with encoded microspheres |
US6028066A (en) * | 1997-05-06 | 2000-02-22 | Imarx Pharmaceutical Corp. | Prodrugs comprising fluorinated amphiphiles |
US6172214B1 (en) * | 1994-10-13 | 2001-01-09 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
US6171850B1 (en) * | 1999-03-08 | 2001-01-09 | Caliper Technologies Corp. | Integrated devices and systems for performing temperature controlled reactions and analyses |
US6171796B1 (en) * | 1998-01-21 | 2001-01-09 | Urocor, Inc. | Biomarkers and targets for diagnosis prognosis and management of prostate disease |
US6174469B1 (en) * | 1996-05-13 | 2001-01-16 | Universidad De Sevilla | Device and method for creating dry particles |
US6174160B1 (en) * | 1999-03-25 | 2001-01-16 | University Of Washington | Staged prevaporizer-premixer |
US6180372B1 (en) * | 1997-04-23 | 2001-01-30 | Bruker Daltonik Gmbh | Method and devices for extremely fast DNA replication by polymerase chain reactions (PCR) |
US6184012B1 (en) * | 1996-04-25 | 2001-02-06 | Medical Research Council | Isolation of enzymes |
US6187214B1 (en) * | 1996-05-13 | 2001-02-13 | Universidad De Seville | Method and device for production of components for microfabrication |
US6189803B1 (en) * | 1996-05-13 | 2001-02-20 | University Of Seville | Fuel injection nozzle and method of use |
US6336463B1 (en) * | 1998-03-31 | 2002-01-08 | Nec Corporation | Cleaning/drying station and production line for semiconductor devices |
US20020004532A1 (en) * | 2000-05-26 | 2002-01-10 | Michelle Matathia | Low emulsifier multiple emulsions |
US20020005354A1 (en) * | 1997-09-23 | 2002-01-17 | California Institute Of Technology | Microfabricated cell sorter |
US20020008028A1 (en) * | 2000-01-12 | 2002-01-24 | Jacobson Stephen C. | Microfluidic device and method for focusing, segmenting, and dispensing of a fluid stream |
US20020012971A1 (en) * | 2000-03-20 | 2002-01-31 | Mehta Tammy Burd | PCR compatible nucleic acid sieving medium |
US6344325B1 (en) * | 1996-09-25 | 2002-02-05 | California Institute Of Technology | Methods for analysis and sorting of polynucleotides |
US20020022038A1 (en) * | 2000-05-05 | 2002-02-21 | Bruno Biatry | Microcapsules with an aqueous core containing at least one water-soluble cosmetic or dermatological active principle and cosmetic or dermatological compositions containing them |
US20020022261A1 (en) * | 1995-06-29 | 2002-02-21 | Anderson Rolfe C. | Miniaturized genetic analysis systems and methods |
US6503933B1 (en) * | 1998-02-19 | 2003-01-07 | Aventis Cropscience Uk Limited | 2-pyridylmethylamine derivatives useful as fungicides |
US6506609B1 (en) * | 1999-05-17 | 2003-01-14 | Caliper Technologies Corp. | Focusing of microparticles in microfluidic systems |
US20030012586A1 (en) * | 2001-05-24 | 2003-01-16 | Nobuo Iwata | Developer container, developing conveying device and image forming apparatus using the same |
US6508988B1 (en) * | 2000-10-03 | 2003-01-21 | California Institute Of Technology | Combinatorial synthesis system |
US20030017579A1 (en) * | 2001-07-10 | 2003-01-23 | Corn Robert M. | Surface plasmon resonance imaging of micro-arrays |
US20030015425A1 (en) * | 2001-06-20 | 2003-01-23 | Coventor Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
US6520425B1 (en) * | 2001-08-21 | 2003-02-18 | The University Of Akron | Process and apparatus for the production of nanofibers |
US6524456B1 (en) * | 1999-08-12 | 2003-02-25 | Ut-Battelle, Llc | Microfluidic devices for the controlled manipulation of small volumes |
US20030039169A1 (en) * | 1999-12-18 | 2003-02-27 | Wolfgang Ehrfeld | Micromixer |
US20040005594A1 (en) * | 2000-09-13 | 2004-01-08 | Medical Research Council | Directed evolution method |
US20040005582A1 (en) * | 2000-08-10 | 2004-01-08 | Nanobiodynamics, Incorporated | Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators |
US6679441B1 (en) * | 1998-03-27 | 2004-01-20 | Centre National De La Recherche Scientifique (C.N.R.S.) | Electrohydrodynamic spraying means |
US6680178B2 (en) * | 2000-06-02 | 2004-01-20 | The Regents Of The University Of California | Profiling of protease specificity using combinatorial fluorogenic substrate libraries |
US6682890B2 (en) * | 2000-08-17 | 2004-01-27 | Protein Design Labs, Inc. | Methods of diagnosing and determining prognosis of colorectal cancer |
US20040018525A1 (en) * | 2002-05-21 | 2004-01-29 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
US20040027915A1 (en) * | 2000-08-25 | 2004-02-12 | Holger Lowe | Method and statistical micromixer for mixing at least two liquids |
US20040037813A1 (en) * | 1999-02-25 | 2004-02-26 | Simpson David G. | Electroprocessed collagen and tissue engineering |
US6841350B2 (en) * | 1999-02-20 | 2005-01-11 | The North West London Hospitals Nhs Trust Of Northwick Park Hospital | Methods of diagnosing prostate cancer through the detection of the presence or absence of Pax 2 mRNA |
US20050032238A1 (en) * | 2003-08-07 | 2005-02-10 | Nanostream, Inc. | Vented microfluidic separation devices and methods |
US20060003429A1 (en) * | 1999-01-29 | 2006-01-05 | Frost John W | Biocatalytic synthesis of quinic acid and conversion to hydroquinone |
US20060003347A1 (en) * | 2002-09-11 | 2006-01-05 | Medical Research Council | Single-molecule in vitro evolution |
US20060003439A1 (en) * | 2004-07-02 | 2006-01-05 | Ismagilov Rustem F | Microfluidic system |
US20060100788A1 (en) * | 2004-07-14 | 2006-05-11 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
US7156917B2 (en) * | 2003-05-22 | 2007-01-02 | Hideaki Moriyama | Apparatus and method for growing crystal, and apparatus and method for analyzing crystal |
US20070003442A1 (en) * | 2003-08-27 | 2007-01-04 | President And Fellows Of Harvard College | Electronic control of fluidic species |
US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
US7169560B2 (en) * | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
US20070092914A1 (en) * | 2004-03-31 | 2007-04-26 | Medical Research Council, Harvard University | Compartmentalised screening by microfluidic control |
WO2007081385A2 (en) * | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US7314721B2 (en) * | 2000-01-21 | 2008-01-01 | Ludwig Institute For Cancer Research | Small cell lung cancer associated antigens and uses therefor |
US20080003142A1 (en) * | 2006-05-11 | 2008-01-03 | Link Darren R | Microfluidic devices |
US7316906B2 (en) * | 1999-10-08 | 2008-01-08 | The Feinstein Institute For Medical Research | CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia |
US20080009005A1 (en) * | 2006-02-09 | 2008-01-10 | Kruk Patricia A | Detection of cancer by elevated levels of BCL-2 |
US20080014590A1 (en) * | 2004-01-27 | 2008-01-17 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer |
US20080020940A1 (en) * | 2006-07-24 | 2008-01-24 | Miraculins Inc. | Biomarkers for use in the diagnosis and treatment of colorectal cancer |
US20080021330A1 (en) * | 2006-07-21 | 2008-01-24 | Samsung Electronics Co., Ltd. | Apparatus, method and optical sensor module using a tilter for body fat measurement |
US20080023330A1 (en) * | 2004-09-09 | 2008-01-31 | Institut Curie | Device for Manipulation of Packets in Micro-Containers, in Particular in Microchannels |
WO2008021123A1 (en) * | 2006-08-07 | 2008-02-21 | President And Fellows Of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
US20090004687A1 (en) * | 2007-06-29 | 2009-01-01 | Mansfield Brian C | Predictive markers for ovarian cancer |
US7473530B2 (en) * | 2005-05-04 | 2009-01-06 | Wayne State University | Method to detect lung cancer |
US7473531B1 (en) * | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
US20090012187A1 (en) * | 2007-03-28 | 2009-01-08 | President And Fellows Of Harvard College | Emulsions and Techniques for Formation |
US7476506B2 (en) * | 2002-06-03 | 2009-01-13 | Novartis Vaccines And Diagnostics, Inc. | Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers |
US20090017463A1 (en) * | 2007-07-10 | 2009-01-15 | Vanderbilt University | Methods for predicting prostate cancer recurrence |
US7479371B2 (en) * | 2002-04-09 | 2009-01-20 | Tokai University | Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor |
US7479376B2 (en) * | 2000-03-27 | 2009-01-20 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
US7479370B2 (en) * | 2003-09-08 | 2009-01-20 | Health Research, Inc. | Detection of 13q14 chromosomal alterations |
US20090021728A1 (en) * | 2007-06-21 | 2009-01-22 | Gen-Probe Incorporated | Multi-Channel Optical Measurement Instrument |
US20090023137A1 (en) * | 2004-07-16 | 2009-01-22 | Oncomethylome Sciences S.A. | ESR1 and Cervical Cancer |
US7482129B2 (en) * | 2004-05-04 | 2009-01-27 | Institute Of Virology, Slovak Academy Of Sciences | MN/CA IX/CA9 and Renal Cancer Prognosis |
US20090029372A1 (en) * | 2007-05-14 | 2009-01-29 | Kobenhavns Universitet | Adam12 as a biomarker for bladder cancer |
US20090026082A1 (en) * | 2006-12-14 | 2009-01-29 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes using large scale FET arrays |
US20100003687A1 (en) * | 2008-07-01 | 2010-01-07 | 454 Life Sciences Corporation | System and method for detection of HIV tropism variants |
US20100009353A1 (en) * | 2006-05-18 | 2010-01-14 | Colin Barnes | Dye Compounds and the Use of their Labelled Conjugates |
US20110000560A1 (en) * | 2009-03-23 | 2011-01-06 | Raindance Technologies, Inc. | Manipulation of Microfluidic Droplets |
US20120010098A1 (en) * | 2003-03-31 | 2012-01-12 | Medical Research Council | Selection by compartmentalised screening |
US20120015822A1 (en) * | 2008-12-19 | 2012-01-19 | President And Fellows Of Harvard College | Particle-assisted nucleic acid sequencing |
US20120015382A1 (en) * | 2007-07-13 | 2012-01-19 | President And Fellows Of Harvard College | Droplet-based selection |
Family Cites Families (974)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2097692A (en) | 1936-03-23 | 1937-11-02 | Bohn Aluminium & Brass Corp | Method and machine for forming bearing shells |
US2164172A (en) | 1938-04-30 | 1939-06-27 | Gen Electric | Liquid-dispensing apparatus |
US2636855A (en) | 1948-03-25 | 1953-04-28 | Hilger & Watts Ltd | Method of producing photoconductive coatings |
US2656508A (en) | 1949-08-27 | 1953-10-20 | Wallace H Coulter | Means for counting particles suspended in a fluid |
US2692800A (en) | 1951-10-08 | 1954-10-26 | Gen Electric | Nozzle flow control |
US2797149A (en) | 1953-01-08 | 1957-06-25 | Technicon International Ltd | Methods of and apparatus for analyzing liquids containing crystalloid and non-crystalloid constituents |
US2879141A (en) | 1955-11-16 | 1959-03-24 | Technicon Instr | Automatic analyzing apparatus |
US3067159A (en) | 1957-10-17 | 1962-12-04 | Chicopee Mfg Corp | Aqueous water repellent dispersions comprising a methylene dialkylamide, a methylol cndensate, and a non-ionic surface active agent |
US3012382A (en) | 1960-06-06 | 1961-12-12 | Charles D Keck | Grinding device |
GB1143839A (en) | 1965-10-15 | |||
CH455414A (en) | 1966-01-10 | 1968-07-15 | Bachofen Willy A | Installation element for optical flow control on pipelines |
US3479141A (en) | 1967-05-17 | 1969-11-18 | Technicon Corp | Method and apparatus for analysis |
US3980541A (en) | 1967-06-05 | 1976-09-14 | Aine Harry E | Electrode structures for electric treatment of fluids and filters using same |
US3621059A (en) | 1969-07-30 | 1971-11-16 | Du Pont | Amides of hexafluoropropylene oxide polymer acids and polyalklene oxide |
US3784471A (en) | 1970-05-11 | 1974-01-08 | Avco Corp | Solid additives dispersed in perfluorinated liquids with perfluoroalkyl ether dispersants |
US3828085A (en) | 1970-07-09 | 1974-08-06 | Allied Chem | Novel amidoamine oxides |
DE2100685C2 (en) | 1971-01-08 | 1983-09-22 | Basf Ag, 6700 Ludwigshafen | Process for the preparation of pure 4-amino-5-halogen-pyridazonen- (6) |
US3698635A (en) | 1971-02-22 | 1972-10-17 | Ransburg Electro Coating Corp | Spray charging device |
US3816331A (en) | 1972-07-05 | 1974-06-11 | Ncr | Continuous encapsulation and device therefor |
US3832646A (en) | 1972-10-06 | 1974-08-27 | Westinghouse Electric Corp | Common mode noise suppressing circuit adjustment sequence |
CH563807A5 (en) | 1973-02-14 | 1975-07-15 | Battelle Memorial Institute | Fine granules and microcapsules mfrd. from liquid droplets - partic. of high viscosity requiring forced sepn. of droplets |
CH564966A5 (en) | 1974-02-25 | 1975-08-15 | Sauter Fr Ag Fabrik Elektrisch | |
US3930061A (en) | 1974-04-08 | 1975-12-30 | Ransburg Corp | Electrostatic method for forming structures and articles |
US4059552A (en) | 1974-06-21 | 1977-11-22 | The Dow Chemical Company | Cross-linked water-swellable polymer particles |
US3960187A (en) | 1974-07-23 | 1976-06-01 | Usm Corporation | Method and device for metering and dispersing fluid materials |
US3982541A (en) | 1974-07-29 | 1976-09-28 | Esperance Jr Francis A L | Eye surgical instrument |
DK150802C (en) | 1974-09-16 | 1988-02-01 | Bifok Ab | METHOD AND APPARATUS FOR CONTINUOUS HIGH-SPEED ANALYSIS OF A LIQUID TEST IN A BEARING FLOW |
US4098897A (en) | 1975-04-14 | 1978-07-04 | Beecham Group Limited | Anti bacterial agents |
US4034966A (en) | 1975-11-05 | 1977-07-12 | Massachusetts Institute Of Technology | Method and apparatus for mixing particles |
US4014469A (en) | 1975-11-17 | 1977-03-29 | Kozo Sato | Nozzle of gas cutting torch |
JPS5372016A (en) | 1976-12-08 | 1978-06-27 | Toyo Tire & Rubber Co Ltd | Apparatus for preparation and supply of heavy oil w/o emulsion fuel |
US4117550A (en) | 1977-02-14 | 1978-09-26 | Folland Enertec Ltd. | Emulsifying system |
US4091042A (en) | 1977-08-19 | 1978-05-23 | American Cyanamid Company | Continuous adiabatic process for the mononitration of benzene |
US4130394A (en) | 1977-10-03 | 1978-12-19 | Technicon Instruments Corporation | Short sample detection |
AU531759B2 (en) | 1978-04-17 | 1983-09-08 | Ici Ltd. | Electrostatic spraying |
SU1226392A1 (en) | 1978-08-11 | 1986-04-23 | Научно-исследовательский институт часовой промышленности | Reduction gear box for electronic-mechanical clock with step motor |
US4210809A (en) | 1979-03-16 | 1980-07-01 | Technicon Instruments Corporation | Method and apparatus for the non-invasive determination of the characteristics of a segmented fluid stream |
US4279345A (en) | 1979-08-03 | 1981-07-21 | Allred John C | High speed particle sorter using a field emission electrode |
US4266721A (en) | 1979-09-17 | 1981-05-12 | Ppg Industries, Inc. | Spray application of coating compositions utilizing induction and corona charging means |
JPS5665627A (en) | 1979-11-05 | 1981-06-03 | Agency Of Ind Science & Technol | Method of combining particles of liquid, etc. |
US4253846A (en) | 1979-11-21 | 1981-03-03 | Technicon Instruments Corporation | Method and apparatus for automated analysis of fluid samples |
EP0047130B1 (en) | 1980-08-28 | 1985-02-13 | E.I. Du Pont De Nemours And Company | Flow analysis |
GB2097692B (en) | 1981-01-10 | 1985-05-22 | Shaw Stewart P D | Combining chemical reagents |
GB2092497B (en) | 1981-02-06 | 1985-01-16 | Honda Motor Co Ltd | Welding torch assembly |
JPS6057907B2 (en) | 1981-06-18 | 1985-12-17 | 工業技術院長 | Liquid mixing and atomization method |
US4439980A (en) | 1981-11-16 | 1984-04-03 | The United States Of America As Represented By The Secretary Of The Navy | Electrohydrodynamic (EHD) control of fuel injection in gas turbines |
ATE41610T1 (en) | 1982-10-13 | 1989-04-15 | Ici Plc | ELECTROSTATIC SPRAY UNIT. |
CA1238900A (en) | 1982-11-15 | 1988-07-05 | Stephen Saros | Single channel continuous slug flow mixing of discrete fluid components |
US4853336A (en) | 1982-11-15 | 1989-08-01 | Technicon Instruments Corporation | Single channel continuous flow system |
US4533634A (en) | 1983-01-26 | 1985-08-06 | Amf Inc. | Tissue culture medium |
US4585209A (en) | 1983-10-27 | 1986-04-29 | Harry E. Aine | Miniature valve and method of making same |
US4618476A (en) | 1984-02-10 | 1986-10-21 | Eastman Kodak Company | Capillary transport device having speed and meniscus control means |
US4566908A (en) | 1984-02-24 | 1986-01-28 | Mita Industrial Company, Limited | Azoic pigments having a silica core |
US4865444A (en) | 1984-04-05 | 1989-09-12 | Mobil Oil Corporation | Apparatus and method for determining luminosity of hydrocarbon fuels |
US4675285A (en) | 1984-09-19 | 1987-06-23 | Genetics Institute, Inc. | Method for identification and isolation of DNA encoding a desired protein |
US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
GB8504916D0 (en) | 1985-02-26 | 1985-03-27 | Isc Chemicals Ltd | Emulsions of perfluorocarbons in aqueous media |
US4676274A (en) | 1985-02-28 | 1987-06-30 | Brown James F | Capillary flow control |
US5333675C1 (en) | 1986-02-25 | 2001-05-01 | Perkin Elmer Corp | Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps |
US5656493A (en) | 1985-03-28 | 1997-08-12 | The Perkin-Elmer Corporation | System for automated performance of the polymerase chain reaction |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4739044A (en) | 1985-06-13 | 1988-04-19 | Amgen | Method for derivitization of polynucleotides |
US4963498A (en) | 1985-08-05 | 1990-10-16 | Biotrack | Capillary flow device |
US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
GB8604328D0 (en) | 1986-02-21 | 1986-03-26 | Ici Plc | Producing spray of droplets of liquid |
CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
US4916070A (en) | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
US5204112A (en) | 1986-06-16 | 1993-04-20 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US4767929A (en) | 1986-10-06 | 1988-08-30 | The United States Of America As Represented By The United State Department Of Energy | Extended range radiation dose-rate monitor |
US4767515A (en) | 1987-07-30 | 1988-08-30 | The United States Of America As Represented By The United States Department Of Energy | Surface area generation and droplet size control in solvent extraction systems utilizing high intensity electric fields |
US5149625A (en) | 1987-08-11 | 1992-09-22 | President And Fellows Of Harvard College | Multiplex analysis of DNA |
EP0304312B1 (en) | 1987-08-21 | 1992-10-21 | Sharp Kabushiki Kaisha | An optical disk for use in optical memory devices |
JPS6489884A (en) | 1987-09-30 | 1989-04-05 | Sony Corp | White balance correction circuit |
US4931225A (en) | 1987-12-30 | 1990-06-05 | Union Carbide Industrial Gases Technology Corporation | Method and apparatus for dispersing a gas into a liquid |
US4856363A (en) | 1988-02-10 | 1989-08-15 | Wickes Manufacturing Company | Parking brake assembly |
US5055390A (en) | 1988-04-22 | 1991-10-08 | Massachusetts Institute Of Technology | Process for chemical manipulation of non-aqueous surrounded microdroplets |
US4908112A (en) | 1988-06-16 | 1990-03-13 | E. I. Du Pont De Nemours & Co. | Silicon semiconductor wafer for analyzing micronic biological samples |
US5498523A (en) | 1988-07-12 | 1996-03-12 | President And Fellows Of Harvard College | DNA sequencing with pyrophosphatase |
US5096615A (en) | 1988-07-19 | 1992-03-17 | The United States Of America As Represented By The United States Department Of Energy | Solid aerosol generator |
US5104813A (en) | 1989-04-13 | 1992-04-14 | Biotrack, Inc. | Dilution and mixing cartridge |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
CA2016981C (en) | 1989-06-12 | 1994-09-27 | Mark Joseph Devaney, Jr. | Temperature control device and reaction vessel |
DE69002767T2 (en) | 1989-06-22 | 1994-03-17 | Atta | FLUORINE AND PHOSPHORUS AMPHIPHILIC MOLECULES WITH SURFACE-ACTIVE PROPERTIES. |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
GB8917963D0 (en) | 1989-08-05 | 1989-09-20 | Scras | Apparatus for repeated automatic execution of a thermal cycle for treatment of biological samples |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
DE3930376A1 (en) | 1989-09-12 | 1991-03-21 | Biotest Ag | ENZYME IMMUNOMETRIC DETERMINATION METHOD USING PEROXIDASE AS A MARKING ENZYME |
EP0494955B1 (en) | 1989-10-05 | 1998-07-15 | Optein, Inc. | Cell-free synthesis and isolation of novel genes and polypeptides |
US5310653A (en) | 1989-10-24 | 1994-05-10 | Board Of Regents, The University Of Texas System | Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis |
US5122360A (en) | 1989-11-27 | 1992-06-16 | Martin Marietta Energy Systems, Inc. | Method and apparatus for the production of metal oxide powder |
US4941959A (en) | 1989-11-27 | 1990-07-17 | Martin Marietta Energy Systems, Inc. | Electric field-driven, magnetically-stabilized ferro-emulsion phase contactor |
US5207973A (en) | 1989-11-27 | 1993-05-04 | Martin Marietta Energy Systems, Inc. | Method and apparatus for the production of metal oxide powder |
US5313009A (en) | 1990-01-04 | 1994-05-17 | Nrm International Technologies C.V. | Nitration process |
JP3176607B2 (en) | 1990-02-07 | 2001-06-18 | 群馬大学長 | Method for forming uniform droplets |
US5523162A (en) | 1990-04-03 | 1996-06-04 | Ppg Industries, Inc. | Water repellent surface treatment for plastic and coated plastic substrates |
SE470347B (en) | 1990-05-10 | 1994-01-31 | Pharmacia Lkb Biotech | Microstructure for fluid flow systems and process for manufacturing such a system |
WO1991019813A1 (en) | 1990-06-11 | 1991-12-26 | The University Of Colorado Foundation, Inc. | Nucleic acid ligands |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
WO1992003734A1 (en) | 1990-08-20 | 1992-03-05 | Alain De Weck | A method for measuring t-lymphocyte responses by chemiluminescent assays |
ES2030639T1 (en) | 1990-09-21 | 1992-11-16 | Bioplex Medical B.V. | DEVICE FOR PLACING STYPTIC MATERIAL, IN CONCRETE IN A FIBROUS OR SPONJIFORM FORM ON PERFORATED BLOOD VESSELS, IN CONCRETE ARTERIES. |
US6149789A (en) | 1990-10-31 | 2000-11-21 | Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Process for manipulating microscopic, dielectric particles and a device therefor |
FR2669028B1 (en) | 1990-11-13 | 1992-12-31 | Rhone Poulenc Chimie | PROCESS FOR THE MANUFACTURE OF DOUBLE RARE EARTH AND AMMONIUM OXALATES AND THEIR USES FOR THE MANUFACTURE OF RARE EARTH OXIDES. |
KR100236506B1 (en) | 1990-11-29 | 2000-01-15 | 퍼킨-엘머시터스인스트루먼츠 | Apparatus for polymerase chain reaction |
US5490505A (en) | 1991-03-07 | 1996-02-13 | Masimo Corporation | Signal processing apparatus |
US5262027A (en) | 1991-03-22 | 1993-11-16 | Martin Marietta Energy Systems, Inc. | Method of using an electric field controlled emulsion phase contactor |
GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US5460945A (en) | 1991-05-30 | 1995-10-24 | Center For Blood Research, Inc. | Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response |
NZ242896A (en) | 1991-05-30 | 1996-05-28 | Blood Res Center | Apparatus and methods for analysing blood components especially leukocyte content |
NZ264353A (en) | 1991-05-30 | 1996-05-28 | For Blood Research Inc Centre | Method of collecting or purifying leukocytes from a fluid sample, apparatus, immune response inhibitor test |
DE4119955C2 (en) | 1991-06-18 | 2000-05-31 | Danfoss As | Miniature actuator |
EP0546174B1 (en) | 1991-06-29 | 1997-10-29 | Miyazaki-Ken | Monodisperse single and double emulsions and production thereof |
GB9117191D0 (en) | 1991-08-08 | 1991-09-25 | Tioxide Chemicals Limited | Preparation of titanium derivatives |
EP0597960B1 (en) | 1991-08-10 | 1999-01-20 | Medical Research Council | Treatment of cell populations |
DE4127405C2 (en) | 1991-08-19 | 1996-02-29 | Fraunhofer Ges Forschung | Process for the separation of mixtures of microscopic dielectric particles suspended in a liquid or a gel and device for carrying out the process |
WO1993008472A1 (en) | 1991-10-15 | 1993-04-29 | Multilyte Limited | Binding assay employing labelled reagent |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
JP3164919B2 (en) | 1991-10-29 | 2001-05-14 | ゼロックス コーポレーション | Method of forming dichroic balls |
US6048690A (en) | 1991-11-07 | 2000-04-11 | Nanogen, Inc. | Methods for electronic fluorescent perturbation for analysis and electronic perturbation catalysis for synthesis |
US5344489A (en) | 1991-11-15 | 1994-09-06 | Manfred R. Kuehnle | Synthetic, monodispersed color pigments for the coloration of media such as printing inks, and method and apparatus for making same |
US5612188A (en) | 1991-11-25 | 1997-03-18 | Cornell Research Foundation, Inc. | Automated, multicompartmental cell culture system |
EP0620858B1 (en) | 1991-12-24 | 2003-05-02 | The President And Fellows Of Harvard College | Site-directed mutagenesis of dna |
US5413924A (en) | 1992-02-13 | 1995-05-09 | Kosak; Kenneth M. | Preparation of wax beads containing a reagent for release by heating |
JP2675945B2 (en) | 1992-02-21 | 1997-11-12 | 富士写真フイルム株式会社 | Silver halide emulsion |
US5241159A (en) | 1992-03-11 | 1993-08-31 | Eastman Kodak Company | Multi-zone heating for a fuser roller |
US6107059A (en) | 1992-04-29 | 2000-08-22 | Affymax Technologies N.V. | Peptide library and screening method |
US5587128A (en) | 1992-05-01 | 1996-12-24 | The Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification devices |
US5304487A (en) | 1992-05-01 | 1994-04-19 | Trustees Of The University Of Pennsylvania | Fluid handling in mesoscale analytical devices |
US5296375A (en) | 1992-05-01 | 1994-03-22 | Trustees Of The University Of Pennsylvania | Mesoscale sperm handling devices |
JP3558294B2 (en) | 1992-05-01 | 2004-08-25 | トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | Polynucleotide amplification analysis using microfabrication equipment |
US5498392A (en) | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
US5744366A (en) | 1992-05-01 | 1998-04-28 | Trustees Of The University Of Pennsylvania | Mesoscale devices and methods for analysis of motile cells |
US5726026A (en) | 1992-05-01 | 1998-03-10 | Trustees Of The University Of Pennsylvania | Mesoscale sample preparation device and systems for determination and processing of analytes |
US5397605A (en) | 1992-05-29 | 1995-03-14 | Barbieri; Girolamo | Method and apparatus for electrostatically coating a workpiece with paint |
SE500071C2 (en) | 1992-06-25 | 1994-04-11 | Vattenfall Utveckling Ab | Device for mixing two fluids, in particular liquids of different temperature |
DE4223169C1 (en) | 1992-07-10 | 1993-11-25 | Ferring Arzneimittel Gmbh | Process for the microencapsulation of water-soluble active substances |
JPH0665609A (en) | 1992-08-25 | 1994-03-08 | Mitsubishi Materials Corp | Production of ferrous sintered and forged parts |
RU2048522C1 (en) | 1992-10-14 | 1995-11-20 | Институт белка РАН | Method of nucleic acid copying, method of their expression and a medium for their realization |
GB9225098D0 (en) | 1992-12-01 | 1993-01-20 | Coffee Ronald A | Charged droplet spray mixer |
US6105571A (en) | 1992-12-22 | 2000-08-22 | Electrosols, Ltd. | Dispensing device |
IL104384A (en) | 1993-01-13 | 1996-11-14 | Yeda Res & Dev | Method for screening catalytic non-enzyme polypeptides and proteins |
US5436149A (en) | 1993-02-19 | 1995-07-25 | Barnes; Wayne M. | Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension |
DE4308839C2 (en) | 1993-03-19 | 1997-04-30 | Jordanow & Co Gmbh | Device for mixing flow media |
FR2703263B1 (en) | 1993-03-31 | 1995-05-19 | Rhone Poulenc Nutrition Animal | Process for the preparation of spherules of active principles. |
EP0620432B1 (en) | 1993-04-15 | 2004-08-25 | Zeptosens AG | Method for controlling sample introduction in microcolumn separation techniques and sampling device |
WO1994024314A1 (en) | 1993-04-19 | 1994-10-27 | Kauffman Stuart A | Random chemistry for the generation of new compounds |
CA2160878A1 (en) | 1993-04-19 | 1994-10-27 | Sandra Gertrude Mcelligott | Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression |
AU695292B2 (en) | 1993-04-22 | 1998-08-13 | Federalloy, Inc. | Copper-bismuth casting alloys |
EP0705271B1 (en) | 1993-06-25 | 2002-11-13 | Affymetrix, Inc. (a Delaware Corporation) | Hybridization and sequencing of nucleic acids |
US7229770B1 (en) | 1998-10-01 | 2007-06-12 | The Regents Of The University Of California | YKL-40 as a marker and prognostic indicator for cancers |
US20040091923A1 (en) | 1993-07-23 | 2004-05-13 | Bio-Rad Laboratories, Inc. | Linked linear amplification of nucleic acids |
US5417235A (en) | 1993-07-28 | 1995-05-23 | Regents Of The University Of Michigan | Integrated microvalve structures with monolithic microflow controller |
US5403617A (en) | 1993-09-15 | 1995-04-04 | Mobium Enterprises Corporation | Hybrid pulsed valve for thin film coating and method |
US5512131A (en) | 1993-10-04 | 1996-04-30 | President And Fellows Of Harvard College | Formation of microstamped patterns on surfaces and derivative articles |
US6776094B1 (en) | 1993-10-04 | 2004-08-17 | President & Fellows Of Harvard College | Kit For Microcontact Printing |
AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US6165778A (en) | 1993-11-02 | 2000-12-26 | Affymax Technologies N.V. | Reaction vessel agitation apparatus |
US6316208B1 (en) | 1994-01-07 | 2001-11-13 | Memorial Sloan-Kettering Cancer Center | Methods for determining isolated p27 protein levels and uses thereof |
DE4402038A1 (en) | 1994-01-25 | 1995-07-27 | Borries Horst Von | Blister pack |
PH31414A (en) | 1994-02-24 | 1998-10-29 | Boehringer Ingelheim Int | Method of diagnosing cancer precancerous state, orsusceptibility to other forms of diseases by anal ysis of irf-1 specific rna in biopsy samples. |
EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
US5989815A (en) | 1994-03-18 | 1999-11-23 | University Of Utah Research Foundation | Methods for detecting predisposition to cancer at the MTS gene |
GB9406171D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
JPH07270319A (en) | 1994-03-30 | 1995-10-20 | Mochida Pharmaceut Co Ltd | Method for measuring substance containing adenyl group using heteropoly acid |
US5587081A (en) | 1994-04-26 | 1996-12-24 | Jet-Tech, Inc. | Thermophilic aerobic waste treatment process |
GB9411671D0 (en) | 1994-06-10 | 1994-08-03 | Univ Singapore | Tumor diagnosis and prognosis |
BR9502777A (en) | 1994-06-13 | 1996-04-23 | Praxair Technology Inc | Liquid fuel atomization equipment and process |
US5750988A (en) | 1994-07-11 | 1998-05-12 | Hewlett-Packard Company | Orthogonal ion sampling for APCI mass spectrometry |
US6653626B2 (en) | 1994-07-11 | 2003-11-25 | Agilent Technologies, Inc. | Ion sampling for APPI mass spectrometry |
US5641658A (en) | 1994-08-03 | 1997-06-24 | Mosaic Technologies, Inc. | Method for performing amplification of nucleic acid with two primers bound to a single solid support |
US6124439A (en) | 1994-08-17 | 2000-09-26 | The Rockefeller University | OB polypeptide antibodies and method of making |
US5935331A (en) | 1994-09-09 | 1999-08-10 | Matsushita Electric Industrial Co., Ltd. | Apparatus and method for forming films |
US5762775A (en) | 1994-09-21 | 1998-06-09 | Lockheed Martin Energy Systems, Inc. | Method for electrically producing dispersions of a nonconductive fluid in a conductive medium |
US5680283A (en) | 1994-09-30 | 1997-10-21 | Kabushiki Kaisha Toshiba | Magnetic head and magnetic disk drive |
JPH08153669A (en) | 1994-11-30 | 1996-06-11 | Hitachi Ltd | Thin film forming method and formation device |
US5813988A (en) | 1995-02-03 | 1998-09-29 | Research Foundation | Time-resolved diffusion tomographic imaging in highly scattering turbid media |
WO1996029629A2 (en) | 1995-03-01 | 1996-09-26 | President And Fellows Of Harvard College | Microcontact printing on surfaces and derivative articles |
US5661222A (en) | 1995-04-13 | 1997-08-26 | Dentsply Research & Development Corp. | Polyvinylsiloxane impression material |
EP0822990A4 (en) | 1995-04-24 | 2002-07-03 | Chromaxome Corp | Methods for generating and screening novel metabolic pathways |
US5840254A (en) | 1995-06-02 | 1998-11-24 | Cdc Technologies, Inc. | Apparatus for mixing fluids for analysis |
JPH11506649A (en) | 1995-06-06 | 1999-06-15 | クウォンティック バイオメディカル パートナーズ | Wound sealant preparation and application device and method |
HUP9900879A2 (en) | 1995-06-07 | 1999-08-30 | Alliance Pharmaceutical Corp. | Reverse fluorocarbon emulsion compositions for drug delivery |
US5910408A (en) | 1995-06-07 | 1999-06-08 | The General Hospital Corporation | Catalytic DNA having ligase activity |
US5882856A (en) | 1995-06-07 | 1999-03-16 | Genzyme Corporation | Universal primer sequence for multiplex DNA amplification |
US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
US5989892A (en) | 1995-06-14 | 1999-11-23 | Tonen Corporation | Microorganisms, demulsifiers and processes for breaking an emulsion |
US5932100A (en) | 1995-06-16 | 1999-08-03 | University Of Washington | Microfabricated differential extraction device and method |
TW293783B (en) | 1995-06-16 | 1996-12-21 | Ciba Geigy Ag | |
US5589136A (en) | 1995-06-20 | 1996-12-31 | Regents Of The University Of California | Silicon-based sleeve devices for chemical reactions |
US5789206A (en) | 1995-07-07 | 1998-08-04 | Myriad Genetics, Inc. | Method for ligating adaptors to nucleic acids which methods are useful for obtaining the ends of genes |
US6124388A (en) | 1995-07-19 | 2000-09-26 | Nippon Telegraph And Telephone Corporation | Water repellent composition, fluorocarbon polymer coating composition and coating film therefrom |
AU6691496A (en) | 1995-08-01 | 1997-02-26 | Advanced Therapies, Inc. | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
US5636400A (en) | 1995-08-07 | 1997-06-10 | Young; Keenan L. | Automatic infant bottle cleaner |
JP3232525B2 (en) | 1995-08-22 | 2001-11-26 | 信越化学工業株式会社 | Water repellent agent |
US6130098A (en) | 1995-09-15 | 2000-10-10 | The Regents Of The University Of Michigan | Moving microdroplets |
EP0851938A1 (en) | 1995-09-22 | 1998-07-08 | Terragen Diversity Inc. | Method for isolating xylanase gene sequences from soil dna, compositions useful in such method and compositions obtained thereby |
US5851769A (en) | 1995-09-27 | 1998-12-22 | The Regents Of The University Of California | Quantitative DNA fiber mapping |
US6243373B1 (en) | 1995-11-01 | 2001-06-05 | Telecom Internet Ltd. | Method and apparatus for implementing a computer network/internet telephone system |
US6562605B1 (en) | 1995-11-13 | 2003-05-13 | Genencor International, Inc. | Extraction of water soluble biomaterials from fluids using a carbon dioxide/surfactant mixture |
JP3759986B2 (en) | 1995-12-07 | 2006-03-29 | フロイント産業株式会社 | Seamless capsule and manufacturing method thereof |
US20030215798A1 (en) | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
US5808691A (en) | 1995-12-12 | 1998-09-15 | Cirrus Logic, Inc. | Digital carrier synthesis synchronized to a reference signal that is asynchronous with respect to a digital sampling clock |
US5733526A (en) | 1995-12-14 | 1998-03-31 | Alliance Pharmaceutical Corp. | Hydrocarbon oil/fluorochemical preparations and methods of use |
US5681600A (en) | 1995-12-18 | 1997-10-28 | Abbott Laboratories | Stabilization of liquid nutritional products and method of making |
US5670325A (en) | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
US6261797B1 (en) | 1996-01-29 | 2001-07-17 | Stratagene | Primer-mediated polynucleotide synthesis and manipulation techniques |
JP2975943B2 (en) | 1996-02-20 | 1999-11-10 | 農林水産省食品総合研究所長 | Emulsion manufacturing method and emulsion manufacturing apparatus |
US6355198B1 (en) | 1996-03-15 | 2002-03-12 | President And Fellows Of Harvard College | Method of forming articles including waveguides via capillary micromolding and microtransfer molding |
EP0891555A1 (en) | 1996-04-04 | 1999-01-20 | Novartis AG | Device for counting small particles and a sorting apparatus comprising such a device |
EP0832436A1 (en) | 1996-04-15 | 1998-04-01 | Dade Behring Inc. | Apparatus and method for analysis |
US5942443A (en) | 1996-06-28 | 1999-08-24 | Caliper Technologies Corporation | High throughput screening assay systems in microscale fluidic devices |
US6207397B1 (en) | 1996-04-18 | 2001-03-27 | Ariad Pharmaceuticals, Inc. | In vitro fluorescence polarization assay |
GB9608129D0 (en) | 1996-04-19 | 1996-06-26 | Central Research Lab Ltd | Method and apparatus for diffusive transfer between immiscible fluids |
US5783431A (en) | 1996-04-24 | 1998-07-21 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
US6386463B1 (en) | 1996-05-13 | 2002-05-14 | Universidad De Sevilla | Fuel injection nozzle and method of use |
US6196525B1 (en) | 1996-05-13 | 2001-03-06 | Universidad De Sevilla | Device and method for fluid aeration via gas forced through a liquid within an orifice of a pressure chamber |
US6405936B1 (en) | 1996-05-13 | 2002-06-18 | Universidad De Sevilla | Stabilized capillary microjet and devices and methods for producing same |
US6248378B1 (en) | 1998-12-16 | 2001-06-19 | Universidad De Sevilla | Enhanced food products |
US6197835B1 (en) | 1996-05-13 | 2001-03-06 | Universidad De Sevilla | Device and method for creating spherical particles of uniform size |
US6299145B1 (en) | 1996-05-13 | 2001-10-09 | Universidad De Sevilla | Device and method for fluid aeration via gas forced through a liquid within an orifice of a pressure chamber |
EP0912761A4 (en) | 1996-05-29 | 2004-06-09 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US5726404A (en) | 1996-05-31 | 1998-03-10 | University Of Washington | Valveless liquid microswitch |
US5840506A (en) | 1996-06-05 | 1998-11-24 | Thomas Jefferson University | Methods for the diagnosis and prognosis of cancer |
US6083693A (en) | 1996-06-14 | 2000-07-04 | Curagen Corporation | Identification and comparison of protein-protein interactions that occur in populations |
US5876771A (en) | 1996-06-20 | 1999-03-02 | Tetra Laval Holdings & Finance, Sa | Process and article for determining the residence time of a food particle |
CA2258481C (en) | 1996-06-28 | 2006-05-23 | Caliper Technologies Corporation | Electropipettor and compensation means for electrophoretic bias |
NZ333346A (en) | 1996-06-28 | 2000-03-27 | Caliper Techn Corp | High-throughput screening assay systems in microscale fluidic devices |
US5779868A (en) | 1996-06-28 | 1998-07-14 | Caliper Technologies Corporation | Electropipettor and compensation means for electrophoretic bias |
AU729537B2 (en) | 1996-06-28 | 2001-02-01 | Caliper Technologies Corporation | High throughput screening assay systems in microscale fluidic devices |
AU726987B2 (en) | 1996-06-28 | 2000-11-30 | Caliper Life Sciences, Inc. | Electropipettor and compensation means for electrophoretic bias |
ATE206633T1 (en) | 1996-07-15 | 2001-10-15 | Calcitech Ltd | PRODUCTION OF POWDER |
US6252129B1 (en) | 1996-07-23 | 2001-06-26 | Electrosols, Ltd. | Dispensing device and method for forming material |
US6100029A (en) | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
US6203993B1 (en) | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
US5928870A (en) | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US6146828A (en) | 1996-08-14 | 2000-11-14 | Exact Laboratories, Inc. | Methods for detecting differences in RNA expression levels and uses therefor |
JP2002503334A (en) | 1996-09-04 | 2002-01-29 | テクニカル ユニバーシティ オブ デンマーク | Microflow system for particle separation and analysis |
US5884846A (en) | 1996-09-19 | 1999-03-23 | Tan; Hsiaoming Sherman | Pneumatic concentric nebulizer with adjustable and capillaries |
US6120666A (en) | 1996-09-26 | 2000-09-19 | Ut-Battelle, Llc | Microfabricated device and method for multiplexed electrokinetic focusing of fluid streams and a transport cytometry method using same |
GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
CA2236867A1 (en) | 1996-09-27 | 1998-04-02 | Icos Corporation | Method to identify compounds for disrupting protein/protein interactions |
US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
US7054674B2 (en) | 1996-11-19 | 2006-05-30 | Astron Clinica Limited | Method of and apparatus for investigating tissue histology |
GB9624003D0 (en) | 1996-11-19 | 1997-01-08 | Univ Birmingham | Method and apparatus for measurement of skin histology |
US6379929B1 (en) | 1996-11-20 | 2002-04-30 | The Regents Of The University Of Michigan | Chip-based isothermal amplification devices and methods |
US6395524B2 (en) | 1996-11-27 | 2002-05-28 | University Of Washington | Thermostable polymerases having altered fidelity and method of identifying and using same |
US5958703A (en) | 1996-12-03 | 1999-09-28 | Glaxo Group Limited | Use of modified tethers in screening compound libraries |
US6310354B1 (en) | 1996-12-03 | 2001-10-30 | Erkki Soini | Method and a device for monitoring nucleic acid amplification reactions |
US20030104372A1 (en) | 1996-12-23 | 2003-06-05 | Pyrosequencing Ab. | Allele specific primer extension |
GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
US20020034737A1 (en) | 1997-03-04 | 2002-03-21 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
CN1238366C (en) | 1997-01-21 | 2006-01-25 | 综合医院公司 | Selection of proteins using RNA-protein fusions |
JPH10259038A (en) | 1997-01-24 | 1998-09-29 | Samsung Corning Co Ltd | Durable water-repelling glass and its production |
US5890745A (en) | 1997-01-29 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Micromachined fluidic coupler |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
EP1030733A1 (en) | 1997-02-05 | 2000-08-30 | California Institute Of Technology | Microfluidic sub-millisecond mixers |
JPH10217477A (en) | 1997-02-07 | 1998-08-18 | Fuji Xerox Co Ltd | Ink jet recording device |
CA2281205A1 (en) | 1997-02-12 | 1998-08-13 | Eugene Y. Chan | Methods and products for analyzing polymers |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
WO1998037811A1 (en) | 1997-02-28 | 1998-09-03 | Electro-Optical Sciences, Inc. | Systems and methods for the multispectral imaging and characterization of skin tissue |
US6081612A (en) | 1997-02-28 | 2000-06-27 | Electro Optical Sciences Inc. | Systems and methods for the multispectral imaging and characterization of skin tissue |
US6307957B1 (en) | 1997-02-28 | 2001-10-23 | Electro-Optical Sciences Inc | Multispectral imaging and characterization of biological tissue |
US6045755A (en) | 1997-03-10 | 2000-04-04 | Trega Biosciences,, Inc. | Apparatus and method for combinatorial chemistry synthesis |
US5994068A (en) | 1997-03-11 | 1999-11-30 | Wisconsin Alumni Research Foundation | Nucleic acid indexing |
EP0975969A4 (en) | 1997-03-18 | 2002-07-31 | Chromaxome Corp | Methods for screening compounds using encapsulated cells |
US6294344B1 (en) | 1997-03-19 | 2001-09-25 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian cancer |
US6268165B1 (en) | 1997-03-19 | 2001-07-31 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian cancer |
US6316213B1 (en) | 1997-03-19 | 2001-11-13 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian, breast and lung cancer |
US6048551A (en) | 1997-03-27 | 2000-04-11 | Hilfinger; John M. | Microsphere encapsulation of gene transfer vectors |
JPH10288131A (en) | 1997-04-11 | 1998-10-27 | Yanmar Diesel Engine Co Ltd | Injection nozzle of diesel engine |
US6143496A (en) | 1997-04-17 | 2000-11-07 | Cytonix Corporation | Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly |
US5879892A (en) | 1997-04-25 | 1999-03-09 | Ludwig Institute For Cancer Research | Leukemia associated genes |
JP4102459B2 (en) | 1997-05-14 | 2008-06-18 | 森下仁丹株式会社 | Seamless capsule for synthesizing biopolymer and method for producing the same |
WO1998052691A1 (en) | 1997-05-16 | 1998-11-26 | Alberta Research Council | Microfluidic system and methods of use |
US6632619B1 (en) | 1997-05-16 | 2003-10-14 | The Governors Of The University Of Alberta | Microfluidic system and methods of use |
US6004025A (en) | 1997-05-16 | 1999-12-21 | Life Technologies, Inc. | Automated liquid manufacturing system |
US5869004A (en) | 1997-06-09 | 1999-02-09 | Caliper Technologies Corp. | Methods and apparatus for in situ concentration and/or dilution of materials in microfluidic systems |
US5888778A (en) | 1997-06-16 | 1999-03-30 | Exact Laboratories, Inc. | High-throughput screening method for identification of genetic mutations or disease-causing microorganisms using segmented primers |
US20020015997A1 (en) | 1997-06-16 | 2002-02-07 | Lafferty William Michael | Capillary array-based sample screening |
US6074879A (en) | 1997-06-23 | 2000-06-13 | Bayer Corporation | Synthetic polymer particles for use as standards and calibrators in flow cytometry |
JP2843319B1 (en) | 1997-06-27 | 1999-01-06 | 科学技術振興事業団 | Microstrip gas chamber high-speed data acquisition system and sample measurement method using the same |
CA2792122C (en) | 1997-07-07 | 2015-09-08 | Medical Research Council | In vitro sorting method |
JP3557859B2 (en) | 1997-07-15 | 2004-08-25 | コニカミノルタホールディングス株式会社 | Silver halide photographic emulsion, production method thereof and silver halide photographic light-sensitive material |
US6403373B1 (en) | 1997-10-10 | 2002-06-11 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these |
US20050037397A1 (en) | 2001-03-28 | 2005-02-17 | Nanosphere, Inc. | Bio-barcode based detection of target analytes |
US6974669B2 (en) | 2000-03-28 | 2005-12-13 | Nanosphere, Inc. | Bio-barcodes based on oligonucleotide-modified nanoparticles |
US6165578A (en) | 1997-07-23 | 2000-12-26 | Matsushita Electric Industrial Co., Ltd. | Optical information recording medium and method for producing the same |
FR2767064B1 (en) | 1997-08-07 | 1999-11-12 | Centre Nat Rech Scient | METHOD FOR RELEASING AN ACTIVE INGREDIENT CONTAINED IN A MULTIPLE EMULSION |
US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
NZ328751A (en) | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
WO2000042209A1 (en) | 1999-01-15 | 2000-07-20 | Ljl Biosystems, Inc. | Methods and apparatus for detecting polynucleotide hybridization |
US6833242B2 (en) | 1997-09-23 | 2004-12-21 | California Institute Of Technology | Methods for detecting and sorting polynucleotides based on size |
US6540895B1 (en) | 1997-09-23 | 2003-04-01 | California Institute Of Technology | Microfabricated cell sorter for chemical and biological materials |
EP1029244A4 (en) | 1997-10-02 | 2003-07-23 | Aclara Biosciences Inc | Capillary assays involving separation of free and bound species |
US6511803B1 (en) | 1997-10-10 | 2003-01-28 | President And Fellows Of Harvard College | Replica amplification of nucleic acid arrays |
US6008003A (en) | 1997-10-28 | 1999-12-28 | Promega Corporation | Non-invasive diagnostic method for interstitial cystitis and bladder cancer |
GB9723262D0 (en) | 1997-11-05 | 1998-01-07 | British Nuclear Fuels Plc | Reactions of aromatic compounds |
US6162421A (en) | 1997-11-17 | 2000-12-19 | Revlon Consumer Products Corporation | Pigmented water-in-oil emulsion cosmetic sticks |
US5927852A (en) | 1997-12-01 | 1999-07-27 | Minnesota Mining And Manfacturing Company | Process for production of heat sensitive dispersions or emulsions |
US6972170B1 (en) | 1997-12-01 | 2005-12-06 | Sloan-Kettering Institute For Cancer Research | Markers for prostate cancer |
JP2002508250A (en) | 1997-12-17 | 2002-03-19 | ユニバーシィダッド デ セビリヤ | Device and method for producing spherical particles of uniform size |
ATE239801T1 (en) | 1998-01-22 | 2003-05-15 | Luminex Corp | MICROPARTICLES WITH MULTIPLE FLUORESCENCE SIGNALS |
GB2334271B (en) | 1998-02-17 | 2000-09-20 | Sofitech Nv | Water based drilling fluid with shale swelling inhibiting agent and phosphonate |
US7022821B1 (en) | 1998-02-20 | 2006-04-04 | O'brien Timothy J | Antibody kit for the detection of TADG-15 protein |
US6064149A (en) | 1998-02-23 | 2000-05-16 | Micron Technology Inc. | Field emission device with silicon-containing adhesion layer |
US6897018B1 (en) | 1998-02-25 | 2005-05-24 | The United States Of America As Represented By The Department Of Health And Human Services | DLC-1 gene deleted in cancers |
US6292756B1 (en) | 1998-02-26 | 2001-09-18 | Premier Instruments, Inc. | Narrow band infrared water fraction apparatus for gas well and liquid hydrocarbon flow stream use |
JP3081880B2 (en) | 1998-03-30 | 2000-08-28 | 農林水産省食品総合研究所長 | Microsphere continuous manufacturing equipment |
FI980874A (en) | 1998-04-20 | 1999-10-21 | Wallac Oy | Method and apparatus for conducting chemical analysis on small amounts of liquid |
US6395253B2 (en) | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
US20060269558A1 (en) | 1998-04-27 | 2006-11-30 | Murphy Gerald P | Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
US5997636A (en) | 1998-05-01 | 1999-12-07 | Instrumentation Technology Associates, Inc. | Method and apparatus for growing crystals |
DE19822674A1 (en) | 1998-05-20 | 1999-12-09 | Gsf Forschungszentrum Umwelt | Gas inlet for an ion source |
ATE530891T1 (en) | 1998-05-22 | 2011-11-15 | California Inst Of Techn | MINIATURIZED CELL SORTER |
EP1457264B2 (en) | 1998-05-25 | 2012-02-29 | Fuji BC Engineering Co., Ltd. | Liquid spray device and cutting method |
AU747464B2 (en) | 1998-06-08 | 2002-05-16 | Caliper Technologies Corporation | Microfluidic devices, systems and methods for performing integrated reactions and separations |
GB9812768D0 (en) | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
US7700568B2 (en) | 1998-06-30 | 2010-04-20 | Sloan-Kettering Institute For Cancer Research | Uses of DNA-PK |
JP2981547B1 (en) | 1998-07-02 | 1999-11-22 | 農林水産省食品総合研究所長 | Cross-flow type microchannel device and method for producing or separating emulsion using the device |
EP1100889A4 (en) | 1998-07-17 | 2002-03-06 | Mirus Corp | Micellar systems |
US6003794A (en) | 1998-08-04 | 1999-12-21 | Progressive Grower Technologies, Inc. | Electrostatic spray module |
DE69931497T2 (en) | 1998-08-07 | 2007-05-03 | Cellay LLC, Cambridge | GEL MICRO-DROPS FOR GENETIC ANALYSIS |
US6210896B1 (en) | 1998-08-13 | 2001-04-03 | Us Genomics | Molecular motors |
CN1312474C (en) | 1998-09-17 | 2007-04-25 | 阿德文生物科学公司 | Integrated chemical analysis system |
DE69905832T2 (en) | 1998-09-18 | 2004-02-05 | Massachusetts Institute Of Technology, Cambridge | Biological uses of semiconducting nanocrystals |
DE19845078A1 (en) | 1998-09-30 | 2000-04-06 | Basf Ag | Polymer particles containing dye |
US6591852B1 (en) | 1998-10-13 | 2003-07-15 | Biomicro Systems, Inc. | Fluid circuit components based upon passive fluid dynamics |
US6601613B2 (en) | 1998-10-13 | 2003-08-05 | Biomicro Systems, Inc. | Fluid circuit components based upon passive fluid dynamics |
US6637463B1 (en) | 1998-10-13 | 2003-10-28 | Biomicro Systems, Inc. | Multi-channel microfluidic system design with balanced fluid flow distribution |
JP2002527250A (en) | 1998-10-13 | 2002-08-27 | バイオマイクロ システムズ インコーポレイテッド | Fluid circuit components based on passive hydrodynamics |
US6902892B1 (en) | 1998-10-19 | 2005-06-07 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
US6960433B1 (en) | 1998-10-19 | 2005-11-01 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
US7022472B2 (en) | 1998-10-22 | 2006-04-04 | Diadexus, Inc. | Mutations in human MLH1 and human MSH2 genes useful in diagnosing colorectal cancer |
US6086740A (en) | 1998-10-29 | 2000-07-11 | Caliper Technologies Corp. | Multiplexed microfluidic devices and systems |
US20030045491A1 (en) | 2001-02-23 | 2003-03-06 | Christoph Reinhard | TTK in diagnosis and as a therapeutic target in cancer |
US6614598B1 (en) | 1998-11-12 | 2003-09-02 | Institute Of Technology, California | Microlensing particles and applications |
US6569631B1 (en) | 1998-11-12 | 2003-05-27 | 3-Dimensional Pharmaceuticals, Inc. | Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes |
US6450189B1 (en) | 1998-11-13 | 2002-09-17 | Universidad De Sevilla | Method and device for production of components for microfabrication |
US6139303A (en) | 1998-11-20 | 2000-10-31 | United Technologies Corporation | Fixture for disposing a laser blocking material in an airfoil |
US6353226B1 (en) | 1998-11-23 | 2002-03-05 | Abbott Laboratories | Non-invasive sensor capable of determining optical parameters in a sample having multiple layers |
US6465193B2 (en) | 1998-12-11 | 2002-10-15 | The Regents Of The University Of California | Targeted molecular bar codes and methods for using the same |
DE19857302C2 (en) | 1998-12-14 | 2000-10-26 | Forschungszentrum Juelich Gmbh | Process for the enantioselective reduction of 3,5-dioxocarboxylic acids, their salts and esters |
US20030069601A1 (en) | 1998-12-15 | 2003-04-10 | Closys Corporation | Clotting cascade initiating apparatus and methods of use |
US6205353B1 (en) | 1998-12-22 | 2001-03-20 | Research Foundation Of Cuny | Time-resolved optical backscattering tomographic image reconstruction in scattering turbid media |
GB9900298D0 (en) | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
US6565727B1 (en) | 1999-01-25 | 2003-05-20 | Nanolytics, Inc. | Actuators for microfluidics without moving parts |
US6294063B1 (en) | 1999-02-12 | 2001-09-25 | Board Of Regents, The University Of Texas System | Method and apparatus for programmable fluidic processing |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
US6633031B1 (en) | 1999-03-02 | 2003-10-14 | Advion Biosciences, Inc. | Integrated monolithic microfabricated dispensing nozzle and liquid chromatography-electrospray system and method |
US6942978B1 (en) | 1999-03-03 | 2005-09-13 | The Board Of Trustees Of The University Of Arkansas | Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof |
US6428053B1 (en) | 1999-03-12 | 2002-08-06 | California Institute Of Technology | Micromachined fluidic coupler and method of making the same |
CN1181337C (en) | 2000-08-08 | 2004-12-22 | 清华大学 | Solid molecule operating method in microfluid system |
DE19911777A1 (en) | 1999-03-17 | 2000-09-21 | Merck Patent Gmbh | Process for the preparation of cosmetic formulations |
JP2000271475A (en) | 1999-03-23 | 2000-10-03 | Shinji Katsura | Finely controlling method of chemical reaction by fine operation of water-in-oil emulsion |
US7153700B1 (en) | 1999-03-26 | 2006-12-26 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for diagnosing and predicting the behavior of cancer |
JP2002540930A (en) | 1999-04-08 | 2002-12-03 | ペント ベルント | Method and apparatus for performing chemical and physical processes |
US6267353B1 (en) | 1999-04-19 | 2001-07-31 | Pbm, Inc. | Self draining valve |
US20030215821A1 (en) | 1999-04-20 | 2003-11-20 | Kevin Gunderson | Detection of nucleic acid reactions on bead arrays |
KR20020005721A (en) | 1999-04-23 | 2002-01-17 | 추후기재 | High mass transfer electrosprayer |
US6682940B2 (en) | 1999-05-04 | 2004-01-27 | Dan A. Pankowsky | Products and methods for single parameter and multiparameter phenotyping of cells |
US6399952B1 (en) | 1999-05-12 | 2002-06-04 | Aclara Biosciences, Inc. | Multiplexed fluorescent detection in microfluidic devices |
US6592821B1 (en) | 1999-05-17 | 2003-07-15 | Caliper Technologies Corp. | Focusing of microparticles in microfluidic systems |
US6738502B1 (en) | 1999-06-04 | 2004-05-18 | Kairos Scientific, Inc. | Multispectral taxonomic identification |
EP1192009B1 (en) | 1999-06-11 | 2013-05-01 | Aradigm Corporation | Method for producing an aerosol |
US20060169800A1 (en) | 1999-06-11 | 2006-08-03 | Aradigm Corporation | Aerosol created by directed flow of fluids and devices and methods for producing same |
US6296673B1 (en) | 1999-06-18 | 2001-10-02 | The Regents Of The University Of California | Methods and apparatus for performing array microcrystallizations |
US6630006B2 (en) | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
JP3623479B2 (en) | 1999-06-22 | 2005-02-23 | テカン トレーディング アーゲー | Apparatus and method for performing miniaturized in vitro amplification assays |
JP2003502655A (en) | 1999-06-22 | 2003-01-21 | アジレント・テクノロジーズ・インコーポレーテッド | Equipment for operating microfluidic devices |
US6210396B1 (en) | 1999-06-24 | 2001-04-03 | Medtronic, Inc. | Guiding catheter with tungsten loaded band |
CA2721172C (en) | 1999-06-28 | 2012-04-10 | California Institute Of Technology | Microfabricated elastomeric valve and pump systems |
US7195670B2 (en) | 2000-06-27 | 2007-03-27 | California Institute Of Technology | High throughput screening of crystallization of materials |
US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
US6964847B1 (en) | 1999-07-14 | 2005-11-15 | Packard Biosciences Company | Derivative nucleic acids and uses thereof |
US6977145B2 (en) | 1999-07-28 | 2005-12-20 | Serono Genetics Institute S.A. | Method for carrying out a biochemical protocol in continuous flow in a microreactor |
US6440706B1 (en) | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
US6632800B1 (en) | 1999-08-17 | 2003-10-14 | Mayo Foundation For Medical Education And Research | System for monitoring the expression of transgenes |
AU6788100A (en) | 1999-08-20 | 2001-03-19 | Luminex Corporation | Liquid array technology |
US6439103B1 (en) | 1999-09-07 | 2002-08-27 | Vector Engineering Co. | Hydraulic and pneumatic cylinder construction |
GB9921155D0 (en) | 1999-09-08 | 1999-11-10 | Medical Res Council | Selection system |
WO2001020333A1 (en) | 1999-09-10 | 2001-03-22 | Meiji Milk Prod Co Ltd | Early cancer tumor marker |
US6274320B1 (en) | 1999-09-16 | 2001-08-14 | Curagen Corporation | Method of sequencing a nucleic acid |
TW507305B (en) | 1999-09-18 | 2002-10-21 | Samsung Electronics Co Ltd | Method of measuring etched state of semiconductor wafer |
US20010050881A1 (en) | 1999-09-20 | 2001-12-13 | Depaoli David W. | Continuous flow, electrohydrodynamic micromixing apparatus and methods |
US6998232B1 (en) | 1999-09-27 | 2006-02-14 | Quark Biotech, Inc. | Methods of diagnosing bladder cancer |
US6890487B1 (en) | 1999-09-30 | 2005-05-10 | Science & Technology Corporation ©UNM | Flow cytometry for high throughput screening |
DE19947496C2 (en) | 1999-10-01 | 2003-05-22 | Agilent Technologies Inc | Microfluidic microchip |
US7393634B1 (en) | 1999-10-12 | 2008-07-01 | United States Of America As Represented By The Secretary Of The Air Force | Screening for disease susceptibility by genotyping the CCR5 and CCR2 genes |
US7332275B2 (en) | 1999-10-13 | 2008-02-19 | Sequenom, Inc. | Methods for detecting methylated nucleotides |
DK1228208T3 (en) | 1999-10-28 | 2010-11-22 | Agensys Inc | 36P6D5: secreted tumor antigen |
US20020048777A1 (en) | 1999-12-06 | 2002-04-25 | Shujath Ali | Method of diagnosing monitoring, staging, imaging and treating prostate cancer |
US7510707B2 (en) | 1999-12-20 | 2009-03-31 | New York University Mt. Sinai School Of Medicine | PAR, a novel marker gene for breast and prostate cancers |
EP1110599B1 (en) | 1999-12-23 | 2003-04-09 | Ernst Mühlbauer GmbH & Co.KG | Dynamic mixer for dental impression pastes |
US6379884B2 (en) | 2000-01-06 | 2002-04-30 | Caliper Technologies Corp. | Methods and systems for monitoring intracellular binding reactions |
US20010032053A1 (en) | 2000-01-24 | 2001-10-18 | Hielscher Andreas H. | Imaging of a scattering medium using the equation of radiative transfer |
CA2396755A1 (en) | 2000-02-03 | 2001-08-09 | Nanoscale Combinatorial Synthesis, Inc. | Structure identification methods using mass measurements |
US7582420B2 (en) | 2001-07-12 | 2009-09-01 | Illumina, Inc. | Multiplex nucleic acid reactions |
US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US6355193B1 (en) | 2000-03-01 | 2002-03-12 | Gale Stott | Method for making a faux stone concrete panel |
GB2359765B (en) | 2000-03-02 | 2003-03-05 | Univ Newcastle | Capillary reactor distribution device and method |
US7485454B1 (en) | 2000-03-10 | 2009-02-03 | Bioprocessors Corp. | Microreactor |
CN1429181A (en) | 2000-03-10 | 2003-07-09 | 流体聚焦公司 | Methods for producing optical fiber by focusing high viscosity liquid |
ITPR20000017A1 (en) | 2000-03-15 | 2001-09-15 | Lino Lanfranchi | APPARATUS FOR THE CONTROL OF CONTAINERS, IN PARTICULAR PREFORMS |
JP3442338B2 (en) | 2000-03-17 | 2003-09-02 | 株式会社日立製作所 | DNA analyzer, DNA base sequencer, DNA base sequence determination method, and reaction module |
US6565010B2 (en) | 2000-03-24 | 2003-05-20 | Praxair Technology, Inc. | Hot gas atomization |
EP1370683B1 (en) | 2000-03-24 | 2006-06-07 | Micromet AG | mRNA AMPLIFICATION |
DE10015109A1 (en) | 2000-03-28 | 2001-10-04 | Peter Walzel | Processes and devices for producing drops of equal size |
AU5121801A (en) | 2000-03-31 | 2001-10-15 | Micronics Inc | Protein crystallization in microfluidic structures |
US7867763B2 (en) | 2004-01-25 | 2011-01-11 | Fluidigm Corporation | Integrated chip carriers with thermocycler interfaces and methods of using the same |
EP2206791B1 (en) | 2000-04-10 | 2016-07-13 | Taxon Biosciences, Inc. | Methods for the survey and genetic analysis of populations |
US6481453B1 (en) | 2000-04-14 | 2002-11-19 | Nanostream, Inc. | Microfluidic branch metering systems and methods |
WO2001080283A1 (en) | 2000-04-18 | 2001-10-25 | Waters Investments Limited | Improved electrospray and other lc/ms interfaces |
JP2001301154A (en) | 2000-04-20 | 2001-10-30 | Dainippon Printing Co Ltd | Field jet sticking method of liquid having surface tension lowering upon application of voltage |
US6469094B1 (en) | 2000-04-28 | 2002-10-22 | Xerox Corporation | Polymerization processes |
US6828098B2 (en) | 2000-05-20 | 2004-12-07 | The Regents Of The University Of Michigan | Method of producing a DNA library using positional amplification based on the use of adaptors and nick translation |
DE10025290B4 (en) | 2000-05-22 | 2005-03-24 | Fico I.T.M. S.A. | Sun visor outer surfaces |
WO2001089696A2 (en) | 2000-05-24 | 2001-11-29 | Micronics, Inc. | Microfluidic concentration gradient loop |
US6645432B1 (en) | 2000-05-25 | 2003-11-11 | President & Fellows Of Harvard College | Microfluidic systems including three-dimensionally arrayed channel networks |
US6686184B1 (en) | 2000-05-25 | 2004-02-03 | President And Fellows Of Harvard College | Patterning of surfaces utilizing microfluidic stamps including three-dimensionally arrayed channel networks |
JP3939077B2 (en) | 2000-05-30 | 2007-06-27 | 大日本スクリーン製造株式会社 | Substrate cleaning device |
US20060263888A1 (en) | 2000-06-02 | 2006-11-23 | Honeywell International Inc. | Differential white blood count on a disposable card |
US7351376B1 (en) | 2000-06-05 | 2008-04-01 | California Institute Of Technology | Integrated active flux microfluidic devices and methods |
US7049072B2 (en) | 2000-06-05 | 2006-05-23 | University Of South Florida | Gene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a leukemic disease state |
US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
US6592321B2 (en) | 2000-08-03 | 2003-07-15 | Demag Cranes & Components Gmbh | Control and guiding device for manually operating a handling unit, and modular construction kit for making such devices of different configuration |
FR2812942B1 (en) | 2000-08-08 | 2002-10-31 | Commissariat Energie Atomique | POLARIZED LIGHT FLUORESCENCE IMAGING DEVICE |
US6301055B1 (en) | 2000-08-16 | 2001-10-09 | California Institute Of Technology | Solid immersion lens structures and methods for producing solid immersion lens structures |
US20030148273A1 (en) | 2000-08-26 | 2003-08-07 | Shoulian Dong | Target enrichment and amplification |
US6610499B1 (en) | 2000-08-31 | 2003-08-26 | The Regents Of The University Of California | Capillary array and related methods |
JP2002071687A (en) | 2000-08-31 | 2002-03-12 | Canon Inc | Screening method for variant gene |
JP3993372B2 (en) | 2000-09-13 | 2007-10-17 | 独立行政法人理化学研究所 | Reactor manufacturing method |
US6739036B2 (en) | 2000-09-13 | 2004-05-25 | Fuji Machine Mfg., Co., Ltd. | Electric-component mounting system |
DE10045586C2 (en) | 2000-09-15 | 2002-07-18 | Alstom Power Boiler Gmbh | Process and device for cleaning smoke gases containing sulfur dioxide |
EP1334347A1 (en) | 2000-09-15 | 2003-08-13 | California Institute Of Technology | Microfabricated crossflow devices and methods |
AU2001292728A1 (en) | 2000-09-18 | 2002-03-26 | Thomas Jefferson University | Compositions and methods for identifying and targeting stomach and esophageal cancer cells |
US6775405B1 (en) | 2000-09-29 | 2004-08-10 | Koninklijke Philips Electronics, N.V. | Image registration system and method using cross-entropy optimization |
EP1364052A2 (en) | 2000-10-10 | 2003-11-26 | Diversa Corporation | High throughput or capillary-based screening for a bioactivity or biomolecule |
JP2004537712A (en) | 2000-10-18 | 2004-12-16 | バーチャル・アレイズ・インコーポレーテッド | Multiple cell analysis system |
JP2004526949A (en) | 2000-10-19 | 2004-09-02 | ストラクチュラル ジェノミックス,インコーポレーテッド | Apparatus and method for crystal identification by in situ X-ray diffraction |
JP3946430B2 (en) | 2000-10-20 | 2007-07-18 | 株式会社日立製作所 | Valve timing control device for internal combustion engine |
GB0026424D0 (en) | 2000-10-28 | 2000-12-13 | Ncimb Ltd | Genetic analysis of microorganisms |
EP1343973B2 (en) | 2000-11-16 | 2020-09-16 | California Institute Of Technology | Apparatus and methods for conducting assays and high throughput screening |
KR100426453B1 (en) | 2000-11-28 | 2004-04-13 | 김진우 | Human cervical cancer 2 protooncogene and protein encoded by same, expression vector containing same, and cell transformed by said vector |
US6778724B2 (en) | 2000-11-28 | 2004-08-17 | The Regents Of The University Of California | Optical switching and sorting of biological samples and microparticles transported in a micro-fluidic device, including integrated bio-chip devices |
WO2002044331A2 (en) | 2000-11-29 | 2002-06-06 | Cangen International | Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer |
US6849423B2 (en) | 2000-11-29 | 2005-02-01 | Picoliter Inc | Focused acoustics for detection and sorting of fluid volumes |
EP1385488A2 (en) | 2000-12-07 | 2004-02-04 | President And Fellows Of Harvard College | Methods and compositions for encapsulating active agents |
US20040096515A1 (en) | 2001-12-07 | 2004-05-20 | Bausch Andreas R. | Methods and compositions for encapsulating active agents |
AU2002239823B2 (en) | 2001-01-08 | 2008-01-17 | President And Fellows Of Harvard College | Valves and pumps for microfluidic systems and method for making microfluidic systems |
US7279883B2 (en) | 2001-01-23 | 2007-10-09 | Lydia L. Sohn | Particle analyzer and methods for use thereof |
KR100475649B1 (en) | 2001-01-29 | 2005-03-10 | 배석철 | RUNX3 gene showing anti-tumor activity and use thereof |
ES2180405B1 (en) | 2001-01-31 | 2004-01-16 | Univ Sevilla | DEVICE AND PROCEDURE FOR PRODUCING MULTICOMPONENT COMPOSITE LIQUID JEANS AND MULTICOMPONENT AND / OR MULTI-PAPER MICRO AND NANOMETRIC SIZE CAPSULES. |
CA2438856C (en) | 2001-02-23 | 2007-08-07 | Japan Science And Technology Corporation | Process and apparatus for producing emulsion and microcapsules |
JP3805746B2 (en) | 2001-02-23 | 2006-08-09 | 独立行政法人科学技術振興機構 | Method and apparatus for handling liquid fine particles |
EP1741482B1 (en) | 2001-02-23 | 2008-10-15 | Japan Science and Technology Agency | Process and apparatus for producing microcapsules |
US6936264B2 (en) | 2001-03-05 | 2005-08-30 | The Procter & Gamble Company | Delivery of reactive agents via multiple emulsions for use in shelf stable products |
NO325061B1 (en) | 2001-03-06 | 2008-01-28 | Photosense As | Method and arrangement for determining the optical property of a multilayer tissue |
JP4148778B2 (en) | 2001-03-09 | 2008-09-10 | バイオミクロ システムズ インコーポレイティッド | Microfluidic interface equipment with arrays |
CA2440754A1 (en) | 2001-03-12 | 2002-09-19 | Stephen Quake | Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension |
US6717136B2 (en) | 2001-03-19 | 2004-04-06 | Gyros Ab | Microfludic system (EDI) |
US7010391B2 (en) | 2001-03-28 | 2006-03-07 | Handylab, Inc. | Methods and systems for control of microfluidic devices |
US20030064414A1 (en) | 2001-03-30 | 2003-04-03 | Benecky Michael J. | Rapid assessment of coagulation activity in whole blood |
AU2002307152A1 (en) | 2001-04-06 | 2002-10-21 | California Institute Of Technology | Nucleic acid amplification utilizing microfluidic devices |
US6752922B2 (en) | 2001-04-06 | 2004-06-22 | Fluidigm Corporation | Microfluidic chromatography |
US7318642B2 (en) | 2001-04-10 | 2008-01-15 | Essilor International (Compagnie Générale d'Optique) | Progressive addition lenses with reduced unwanted astigmatism |
US7756558B2 (en) | 2004-05-24 | 2010-07-13 | Trutouch Technologies, Inc. | Apparatus and methods for mitigating the effects of foreign interferents on analyte measurements in spectroscopy |
EP1392814B1 (en) | 2001-04-25 | 2007-06-13 | Cornell Research Foundation, Inc. | Devices and methods for pharmacokinetic-based cell culture system |
US20020164271A1 (en) | 2001-05-02 | 2002-11-07 | Ho Winston Z. | Wavelength-coded bead for bioassay and signature recogniton |
KR100917731B1 (en) | 2001-05-11 | 2009-09-15 | 파나소닉 주식회사 | Biomolecular substrate and method and apparatus for examination and diagnosis using the same |
US7320027B1 (en) | 2001-05-14 | 2008-01-15 | At&T Corp. | System having generalized client-server computing |
WO2002095362A2 (en) | 2001-05-24 | 2002-11-28 | New Objective, Inc. | Method and apparatus for feedback controlled electrospray |
ATE410680T1 (en) | 2001-05-26 | 2008-10-15 | One Cell Systems Inc | SECRETION OF PROTEINS BY ENCAPSULATED CELLS |
EP1262545A1 (en) | 2001-05-31 | 2002-12-04 | Direvo Biotech AG | Microstructures and the use thereof in the targeted evolution of biomolecules |
US6719840B2 (en) | 2001-06-08 | 2004-04-13 | Syrrx, Inc. | In situ crystal growth and crystallization |
US6797056B2 (en) | 2001-06-08 | 2004-09-28 | Syrrx, Inc. | Microfluidic method employing delivery of plural different fluids to same lumen |
AU2002316251A1 (en) | 2001-06-18 | 2003-01-02 | Rosetta Inpharmatics, Inc. | Diagnosis and prognosis of breast cancer patients |
GB0114856D0 (en) | 2001-06-18 | 2001-08-08 | Medical Res Council | Selection by avidity capture |
GB0114854D0 (en) | 2001-06-18 | 2001-08-08 | Medical Res Council | Selective gene amplification |
WO2003003015A2 (en) | 2001-06-28 | 2003-01-09 | Advanced Research And Technology Institute, Inc. | Methods of preparing multicolor quantum dot tagged beads and conjugates thereof |
US6553944B1 (en) | 2001-07-03 | 2003-04-29 | Virginia A. Allen | Wrist worn leash retaining device |
US6656267B2 (en) | 2001-07-10 | 2003-12-02 | Structural Genomix, Inc. | Tray for macromolecule crystallization and method of using the same |
CA2353030A1 (en) | 2001-07-13 | 2003-01-13 | Willem Jager | Caster mounted reel mower |
US7314599B2 (en) | 2001-07-17 | 2008-01-01 | Agilent Technologies, Inc. | Paek embossing and adhesion for microfluidic devices |
WO2003008943A1 (en) | 2001-07-19 | 2003-01-30 | Tufts University | Optical array device and methods of use thereof for screening, analysis and manipulation of particles |
US7410758B2 (en) | 2001-07-20 | 2008-08-12 | Board Of Regents, The University Of Texas System | Methods and compositions relating to HPV-associated pre-cancerous and cancerous growths, including CIN |
US6766817B2 (en) | 2001-07-25 | 2004-07-27 | Tubarc Technologies, Llc | Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action |
WO2003011443A2 (en) | 2001-07-27 | 2003-02-13 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
JP2005503145A (en) | 2001-08-16 | 2005-02-03 | ザ ユナイテッド ステイツ オブ アメリカ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Molecular characteristics of non-small cell lung cancer |
WO2003015890A1 (en) | 2001-08-20 | 2003-02-27 | President And Fellows Of Harvard College | Fluidic arrays and method of using |
JP2003053996A (en) | 2001-08-22 | 2003-02-26 | Canon Inc | Ink supply mechanism and ink jet recorder comprising it |
AU2002339865A1 (en) | 2001-09-05 | 2003-03-18 | The Children's Hospital Of Philadelphia | Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors |
US7390463B2 (en) | 2001-09-07 | 2008-06-24 | Corning Incorporated | Microcolumn-based, high-throughput microfluidic device |
DE10145568A1 (en) | 2001-09-14 | 2003-04-03 | Knoell Hans Forschung Ev | Process for the cultivation and analysis of microbial single cell cultures |
FR2829948B1 (en) | 2001-09-21 | 2004-07-09 | Commissariat Energie Atomique | METHOD FOR MOVING A FLUID OF INTEREST INTO A CAPILLARY AND FLUIDIC MICROSYSTEM |
DE10149725B4 (en) | 2001-10-09 | 2004-04-15 | Promos Technologies, Inc. | Anisotropic manufacturing process of oxide layers in a substrate trench |
WO2003031591A2 (en) | 2001-10-10 | 2003-04-17 | Superarray Bioscience Corporation | Detecting targets by unique identifier nucleotide tags |
US7179420B2 (en) | 2001-10-25 | 2007-02-20 | Techelan, Llc | Apparatus comprising a particle sorter/dispenser and method therefor |
US6670142B2 (en) | 2001-10-26 | 2003-12-30 | The Regents Of The University Of California | Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells |
WO2003037302A1 (en) | 2001-10-30 | 2003-05-08 | Windsor J Brian | Method and system for the co-isolation of cognate dna, rna and protein sequences and method for screening co-isolates for defined activities |
US6464336B1 (en) | 2001-10-31 | 2002-10-15 | Eastman Kodak Company | Ink jet printing with color-balanced ink drops mixed using bleached ink |
US7308364B2 (en) | 2001-11-07 | 2007-12-11 | The University Of Arkansas For Medical Sciences | Diagnosis of multiple myeloma on gene expression profiling |
US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
JP2003149136A (en) | 2001-11-13 | 2003-05-21 | Shimadzu Corp | Optical image measuring method |
JP2005535283A (en) | 2001-11-13 | 2005-11-24 | ルビコン ゲノミクス インコーポレイテッド | DNA amplification and sequencing using DNA molecules generated by random fragmentation |
GB0127564D0 (en) | 2001-11-16 | 2002-01-09 | Medical Res Council | Emulsion compositions |
JP4381142B2 (en) | 2001-11-16 | 2009-12-09 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | Prostate cancer detection |
DE60235491D1 (en) | 2001-11-28 | 2010-04-08 | Bio Rad Laboratories | PARALLEL SCORING OF POLYMORPHISMS WITH AMPLIFICATION AND ERROR CORRECTION |
EP1463796B1 (en) | 2001-11-30 | 2013-01-09 | Fluidigm Corporation | Microfluidic device and methods of using same |
US7057026B2 (en) | 2001-12-04 | 2006-06-06 | Solexa Limited | Labelled nucleotides |
GB0129374D0 (en) | 2001-12-07 | 2002-01-30 | Univ Brunel | Test apparatus |
US6800849B2 (en) | 2001-12-19 | 2004-10-05 | Sau Lan Tang Staats | Microfluidic array devices and methods of manufacture and uses thereof |
US20030198972A1 (en) | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
US6949342B2 (en) | 2001-12-21 | 2005-09-27 | Whitehead Institute For Biomedical Research | Prostate cancer diagnosis and outcome prediction by expression analysis |
US20030144260A1 (en) | 2002-01-03 | 2003-07-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method |
CA2472649A1 (en) | 2002-01-08 | 2003-07-17 | Japan Science And Technology Agency | Pcr and hybridization methods utilizing electrostatic transportation and devices therefor |
WO2003062418A1 (en) | 2002-01-25 | 2003-07-31 | Olympus Corporation | Method and apparatus for detecting nucleic acid data |
JP2003222633A (en) | 2002-01-30 | 2003-08-08 | Nippon Sheet Glass Co Ltd | Microchip |
MXPA03006862A (en) | 2002-01-30 | 2004-10-15 | Kraft Foods Holdings Inc | Production of capsules and particles for improvement of food products. |
DE60320383D1 (en) | 2002-02-04 | 2008-05-29 | Univ Sevilla | DEVICE FOR PRODUCING CAPILLARY RAYS AND MICRO AND NANOMETER PARTICLES |
AU2003212954A1 (en) | 2002-02-08 | 2003-09-02 | Integriderm, Inc. | Skin cell biomarkers and methods for identifying biomarkers using nucleic acid microarrays |
AU2003211688A1 (en) | 2002-02-11 | 2003-09-04 | Rhodia Chimie | Method for controlling the stability of emulsions and stabilized emulsions |
US7101467B2 (en) | 2002-03-05 | 2006-09-05 | Caliper Life Sciences, Inc. | Mixed mode microfluidic systems |
WO2003076052A1 (en) | 2002-03-05 | 2003-09-18 | Caliper Life Sciences, Inc. | Mixed mode microfluidic systems |
EP2799555B1 (en) | 2002-03-13 | 2017-02-22 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
EP1488006B1 (en) | 2002-03-20 | 2008-05-28 | InnovativeBio.Biz | Microcapsules with controlable permeability encapsulating a nucleic acid amplification reaction mixture and their use as reaction compartments for parallels reactions |
US7348142B2 (en) | 2002-03-29 | 2008-03-25 | Veridex, Lcc | Cancer diagnostic panel |
US7147763B2 (en) | 2002-04-01 | 2006-12-12 | Palo Alto Research Center Incorporated | Apparatus and method for using electrostatic force to cause fluid movement |
EP1499706A4 (en) | 2002-04-01 | 2010-11-03 | Fluidigm Corp | Microfluidic particle-analysis systems |
GB0207533D0 (en) | 2002-04-02 | 2002-05-08 | Oxford Glycosciences Uk Ltd | Protein |
US6976590B2 (en) | 2002-06-24 | 2005-12-20 | Cytonome, Inc. | Method and apparatus for sorting particles |
WO2003096015A1 (en) | 2002-05-08 | 2003-11-20 | Matsushita Electric Industrial Co., Ltd. | Biomolecular substrate, method of testing or diagnosis with use thereof and apparatus therefor |
US7901939B2 (en) | 2002-05-09 | 2011-03-08 | University Of Chicago | Method for performing crystallization and reactions in pressure-driven fluid plugs |
ATE479899T1 (en) | 2002-05-09 | 2010-09-15 | Univ Chicago | EQUIPMENT AND METHODS FOR PRESSURE CONTROLLED PLUG TRANSPORT AND REACTION |
AU2003233595A1 (en) | 2002-05-20 | 2003-12-12 | Dow Corning Corporation | Peptide derivatives, and their use for the synthesis of silicon-based composite materials |
US20030219754A1 (en) | 2002-05-23 | 2003-11-27 | Oleksy Jerome E. | Fluorescence polarization detection of nucleic acids |
AU2003238401A1 (en) | 2002-05-24 | 2003-12-12 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Method for transferring heterogeneous liquids in microchannels without the occurrence of mixing |
US7218959B2 (en) | 2002-06-05 | 2007-05-15 | Research Foundation Of City University | Hybrid-dual-fourier tomographic algorithm for a fast three-dimensionial optical image reconstruction in turbid media |
JP3883060B2 (en) | 2002-06-17 | 2007-02-21 | 株式会社リガク | Crystal evaluation equipment |
US7776348B2 (en) | 2002-06-26 | 2010-08-17 | L'oreal S.A. | Water-in-oil emulsion foundation |
US20050019776A1 (en) | 2002-06-28 | 2005-01-27 | Callow Matthew James | Universal selective genome amplification and universal genotyping system |
JP2006507921A (en) | 2002-06-28 | 2006-03-09 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Method and apparatus for fluid dispersion |
US7244961B2 (en) | 2002-08-02 | 2007-07-17 | Silicon Valley Scientific | Integrated system with modular microfluidic components |
US7150412B2 (en) | 2002-08-06 | 2006-12-19 | Clean Earth Technologies Llc | Method and apparatus for electrostatic spray |
EP3002289B1 (en) | 2002-08-23 | 2018-02-28 | Illumina Cambridge Limited | Modified nucleotides for polynucleotide sequencing |
GB0220063D0 (en) | 2002-08-29 | 2002-10-09 | Isis Innovation | Magnetic particle and process for preparation |
US20040115254A1 (en) | 2002-09-06 | 2004-06-17 | Genteric, Inc. | Microcapsules and methods of use |
JP2005538735A (en) | 2002-09-17 | 2005-12-22 | パーキネルマー ラス インコーポレイテッド | Real-time detection method of nucleic acid reaction |
US7078681B2 (en) | 2002-09-18 | 2006-07-18 | Agilent Technologies, Inc. | Multimode ionization source |
US7357937B2 (en) | 2002-09-24 | 2008-04-15 | Therox, Inc. | Perfluorocarbon emulsions with non-fluorinated surfactants |
US7329545B2 (en) | 2002-09-24 | 2008-02-12 | Duke University | Methods for sampling a liquid flow |
DE60229890D1 (en) | 2002-09-30 | 2008-12-24 | Hoffmann La Roche | OLIGONUCLEOTIDES FOR GENOTYPIZING THE THYMIDYLATE SYNTHASE GENE |
US6966990B2 (en) | 2002-10-11 | 2005-11-22 | Ferro Corporation | Composite particles and method for preparing |
ATE463292T1 (en) | 2002-10-23 | 2010-04-15 | Univ Princeton | METHOD FOR CONTINUOUS PARTICLE SEPARATION USING OBSTACLE ARRAYS ASYMMETRICALLY ALIGNED IN FIELDS |
US20040136497A1 (en) | 2002-10-30 | 2004-07-15 | Meldrum Deirdre R | Preparation of samples and sample evaluation |
AU2003283663A1 (en) | 2002-11-01 | 2004-05-25 | Cellectricon Ab | Computer programs,workstations, systems and methods for microfluidic substrates in cell |
US20040086892A1 (en) | 2002-11-06 | 2004-05-06 | Crothers Donald M. | Universal tag assay |
GB2395196B (en) | 2002-11-14 | 2006-12-27 | Univ Cardiff | Microfluidic device and methods for construction and application |
DE10254601A1 (en) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Gene products differentially expressed in tumors and their use |
US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
JP2004354364A (en) | 2002-12-02 | 2004-12-16 | Nec Corp | Fine particle manipulating unit, chip mounted with the same and detector, and method for separating, capturing and detecting protein |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
WO2004061410A2 (en) | 2002-12-18 | 2004-07-22 | Ciphergen Biosystems, Inc. | Serum biomarkers in lung cancer |
US20050042639A1 (en) | 2002-12-20 | 2005-02-24 | Caliper Life Sciences, Inc. | Single molecule amplification and detection of DNA length |
JP4395133B2 (en) | 2002-12-20 | 2010-01-06 | カリパー・ライフ・サイエンシズ・インク. | Single molecule amplification and detection of DNA |
EP1585511B1 (en) | 2002-12-20 | 2013-01-23 | Amgen Inc. | Asthma and allergic inflammation modulators |
US8275554B2 (en) | 2002-12-20 | 2012-09-25 | Caliper Life Sciences, Inc. | System for differentiating the lengths of nucleic acids of interest in a sample |
US7445926B2 (en) | 2002-12-30 | 2008-11-04 | The Regents Of The University Of California | Fluid control structures in microfluidic devices |
CA2513308A1 (en) | 2003-01-17 | 2004-08-05 | Josef Michl | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
US20040142329A1 (en) | 2003-01-17 | 2004-07-22 | Ingeneus Corporation | Probe conjugation to increase multiplex binding motif preference |
WO2004065628A1 (en) | 2003-01-21 | 2004-08-05 | Guoliang Fu | Quantitative multiplex detection of nucleic acids |
US6832787B1 (en) | 2003-01-24 | 2004-12-21 | Sandia National Laboratories | Edge compression manifold apparatus |
CA2514187A1 (en) | 2003-01-24 | 2004-08-12 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
US7575865B2 (en) | 2003-01-29 | 2009-08-18 | 454 Life Sciences Corporation | Methods of amplifying and sequencing nucleic acids |
AU2004254552B2 (en) | 2003-01-29 | 2008-04-24 | 454 Life Sciences Corporation | Methods of amplifying and sequencing nucleic acids |
WO2004071638A2 (en) | 2003-02-11 | 2004-08-26 | Regents Of The University Of California, The | Microfluidic devices and method for controlled viscous shearing and formation of amphiphilic vesicles |
US7361474B2 (en) | 2003-02-24 | 2008-04-22 | United States Of America As Represented By The Department Of Veterans Affairs | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer |
EP1605817A2 (en) | 2003-02-25 | 2005-12-21 | Inlight Solutions, Inc. | DETERMINATION OF pH INCLUDING HEMOGLOBIN CORRECTION |
US20050170431A1 (en) | 2003-02-28 | 2005-08-04 | Plexxikon, Inc. | PYK2 crystal structure and uses |
WO2004092708A2 (en) | 2003-03-07 | 2004-10-28 | University Of North Carolina At Chapel Hill | Methods for the electrochemical detection of target compounds |
US20040209299A1 (en) | 2003-03-07 | 2004-10-21 | Rubicon Genomics, Inc. | In vitro DNA immortalization and whole genome amplification using libraries generated from randomly fragmented DNA |
US7041481B2 (en) | 2003-03-14 | 2006-05-09 | The Regents Of The University Of California | Chemical amplification based on fluid partitioning |
US20220042995A1 (en) | 2003-03-14 | 2022-02-10 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US7045040B2 (en) | 2003-03-20 | 2006-05-16 | Asm Nutool, Inc. | Process and system for eliminating gas bubbles during electrochemical processing |
KR100620303B1 (en) | 2003-03-25 | 2006-09-13 | 도요다 지도샤 가부시끼가이샤 | Gas storage tank and its manufacturing method |
US20060078893A1 (en) * | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
US6926313B1 (en) | 2003-04-02 | 2005-08-09 | Sandia National Laboratories | High pressure capillary connector |
EP1610888A2 (en) | 2003-04-10 | 2006-01-04 | President And Fellows Of Harvard College | Formation and control of fluidic species |
US7378233B2 (en) | 2003-04-12 | 2008-05-27 | The Johns Hopkins University | BRAF mutation T1796A in thyroid cancers |
WO2004099379A2 (en) | 2003-05-02 | 2004-11-18 | Health Research, Inc. | Use of jag2 expression in diagnosis of plasma cell disorders |
WO2004099432A2 (en) | 2003-05-02 | 2004-11-18 | The Johns Hopkins University | Identification of biomarkers for detecting pancreatic cancer |
US7262059B2 (en) | 2003-05-06 | 2007-08-28 | Thrombodyne, Inc. | Systems and methods for measuring fluid properties |
EP1629286A1 (en) | 2003-05-16 | 2006-03-01 | Global Technologies (NZ) Ltd. | Method and apparatus for mixing sample and reagent in a suspension fluid |
WO2004103565A2 (en) | 2003-05-19 | 2004-12-02 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Device and method for structuring liquids and for dosing reaction liquids into liquid compartments immersed in a separation medium |
DE10322893A1 (en) | 2003-05-19 | 2004-12-16 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Equipment for microtechnological structuring of fluids used in analytical or combinatorial biology or chemistry, has dosing, splitting and fusion devices in fluid pathway |
EP1633481A1 (en) | 2003-06-06 | 2006-03-15 | Micronics, Inc. | System and method for heating, cooling and heat cycling on microfluidic device |
JP2006526992A (en) | 2003-06-12 | 2006-11-30 | ユニバーシティ オブ マニトバ | Methods for detecting cancer and monitoring cancer progression |
ES2488845T5 (en) | 2003-06-24 | 2017-07-11 | Genomic Health, Inc. | Prediction of the probability of cancer recurrence |
JP2005037346A (en) | 2003-06-25 | 2005-02-10 | Aisin Seiki Co Ltd | Micro fluid control system |
EP1636379A2 (en) | 2003-06-26 | 2006-03-22 | Exonhit Therapeutics S.A. | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis |
US7115230B2 (en) | 2003-06-26 | 2006-10-03 | Intel Corporation | Hydrodynamic focusing devices |
AU2003903296A0 (en) | 2003-06-30 | 2003-07-10 | Raustech Pty Ltd | Chemical compositions of matter |
GB0315438D0 (en) | 2003-07-02 | 2003-08-06 | Univ Manchester | Analysis of mixed cell populations |
EP2918595B1 (en) | 2003-07-05 | 2019-12-11 | The Johns-Hopkins University | Method and compositions for detection and enumeration of genetic variations |
US10179935B2 (en) | 2003-07-17 | 2019-01-15 | Pacific Edge Limited | Markers for detection of gastric cancer |
US20050014165A1 (en) | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
US20070065810A1 (en) | 2003-07-18 | 2007-03-22 | Georgetown University | Diagnosis and treatment of cervical cancer |
US7731906B2 (en) | 2003-07-31 | 2010-06-08 | Handylab, Inc. | Processing particle-containing samples |
US8114978B2 (en) | 2003-08-05 | 2012-02-14 | Affymetrix, Inc. | Methods for genotyping selected polymorphism |
AU2004269406B2 (en) | 2003-08-28 | 2010-12-16 | Progenity, Inc. | Methods and apparatus for sorting cells using an optical switch in a microfluidic channel network |
EP1663497B2 (en) | 2003-09-05 | 2020-03-25 | Stokes Bio Limited | A microfluidic analysis system |
WO2005024054A1 (en) | 2003-09-05 | 2005-03-17 | Royal Women's Hospital | Diagnostic marker for ovarian cancer |
US7354706B2 (en) | 2003-09-09 | 2008-04-08 | The Regents Of The University Of Colorado, A Body Corporate | Use of photopolymerization for amplification and detection of a molecular recognition event |
US7824856B2 (en) | 2003-09-10 | 2010-11-02 | Althea Technologies, Inc. | Expression profiling using microarrays |
WO2005029041A2 (en) | 2003-09-19 | 2005-03-31 | Applera Corporation | High density sequence detection methods and apparatus |
US7504214B2 (en) | 2003-09-19 | 2009-03-17 | Biotheranostics, Inc. | Predicting outcome with tamoxifen in breast cancer |
EP2186914A3 (en) | 2003-09-22 | 2010-07-21 | Trisogen Biotechnology Limited Partnership | Methods useful for detecting an alteration in a locus copy number |
US20060269971A1 (en) | 2003-09-26 | 2006-11-30 | Mount Sinai Hospital | Methods for detecting prostate cancer |
EP1676122A2 (en) | 2003-09-30 | 2006-07-05 | Singulex, Inc. | Methods for enhancing the analysis of particle detection |
US7332280B2 (en) | 2003-10-14 | 2008-02-19 | Ronald Levy | Classification of patients having diffuse large B-cell lymphoma based upon gene expression |
US20050221341A1 (en) | 2003-10-22 | 2005-10-06 | Shimkets Richard A | Sequence-based karyotyping |
WO2005041884A2 (en) | 2003-10-31 | 2005-05-12 | Engineered Release Systems, Inc | Polymer-based microstructures |
US7204431B2 (en) | 2003-10-31 | 2007-04-17 | Agilent Technologies, Inc. | Electrospray ion source for mass spectroscopy |
US20050152908A1 (en) | 2003-11-03 | 2005-07-14 | Genenews Inc. | Liver cancer biomarkers |
GB0325653D0 (en) | 2003-11-03 | 2003-12-10 | Medical Res Council | CST emulsions |
JP2007512811A (en) | 2003-11-10 | 2007-05-24 | インベスチゲン, インコーポレイテッド | Methods for preparing nucleic acids for detection |
US20050103690A1 (en) | 2003-11-19 | 2005-05-19 | Aisin Seiki Kabushiki Kaisha | Micro liquid control system |
EP1691792A4 (en) * | 2003-11-24 | 2008-05-28 | Yeda Res & Dev | Compositions and methods for in vitro sorting of molecular and cellular libraries |
EP1697750B1 (en) * | 2003-12-01 | 2013-03-20 | Dako Denmark A/S | Methods and compositions for immuno-histochemical detection |
US7736890B2 (en) | 2003-12-31 | 2010-06-15 | President And Fellows Of Harvard College | Assay device and method |
JP4437202B2 (en) | 2004-01-09 | 2010-03-24 | 学校法人慶應義塾 | Telemedicine system for pigmentation site |
US7389879B2 (en) | 2004-01-21 | 2008-06-24 | Hewlett-Packard Development Company, L.P. | Sorting particles |
US7569662B2 (en) | 2004-01-27 | 2009-08-04 | Compugen Ltd | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer |
WO2005073410A2 (en) | 2004-01-28 | 2005-08-11 | 454 Corporation | Nucleic acid amplification with continuous flow emulsion |
US20050186215A1 (en) | 2004-02-04 | 2005-08-25 | Kwok Tim T. | CUDR as biomarker for cancer progression and therapeutic response |
US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
US7507532B2 (en) | 2004-03-08 | 2009-03-24 | Medigen Biotechnology Corporation | Cancer specific gene MH15 |
KR100552706B1 (en) | 2004-03-12 | 2006-02-20 | 삼성전자주식회사 | Method and apparatus for nucleic acid amplification |
JP4938451B2 (en) | 2004-03-23 | 2012-05-23 | オンコセラピー・サイエンス株式会社 | Methods for diagnosis of non-small cell lung cancer |
US7157233B2 (en) | 2004-03-24 | 2007-01-02 | Tripath Imaging, Inc. | Methods and compositions for the detection of cervical disease |
KR100885177B1 (en) | 2004-04-12 | 2009-02-23 | 학교법인 포항공과대학교 | Oligonucleotide for detecting target dna or rna |
US7665393B2 (en) | 2004-04-22 | 2010-02-23 | Black & Decker Inc. | Table saw guard |
US8696952B2 (en) | 2004-04-23 | 2014-04-15 | Eugenia Kumacheva | Method of producing polymeric particles with selected size, shape, morphology and composition |
US7622281B2 (en) | 2004-05-20 | 2009-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for clonal amplification of nucleic acid |
US7828175B2 (en) | 2004-05-21 | 2010-11-09 | Pepsico, Inc. | Beverage dispensing system with a head capable of dispensing plural different beverages |
WO2006007207A2 (en) | 2004-05-25 | 2006-01-19 | Helicos Biosciences Corporation | Methods and devices for nucleic acid sequence determination |
US7799553B2 (en) | 2004-06-01 | 2010-09-21 | The Regents Of The University Of California | Microfabricated integrated DNA analysis system |
WO2005118138A1 (en) | 2004-06-04 | 2005-12-15 | Crystal Vision Microsystems Llc | Device and process for continuous on-chip flow injection analysis |
WO2006009910A2 (en) | 2004-06-17 | 2006-01-26 | The Regents Of The University Of California | Time-resolved optometric fluorescence detection for skin diagnostics |
US7991557B2 (en) | 2004-06-19 | 2011-08-02 | Genenews Corporation | Computer system and methods for constructing biological classifiers and uses thereof |
US20070154889A1 (en) | 2004-06-25 | 2007-07-05 | Veridex, Llc | Methods and reagents for the detection of melanoma |
EP1796828A1 (en) | 2004-07-02 | 2007-06-20 | VersaMatrix A/S | Spherical radiofrequency-encoded beads |
US7655470B2 (en) | 2004-10-29 | 2010-02-02 | University Of Chicago | Method for manipulating a plurality of plugs and performing reactions therein in microfluidic systems |
CA2573112A1 (en) | 2004-07-09 | 2006-01-26 | Tripath Imaging, Inc. | Methods and compositions for the detection of ovarian cancer |
US7670792B2 (en) | 2004-07-14 | 2010-03-02 | The Regents Of The University Of California | Biomarkers for early detection of ovarian cancer |
WO2006015308A2 (en) | 2004-07-29 | 2006-02-09 | California Institute Of Technology | Modular microfluidic packaging system |
US7405002B2 (en) | 2004-08-04 | 2008-07-29 | Agency For Science, Technology And Research | Coated water-soluble nanoparticles comprising semiconductor core and silica coating |
JP2006058652A (en) | 2004-08-20 | 2006-03-02 | Toshiba Corp | Toner |
US7759111B2 (en) | 2004-08-27 | 2010-07-20 | The Regents Of The University Of California | Cell encapsulation microfluidic device |
US20060068398A1 (en) | 2004-09-24 | 2006-03-30 | Cepheid | Universal and target specific reagent beads for nucleic acid amplification |
JPWO2006035773A1 (en) | 2004-09-30 | 2008-05-15 | 日本碍子株式会社 | Droplet ejection piezoelectric device |
US7698287B2 (en) | 2004-09-30 | 2010-04-13 | Microsoft Corporation | Design of spreadsheet functions for working with tables of data |
US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
US20060078894A1 (en) | 2004-10-12 | 2006-04-13 | Winkler Matthew M | Methods and compositions for analyzing nucleic acids |
US7482123B2 (en) | 2004-11-05 | 2009-01-27 | The Regents Of The University Of California | Biomarkers for prostate cancer metastasis |
US7416851B2 (en) | 2004-11-08 | 2008-08-26 | Institut Pasteur | Method of diagnosis/prognosis of human chronic lymphocytic leukemia comprising the profiling of LPL/ADAM genes |
US20130071836A9 (en) | 2004-11-08 | 2013-03-21 | Sungwhan An | Colon cancer biomarker discovery |
US20080004436A1 (en) | 2004-11-15 | 2008-01-03 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Directed Evolution and Selection Using in Vitro Compartmentalization |
WO2006060653A2 (en) | 2004-11-30 | 2006-06-08 | Veridex Llc | Lung cancer prognostics |
WO2006062895A2 (en) | 2004-12-06 | 2006-06-15 | Cambridge Research And Instrumentation, Inc. | Systems and methods for in-vivo optical imaging and measurement |
US20060160762A1 (en) | 2004-12-13 | 2006-07-20 | Children's Medical Center Corporation | Methods for the treatment, diagnosis, and prognosis of cancer |
US8299216B2 (en) | 2005-01-07 | 2012-10-30 | The Johns Hopkins University | Biomarkers for melanoma |
US7392908B2 (en) | 2005-01-12 | 2008-07-01 | Beckman Coulter, Inc. | Methods and apparatus for sorting particles hydraulically |
WO2006078841A1 (en) | 2005-01-21 | 2006-07-27 | President And Fellows Of Harvard College | Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles |
EP1845837B1 (en) | 2005-01-21 | 2013-05-29 | Verisante Technology, Inc. | Method and apparatus for measuring cancerous changes from reflectance spectral measurements obtained during endoscopic imaging |
US7442507B2 (en) | 2005-01-24 | 2008-10-28 | New York University School Of Medicine | Methods for detecting circulating mutant BRAF DNA |
WO2006081473A2 (en) | 2005-01-28 | 2006-08-03 | Children's Medical Center Corporation | Methods for diagnosis and prognosis of epithelial cancers |
EP1844162B1 (en) | 2005-02-01 | 2014-10-15 | Applied Biosystems, LLC | Method for identifying a sequence in a polynucleotide |
JP4047336B2 (en) | 2005-02-08 | 2008-02-13 | 独立行政法人科学技術振興機構 | Cell sorter chip with gel electrode |
US7407757B2 (en) | 2005-02-10 | 2008-08-05 | Population Genetics Technologies | Genetic analysis by sequence-specific sorting |
US7393665B2 (en) | 2005-02-10 | 2008-07-01 | Population Genetics Technologies Ltd | Methods and compositions for tagging and identifying polynucleotides |
CA2597271A1 (en) | 2005-02-16 | 2006-08-24 | Dana-Farber Cancer Institute | Methods of detecting ovarian cancer |
JP2008536098A (en) | 2005-02-17 | 2008-09-04 | チルドレンズ メディカル センター コーポレイション | ADAMTS-7 as a biomarker for epithelial derived cancer |
EP1849002A4 (en) | 2005-02-18 | 2008-08-20 | Childrens Medical Center | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
ATE538213T1 (en) | 2005-02-18 | 2012-01-15 | Canon Us Life Sciences Inc | DEVICE AND METHOD FOR IDENTIFYING GENOMIC DNA OF ORGANISMS |
US7666595B2 (en) | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
WO2006092959A1 (en) | 2005-03-01 | 2006-09-08 | Rohm Co., Ltd | Microchannel and microfluid chip |
CA2599683A1 (en) | 2005-03-04 | 2006-09-14 | President And Fellows Of Harvard College | Method and apparatus for forming multiple emulsions |
US20070054119A1 (en) | 2005-03-04 | 2007-03-08 | Piotr Garstecki | Systems and methods of forming particles |
CN101133529A (en) | 2005-03-04 | 2008-02-27 | 独立行政法人科学技术振兴机构 | Wide-band optical amplifier |
EP1869462B1 (en) | 2005-03-11 | 2013-05-08 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
FR2882939B1 (en) | 2005-03-11 | 2007-06-08 | Centre Nat Rech Scient | FLUIDIC SEPARATION DEVICE |
US20060234264A1 (en) | 2005-03-14 | 2006-10-19 | Affymetrix, Inc. | Multiplex polynucleotide synthesis |
WO2006099579A2 (en) | 2005-03-16 | 2006-09-21 | Applera Corporation | Compositions and methods for clonal amplification and analysis of polynucleotides |
ATE529734T1 (en) | 2005-04-06 | 2011-11-15 | Harvard College | MOLECULAR CHARACTERIZATION WITH CARBON NANOTUBE CONTROL |
US7570988B2 (en) | 2005-05-02 | 2009-08-04 | Wisconsin Alumni Research Foundation | Method for extraction of optical properties from diffuse reflectance spectra |
US7918244B2 (en) | 2005-05-02 | 2011-04-05 | Massachusetts Institute Of Technology | Microfluidic bubble logic devices |
US8084001B2 (en) | 2005-05-02 | 2011-12-27 | Cornell Research Foundation, Inc. | Photoluminescent silica-based sensors and methods of use |
WO2006122311A2 (en) | 2005-05-11 | 2006-11-16 | The Trustees Of The University Of Pennsylvania | Microfluidic chip |
CA2606750C (en) | 2005-05-11 | 2015-11-24 | Nanolytics, Inc. | Method and device for conducting biochemical or chemical reactions at multiple temperatures |
EP1891201A4 (en) | 2005-05-18 | 2011-11-09 | Cornell Res Foundation Inc | Pharmacokinetic-based culture system with biological barriers |
EP2703499A1 (en) | 2005-06-02 | 2014-03-05 | Fluidigm Corporation | Analysis using microfluidic partitioning devices to generate single cell samples |
US8407013B2 (en) | 2005-06-07 | 2013-03-26 | Peter K. Rogan | AB initio generation of single copy genomic probes |
US7368242B2 (en) | 2005-06-14 | 2008-05-06 | Affymetrix, Inc. | Method and kits for multiplex hybridization assays |
US7494776B2 (en) | 2005-07-07 | 2009-02-24 | Beckman Coulter, Inc. | Labeled complementary oligonucleotides to detect oligonucleotide-linked ligands |
WO2007011867A2 (en) | 2005-07-15 | 2007-01-25 | Applera Corporation | Fluid processing device and method |
GB0514936D0 (en) | 2005-07-20 | 2005-08-24 | Solexa Ltd | Preparation of templates for nucleic acid sequencing |
FR2888912B1 (en) | 2005-07-25 | 2007-08-24 | Commissariat Energie Atomique | METHOD FOR CONTROLLING COMMUNICATION BETWEEN TWO ZONES BY ELECTROWRINKING, DEVICE COMPRISING ISOLABLE ZONES AND OTHERS AND METHOD FOR PRODUCING SUCH DEVICE |
US7632562B2 (en) | 2005-08-04 | 2009-12-15 | Eastman Kodak Company | Universal print media |
JP4756948B2 (en) | 2005-08-08 | 2011-08-24 | ベイバイオサイエンス株式会社 | Flow cytometer and flow cytometry method |
FR2893626B1 (en) | 2005-11-18 | 2008-01-04 | Inst Francais Du Petrole | WELL FLUID COMPRISING A FLUORINATED LIQUID PHASE |
WO2007024778A2 (en) | 2005-08-22 | 2007-03-01 | Applera Corporation | Device, system and method for depositing processed immiscible-fluid-discrete-volumes |
US7666593B2 (en) | 2005-08-26 | 2010-02-23 | Helicos Biosciences Corporation | Single molecule sequencing of captured nucleic acids |
US7915030B2 (en) | 2005-09-01 | 2011-03-29 | Canon U.S. Life Sciences, Inc. | Method and molecular diagnostic device for detection, analysis and identification of genomic DNA |
JP5306651B2 (en) | 2005-09-02 | 2013-10-02 | ポーラ化成工業株式会社 | Method for determining skin condition and method for predicting skin thickness |
US7556776B2 (en) | 2005-09-08 | 2009-07-07 | President And Fellows Of Harvard College | Microfluidic manipulation of fluids and reactions |
US20090098057A1 (en) | 2007-10-16 | 2009-04-16 | Shiying Zheng | Silica-cored carrier particle |
EP1938101A2 (en) * | 2005-09-13 | 2008-07-02 | Fluidigm Corporation | Microfluidic assay devices and methods |
US8734003B2 (en) | 2005-09-15 | 2014-05-27 | Alcatel Lucent | Micro-chemical mixing |
GB2429385C (en) | 2005-09-23 | 2008-04-24 | Astron Clinica Ltd | Image processing method and apparatus. |
SI1948816T1 (en) | 2005-10-24 | 2012-04-30 | Johns Hopkins University Johns Hopkins Technology Transfer | Improved methods for beaming |
JP2009515167A (en) | 2005-11-02 | 2009-04-09 | バイエル ヘルスケア エルエルシー | Cancer prediction and prognosis testing methods, and cancer treatment monitoring |
WO2007061284A1 (en) | 2005-11-22 | 2007-05-31 | Plant Research International B.V. | Multiplex nucleic acid detection |
US7358231B1 (en) | 2005-12-01 | 2008-04-15 | Applera Corporation | Pancreatic cancer secreted targets and uses thereof |
US7846664B2 (en) | 2005-12-07 | 2010-12-07 | The Regents Of The University Of California | Diagnosis and treatment of chronic lymphocytic leukemia (CLL) |
WO2007070572A2 (en) | 2005-12-12 | 2007-06-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Probe for nucleic acid sequencing and methods of use |
EP1966608A1 (en) | 2005-12-21 | 2008-09-10 | Roche Diagnostics GmbH | Method of assessing colorectal cancer by measuring hemoglobin and m2-pk in a stool sample |
ES2277785B1 (en) | 2005-12-21 | 2008-06-16 | Oryzon Genomics, S.A. | METHOD OF DIFFERENTIAL EXPRESSION ANALYSIS IN COLORECTAL CANCER. |
WO2007087310A2 (en) | 2006-01-23 | 2007-08-02 | Population Genetics Technologies Ltd. | Nucleic acid analysis using sequence tokens |
US7537897B2 (en) | 2006-01-23 | 2009-05-26 | Population Genetics Technologies, Ltd. | Molecular counting |
WO2007090076A2 (en) | 2006-01-27 | 2007-08-09 | Tripath Imaging, Inc. | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor |
DE602007009811D1 (en) | 2006-01-27 | 2010-11-25 | Harvard College | COALESCENCE FLUIDER DROPLET |
HUE030215T2 (en) | 2006-02-02 | 2017-04-28 | Univ Leland Stanford Junior | Non-invasive fetal genetic screening by digital analysis |
US8735169B2 (en) | 2006-02-07 | 2014-05-27 | Stokes Bio Limited | Methods for analyzing agricultural and environmental samples |
WO2007091228A1 (en) | 2006-02-07 | 2007-08-16 | Stokes Bio Limited | A liquid bridge and system |
CN101395280A (en) | 2006-03-01 | 2009-03-25 | 凯津公司 | High throughput sequence-based detection of snps using ligation assays |
US20070292869A1 (en) | 2006-03-02 | 2007-12-20 | Ppd Biomarker Discovery Sciences, Llc | Compositions and Methods for Analyzing Renal Cancer |
EP1996729A2 (en) | 2006-03-03 | 2008-12-03 | Veridex, LLC | Molecular assay to predict recurrence of dukes' b colon cancer |
JP2009530457A (en) | 2006-03-21 | 2009-08-27 | ディーエスエム アイピー アセッツ ビー.ブイ. | Fine particles containing crosslinked polymer |
EP2674435A3 (en) | 2006-03-24 | 2014-04-30 | Phenomenome Discoveries Inc. | Biomarkers useful for diagnosing prostate cancer, and methods thereof |
WO2007114794A1 (en) | 2006-03-31 | 2007-10-11 | Nam Trung Nguyen | Active control for droplet-based microfluidics |
WO2007123744A2 (en) | 2006-03-31 | 2007-11-01 | Solexa, Inc. | Systems and devices for sequence by synthesis analysis |
US8613889B2 (en) | 2006-04-13 | 2013-12-24 | Advanced Liquid Logic, Inc. | Droplet-based washing |
US8492168B2 (en) | 2006-04-18 | 2013-07-23 | Advanced Liquid Logic Inc. | Droplet-based affinity assays |
US7282337B1 (en) | 2006-04-14 | 2007-10-16 | Helicos Biosciences Corporation | Methods for increasing accuracy of nucleic acid sequencing |
US7439014B2 (en) | 2006-04-18 | 2008-10-21 | Advanced Liquid Logic, Inc. | Droplet-based surface modification and washing |
US8980198B2 (en) * | 2006-04-18 | 2015-03-17 | Advanced Liquid Logic, Inc. | Filler fluids for droplet operations |
US7815871B2 (en) * | 2006-04-18 | 2010-10-19 | Advanced Liquid Logic, Inc. | Droplet microactuator system |
US7901947B2 (en) | 2006-04-18 | 2011-03-08 | Advanced Liquid Logic, Inc. | Droplet-based particle sorting |
US7702468B2 (en) | 2006-05-03 | 2010-04-20 | Population Diagnostics, Inc. | Evaluating genetic disorders |
US20070259368A1 (en) | 2006-05-03 | 2007-11-08 | Genomictree, Inc. | Gastric cancer biomarker discovery |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
EP2636755A1 (en) | 2006-05-26 | 2013-09-11 | AltheaDx Incorporated | Biochemical analysis of partitioned cells |
US20080081333A1 (en) | 2006-05-26 | 2008-04-03 | University Of Maryland, Baltimore | Methylated promoters as biomarkers of colon cancer |
FR2901717A1 (en) | 2006-05-30 | 2007-12-07 | Centre Nat Rech Scient | METHOD FOR TREATING DROPS IN A MICROFLUIDIC CIRCUIT |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8715934B2 (en) | 2006-06-19 | 2014-05-06 | The Johns Hopkins University | Single-molecule PCR on microparticles in water-in-oil emulsions |
US20080050723A1 (en) | 2006-08-23 | 2008-02-28 | Nabil Belacel | Molecular method for diagnosis of colon cancer |
EP2061909A2 (en) | 2006-08-24 | 2009-05-27 | Illumina Cambridge Limited | Method for retaining even coverage of short insert libraries |
KR20090046876A (en) | 2006-08-31 | 2009-05-11 | 도요 세이칸 가부시키가이샤 | Nucleic acid amplification method |
US7811778B2 (en) | 2006-09-06 | 2010-10-12 | Vanderbilt University | Methods of screening for gastrointestinal cancer |
DE102006042040B4 (en) | 2006-09-07 | 2013-04-18 | Siemens Audiologische Technik Gmbh | A method of adapting a hearing aid using a genetic feature and arrangement for performing the method |
US20080081330A1 (en) | 2006-09-28 | 2008-04-03 | Helicos Biosciences Corporation | Method and devices for analyzing small RNA molecules |
WO2008042870A2 (en) | 2006-09-29 | 2008-04-10 | The Administrators Of The Tulane Educational Fund | Methods and devices for simultaneously monitoring microscopic particles in suspension |
AU2007324128B2 (en) | 2006-10-10 | 2013-10-10 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations |
TWM319361U (en) | 2006-10-20 | 2007-09-21 | Tai Sol Electronics Co Ltd | Flexible heat pipe |
US8841116B2 (en) | 2006-10-25 | 2014-09-23 | The Regents Of The University Of California | Inline-injection microdevice and microfabricated integrated DNA analysis system using same |
US20110045462A1 (en) | 2006-11-14 | 2011-02-24 | The Regents Of The University Of California | Digital analysis of gene expression |
US8026055B2 (en) | 2006-11-15 | 2011-09-27 | University Health Network | Materials and methods for prognosing lung cancer survival |
TW200825414A (en) | 2006-12-08 | 2008-06-16 | Univ Nat Taiwan | Biomarker molecule of gastrointestinal disease and measurement method thereof |
US20080213377A1 (en) | 2006-12-08 | 2008-09-04 | Bhatia Sangeeta N | Delivery of Nanoparticles and/or Agents to Cells |
WO2008073290A1 (en) | 2006-12-08 | 2008-06-19 | The Board Of Trustees Of The University Of Arkansas | Tp53 gene expression and uses thereof |
US8349167B2 (en) | 2006-12-14 | 2013-01-08 | Life Technologies Corporation | Methods and apparatus for detecting molecular interactions using FET arrays |
US20100093107A1 (en) | 2006-12-14 | 2010-04-15 | University Of Massachusetts | Polymer-protein substrates for immunosorbent fluorescence assays |
CA2672315A1 (en) | 2006-12-14 | 2008-06-26 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes using large scale fet arrays |
JP5340167B2 (en) | 2006-12-21 | 2013-11-13 | ジェン−プロウブ インコーポレイテッド | Methods and compositions for nucleic acid amplification |
US8338166B2 (en) | 2007-01-04 | 2012-12-25 | Lawrence Livermore National Security, Llc | Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture |
US20080171078A1 (en) | 2007-01-12 | 2008-07-17 | Mark Gray | Uniformly sized liposomes |
US7807393B2 (en) | 2007-01-29 | 2010-10-05 | Northwestern University | Biomarkers for prostate cancer |
US20090170085A1 (en) | 2007-02-02 | 2009-07-02 | Orion Genomics Llc | Gene Methylation in Head and Neck Cancer Diagnosis |
WO2008093098A2 (en) | 2007-02-02 | 2008-08-07 | Illumina Cambridge Limited | Methods for indexing samples and sequencing multiple nucleotide templates |
CN101715483A (en) | 2007-02-05 | 2010-05-26 | 微芯片生物工艺学股份有限公司 | microfluidic and nanofluidic devices, systems, and applications |
WO2008097559A2 (en) | 2007-02-06 | 2008-08-14 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
WO2008109176A2 (en) | 2007-03-07 | 2008-09-12 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
CA2680549A1 (en) | 2007-03-12 | 2008-09-18 | Alan D. D'andrea | Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents |
EP2479552B1 (en) | 2007-04-02 | 2015-09-02 | Acoustic Cytometry Systems, Inc. | Methods for enhanced analysis of acoustic field focused cells and particles |
US20090062144A1 (en) | 2007-04-03 | 2009-03-05 | Nancy Lan Guo | Gene signature for prognosis and diagnosis of lung cancer |
US8290625B2 (en) | 2007-04-04 | 2012-10-16 | Beckman Coulter, Inc. | Flow cytometer sorter |
WO2008130623A1 (en) | 2007-04-19 | 2008-10-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US8691164B2 (en) | 2007-04-20 | 2014-04-08 | Celula, Inc. | Cell sorting system and methods |
WO2008134153A1 (en) | 2007-04-23 | 2008-11-06 | Advanced Liquid Logic, Inc. | Bead-based multiplexed analytical methods and instrumentation |
BRPI0811503A2 (en) | 2007-05-04 | 2014-11-18 | Dermtech Int | MELANOMA DIAGNOSIS BY NUCLEIC ACID ANALYSIS |
US7901888B2 (en) | 2007-05-09 | 2011-03-08 | The Regents Of The University Of California | Multigene diagnostic assay for malignant thyroid neoplasm |
JP2010528608A (en) | 2007-06-01 | 2010-08-26 | 454 ライフ サイエンシーズ コーポレイション | System and method for identifying individual samples from complex mixtures |
WO2009045579A2 (en) | 2007-06-14 | 2009-04-09 | The Regents Of The University Of California | Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics |
US7820386B2 (en) | 2007-06-15 | 2010-10-26 | National Defense Medical Center | Cancer screening method |
WO2009012340A2 (en) | 2007-07-16 | 2009-01-22 | California Institute Of Technology | Microfluidic devices, methods and systems for detecting target molecules |
DE102007034020A1 (en) | 2007-07-20 | 2009-01-22 | Biotronik Crm Patent Ag | Active element and battery and method of making same |
KR101829565B1 (en) | 2007-07-23 | 2018-03-29 | 더 차이니즈 유니버시티 오브 홍콩 | Determining a nucleic acid sequence imbalance |
WO2009015296A1 (en) | 2007-07-24 | 2009-01-29 | The Regents Of The University Of California | Microfabricated dropley generator |
CN101842159B (en) | 2007-08-09 | 2014-09-24 | 赛路拉公司 | Methods and devices for correlated, multi-parameter single cell measurements and recovery of remnant biological material |
WO2009029229A2 (en) | 2007-08-24 | 2009-03-05 | President And Fellows Of Harvard College | Ferrofluid emulsions, particles, and systems and methods for making and using the same |
WO2009032974A2 (en) | 2007-09-06 | 2009-03-12 | Tripath Imaging, Inc. | Nucleic acid-based methods for the detection of ovarian cancer |
BRPI0816393A2 (en) | 2007-09-07 | 2015-03-03 | Fluidigm Corp | METHOD FOR DETERMINING THE NUMBER OF COPIES REGARDING A TARGET POLINUCLEOTIDE SEQUENCE IN A GENOME OF AN INDIVIDUAL |
US20100304378A1 (en) | 2007-09-17 | 2010-12-02 | Universite De Strasbourg | Method for Detecting or Quantifying a Truncating Mutation |
WO2009036525A2 (en) | 2007-09-21 | 2009-03-26 | Katholieke Universiteit Leuven | Tools and methods for genetic tests using next generation sequencing |
US8268564B2 (en) | 2007-09-26 | 2012-09-18 | President And Fellows Of Harvard College | Methods and applications for stitched DNA barcodes |
WO2009049214A2 (en) | 2007-10-12 | 2009-04-16 | Northwestern University | Inhibition and treatment of prostate cancer metastasis |
US20100086914A1 (en) | 2008-10-03 | 2010-04-08 | Roche Molecular Systems, Inc. | High resolution, high throughput hla genotyping by clonal sequencing |
ATE509123T1 (en) | 2007-10-16 | 2011-05-15 | Hoffmann La Roche | HIGH-RESOLUTION HIGH-THROUGHPUT HLA GENOTYPING USING CLONAL SEQUENCING |
EP2212437A4 (en) | 2007-11-07 | 2011-09-28 | Univ British Columbia | Microfluidic device and method of using same |
US7923517B2 (en) | 2007-11-09 | 2011-04-12 | Ricoh Company, Ltd. | Polymer microparticles and production method for the same |
US8462269B2 (en) | 2007-11-16 | 2013-06-11 | Mediatek Inc. | Devices and methods for extracting a synchronization signal from a video signal |
US8592150B2 (en) | 2007-12-05 | 2013-11-26 | Complete Genomics, Inc. | Methods and compositions for long fragment read sequencing |
WO2009085929A1 (en) | 2007-12-20 | 2009-07-09 | The Polymer Technology Group, Inc. | Hybrid polyurethane block copolymers with thermoplastic processability and thermoset properties |
US9797010B2 (en) | 2007-12-21 | 2017-10-24 | President And Fellows Of Harvard College | Systems and methods for nucleic acid sequencing |
KR20090127893A (en) | 2007-12-26 | 2009-12-14 | 아크레이 가부시키가이샤 | Method for amplifying target nucleic acid sequence and probe used for the same |
US9170060B2 (en) | 2008-01-22 | 2015-10-27 | Lawrence Livermore National Security, Llc | Rapid microfluidic thermal cycler for nucleic acid amplification |
US20090226971A1 (en) | 2008-01-22 | 2009-09-10 | Neil Reginald Beer | Portable Rapid Microfluidic Thermal Cycler for Extremely Fast Nucleic Acid Amplification |
NZ587375A (en) | 2008-01-24 | 2013-04-26 | Balter Inc | A method and system using optical transfer diagnosis for discriminating between malignant and benign tissue lesions |
NO2255173T3 (en) | 2008-03-18 | 2018-06-23 | ||
US20090246788A1 (en) | 2008-04-01 | 2009-10-01 | Roche Nimblegen, Inc. | Methods and Assays for Capture of Nucleic Acids |
JP2009265751A (en) | 2008-04-22 | 2009-11-12 | Oki Electric Ind Co Ltd | Character recognition device, optical character recognition system and character recognition program |
WO2009134395A2 (en) | 2008-04-28 | 2009-11-05 | President And Fellows Of Harvard College | Microfluidic device for storage and well-defined arrangement of droplets |
WO2009135205A2 (en) | 2008-05-02 | 2009-11-05 | Advanced Liquid Logic, Inc. | Droplet actuator techniques using coagulatable samples |
US8852952B2 (en) | 2008-05-03 | 2014-10-07 | Advanced Liquid Logic, Inc. | Method of loading a droplet actuator |
US20100075436A1 (en) | 2008-05-06 | 2010-03-25 | Urdea Michael S | Methods for use with nanoreactors |
US9068181B2 (en) | 2008-05-23 | 2015-06-30 | The General Hospital Corporation | Microfluidic droplet encapsulation |
JP2011525811A (en) | 2008-06-27 | 2011-09-29 | マサチューセッツ インスティテュート オブ テクノロジー | Microfluidic droplets for metabolic engineering and other applications |
NZ590166A (en) | 2008-06-30 | 2013-09-27 | Microbix Biosystems Inc | Method and apparatus for sorting cells |
US20110274706A1 (en) | 2010-05-04 | 2011-11-10 | General Electric Company | Nucleic acid delivery vehicle and uses thereof |
WO2010005593A1 (en) | 2008-07-11 | 2010-01-14 | President And Fellows Of Harvard College | Systems and methods of droplet-based selection |
FR2934050B1 (en) | 2008-07-15 | 2016-01-29 | Univ Paris Curie | METHOD AND DEVICE FOR READING EMULSION |
US20220050108A1 (en) | 2008-07-18 | 2022-02-17 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
EP4047367A1 (en) | 2008-07-18 | 2022-08-24 | Bio-Rad Laboratories, Inc. | Method for detecting target analytes with droplet libraries |
US20100035252A1 (en) | 2008-08-08 | 2010-02-11 | Ion Torrent Systems Incorporated | Methods for sequencing individual nucleic acids under tension |
PL3663411T3 (en) | 2008-08-12 | 2022-02-07 | Stokes Bio Limited | Methods for digital pcr |
US9180453B2 (en) | 2008-08-15 | 2015-11-10 | University Of Washington | Method and apparatus for the discretization and manipulation of sample volumes |
EP2329043B1 (en) | 2008-08-26 | 2014-12-17 | Becton Dickinson and Company | Assay for chlamydia trachomatis by amplification and detection of chlamydia trachomatis cytotoxin gene |
US8586310B2 (en) | 2008-09-05 | 2013-11-19 | Washington University | Method for multiplexed nucleic acid patch polymerase chain reaction |
WO2010033200A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Creation of libraries of droplets and related species |
US9156010B2 (en) | 2008-09-23 | 2015-10-13 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
US9132394B2 (en) | 2008-09-23 | 2015-09-15 | Bio-Rad Laboratories, Inc. | System for detection of spaced droplets |
US20100162643A1 (en) | 2008-10-02 | 2010-07-01 | Blomberg Jerome O | Curbless multiple skylight and smoke vent system |
US20100301398A1 (en) | 2009-05-29 | 2010-12-02 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
US8546128B2 (en) | 2008-10-22 | 2013-10-01 | Life Technologies Corporation | Fluidics system for sequential delivery of reagents |
US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
US9080211B2 (en) | 2008-10-24 | 2015-07-14 | Epicentre Technologies Corporation | Transposon end compositions and methods for modifying nucleic acids |
WO2010056728A1 (en) | 2008-11-11 | 2010-05-20 | Helicos Biosciences Corporation | Nucleic acid encoding for multiplex analysis |
US9080056B2 (en) | 2008-11-26 | 2015-07-14 | University College Cork—National University of Ireland, Cork | Process for preparing silica microparticles |
US9404924B2 (en) | 2008-12-04 | 2016-08-02 | Massachusetts Institute Of Technology | Method of performing one-step, single cell RT-PCR |
US11634747B2 (en) | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
JP5382852B2 (en) | 2009-02-06 | 2014-01-08 | 株式会社オンチップ・バイオテクノロジーズ | Disposable chip type flow cell and flow cytometer using the same |
JP5457222B2 (en) | 2009-02-25 | 2014-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | Miniaturized high-throughput nucleic acid analysis |
JP2010198393A (en) | 2009-02-26 | 2010-09-09 | Alpine Electronics Inc | Map display device |
US8481698B2 (en) | 2009-03-19 | 2013-07-09 | The President And Fellows Of Harvard College | Parallel proximity ligation event analysis |
EP2230312A1 (en) | 2009-03-19 | 2010-09-22 | Helmholtz-Zentrum für Infektionsforschung GmbH | Probe compound for detecting and isolating enzymes and means and methods using the same |
CN102439177B (en) | 2009-04-02 | 2014-10-01 | 弗卢伊蒂格姆公司 | Multi-primer amplification method for barcoding of target nucleic acids |
CN101892291A (en) | 2009-05-08 | 2010-11-24 | 中国科学院苏州纳米技术与纳米仿生研究所 | Universal tag, probe and detection method for biomolecule multi-target detection |
FR2945545B1 (en) | 2009-05-14 | 2011-08-05 | Univ Aix Marseille Ii | METHOD FOR DETECTION OF PROCARYOTE DNA EXTRACTED FROM A SAMPLE SAMPLE |
US8574835B2 (en) | 2009-05-29 | 2013-11-05 | Life Technologies Corporation | Scaffolded nucleic acid polymer particles and methods of making and using |
US8673627B2 (en) | 2009-05-29 | 2014-03-18 | Life Technologies Corporation | Apparatus and methods for performing electrochemical reactions |
US9757698B2 (en) | 2009-06-26 | 2017-09-12 | President And Fellows Of Harvard College | Fluid injection |
JP4528885B1 (en) | 2009-06-29 | 2010-08-25 | 株式会社東芝 | Sample analysis method and assay kit used therefor |
US9364831B2 (en) | 2009-08-08 | 2016-06-14 | The Regents Of The University Of California | Pulsed laser triggered high speed microfluidic switch and applications in fluorescent activated cell sorting |
WO2011020011A2 (en) | 2009-08-13 | 2011-02-17 | Advanced Liquid Logic, Inc. | Droplet actuator and droplet-based techniques |
RU2552215C2 (en) | 2009-09-01 | 2015-06-10 | Конинклейке Филипс Электроникс Н.В. | Device and method of selecting nucleic acids by means of micro-arrays |
CA2767056C (en) | 2009-09-02 | 2018-12-04 | Bio-Rad Laboratories, Inc. | System for mixing fluids by coalescence of multiple emulsions |
US9625454B2 (en) | 2009-09-04 | 2017-04-18 | The Research Foundation For The State University Of New York | Rapid and continuous analyte processing in droplet microfluidic devices |
WO2011042564A1 (en) | 2009-10-09 | 2011-04-14 | Universite De Strasbourg | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
JP2013511991A (en) | 2009-11-25 | 2013-04-11 | クアンタライフ, インコーポレイテッド | Methods and compositions for detecting genetic material |
US9315857B2 (en) | 2009-12-15 | 2016-04-19 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse label-tags |
EP2336354A1 (en) | 2009-12-18 | 2011-06-22 | Roche Diagnostics GmbH | A method for the detection of a RNA molecule, a kit and a use related thereof |
EP2517025B1 (en) | 2009-12-23 | 2019-11-27 | Bio-Rad Laboratories, Inc. | Methods for reducing the exchange of molecules between droplets |
US10101261B2 (en) | 2010-01-15 | 2018-10-16 | On-Chip Biotechnologies Co., Ltd. | Disposable chip-type flow cell and cell sorter using the same |
US20120010085A1 (en) | 2010-01-19 | 2012-01-12 | Rava Richard P | Methods for determining fraction of fetal nucleic acids in maternal samples |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
EP2534267B1 (en) | 2010-02-12 | 2018-04-11 | Raindance Technologies, Inc. | Digital analyte analysis |
US9494520B2 (en) | 2010-02-12 | 2016-11-15 | Raindance Technologies, Inc. | Digital analyte analysis |
US20110257031A1 (en) | 2010-02-12 | 2011-10-20 | Life Technologies Corporation | Nucleic acid, biomolecule and polymer identifier codes |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
JP5901046B2 (en) | 2010-02-19 | 2016-04-06 | 国立大学法人 千葉大学 | Novel alternative splicing variant of OATP1B3 mRNA |
EP2539450B1 (en) | 2010-02-25 | 2016-02-17 | Advanced Liquid Logic, Inc. | Method of making nucleic acid libraries |
US20110223314A1 (en) | 2010-03-10 | 2011-09-15 | Xiaoxiao Zhang | Efficient microencapsulation |
CA2767182C (en) | 2010-03-25 | 2020-03-24 | Bio-Rad Laboratories, Inc. | Droplet generation for droplet-based assays |
US8865675B2 (en) | 2010-05-12 | 2014-10-21 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
SG186987A1 (en) | 2010-06-11 | 2013-02-28 | Pathogenica Inc | Nucleic acids for multiplex organism detection and methods of use and making the same |
CN103069006A (en) | 2010-07-23 | 2013-04-24 | 艾索特里克斯遗传实验室有限责任公司 | Identification of differentially represented fetal or maternal genomic regions and uses thereof |
US8821304B2 (en) | 2010-07-28 | 2014-09-02 | Whitewater West Industries Ltd. | Water eruption effect and interactive water play structure |
GB2482911A (en) | 2010-08-20 | 2012-02-22 | Sphere Fluidics Ltd | Microdroplet emulsion system |
WO2012036679A1 (en) | 2010-09-15 | 2012-03-22 | Life Technologies Corporation | Methods and apparatus for measuring analytes |
US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
US20120088691A1 (en) | 2010-10-08 | 2012-04-12 | Gao Chen | Highly multiplexed real-time pcr using encoded microbeads |
US10392726B2 (en) | 2010-10-08 | 2019-08-27 | President And Fellows Of Harvard College | High-throughput immune sequencing |
CA2814049C (en) | 2010-10-08 | 2021-07-13 | President And Fellows Of Harvard College | High-throughput single cell barcoding |
US20130225623A1 (en) | 2010-10-27 | 2013-08-29 | Mount Sinai School Of Medicine | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists |
US8829171B2 (en) | 2011-02-10 | 2014-09-09 | Illumina, Inc. | Linking sequence reads using paired code tags |
US8278711B2 (en) | 2010-11-23 | 2012-10-02 | General Electric Company | Semiconductor device and method of making the same |
DK2652155T3 (en) | 2010-12-16 | 2017-02-13 | Gigagen Inc | Methods for Massive Parallel Analysis of Nucleic Acids in Single Cells |
US20120167142A1 (en) | 2010-12-23 | 2012-06-28 | Eldon Technology Limited | Methods and apparatuses to facilitate preselection of programming preferences |
EP3181704B1 (en) | 2010-12-27 | 2021-01-27 | Abbott Molecular Inc. | Quantitating high titer samples by digital pcr |
MX337700B (en) | 2011-01-26 | 2016-03-16 | Firestone Ind Products Co Llc | Gas spring piston as well as gas spring assembly, suspension system, kit and method including same. |
US20120244043A1 (en) | 2011-01-28 | 2012-09-27 | Sean Leblanc | Elastomeric gasket for fluid interface to a microfluidic chip |
CN103703143B (en) | 2011-01-31 | 2016-12-14 | 爱普瑞斯生物公司 | The method of the multiple epi-positions in identification of cell |
WO2012106668A2 (en) | 2011-02-03 | 2012-08-09 | Fluidigm Corporation | Multifunctional probe-primers |
CA2826748C (en) | 2011-02-09 | 2020-08-04 | Bio-Rad Laboratories, Inc. | Method of detecting variations in copy number of a target nucleic acid |
US9364803B2 (en) | 2011-02-11 | 2016-06-14 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
EP2673382B1 (en) | 2011-02-11 | 2020-05-06 | Bio-Rad Laboratories, Inc. | Thermocycling device for nucleic acid amplification and methods of use |
US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
WO2012129363A2 (en) | 2011-03-24 | 2012-09-27 | President And Fellows Of Harvard College | Single cell nucleic acid detection and analysis |
JP5711583B2 (en) | 2011-03-28 | 2015-05-07 | 株式会社タムラ製作所 | Reflow device |
WO2012139125A2 (en) | 2011-04-07 | 2012-10-11 | Life Technologies Corporation | System and methods for making and processing emulsions |
EP3907299A1 (en) | 2011-04-15 | 2021-11-10 | The Johns Hopkins University | Safe sequencing system |
US9110026B2 (en) | 2011-05-05 | 2015-08-18 | Biopico Systems Inc | Microfluidic devices and methods based on massively parallel picoreactors for cell and molecular diagnostics |
EP3709018A1 (en) | 2011-06-02 | 2020-09-16 | Bio-Rad Laboratories, Inc. | Microfluidic apparatus for identifying components of a chemical reaction |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US20130178378A1 (en) | 2011-06-09 | 2013-07-11 | Andrew C. Hatch | Multiplex digital pcr |
US9150916B2 (en) | 2011-06-24 | 2015-10-06 | Beat Christen | Compositions and methods for identifying the essential genome of an organism |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
FR2978498B1 (en) | 2011-07-28 | 2018-03-02 | Valeo Equipements Electriques Moteur | MOTOR VEHICLE STARTER CIRCUIT COMPRISING A VOLTAGE-INCREASING DEVICE AND EQUIPPED STARTER |
US10466160B2 (en) | 2011-08-01 | 2019-11-05 | Celsee Diagnostics, Inc. | System and method for retrieving and analyzing particles |
US9249460B2 (en) | 2011-09-09 | 2016-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for obtaining a sequence |
WO2013056241A2 (en) | 2011-10-14 | 2013-04-18 | Pacific Biosciences Of California, Inc. | Real-time redox sequencing |
US8894946B2 (en) | 2011-10-21 | 2014-11-25 | Integenx Inc. | Sample preparation, processing and analysis systems |
EP2798089B1 (en) | 2011-12-30 | 2018-05-23 | Bio-rad Laboratories, Inc. | Methods and compositions for performing nucleic acid amplification reactions |
US9701959B2 (en) | 2012-02-02 | 2017-07-11 | Invenra Inc. | High throughput screen for biologically active polypeptides |
WO2013120089A1 (en) | 2012-02-10 | 2013-08-15 | Raindance Technologies, Inc. | Molecular diagnostic screening assay |
US20130210638A1 (en) | 2012-02-10 | 2013-08-15 | Jeffrey Charles Olson | Methods for sequencing nucleic acid |
US9176031B2 (en) | 2012-02-24 | 2015-11-03 | Raindance Technologies, Inc. | Labeling and sample preparation for sequencing |
WO2013165748A1 (en) | 2012-04-30 | 2013-11-07 | Raindance Technologies, Inc | Digital analyte analysis |
US20160115532A1 (en) | 2012-08-10 | 2016-04-28 | Sequenta, Inc. | High sensitivity mutation detection using sequence tags |
US9790546B2 (en) | 2012-08-31 | 2017-10-17 | Roche Molecular Systems, Inc. | Microfluidic chip, device and system for the generation of aqueous droplets in emulsion oil for nucleic acid amplification |
EP2895626B1 (en) | 2012-09-12 | 2019-12-18 | The Regents of The University of California | Accurate genome sequencing of single cells by single-stranded amplification and sequencing |
US9783841B2 (en) | 2012-10-04 | 2017-10-10 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of target nucleic acids in a cellular sample |
GB201218909D0 (en) | 2012-10-22 | 2012-12-05 | Univ Singapore | Assay for the parallel detection of biological material based on PCR |
US9840734B2 (en) | 2012-10-22 | 2017-12-12 | Raindance Technologies, Inc. | Methods for analyzing DNA |
WO2014085802A1 (en) | 2012-11-30 | 2014-06-05 | The Broad Institute, Inc. | High-throughput dynamic reagent delivery system |
US9297784B2 (en) | 2012-12-05 | 2016-03-29 | Caliper Life Sciences, Inc. | Device and method for extracting target objects from a sample |
WO2014138688A1 (en) | 2013-03-07 | 2014-09-12 | Bio-Rad Laboratories, Inc. | Repetitive reverse transcription partition assay |
US9273349B2 (en) | 2013-03-14 | 2016-03-01 | Affymetrix, Inc. | Detection of nucleic acids |
EP2970849B1 (en) | 2013-03-15 | 2019-08-21 | Fluidigm Corporation | Methods and devices for analysis of defined multicellular combinations |
WO2014146025A1 (en) | 2013-03-15 | 2014-09-18 | Bio-Rad Laboratories, Inc. | Digital assays with associated targets |
BR112015023712B1 (en) | 2013-03-15 | 2021-01-05 | Beckman Coulter, Inc. | classification flow cytometer and method of filtering irradiated light in a classification flow cytometer |
WO2014165559A2 (en) | 2013-04-02 | 2014-10-09 | Raindance Technologies, Inc. | Systems and methods for handling microfluidic droplets |
CN105431553B (en) | 2013-05-29 | 2020-02-07 | 生物辐射实验室股份有限公司 | Systems and methods for sequencing in emulsion-based microfluidics |
US20150011397A1 (en) | 2013-06-17 | 2015-01-08 | Kim Lewis | Methods for quantitative determination of multiple proteins in complex mixtures |
WO2015013681A1 (en) | 2013-07-25 | 2015-01-29 | Bio-Rad Laboratories, Inc. | Genetic assays |
US10343165B2 (en) | 2013-09-05 | 2019-07-09 | Bio-Rad Laboratories, Inc. | On-demand particle dispensing system |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
EP3495506B1 (en) | 2013-12-11 | 2023-07-12 | AccuraGen Holdings Limited | Methods for detecting rare sequence variants |
US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
EP2986742A4 (en) | 2014-01-10 | 2016-12-07 | Bio Rad Laboratories Inc | Intercalating dyes for differential detection |
US8820538B1 (en) | 2014-03-17 | 2014-09-02 | Namocell LLC | Method and apparatus for particle sorting |
EP3456846B1 (en) | 2014-04-21 | 2022-06-22 | President and Fellows of Harvard College | Systems and methods for barcoding nucleic acid |
US20150298091A1 (en) | 2014-04-21 | 2015-10-22 | President And Fellows Of Harvard College | Systems and methods for barcoding nucleic acids |
CN114214314A (en) | 2014-06-24 | 2022-03-22 | 生物辐射实验室股份有限公司 | Digital PCR barcoding |
CN106795553B (en) | 2014-06-26 | 2021-06-04 | 10X基因组学有限公司 | Methods of analyzing nucleic acids from individual cells or cell populations |
KR101702745B1 (en) | 2014-11-13 | 2017-02-03 | 인제대학교 산학협력단 | Apparatus and method for separating single cell |
US20160200847A1 (en) | 2014-12-12 | 2016-07-14 | Marcella Chiari | Clickable polymers and gels for microarray and other applications |
US11725179B2 (en) | 2015-05-12 | 2023-08-15 | On-Chip Biotechnologies Co., Ltd. | Single-particle analysis method, and system for performing said analysis |
JP6518515B2 (en) | 2015-05-28 | 2019-05-22 | 山洋電気株式会社 | Motor sensor |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
EP3387128A4 (en) | 2015-12-07 | 2019-12-04 | Bio-Rad Laboratories, Inc. | Multiplexing in partitions using microparticles |
US20170192013A1 (en) | 2015-12-30 | 2017-07-06 | Bio-Rad Laboratories, Inc. | Digital protein quantification |
EP3430376A1 (en) | 2016-03-17 | 2019-01-23 | BD Biosciences | Cell sorting using a high throughput fluorescence flow cytometer |
US10650602B2 (en) | 2016-04-15 | 2020-05-12 | Center Of Human-Centered Interaction For Coexistence | Apparatus and method for three-dimensional information augmented video see-through display, and rectification apparatus |
US10036024B2 (en) | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
WO2018044831A1 (en) | 2016-08-30 | 2018-03-08 | Integrated Dna Technologies, Inc. | Cleavable hairpin primers |
US10611995B2 (en) | 2018-08-15 | 2020-04-07 | Deepcell, Inc. | Systems and methods for particle analysis |
US20210230681A1 (en) | 2020-01-24 | 2021-07-29 | 10X Genomics, Inc. | Methods for spatial analysis using proximity ligation |
-
2009
- 2009-07-17 EP EP21208862.9A patent/EP4047367A1/en active Pending
- 2009-07-17 EP EP09790559.0A patent/EP2315629B1/en active Active
- 2009-07-17 US US12/504,764 patent/US20100022414A1/en not_active Abandoned
- 2009-07-17 WO PCT/US2009/050931 patent/WO2010009365A1/en active Application Filing
-
2016
- 2016-10-11 US US15/290,378 patent/US11534727B2/en active Active
-
2018
- 2018-08-20 US US16/105,042 patent/US11596908B2/en active Active
-
2021
- 2021-10-25 US US17/510,092 patent/US11511242B2/en active Active
-
2023
- 2023-03-06 US US18/178,965 patent/US20230219043A1/en active Pending
Patent Citations (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2971700A (en) * | 1957-07-22 | 1961-02-14 | Vilbiss Co | Apparatus for coating articles with chemically reactive liquids |
US4315754A (en) * | 1979-08-28 | 1982-02-16 | Bifok Ab | Flow injection analysis with intermittent flow |
US4996004A (en) * | 1982-08-14 | 1991-02-26 | Bayer Aktiengesellschaft | Preparation of pharmaceutical or cosmetic dispersions |
US4801086A (en) * | 1985-02-19 | 1989-01-31 | Imperial Chemical Industries Plc | Spraying apparatus |
US4801529A (en) * | 1985-06-18 | 1989-01-31 | Brandeis University | Methods for isolating mutant microoganisms using microcapsules coated with indicator material |
US5180662A (en) * | 1988-01-05 | 1993-01-19 | The United States Of America As Represented By The Department Of Health And Human Services | Cytotoxic T lymphocyte activation assay |
US5185099A (en) * | 1988-04-20 | 1993-02-09 | Institut National De Recherche Chimique Appliquee | Visco-elastic, isotropic materials based on water, fluorinate sufactants and fluorinated oils, process for their preparation, and their use in various fields, such as optics, pharmacology and electrodynamics |
US4981580A (en) * | 1989-05-01 | 1991-01-01 | Coulter Corporation | Coincidence arbitration in a flow cytomery sorting system |
US5188291A (en) * | 1989-05-31 | 1993-02-23 | Her Majesty The Queen In Right Of New Zealand | Fluid distribution device |
US5378957A (en) * | 1989-11-17 | 1995-01-03 | Charged Injection Corporation | Methods and apparatus for dispersing a fluent material utilizing an electron beam |
US5091652A (en) * | 1990-01-12 | 1992-02-25 | The Regents Of The University Of California | Laser excited confocal microscope fluorescence scanner and method |
US5188290A (en) * | 1990-02-16 | 1993-02-23 | J. Wagner Gmbh | Electrostatic compressed air paint spray gun |
US5858670A (en) * | 1990-07-02 | 1999-01-12 | The Arizona Board Of Regents | Bio-oligomer libraries and a method of use thereof |
US5858655A (en) * | 1991-03-11 | 1999-01-12 | The General Hospital Corporation | Method for diagnosing neoplasia by detecting expression of PRAD1 cyclin |
US5486335A (en) * | 1992-05-01 | 1996-01-23 | Trustees Of The University Of Pennsylvania | Analysis based on flow restriction |
US5480614A (en) * | 1993-03-16 | 1996-01-02 | Hitachi, Ltd. | Micro-reactor device for minute sample analysis |
US5904933A (en) * | 1994-06-09 | 1999-05-18 | Alliance Pharmaceutical Corp. | Stable reverse and multiple fluorocarbon emulsions |
US5604097A (en) * | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
US6172218B1 (en) * | 1994-10-13 | 2001-01-09 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
US5863722A (en) * | 1994-10-13 | 1999-01-26 | Lynx Therapeutics, Inc. | Method of sorting polynucleotides |
US6172214B1 (en) * | 1994-10-13 | 2001-01-09 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
US20020022261A1 (en) * | 1995-06-29 | 2002-02-21 | Anderson Rolfe C. | Miniaturized genetic analysis systems and methods |
US5872010A (en) * | 1995-07-21 | 1999-02-16 | Northeastern University | Microscale fluid handling system |
US5868322A (en) * | 1996-01-31 | 1999-02-09 | Hewlett-Packard Company | Apparatus for forming liquid droplets having a mechanically fixed inner microtube |
US6184012B1 (en) * | 1996-04-25 | 2001-02-06 | Medical Research Council | Isolation of enzymes |
US6189803B1 (en) * | 1996-05-13 | 2001-02-20 | University Of Seville | Fuel injection nozzle and method of use |
US6187214B1 (en) * | 1996-05-13 | 2001-02-13 | Universidad De Seville | Method and device for production of components for microfabrication |
US6174469B1 (en) * | 1996-05-13 | 2001-01-16 | Universidad De Sevilla | Device and method for creating dry particles |
US6344325B1 (en) * | 1996-09-25 | 2002-02-05 | California Institute Of Technology | Methods for analysis and sorting of polynucleotides |
US5858187A (en) * | 1996-09-26 | 1999-01-12 | Lockheed Martin Energy Systems, Inc. | Apparatus and method for performing electrodynamic focusing on a microchip |
US6023540A (en) * | 1997-03-14 | 2000-02-08 | Trustees Of Tufts College | Fiber optic sensor with encoded microspheres |
US6180372B1 (en) * | 1997-04-23 | 2001-01-30 | Bruker Daltonik Gmbh | Method and devices for extremely fast DNA replication by polymerase chain reactions (PCR) |
US6028066A (en) * | 1997-05-06 | 2000-02-22 | Imarx Pharmaceutical Corp. | Prodrugs comprising fluorinated amphiphiles |
US20020005354A1 (en) * | 1997-09-23 | 2002-01-17 | California Institute Of Technology | Microfabricated cell sorter |
US6171796B1 (en) * | 1998-01-21 | 2001-01-09 | Urocor, Inc. | Biomarkers and targets for diagnosis prognosis and management of prostate disease |
US6503933B1 (en) * | 1998-02-19 | 2003-01-07 | Aventis Cropscience Uk Limited | 2-pyridylmethylamine derivatives useful as fungicides |
US6679441B1 (en) * | 1998-03-27 | 2004-01-20 | Centre National De La Recherche Scientifique (C.N.R.S.) | Electrohydrodynamic spraying means |
US6336463B1 (en) * | 1998-03-31 | 2002-01-08 | Nec Corporation | Cleaning/drying station and production line for semiconductor devices |
US20060003429A1 (en) * | 1999-01-29 | 2006-01-05 | Frost John W | Biocatalytic synthesis of quinic acid and conversion to hydroquinone |
US6841350B2 (en) * | 1999-02-20 | 2005-01-11 | The North West London Hospitals Nhs Trust Of Northwick Park Hospital | Methods of diagnosing prostate cancer through the detection of the presence or absence of Pax 2 mRNA |
US20040037813A1 (en) * | 1999-02-25 | 2004-02-26 | Simpson David G. | Electroprocessed collagen and tissue engineering |
US6171850B1 (en) * | 1999-03-08 | 2001-01-09 | Caliper Technologies Corp. | Integrated devices and systems for performing temperature controlled reactions and analyses |
US6174160B1 (en) * | 1999-03-25 | 2001-01-16 | University Of Washington | Staged prevaporizer-premixer |
US6506609B1 (en) * | 1999-05-17 | 2003-01-14 | Caliper Technologies Corp. | Focusing of microparticles in microfluidic systems |
US6524456B1 (en) * | 1999-08-12 | 2003-02-25 | Ut-Battelle, Llc | Microfluidic devices for the controlled manipulation of small volumes |
US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
US7316906B2 (en) * | 1999-10-08 | 2008-01-08 | The Feinstein Institute For Medical Research | CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia |
US20030039169A1 (en) * | 1999-12-18 | 2003-02-27 | Wolfgang Ehrfeld | Micromixer |
US20020008028A1 (en) * | 2000-01-12 | 2002-01-24 | Jacobson Stephen C. | Microfluidic device and method for focusing, segmenting, and dispensing of a fluid stream |
US7314721B2 (en) * | 2000-01-21 | 2008-01-01 | Ludwig Institute For Cancer Research | Small cell lung cancer associated antigens and uses therefor |
US20020012971A1 (en) * | 2000-03-20 | 2002-01-31 | Mehta Tammy Burd | PCR compatible nucleic acid sieving medium |
US7479376B2 (en) * | 2000-03-27 | 2009-01-20 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
US20020022038A1 (en) * | 2000-05-05 | 2002-02-21 | Bruno Biatry | Microcapsules with an aqueous core containing at least one water-soluble cosmetic or dermatological active principle and cosmetic or dermatological compositions containing them |
US20020004532A1 (en) * | 2000-05-26 | 2002-01-10 | Michelle Matathia | Low emulsifier multiple emulsions |
US6680178B2 (en) * | 2000-06-02 | 2004-01-20 | The Regents Of The University Of California | Profiling of protease specificity using combinatorial fluorogenic substrate libraries |
US20040005582A1 (en) * | 2000-08-10 | 2004-01-08 | Nanobiodynamics, Incorporated | Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators |
US6682890B2 (en) * | 2000-08-17 | 2004-01-27 | Protein Design Labs, Inc. | Methods of diagnosing and determining prognosis of colorectal cancer |
US20040027915A1 (en) * | 2000-08-25 | 2004-02-12 | Holger Lowe | Method and statistical micromixer for mixing at least two liquids |
US20040005594A1 (en) * | 2000-09-13 | 2004-01-08 | Medical Research Council | Directed evolution method |
US6508988B1 (en) * | 2000-10-03 | 2003-01-21 | California Institute Of Technology | Combinatorial synthesis system |
US20030012586A1 (en) * | 2001-05-24 | 2003-01-16 | Nobuo Iwata | Developer container, developing conveying device and image forming apparatus using the same |
US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
US20030015425A1 (en) * | 2001-06-20 | 2003-01-23 | Coventor Inc. | Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system |
US20030017579A1 (en) * | 2001-07-10 | 2003-01-23 | Corn Robert M. | Surface plasmon resonance imaging of micro-arrays |
US6520425B1 (en) * | 2001-08-21 | 2003-02-18 | The University Of Akron | Process and apparatus for the production of nanofibers |
US7479371B2 (en) * | 2002-04-09 | 2009-01-20 | Tokai University | Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor |
US20040018525A1 (en) * | 2002-05-21 | 2004-01-29 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
US7476506B2 (en) * | 2002-06-03 | 2009-01-13 | Novartis Vaccines And Diagnostics, Inc. | Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers |
US20060003347A1 (en) * | 2002-09-11 | 2006-01-05 | Medical Research Council | Single-molecule in vitro evolution |
US20120010098A1 (en) * | 2003-03-31 | 2012-01-12 | Medical Research Council | Selection by compartmentalised screening |
US7156917B2 (en) * | 2003-05-22 | 2007-01-02 | Hideaki Moriyama | Apparatus and method for growing crystal, and apparatus and method for analyzing crystal |
US20050032238A1 (en) * | 2003-08-07 | 2005-02-10 | Nanostream, Inc. | Vented microfluidic separation devices and methods |
US7473531B1 (en) * | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
US20070003442A1 (en) * | 2003-08-27 | 2007-01-04 | President And Fellows Of Harvard College | Electronic control of fluidic species |
US7479370B2 (en) * | 2003-09-08 | 2009-01-20 | Health Research, Inc. | Detection of 13q14 chromosomal alterations |
US7169560B2 (en) * | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
US20080014590A1 (en) * | 2004-01-27 | 2008-01-17 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer |
US20070092914A1 (en) * | 2004-03-31 | 2007-04-26 | Medical Research Council, Harvard University | Compartmentalised screening by microfluidic control |
US7482129B2 (en) * | 2004-05-04 | 2009-01-27 | Institute Of Virology, Slovak Academy Of Sciences | MN/CA IX/CA9 and Renal Cancer Prognosis |
US20060003439A1 (en) * | 2004-07-02 | 2006-01-05 | Ismagilov Rustem F | Microfluidic system |
US20060100788A1 (en) * | 2004-07-14 | 2006-05-11 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
US20090023137A1 (en) * | 2004-07-16 | 2009-01-22 | Oncomethylome Sciences S.A. | ESR1 and Cervical Cancer |
US20080023330A1 (en) * | 2004-09-09 | 2008-01-31 | Institut Curie | Device for Manipulation of Packets in Micro-Containers, in Particular in Microchannels |
US20090005254A1 (en) * | 2004-10-12 | 2009-01-01 | Andrew Griffiths | Compartmentalized Screening by Microfluidic Control |
US7473530B2 (en) * | 2005-05-04 | 2009-01-06 | Wayne State University | Method to detect lung cancer |
WO2007081385A2 (en) * | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US20080009005A1 (en) * | 2006-02-09 | 2008-01-10 | Kruk Patricia A | Detection of cancer by elevated levels of BCL-2 |
US20080003142A1 (en) * | 2006-05-11 | 2008-01-03 | Link Darren R | Microfluidic devices |
US20080014589A1 (en) * | 2006-05-11 | 2008-01-17 | Link Darren R | Microfluidic devices and methods of use thereof |
US20100009353A1 (en) * | 2006-05-18 | 2010-01-14 | Colin Barnes | Dye Compounds and the Use of their Labelled Conjugates |
US20080021330A1 (en) * | 2006-07-21 | 2008-01-24 | Samsung Electronics Co., Ltd. | Apparatus, method and optical sensor module using a tilter for body fat measurement |
US20080020940A1 (en) * | 2006-07-24 | 2008-01-24 | Miraculins Inc. | Biomarkers for use in the diagnosis and treatment of colorectal cancer |
WO2008021123A1 (en) * | 2006-08-07 | 2008-02-21 | President And Fellows Of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
US20090026082A1 (en) * | 2006-12-14 | 2009-01-29 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes using large scale FET arrays |
US20090012187A1 (en) * | 2007-03-28 | 2009-01-08 | President And Fellows Of Harvard College | Emulsions and Techniques for Formation |
US20090029372A1 (en) * | 2007-05-14 | 2009-01-29 | Kobenhavns Universitet | Adam12 as a biomarker for bladder cancer |
US20090021728A1 (en) * | 2007-06-21 | 2009-01-22 | Gen-Probe Incorporated | Multi-Channel Optical Measurement Instrument |
US20090004687A1 (en) * | 2007-06-29 | 2009-01-01 | Mansfield Brian C | Predictive markers for ovarian cancer |
US20090017463A1 (en) * | 2007-07-10 | 2009-01-15 | Vanderbilt University | Methods for predicting prostate cancer recurrence |
US20120015382A1 (en) * | 2007-07-13 | 2012-01-19 | President And Fellows Of Harvard College | Droplet-based selection |
US20100003687A1 (en) * | 2008-07-01 | 2010-01-07 | 454 Life Sciences Corporation | System and method for detection of HIV tropism variants |
US20120015822A1 (en) * | 2008-12-19 | 2012-01-19 | President And Fellows Of Harvard College | Particle-assisted nucleic acid sequencing |
US20110000560A1 (en) * | 2009-03-23 | 2011-01-06 | Raindance Technologies, Inc. | Manipulation of Microfluidic Droplets |
Non-Patent Citations (4)
Title |
---|
Beer et al. (Anal. Chem., 2007, 79 (22), pp 8471â8475). * |
Beer et al. (On-chip single-copy real-time reverse-transcription PCR in isolated picoliter droplets, 2008, Analytical chemistry, Vol 80, pp 1854-1858, published online February 16, 2008) * |
Glass et al. (Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes, 1995, Applied and Environmental Microbiology, Vol 61, pp 1323-1330) * |
Nakano et al. (Single-molecule reverse transcription polymerase chain reaction using water-in-oil emulsion, 2005, Journal of Bioscience and engineering, Vol 99, pp 293-295) * |
Cited By (446)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11478799B2 (en) | 2002-05-09 | 2022-10-25 | The University Of Chicago | Method for conducting reactions involving biological molecules in plugs in a microfluidic system |
US8304193B2 (en) | 2002-05-09 | 2012-11-06 | The University Of Chicago | Method for conducting an autocatalytic reaction in plugs in a microfluidic system |
US20110142734A1 (en) * | 2002-05-09 | 2011-06-16 | The University Of Chicago | Device and method for pressure-driven plug transport |
US20110177494A1 (en) * | 2002-05-09 | 2011-07-21 | The University Of Chicago | Device and method for pressure-driven plug transport |
US8889083B2 (en) | 2002-05-09 | 2014-11-18 | The University Of Chicago | Device and method for pressure-driven plug transport and reaction |
US20070172954A1 (en) * | 2002-05-09 | 2007-07-26 | The University Of Chicago | Device and method for pressure-driven plug transport and reaction |
US11413615B2 (en) | 2002-05-09 | 2022-08-16 | The University Of Chicago | Device and method for pressure-driven plug transport and reaction |
US20110174622A1 (en) * | 2002-05-09 | 2011-07-21 | The University Of Chicago | Device and method for pressure-driven plug transport |
US11413614B2 (en) | 2002-05-09 | 2022-08-16 | The University Of Chicago | Device and method for pressure-driven plug transport and reaction |
US10532358B2 (en) | 2002-05-09 | 2020-01-14 | The University Of Chicago | Device and method for pressure-driven plug transport and reaction |
US9592506B2 (en) | 2002-05-09 | 2017-03-14 | The University Of Chicago | Method of crystallization in aqueous plugs flowing in immiscible carrier-fluid in microfluidic system |
US8273573B2 (en) | 2002-05-09 | 2012-09-25 | The University Of Chicago | Method for obtaining a collection of plugs comprising biological molecules |
US9329107B2 (en) | 2002-05-09 | 2016-05-03 | The University Of Chicago | Device for pressure-driven plug transport comprising microchannel with traps |
US11278898B2 (en) | 2002-05-09 | 2022-03-22 | The University Of Chicago | Method for conducting an autocatalytic reaction in plugs in a microfluidic system |
US9968933B2 (en) | 2002-05-09 | 2018-05-15 | The University Of Chicago | Device and method for pressure-driven plug transport and reaction |
US10668471B2 (en) | 2002-05-09 | 2020-06-02 | The University Of Chicago | Device and method for pressure-driven plug transport and reaction |
US8329407B2 (en) | 2002-05-09 | 2012-12-11 | The University Of Chicago | Method for conducting reactions involving biological molecules in plugs in a microfluidic system |
US20100233026A1 (en) * | 2002-05-09 | 2010-09-16 | Ismagliov Rustem F | Device and method for pressure-driven plug transport and reaction |
US8986628B2 (en) | 2002-06-28 | 2015-03-24 | President And Fellows Of Harvard College | Method and apparatus for fluid dispersion |
US11187702B2 (en) | 2003-03-14 | 2021-11-30 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US20100210479A1 (en) * | 2003-03-31 | 2010-08-19 | Medical Research Council | Method of synthesis and testing of cominatorial libraries using microcapsules |
US20060153924A1 (en) * | 2003-03-31 | 2006-07-13 | Medical Research Council | Selection by compartmentalised screening |
US10052605B2 (en) | 2003-03-31 | 2018-08-21 | Medical Research Council | Method of synthesis and testing of combinatorial libraries using microcapsules |
US9448172B2 (en) | 2003-03-31 | 2016-09-20 | Medical Research Council | Selection by compartmentalised screening |
US9857303B2 (en) | 2003-03-31 | 2018-01-02 | Medical Research Council | Selection by compartmentalised screening |
US9038919B2 (en) | 2003-04-10 | 2015-05-26 | President And Fellows Of Harvard College | Formation and control of fluidic species |
US11141731B2 (en) | 2003-04-10 | 2021-10-12 | President And Fellows Of Harvard College | Formation and control of fluidic species |
US20060163385A1 (en) * | 2003-04-10 | 2006-07-27 | Link Darren R | Formation and control of fluidic species |
US10293341B2 (en) | 2003-04-10 | 2019-05-21 | President And Fellows Of Harvard College | Formation and control of fluidic species |
US20150283546A1 (en) | 2003-04-10 | 2015-10-08 | President And Fellows Of Harvard College | Formation and control of fluidic species |
US20070003442A1 (en) * | 2003-08-27 | 2007-01-04 | President And Fellows Of Harvard College | Electronic control of fluidic species |
US9878325B2 (en) | 2003-08-27 | 2018-01-30 | President And Fellows Of Harvard College | Electronic control of fluidic species |
US9789482B2 (en) | 2003-08-27 | 2017-10-17 | President And Fellows Of Harvard College | Methods of introducing a fluid into droplets |
US8765485B2 (en) | 2003-08-27 | 2014-07-01 | President And Fellows Of Harvard College | Electronic control of fluidic species |
US11383234B2 (en) | 2003-08-27 | 2022-07-12 | President And Fellows Of Harvard College | Electronic control of fluidic species |
US10625256B2 (en) | 2003-08-27 | 2020-04-21 | President And Fellows Of Harvard College | Electronic control of fluidic species |
US20100120635A1 (en) * | 2003-09-05 | 2010-05-13 | Stokes Bio Limited | Sample dispensing |
US20100092987A1 (en) * | 2003-09-05 | 2010-04-15 | Stokes Bio Limited | Microfluidic analysis system |
US9597644B2 (en) * | 2003-09-05 | 2017-03-21 | Stokes Bio Limited | Methods for culturing and analyzing cells |
US20100297685A1 (en) * | 2003-09-05 | 2010-11-25 | Stokes Bio Limited | Methods for culturing and analyzing cells |
US11807902B2 (en) | 2003-09-05 | 2023-11-07 | Stokes Bio Ltd. | Microfluidic analysis system |
US10676786B2 (en) | 2003-09-05 | 2020-06-09 | Stokes Bio Ltd. | Microfluidic analysis system |
US10967338B2 (en) | 2003-09-05 | 2021-04-06 | Stokes Bio Ltd. | Methods of releasing and analyzing cellular components |
US8968659B2 (en) | 2003-09-05 | 2015-03-03 | Stokes Bio Limited | Sample dispensing |
US11821109B2 (en) | 2004-03-31 | 2023-11-21 | President And Fellows Of Harvard College | Compartmentalised combinatorial chemistry by microfluidic control |
US20070092914A1 (en) * | 2004-03-31 | 2007-04-26 | Medical Research Council, Harvard University | Compartmentalised screening by microfluidic control |
US9925504B2 (en) | 2004-03-31 | 2018-03-27 | President And Fellows Of Harvard College | Compartmentalised combinatorial chemistry by microfluidic control |
US20060003439A1 (en) * | 2004-07-02 | 2006-01-05 | Ismagilov Rustem F | Microfluidic system |
US10732649B2 (en) | 2004-07-02 | 2020-08-04 | The University Of Chicago | Microfluidic system |
US9477233B2 (en) | 2004-07-02 | 2016-10-25 | The University Of Chicago | Microfluidic system with a plurality of sequential T-junctions for performing reactions in microdroplets |
US8871444B2 (en) | 2004-10-08 | 2014-10-28 | Medical Research Council | In vitro evolution in microfluidic systems |
US20090197248A1 (en) * | 2004-10-08 | 2009-08-06 | President And Fellows Of Harvard College | Vitro evolution in microfluidic systems |
US11786872B2 (en) | 2004-10-08 | 2023-10-17 | United Kingdom Research And Innovation | Vitro evolution in microfluidic systems |
US9186643B2 (en) | 2004-10-08 | 2015-11-17 | Medical Research Council | In vitro evolution in microfluidic systems |
US9029083B2 (en) | 2004-10-08 | 2015-05-12 | Medical Research Council | Vitro evolution in microfluidic systems |
US9498759B2 (en) | 2004-10-12 | 2016-11-22 | President And Fellows Of Harvard College | Compartmentalized screening by microfluidic control |
US20090005254A1 (en) * | 2004-10-12 | 2009-01-01 | Andrew Griffiths | Compartmentalized Screening by Microfluidic Control |
US9910020B1 (en) | 2005-03-30 | 2018-03-06 | Copilot Ventures Fund Iii Llc | Methods and articles for identifying objects using encapsulated perfluorocarbon tracers |
US9410151B2 (en) | 2006-01-11 | 2016-08-09 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9328344B2 (en) | 2006-01-11 | 2016-05-03 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9534216B2 (en) | 2006-01-11 | 2017-01-03 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US20090104637A1 (en) * | 2006-01-31 | 2009-04-23 | Ismagilov Rustem F | Method and Apparatus for Assaying Blood Clotting |
US10730051B2 (en) | 2006-02-07 | 2020-08-04 | Stokes Bio Ltd. | Liquid bridge and system |
US11772096B2 (en) | 2006-02-07 | 2023-10-03 | Stokes Bio Ltd. | System for processing biological sample |
US10639597B2 (en) | 2006-05-11 | 2020-05-05 | Bio-Rad Laboratories, Inc. | Microfluidic devices |
US9273308B2 (en) | 2006-05-11 | 2016-03-01 | Raindance Technologies, Inc. | Selection of compartmentalized screening method |
US11351510B2 (en) | 2006-05-11 | 2022-06-07 | Bio-Rad Laboratories, Inc. | Microfluidic devices |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
US10927407B2 (en) | 2006-05-11 | 2021-02-23 | Bio-Rad Laboratories, Inc. | Systems and methods for handling microfluidic droplets |
US9498761B2 (en) * | 2006-08-07 | 2016-11-22 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US20150217246A1 (en) * | 2006-08-07 | 2015-08-06 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US20100105112A1 (en) * | 2006-08-07 | 2010-04-29 | Christian Holtze | Fluorocarbon emulsion stabilizing surfactants |
US9012390B2 (en) * | 2006-08-07 | 2015-04-21 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US20100078077A1 (en) * | 2006-12-19 | 2010-04-01 | Ismagilov Rustem F | Spacers for Microfluidic Channels |
US11819849B2 (en) | 2007-02-06 | 2023-11-21 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US9017623B2 (en) | 2007-02-06 | 2015-04-28 | Raindance Technologies, Inc. | Manipulation of fluids and reactions in microfluidic systems |
US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US9440232B2 (en) | 2007-02-06 | 2016-09-13 | Raindance Technologies, Inc. | Manipulation of fluids and reactions in microfluidic systems |
US10603662B2 (en) | 2007-02-06 | 2020-03-31 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US20100163109A1 (en) * | 2007-02-06 | 2010-07-01 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US10683524B2 (en) | 2007-03-07 | 2020-06-16 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
US9017948B2 (en) | 2007-03-07 | 2015-04-28 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
US9029085B2 (en) | 2007-03-07 | 2015-05-12 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
US10508294B2 (en) | 2007-03-07 | 2019-12-17 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
US20100136544A1 (en) * | 2007-03-07 | 2010-06-03 | Jeremy Agresti | Assays and other reactions involving droplets |
US10221437B2 (en) | 2007-03-07 | 2019-03-05 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
US9068210B2 (en) | 2007-03-07 | 2015-06-30 | President And Fellows Of Harvard College | Assay and other reactions involving droplets |
US9816121B2 (en) | 2007-03-07 | 2017-11-14 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
US10941430B2 (en) | 2007-03-07 | 2021-03-09 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
US10738337B2 (en) | 2007-03-07 | 2020-08-11 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
US9850526B2 (en) | 2007-03-07 | 2017-12-26 | President And Fellows Of Harvard College | Assays and other reactions involving droplets |
US10675626B2 (en) | 2007-04-19 | 2020-06-09 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US11224876B2 (en) | 2007-04-19 | 2022-01-18 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US9068699B2 (en) | 2007-04-19 | 2015-06-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US10960397B2 (en) | 2007-04-19 | 2021-03-30 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US10357772B2 (en) | 2007-04-19 | 2019-07-23 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US11618024B2 (en) | 2007-04-19 | 2023-04-04 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US20100252118A1 (en) * | 2007-04-19 | 2010-10-07 | Seth Fraden | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US20100317085A1 (en) * | 2007-07-26 | 2010-12-16 | Boedicker James Q | Co-incubating confined microbial communities |
US20100227767A1 (en) * | 2007-07-26 | 2010-09-09 | Boedicker James Q | Stochastic confinement to detect, manipulate, and utilize molecules and organisms |
US9090885B2 (en) | 2007-07-26 | 2015-07-28 | The University Of Chicago | Co-incubating confined microbial communities |
US9797010B2 (en) | 2007-12-21 | 2017-10-24 | President And Fellows Of Harvard College | Systems and methods for nucleic acid sequencing |
US10633701B2 (en) | 2007-12-21 | 2020-04-28 | President And Fellows Of Harvard College | Systems and methods for nucleic acid sequencing |
US8622987B2 (en) | 2008-06-04 | 2014-01-07 | The University Of Chicago | Chemistrode, a plug-based microfluidic device and method for stimulation and sampling with high temporal, spatial, and chemical resolution |
US20110112503A1 (en) * | 2008-06-04 | 2011-05-12 | Ismagilov Rustem F | Chemistrode, a plug-based microfluidic device and method for stimulation and sampling with high temporal, spatial, and chemical resolution |
US11596908B2 (en) | 2008-07-18 | 2023-03-07 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11511242B2 (en) | 2008-07-18 | 2022-11-29 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11534727B2 (en) | 2008-07-18 | 2022-12-27 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US10533998B2 (en) | 2008-07-18 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US11401550B2 (en) | 2008-09-19 | 2022-08-02 | President And Fellows Of Harvard College | Creation of libraries of droplets and related species |
US20110218123A1 (en) * | 2008-09-19 | 2011-09-08 | President And Fellows Of Harvard College | Creation of libraries of droplets and related species |
US10512910B2 (en) | 2008-09-23 | 2019-12-24 | Bio-Rad Laboratories, Inc. | Droplet-based analysis method |
US11612892B2 (en) | 2008-09-23 | 2023-03-28 | Bio-Rad Laboratories, Inc. | Method of performing droplet-based assays |
US9243288B2 (en) | 2008-09-23 | 2016-01-26 | Bio-Rad Laboratories, Inc. | Cartridge with lysis chamber and droplet generator |
US9216392B2 (en) | 2008-09-23 | 2015-12-22 | Bio-Rad Laboratories, Inc. | System for forming an array of emulsions |
US11633739B2 (en) | 2008-09-23 | 2023-04-25 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
US9156010B2 (en) | 2008-09-23 | 2015-10-13 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
US9132394B2 (en) | 2008-09-23 | 2015-09-15 | Bio-Rad Laboratories, Inc. | System for detection of spaced droplets |
US9764322B2 (en) | 2008-09-23 | 2017-09-19 | Bio-Rad Laboratories, Inc. | System for generating droplets with pressure monitoring |
US9126160B2 (en) | 2008-09-23 | 2015-09-08 | Bio-Rad Laboratories, Inc. | System for forming an array of emulsions |
US20110086780A1 (en) * | 2008-09-23 | 2011-04-14 | Quantalife, Inc. | System for forming an array of emulsions |
US9417190B2 (en) | 2008-09-23 | 2016-08-16 | Bio-Rad Laboratories, Inc. | Calibrations and controls for droplet-based assays |
US11130134B2 (en) | 2008-09-23 | 2021-09-28 | Bio-Rad Laboratories, Inc. | Method of performing droplet-based assays |
US11130128B2 (en) | 2008-09-23 | 2021-09-28 | Bio-Rad Laboratories, Inc. | Detection method for a target nucleic acid |
US20110092376A1 (en) * | 2008-09-23 | 2011-04-21 | Quantalife, Inc. | System for droplet-based assays using an array of emulsions |
US9649635B2 (en) | 2008-09-23 | 2017-05-16 | Bio-Rad Laboratories, Inc. | System for generating droplets with push-back to remove oil |
US9248417B2 (en) | 2008-09-23 | 2016-02-02 | Bio-Rad Laboratories, Inc. | System for droplet-based assays using an array of emulsions |
US20110212516A1 (en) * | 2008-09-23 | 2011-09-01 | Ness Kevin D | Flow-based thermocycling system with thermoelectric cooler |
US10258988B2 (en) | 2008-09-23 | 2019-04-16 | Bio-Rad Laboratories, Inc. | Device for generating droplets |
US10258989B2 (en) | 2008-09-23 | 2019-04-16 | Bio-Rad Laboratories, Inc. | Method of making a device for generating droplets |
US10279350B2 (en) | 2008-09-23 | 2019-05-07 | Bio-Rad Laboratories, Inc. | Method of generating droplets |
US9623384B2 (en) | 2008-09-23 | 2017-04-18 | Bio-Rad Laboratories, Inc. | System for transporting emulsions from an array to a detector |
US9636682B2 (en) | 2008-09-23 | 2017-05-02 | Bio-Rad Laboratories, Inc. | System for generating droplets—instruments and cassette |
US8633015B2 (en) | 2008-09-23 | 2014-01-21 | Bio-Rad Laboratories, Inc. | Flow-based thermocycling system with thermoelectric cooler |
US9492797B2 (en) | 2008-09-23 | 2016-11-15 | Bio-Rad Laboratories, Inc. | System for detection of spaced droplets |
US10457977B2 (en) | 2008-12-19 | 2019-10-29 | President And Fellows Of Harvard College | Particle-assisted nucleic acid sequencing |
US8748094B2 (en) | 2008-12-19 | 2014-06-10 | President And Fellows Of Harvard College | Particle-assisted nucleic acid sequencing |
US11517864B2 (en) | 2009-03-13 | 2022-12-06 | President And Fellows Of Harvard College | Scale-up of microfluidic devices |
US10518230B2 (en) * | 2009-03-13 | 2019-12-31 | President And Fellows Of Harvard College | Scale-up of microfluidic devices |
US20170151536A1 (en) * | 2009-03-13 | 2017-06-01 | President And Fellows Of Harvard College | Scale-up of microfluidic devices |
US8528589B2 (en) | 2009-03-23 | 2013-09-10 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
US11268887B2 (en) | 2009-03-23 | 2022-03-08 | Bio-Rad Laboratories, Inc. | Manipulation of microfluidic droplets |
US9493826B2 (en) | 2009-03-24 | 2016-11-15 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
US9464319B2 (en) | 2009-03-24 | 2016-10-11 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes |
US10370705B2 (en) | 2009-03-24 | 2019-08-06 | University Of Chicago | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
US10196700B2 (en) | 2009-03-24 | 2019-02-05 | University Of Chicago | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
US9415392B2 (en) | 2009-03-24 | 2016-08-16 | The University Of Chicago | Slip chip device and methods |
US10543485B2 (en) | 2009-03-24 | 2020-01-28 | University Of Chicago | Slip chip device and methods |
US9447461B2 (en) | 2009-03-24 | 2016-09-20 | California Institute Of Technology | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
US11795494B2 (en) | 2009-04-02 | 2023-10-24 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
US10166522B2 (en) | 2009-09-02 | 2019-01-01 | Bio-Rad Laboratories, Inc. | System for mixing fluids by coalescence of multiple emulsions |
US10677693B2 (en) | 2009-09-02 | 2020-06-09 | Bio-Rad Laboratories, Inc. | System for mixing fluids by coalescence of multiple emulsions |
US20110053798A1 (en) * | 2009-09-02 | 2011-03-03 | Quantalife, Inc. | System for mixing fluids by coalescence of multiple emulsions |
US9194861B2 (en) | 2009-09-02 | 2015-11-24 | Bio-Rad Laboratories, Inc. | Method of mixing fluids by coalescence of multiple emulsions |
US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
US9056289B2 (en) | 2009-10-27 | 2015-06-16 | President And Fellows Of Harvard College | Droplet creation techniques |
US11000849B2 (en) | 2009-10-27 | 2021-05-11 | President And Fellows Of Harvard College | Droplet creation techniques |
US9839911B2 (en) | 2009-10-27 | 2017-12-12 | President And Fellows Of Harvard College | Droplet creation techniques |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US20110165037A1 (en) * | 2010-01-07 | 2011-07-07 | Ismagilov Rustem F | Interfaces that eliminate non-specific adsorption, and introduce specific interactions |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
WO2011100604A3 (en) * | 2010-02-12 | 2014-03-27 | Raindance Technologies, Inc. | Digital analyte analysis |
US11254968B2 (en) | 2010-02-12 | 2022-02-22 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US9228229B2 (en) | 2010-02-12 | 2016-01-05 | Raindance Technologies, Inc. | Digital analyte analysis |
US9074242B2 (en) | 2010-02-12 | 2015-07-07 | Raindance Technologies, Inc. | Digital analyte analysis |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
US11390917B2 (en) | 2010-02-12 | 2022-07-19 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US8535889B2 (en) | 2010-02-12 | 2013-09-17 | Raindance Technologies, Inc. | Digital analyte analysis |
US10808279B2 (en) | 2010-02-12 | 2020-10-20 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US20150038344A1 (en) * | 2010-02-25 | 2015-02-05 | Advanced Liquid Logic, Inc. | Method of Preparing a Nucleic Acid Library |
US11619631B2 (en) | 2010-03-01 | 2023-04-04 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
US10378048B2 (en) | 2010-03-02 | 2019-08-13 | Bio-Rad Laboratories, Inc. | Emulsion chemistry for encapsulated droplets |
WO2011109546A1 (en) * | 2010-03-02 | 2011-09-09 | Quantalife, Inc. | Emulsion chemistry and assays for encapsulated droplets |
US20110217711A1 (en) * | 2010-03-02 | 2011-09-08 | Quantalife, Inc. | Assays with droplets transformed into capsules |
US9598725B2 (en) | 2010-03-02 | 2017-03-21 | Bio-Rad Laboratories, Inc. | Emulsion chemistry for encapsulated droplets |
US11060136B2 (en) | 2010-03-02 | 2021-07-13 | Bio-Rad Laboratories, Inc. | Emulsion chemistry for encapsulated droplets |
US11866771B2 (en) | 2010-03-02 | 2024-01-09 | Bio-Rad Laboratories, Inc. | Emulsion chemistry for encapsulated droplets |
US8709762B2 (en) | 2010-03-02 | 2014-04-29 | Bio-Rad Laboratories, Inc. | System for hot-start amplification via a multiple emulsion |
US8399198B2 (en) | 2010-03-02 | 2013-03-19 | Bio-Rad Laboratories, Inc. | Assays with droplets transformed into capsules |
US9393560B2 (en) | 2010-03-25 | 2016-07-19 | Bio-Rad Laboratories, Inc. | Droplet transport system for detection |
US9500664B2 (en) | 2010-03-25 | 2016-11-22 | Bio-Rad Laboratories, Inc. | Droplet generation for droplet-based assays |
US10099219B2 (en) | 2010-03-25 | 2018-10-16 | Bio-Rad Laboratories, Inc. | Device for generating droplets |
US10272432B2 (en) | 2010-03-25 | 2019-04-30 | Bio-Rad Laboratories, Inc. | Device for generating droplets |
US10744506B2 (en) | 2010-03-25 | 2020-08-18 | Bio-Rad Laboratories, Inc. | Device for generating droplets |
US8730479B2 (en) | 2010-03-25 | 2014-05-20 | Bio-Rad Laboratories, Inc. | Detection system for droplet-based assays |
US20130210680A1 (en) * | 2010-06-10 | 2013-08-15 | President And Fellows Of Harvard College | Systems and methods for amplification and phage display |
WO2012047324A2 (en) | 2010-06-10 | 2012-04-12 | President And Fellows Of Harvard College | Systems and methods for amplification and phage display |
US9499813B2 (en) * | 2010-06-10 | 2016-11-22 | President And Fellows Of Harvard College | Systems and methods for amplification and phage display |
US10125389B2 (en) | 2010-07-22 | 2018-11-13 | Gencell Biosystems Limited | Composite liquid cells |
US9080208B2 (en) | 2010-07-22 | 2015-07-14 | Gencell Biosystems Ltd. | Composite liquid cells |
US9493816B2 (en) | 2010-07-22 | 2016-11-15 | GenCell Biosytems Ltd. | Composite liquid cells |
US20130139477A1 (en) * | 2010-08-20 | 2013-06-06 | Cambridge Enterprise Limited | Method of providing a chemical or biological material in quantised form and system therefor |
US9422067B2 (en) * | 2010-08-20 | 2016-08-23 | Sphere Fluidics Limited | Method of providing a chemical or biological material in quantised form and system therefor |
WO2012022976A1 (en) | 2010-08-20 | 2012-02-23 | Sphere Fluidics Limited | Method of providing a chemical or biological material in quantised form and system therefor |
US11635427B2 (en) | 2010-09-30 | 2023-04-25 | Bio-Rad Laboratories, Inc. | Sandwich assays in droplets |
WO2012045012A3 (en) * | 2010-09-30 | 2012-07-19 | Raindance Technologies, Inc. | Sandwich assays in droplets |
US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
US9089844B2 (en) | 2010-11-01 | 2015-07-28 | Bio-Rad Laboratories, Inc. | System for forming emulsions |
WO2012109604A1 (en) * | 2011-02-11 | 2012-08-16 | Raindance Technologies, Inc. | Thermocycling device for nucleic acid amplification and methods of use |
US9364803B2 (en) | 2011-02-11 | 2016-06-14 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
US11077415B2 (en) | 2011-02-11 | 2021-08-03 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
US11768198B2 (en) | 2011-02-18 | 2023-09-26 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
EP3736281A1 (en) | 2011-02-18 | 2020-11-11 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
WO2012112804A1 (en) | 2011-02-18 | 2012-08-23 | Raindance Technoligies, Inc. | Compositions and methods for molecular labeling |
US11168353B2 (en) | 2011-02-18 | 2021-11-09 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11747327B2 (en) | 2011-02-18 | 2023-09-05 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US9329174B2 (en) * | 2011-03-08 | 2016-05-03 | Japan Science And Technology Agency | Bead trapping method and method for detecting target molecule |
US20130345088A1 (en) * | 2011-03-08 | 2013-12-26 | Japan Science And Technology Agency | Bead sealing method, method for detecting target molecule, array, kit, and target molecule detection device |
US10267793B2 (en) | 2011-03-08 | 2019-04-23 | Japan Science And Technology Agency | Kit for sealing beads and detecting target molecule |
US10018627B2 (en) | 2011-03-08 | 2018-07-10 | Japan Science And Technology Agency | Method for sealing substances, method for detecting target molecule, array, kit, and target molecule detection device |
US10809257B2 (en) | 2011-03-08 | 2020-10-20 | Japan Science And Technology Agency | Method for detecting target molecule |
US9921154B2 (en) | 2011-03-18 | 2018-03-20 | Bio-Rad Laboratories, Inc. | Multiplexed digital assays |
US9222128B2 (en) | 2011-03-18 | 2015-12-29 | Bio-Rad Laboratories, Inc. | Multiplexed digital assays with combinatorial use of signals |
EP3333269A1 (en) | 2011-03-31 | 2018-06-13 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to enable multiplex cold-pcr |
US10513729B2 (en) * | 2011-04-08 | 2019-12-24 | Stokes Bio Limited | Biological detection system and method of use |
US20160281135A1 (en) * | 2011-04-08 | 2016-09-29 | Stokes Bio Limited | Biological Detection System and Method of Use |
US20140120604A1 (en) * | 2011-04-08 | 2014-05-01 | Stokes Bio Limited | Biological Detection System and Method of Use |
US9347059B2 (en) | 2011-04-25 | 2016-05-24 | Bio-Rad Laboratories, Inc. | Methods and compositions for nucleic acid analysis |
US9885034B2 (en) | 2011-04-25 | 2018-02-06 | Bio-Rad Laboratories, Inc. | Methods and compositions for nucleic acid analysis |
US11939573B2 (en) | 2011-04-25 | 2024-03-26 | Bio-Rad Laboratories, Inc. | Methods and compositions for nucleic acid analysis |
US10760073B2 (en) | 2011-04-25 | 2020-09-01 | Bio-Rad Laboratories, Inc. | Methods and compositions for nucleic acid analysis |
US10190115B2 (en) | 2011-04-25 | 2019-01-29 | Bio-Rad Laboratories, Inc. | Methods and compositions for nucleic acid analysis |
WO2012156744A2 (en) | 2011-05-17 | 2012-11-22 | Cambridge Enterprise Limited | Gel beads in microfluidic droplets |
US10501786B2 (en) | 2011-05-20 | 2019-12-10 | Fluidigm Corporation | Nucleic acid encoding reactions |
US11754499B2 (en) | 2011-06-02 | 2023-09-12 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
EP3709018A1 (en) | 2011-06-02 | 2020-09-16 | Bio-Rad Laboratories, Inc. | Microfluidic apparatus for identifying components of a chemical reaction |
DE202012013668U1 (en) | 2011-06-02 | 2019-04-18 | Raindance Technologies, Inc. | enzyme quantification |
WO2012167142A2 (en) | 2011-06-02 | 2012-12-06 | Raindance Technolgies, Inc. | Enzyme quantification |
US10139411B2 (en) * | 2011-06-02 | 2018-11-27 | Raindance Technologies, Inc. | Enzyme quantification |
US9556470B2 (en) * | 2011-06-02 | 2017-01-31 | Raindance Technologies, Inc. | Enzyme quantification |
US20190094226A1 (en) * | 2011-06-02 | 2019-03-28 | Raindance Technologies, Inc. | Enzyme quantification |
US10551382B2 (en) * | 2011-06-02 | 2020-02-04 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
EP3216872A1 (en) | 2011-06-02 | 2017-09-13 | Raindance Technologies, Inc. | Enzyme quantification |
US11193872B2 (en) | 2011-06-17 | 2021-12-07 | Life Technologies Corporation | Flat-field imaging system and methods of use |
US20140203169A1 (en) * | 2011-06-17 | 2014-07-24 | Life Technologies Corporation | Flat-Field Imaging System and Methods of Use |
US10156509B2 (en) * | 2011-06-17 | 2018-12-18 | Life Technologies Corporation | Flat-field imaging system and methods of use |
US8951939B2 (en) | 2011-07-12 | 2015-02-10 | Bio-Rad Laboratories, Inc. | Digital assays with multiplexed detection of two or more targets in the same optical channel |
US11898193B2 (en) | 2011-07-20 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Manipulating droplet size |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
US8663920B2 (en) | 2011-07-29 | 2014-03-04 | Bio-Rad Laboratories, Inc. | Library characterization by digital assay |
US9777269B2 (en) | 2012-01-25 | 2017-10-03 | Gencell Biosystems Ltd. | Biomolecule isolation |
US10081808B2 (en) | 2012-01-25 | 2018-09-25 | Gencell Biosystems Ltd | Biomolecule isolation |
WO2013116698A2 (en) | 2012-02-02 | 2013-08-08 | Invenra, Inc. | High throughput screen for biologically active polypeptides |
EP3309262A1 (en) | 2012-02-24 | 2018-04-18 | Raindance Technologies, Inc. | Labeling and sample preparation for sequencing |
WO2013126741A1 (en) | 2012-02-24 | 2013-08-29 | Raindance Technologies, Inc. | Labeling and sample preparation for sequencing |
US11001883B2 (en) | 2012-03-05 | 2021-05-11 | The General Hospital Corporation | Systems and methods for epigenetic sequencing |
US11047003B2 (en) | 2012-03-05 | 2021-06-29 | The General Hospital Corporation | Systems and methods for epigenetic sequencing |
US9399215B2 (en) | 2012-04-13 | 2016-07-26 | Bio-Rad Laboratories, Inc. | Sample holder with a well having a wicking promoter |
US9689024B2 (en) | 2012-08-14 | 2017-06-27 | 10X Genomics, Inc. | Methods for droplet-based sample preparation |
US10450607B2 (en) | 2012-08-14 | 2019-10-22 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10669583B2 (en) | 2012-08-14 | 2020-06-02 | 10X Genomics, Inc. | Method and systems for processing polynucleotides |
US10752950B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US11035002B2 (en) | 2012-08-14 | 2021-06-15 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10400280B2 (en) | 2012-08-14 | 2019-09-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11359239B2 (en) | 2012-08-14 | 2022-06-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10597718B2 (en) | 2012-08-14 | 2020-03-24 | 10X Genomics, Inc. | Methods and systems for sample processing polynucleotides |
US11078522B2 (en) | 2012-08-14 | 2021-08-03 | 10X Genomics, Inc. | Capsule array devices and methods of use |
US11021749B2 (en) | 2012-08-14 | 2021-06-01 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10221442B2 (en) | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US11441179B2 (en) | 2012-08-14 | 2022-09-13 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9695468B2 (en) | 2012-08-14 | 2017-07-04 | 10X Genomics, Inc. | Methods for droplet-based sample preparation |
US10053723B2 (en) | 2012-08-14 | 2018-08-21 | 10X Genomics, Inc. | Capsule array devices and methods of use |
US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10584381B2 (en) | 2012-08-14 | 2020-03-10 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10626458B2 (en) | 2012-08-14 | 2020-04-21 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9970052B2 (en) | 2012-08-23 | 2018-05-15 | Bio-Rad Laboratories, Inc. | Digital assays with a generic reporter |
US11377684B2 (en) | 2012-08-23 | 2022-07-05 | Bio-Rad Laboratories, Inc. | Digital assays with a generic reporter |
US10252261B2 (en) | 2012-11-27 | 2019-04-09 | Gencell Biosystems Ltd. | Handling liquid samples |
US9776182B2 (en) | 2012-11-27 | 2017-10-03 | Gencell Biosystems Ltd. | Handling liquid samples |
US9427737B2 (en) | 2012-12-14 | 2016-08-30 | Bio-Rad Laboratories, Inc. | Methods and compositions for using oils for analysis and detection of molecules |
US10227648B2 (en) | 2012-12-14 | 2019-03-12 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11421274B2 (en) | 2012-12-14 | 2022-08-23 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11473138B2 (en) | 2012-12-14 | 2022-10-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10612090B2 (en) | 2012-12-14 | 2020-04-07 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10676789B2 (en) | 2012-12-14 | 2020-06-09 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10253364B2 (en) | 2012-12-14 | 2019-04-09 | 10X Genomics, Inc. | Method and systems for processing polynucleotides |
US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP2931259A4 (en) * | 2012-12-14 | 2016-07-13 | Gnubio Inc | Method for maintaining heterogeneous concentrations of molecules in emulsion droplets |
US9856530B2 (en) | 2012-12-14 | 2018-01-02 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9567631B2 (en) | 2012-12-14 | 2017-02-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9410201B2 (en) | 2012-12-14 | 2016-08-09 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US20150346201A1 (en) * | 2013-01-07 | 2015-12-03 | Tali Korny | System and method for picoliter volume microfluidic diagnostics |
US11193121B2 (en) | 2013-02-08 | 2021-12-07 | 10X Genomics, Inc. | Partitioning and processing of analytes and other species |
US10150964B2 (en) | 2013-02-08 | 2018-12-11 | 10X Genomics, Inc. | Partitioning and processing of analytes and other species |
US9644204B2 (en) | 2013-02-08 | 2017-05-09 | 10X Genomics, Inc. | Partitioning and processing of analytes and other species |
US10150963B2 (en) | 2013-02-08 | 2018-12-11 | 10X Genomics, Inc. | Partitioning and processing of analytes and other species |
US9388465B2 (en) | 2013-02-08 | 2016-07-12 | 10X Genomics, Inc. | Polynucleotide barcode generation |
CN105189785A (en) * | 2013-03-08 | 2015-12-23 | 伯乐生命医学产品有限公司 | Compositions, methods and systems for polymerase chain reaction assays |
CN108441541A (en) * | 2013-03-08 | 2018-08-24 | 伯乐生命医学产品有限公司 | Composition, the method and system measured for polymerase chain reaction |
US10676778B2 (en) | 2013-03-08 | 2020-06-09 | Bio-Rad Laboratories, Inc. | Compositions, methods and systems for polymerase chain reaction assays |
US9822393B2 (en) | 2013-03-08 | 2017-11-21 | Bio-Rad Laboratories, Inc. | Compositions, methods and systems for polymerase chain reaction assays |
WO2014138711A1 (en) * | 2013-03-08 | 2014-09-12 | Bio-Rad Laboratories, Inc. | Compositions, methods and systems for polymerase chain reaction assays |
EP2964787A4 (en) * | 2013-03-08 | 2016-08-17 | Bio Rad Laboratories | Compositions, methods and systems for polymerase chain reaction assays |
AU2014225372B2 (en) * | 2013-03-08 | 2019-10-24 | Bio-Rad Laboratories, Inc. | Compositions, methods and systems for polymerase chain reaction assays |
EP3418398A1 (en) * | 2013-03-08 | 2018-12-26 | Bio-Rad Laboratories, Inc. | Compositions for polymerase chain reaction assays |
US10876107B2 (en) | 2013-03-15 | 2020-12-29 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US9816088B2 (en) | 2013-03-15 | 2017-11-14 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US10392614B2 (en) | 2013-03-15 | 2019-08-27 | Abvitro Llc | Methods of single-cell barcoding and sequencing |
US10119134B2 (en) | 2013-03-15 | 2018-11-06 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US11118176B2 (en) | 2013-03-15 | 2021-09-14 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US20140303005A1 (en) * | 2013-04-05 | 2014-10-09 | Raindance Technologies, Inc. | Rare cell analysis after negative selection |
WO2014172288A3 (en) * | 2013-04-19 | 2015-01-29 | Raindance Technologies, Inc. | Digital analyte analysis |
WO2014172288A2 (en) | 2013-04-19 | 2014-10-23 | Raindance Technologies, Inc. | Digital analyte analysis |
EP2986762A4 (en) * | 2013-04-19 | 2017-03-15 | Raindance Technologies Inc. | Digital analyte analysis |
WO2014179596A1 (en) * | 2013-05-01 | 2014-11-06 | Advanced Liquid Logic, Inc. | Analysis of dna |
WO2014189898A1 (en) * | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Compositions for detecting cellular forces |
US8988681B2 (en) * | 2013-05-28 | 2015-03-24 | Nasser Ashgriz | Spray droplet sizer |
US20140355008A1 (en) * | 2013-05-28 | 2014-12-04 | Nasser Ashgriz | Spray Droplet Sizer |
US10395758B2 (en) | 2013-08-30 | 2019-08-27 | 10X Genomics, Inc. | Sequencing methods |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US10471016B2 (en) | 2013-11-08 | 2019-11-12 | President And Fellows Of Harvard College | Microparticles, methods for their preparation and use |
US11174509B2 (en) * | 2013-12-12 | 2021-11-16 | Bio-Rad Laboratories, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US20180223348A1 (en) * | 2013-12-12 | 2018-08-09 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11853389B2 (en) | 2013-12-16 | 2023-12-26 | 10X Genomics, Inc. | Methods and apparatus for sorting data |
US11030276B2 (en) | 2013-12-16 | 2021-06-08 | 10X Genomics, Inc. | Methods and apparatus for sorting data |
US9824068B2 (en) | 2013-12-16 | 2017-11-21 | 10X Genomics, Inc. | Methods and apparatus for sorting data |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
US10060939B2 (en) | 2014-01-31 | 2018-08-28 | Carnegie Mellon University | Device and method for clinical data sampling and specimen banking |
EP3100045A4 (en) * | 2014-01-31 | 2017-10-25 | Carnegie Mellon University | Device and method for clinical data sampling and specimen banking |
US10384187B2 (en) | 2014-02-10 | 2019-08-20 | Gencell Biosystems Ltd | Composite liquid cell (CLC) mediated nucleic acid library preparation device, and methods for using the same |
US11209440B2 (en) | 2014-02-27 | 2021-12-28 | The Broad Institute, Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
US10150117B2 (en) | 2014-04-10 | 2018-12-11 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
US9694361B2 (en) | 2014-04-10 | 2017-07-04 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
US10343166B2 (en) | 2014-04-10 | 2019-07-09 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
US10137449B2 (en) | 2014-04-10 | 2018-11-27 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
US10071377B2 (en) | 2014-04-10 | 2018-09-11 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
US10596541B2 (en) | 2014-04-21 | 2020-03-24 | President And Fellows Of Harvard College | Systems and methods for barcoding nucleic acids |
US11052368B2 (en) | 2014-04-21 | 2021-07-06 | Vilnius University | Systems and methods for barcoding nucleic acids |
US11629344B2 (en) | 2014-06-26 | 2023-04-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11713457B2 (en) | 2014-06-26 | 2023-08-01 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10344329B2 (en) | 2014-06-26 | 2019-07-09 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10480028B2 (en) | 2014-06-26 | 2019-11-19 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10457986B2 (en) | 2014-06-26 | 2019-10-29 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10760124B2 (en) | 2014-06-26 | 2020-09-01 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10030267B2 (en) | 2014-06-26 | 2018-07-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10337061B2 (en) | 2014-06-26 | 2019-07-02 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11133084B2 (en) | 2014-06-26 | 2021-09-28 | 10X Genomics, Inc. | Systems and methods for nucleic acid sequence assembly |
US10208343B2 (en) | 2014-06-26 | 2019-02-19 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10041116B2 (en) | 2014-06-26 | 2018-08-07 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10839939B2 (en) | 2014-06-26 | 2020-11-17 | 10X Genomics, Inc. | Processes and systems for nucleic acid sequence assembly |
US10451619B2 (en) | 2014-07-08 | 2019-10-22 | Japan Science And Technology Agency | Substance sealing method and target molecule detecting method |
US11597964B2 (en) | 2014-09-09 | 2023-03-07 | The Broad Institute, Inc. | Droplet-based method and apparatus for composite single-cell nucleic acid analysis |
US11566279B2 (en) | 2014-09-09 | 2023-01-31 | The Broad Institute, Inc. | Droplet-based method and apparatus for composite single-cell nucleic acid analysis |
EP4105337A1 (en) | 2014-09-09 | 2022-12-21 | The Broad Institute, Inc. | A droplet-based method and apparatus for composite single-cell nucleic acid analysis |
WO2016040476A1 (en) | 2014-09-09 | 2016-03-17 | The Broad Institute, Inc. | A droplet-based method and apparatus for composite single-cell nucleic acid analysis |
US10590483B2 (en) | 2014-09-15 | 2020-03-17 | Abvitro Llc | High-throughput nucleotide library sequencing |
US11739368B2 (en) | 2014-10-29 | 2023-08-29 | 10X Genomics, Inc. | Methods and compositions for targeted nucleic acid sequencing |
US10287623B2 (en) | 2014-10-29 | 2019-05-14 | 10X Genomics, Inc. | Methods and compositions for targeted nucleic acid sequencing |
US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
US10245587B2 (en) | 2014-11-05 | 2019-04-02 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
US11135584B2 (en) | 2014-11-05 | 2021-10-05 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
US11414688B2 (en) | 2015-01-12 | 2022-08-16 | 10X Genomics, Inc. | Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same |
US10557158B2 (en) | 2015-01-12 | 2020-02-11 | 10X Genomics, Inc. | Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same |
US10221436B2 (en) | 2015-01-12 | 2019-03-05 | 10X Genomics, Inc. | Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same |
US10650912B2 (en) | 2015-01-13 | 2020-05-12 | 10X Genomics, Inc. | Systems and methods for visualizing structural variation and phasing information |
US10854315B2 (en) | 2015-02-09 | 2020-12-01 | 10X Genomics, Inc. | Systems and methods for determining structural variation and phasing using variant call data |
US10697000B2 (en) | 2015-02-24 | 2020-06-30 | 10X Genomics, Inc. | Partition processing methods and systems |
US11274343B2 (en) | 2015-02-24 | 2022-03-15 | 10X Genomics, Inc. | Methods and compositions for targeted nucleic acid sequence coverage |
US11603554B2 (en) | 2015-02-24 | 2023-03-14 | 10X Genomics, Inc. | Partition processing methods and systems |
WO2016138488A2 (en) | 2015-02-26 | 2016-09-01 | The Broad Institute Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
US11427869B2 (en) | 2015-02-26 | 2022-08-30 | The Broad Institute, Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
WO2016138490A1 (en) | 2015-02-27 | 2016-09-01 | Fluidigm Corporation | Single-cell nucleic acids for high-throughput studies |
US11873483B2 (en) | 2015-03-11 | 2024-01-16 | The Broad Institute, Inc. | Proteomic analysis with nucleic acid identifiers |
US10883102B2 (en) * | 2015-03-20 | 2021-01-05 | Novozymes A/S | Droplet-based selection by injection |
US11746367B2 (en) | 2015-04-17 | 2023-09-05 | President And Fellows Of Harvard College | Barcoding systems and methods for gene sequencing and other applications |
US11505648B2 (en) * | 2015-04-21 | 2022-11-22 | Ran Biotechnologies, Inc. | Fluorinated surfactants |
US20180112036A1 (en) * | 2015-04-21 | 2018-04-26 | Ran Biotechnologies, Inc | Novel fluorinated surfactants |
US11890617B2 (en) | 2015-06-05 | 2024-02-06 | Miroculus Inc. | Evaporation management in digital microfluidic devices |
US11471888B2 (en) * | 2015-06-05 | 2022-10-18 | Miroculus Inc. | Evaporation management in digital microfluidic devices |
US11944974B2 (en) | 2015-06-05 | 2024-04-02 | Miroculus Inc. | Air-matrix digital microfluidics apparatuses and methods for limiting evaporation and surface fouling |
US20200408747A1 (en) * | 2015-08-25 | 2020-12-31 | Bio-Rad Laboratories, Inc. | Digital immunoassay |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
US11123297B2 (en) | 2015-10-13 | 2021-09-21 | President And Fellows Of Harvard College | Systems and methods for making and using gel microspheres |
WO2017075549A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute, Inc. | High-throughput dynamic reagent delivery system |
US11904310B2 (en) | 2015-10-28 | 2024-02-20 | The Broad Institute, Inc. | High-throughput dynamic reagent delivery system |
US11092607B2 (en) | 2015-10-28 | 2021-08-17 | The Board Institute, Inc. | Multiplex analysis of single cell constituents |
US11624085B2 (en) | 2015-12-04 | 2023-04-11 | 10X Genomics, Inc. | Methods and compositions for nucleic acid analysis |
US11473125B2 (en) | 2015-12-04 | 2022-10-18 | 10X Genomics, Inc. | Methods and compositions for nucleic acid analysis |
US11873528B2 (en) | 2015-12-04 | 2024-01-16 | 10X Genomics, Inc. | Methods and compositions for nucleic acid analysis |
US10774370B2 (en) | 2015-12-04 | 2020-09-15 | 10X Genomics, Inc. | Methods and compositions for nucleic acid analysis |
US11117113B2 (en) | 2015-12-16 | 2021-09-14 | Fluidigm Corporation | High-level multiplex amplification |
US11857940B2 (en) | 2015-12-16 | 2024-01-02 | Fluidigm Corporation | High-level multiplex amplification |
WO2017124101A2 (en) | 2016-01-15 | 2017-07-20 | The Broad Institute Inc. | Semi-permeable arrays for analyzing biological systems and methods of using same |
US11081208B2 (en) | 2016-02-11 | 2021-08-03 | 10X Genomics, Inc. | Systems, methods, and media for de novo assembly of whole genome sequence data |
CN109863398A (en) * | 2016-04-15 | 2019-06-07 | 蒙彼利埃大学医疗中心 | For detecting and/or characterizing the method and relevant apparatus of tumour cell |
US11084036B2 (en) | 2016-05-13 | 2021-08-10 | 10X Genomics, Inc. | Microfluidic systems and methods of use |
US10858702B2 (en) | 2016-12-22 | 2020-12-08 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10793905B2 (en) | 2016-12-22 | 2020-10-06 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11180805B2 (en) | 2016-12-22 | 2021-11-23 | 10X Genomics, Inc | Methods and systems for processing polynucleotides |
US10323278B2 (en) | 2016-12-22 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10480029B2 (en) | 2016-12-22 | 2019-11-19 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US11833516B2 (en) | 2016-12-28 | 2023-12-05 | Miroculus Inc. | Digital microfluidic devices and methods |
US10428326B2 (en) | 2017-01-30 | 2019-10-01 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
US11193122B2 (en) | 2017-01-30 | 2021-12-07 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
US11623219B2 (en) | 2017-04-04 | 2023-04-11 | Miroculus Inc. | Digital microfluidics apparatuses and methods for manipulating and processing encapsulated droplets |
US11072816B2 (en) | 2017-05-03 | 2021-07-27 | The Broad Institute, Inc. | Single-cell proteomic assay using aptamers |
JP2018194318A (en) * | 2017-05-12 | 2018-12-06 | 国立大学法人東北大学 | Immunoassay in micro water droplet |
US11660601B2 (en) | 2017-05-18 | 2023-05-30 | 10X Genomics, Inc. | Methods for sorting particles |
US10544413B2 (en) | 2017-05-18 | 2020-01-28 | 10X Genomics, Inc. | Methods and systems for sorting droplets and beads |
US11898206B2 (en) | 2017-05-19 | 2024-02-13 | 10X Genomics, Inc. | Systems and methods for clonotype screening |
US10400235B2 (en) | 2017-05-26 | 2019-09-03 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
US10927370B2 (en) | 2017-05-26 | 2021-02-23 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
US11155810B2 (en) | 2017-05-26 | 2021-10-26 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
US11198866B2 (en) | 2017-05-26 | 2021-12-14 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
US11773389B2 (en) | 2017-05-26 | 2023-10-03 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
US10844372B2 (en) | 2017-05-26 | 2020-11-24 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
CN110799679A (en) * | 2017-06-20 | 2020-02-14 | 10X基因组学有限公司 | Method and system for improving droplet stabilization |
US11857969B2 (en) | 2017-07-24 | 2024-01-02 | Miroculus Inc. | Digital microfluidics systems and methods with integrated plasma collection device |
US10583440B2 (en) | 2017-08-22 | 2020-03-10 | 10X Genomics, Inc. | Method of producing emulsions |
US10610865B2 (en) | 2017-08-22 | 2020-04-07 | 10X Genomics, Inc. | Droplet forming devices and system with differential surface properties |
US10549279B2 (en) | 2017-08-22 | 2020-02-04 | 10X Genomics, Inc. | Devices having a plurality of droplet formation regions |
US11565263B2 (en) | 2017-08-22 | 2023-01-31 | 10X Genomics, Inc. | Droplet forming devices and system with differential surface properties |
US10821442B2 (en) | 2017-08-22 | 2020-11-03 | 10X Genomics, Inc. | Devices, systems, and kits for forming droplets |
US10898900B2 (en) | 2017-08-22 | 2021-01-26 | 10X Genomics, Inc. | Method of producing emulsions |
US10766032B2 (en) | 2017-08-22 | 2020-09-08 | 10X Genomics, Inc. | Devices having a plurality of droplet formation regions |
US10357771B2 (en) | 2017-08-22 | 2019-07-23 | 10X Genomics, Inc. | Method of producing emulsions |
US11639933B2 (en) * | 2017-09-27 | 2023-05-02 | Bio-Rad Laboratories, Inc. | Digital affinity linkage assay |
US11072820B2 (en) | 2017-10-19 | 2021-07-27 | Bio-Rad Laboratories, Inc. | Digital amplification assays with unconventional and/or inverse changes in photoluminescence |
US11833515B2 (en) | 2017-10-26 | 2023-12-05 | 10X Genomics, Inc. | Microfluidic channel networks for partitioning |
US11884962B2 (en) | 2017-11-15 | 2024-01-30 | 10X Genomics, Inc. | Functionalized gel beads |
US10876147B2 (en) | 2017-11-15 | 2020-12-29 | 10X Genomics, Inc. | Functionalized gel beads |
US10745742B2 (en) | 2017-11-15 | 2020-08-18 | 10X Genomics, Inc. | Functionalized gel beads |
US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
US11155881B2 (en) | 2018-04-06 | 2021-10-26 | 10X Genomics, Inc. | Systems and methods for quality control in single cell processing |
US11305527B2 (en) | 2018-05-16 | 2022-04-19 | Catalog Technologies, Inc. | Printer-finisher system for data storage in DNA |
WO2019222562A1 (en) * | 2018-05-16 | 2019-11-21 | Catalog Technologies, Inc. | Printer-finisher system for data storage in dna |
CN113167715A (en) * | 2018-10-08 | 2021-07-23 | 生物电子公司 | System and method for optically processing a sample |
WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
US11738345B2 (en) | 2019-04-08 | 2023-08-29 | Miroculus Inc. | Multi-cartridge digital microfluidics apparatuses and methods of use |
US11524298B2 (en) | 2019-07-25 | 2022-12-13 | Miroculus Inc. | Digital microfluidics devices and methods of use thereof |
WO2021064084A1 (en) | 2019-10-04 | 2021-04-08 | Eth Zurich | Electrophoretic enrichment of analytes in droplets |
EP3799956A1 (en) * | 2019-10-04 | 2021-04-07 | ETH Zurich | Electrophoretic enrichment of analytes in droplets |
US11772093B2 (en) | 2022-01-12 | 2023-10-03 | Miroculus Inc. | Methods of mechanical microfluidic manipulation |
US11857961B2 (en) | 2022-01-12 | 2024-01-02 | Miroculus Inc. | Sequencing by synthesis using mechanical compression |
Also Published As
Publication number | Publication date |
---|---|
US20170028365A1 (en) | 2017-02-02 |
WO2010009365A1 (en) | 2010-01-21 |
EP2315629B1 (en) | 2021-12-15 |
US20220047998A1 (en) | 2022-02-17 |
US11534727B2 (en) | 2022-12-27 |
US11596908B2 (en) | 2023-03-07 |
EP4047367A1 (en) | 2022-08-24 |
EP2315629A1 (en) | 2011-05-04 |
US20230219043A1 (en) | 2023-07-13 |
US20180353913A1 (en) | 2018-12-13 |
US11511242B2 (en) | 2022-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11511242B2 (en) | Droplet libraries | |
US11187702B2 (en) | Enzyme quantification | |
US20230026713A1 (en) | Microfluidic systems and methods for reducing the exchange of molecules between droplets | |
US20200360876A1 (en) | Microfluidic devices | |
US20220050108A1 (en) | Enzyme quantification | |
US20220042995A1 (en) | Enzyme quantification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RAINDANCE TECHNOLOGIES, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LINK, DARREN;HUTCHISON, BRIAN;SAMUELS, MICHAEL;AND OTHERS;REEL/FRAME:023336/0107;SIGNING DATES FROM 20090917 TO 20090929 |
|
AS | Assignment |
Owner name: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P., TEXAS Free format text: SHORT-FORM PATENT SECURITY AGREEMENT;ASSIGNOR:RAINDANCE TECHNOLOGIES, INC.;REEL/FRAME:031267/0376 Effective date: 20130917 Owner name: PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P., TEXAS Free format text: SHORT-FORM PATENT SECURITY AGREEMENT;ASSIGNOR:RAINDANCE TECHNOLOGIES, INC.;REEL/FRAME:031267/0376 Effective date: 20130917 Owner name: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L. Free format text: SHORT-FORM PATENT SECURITY AGREEMENT;ASSIGNOR:RAINDANCE TECHNOLOGIES, INC.;REEL/FRAME:031267/0376 Effective date: 20130917 Owner name: PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P. Free format text: SHORT-FORM PATENT SECURITY AGREEMENT;ASSIGNOR:RAINDANCE TECHNOLOGIES, INC.;REEL/FRAME:031267/0376 Effective date: 20130917 Owner name: CAPITAL ROYALTY PARTNERS II L.P., TEXAS Free format text: SHORT-FORM PATENT SECURITY AGREEMENT;ASSIGNOR:RAINDANCE TECHNOLOGIES, INC.;REEL/FRAME:031267/0376 Effective date: 20130917 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: RAINDANCE TECHNOLOGIES, INC., MASSACHUSETTS Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:CAPITAL ROYALTY PARTNERS II L.P.;CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.;PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.;AND OTHERS;REEL/FRAME:041290/0585 Effective date: 20170216 |
|
AS | Assignment |
Owner name: BIO-RAD LABORATORIES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RAINDANCE TECHNOLOGIES, INC.;REEL/FRAME:049109/0498 Effective date: 20190503 |